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Abstract
Inhibition of steroid sulphatase activity is an important target for the development of 
new drugs for oncology and immunology. In this work, synthetic procedures to 
synthesise novel, potent non-steroidal, non-estrogenic sulphamate derivatives for the 
treatment o f postmenopausal women with hormone dependent breast cancer, and 2 - 
substituted estrone-3-sulphamide, 3-sulphonamide and 3-S-sulphamate derivatives as 
potential antitubulin, antiangiogenic and apoptotic inducers are described.
The strategies adopted to develop STS inhibitors are to develop compounds which are 
active in vivo and devoid o f any estrogenicity, an unwanted property that would limit 
their clinical use such as the potent estrone-3-O-sulphamate (EMATE). Structure- 
activity studies were carried out on the lead 4-methylcoumarin-7-0-sulphamate 
(COUMATE) by incorporating longer alkyl chains and other functionalities at the C-4 
and/or C-3 positions o f the coumarin ring. Also, a fused third ring was incorporated to 
give tricyclic coumarin sulphamates, which structurally might mimic the ABCD rings 
o f the steroid. Similar to coumarin sulphamates other heterocyclic ring containing 
sulphamates are also of considerable interest. Therefore, several novel 1, 2, and/or 3- 
substituted indole sulphamates were also syntheisesd.
The best inhibitors in the C-3 and C-4 alkyl series were those with 7-9 and 6-9 carbon- 
containing alkyl chains at the C-3 or C-4 positions, respectively inhibiting the El-STS 
activity in MCF-7 cells at 0.01 juM by 85-91% and >90%. (c.f. 35% for COUMATE). 
The 3-benzyl-4-methylcoumarin-7-Osulphamate (95) was found to be a potent 
inhibitor with an IC50 o f 8 nM. In the tricyclic coumarin-based analogues with a third 
ring o f sizes between 5 and 15 carbons (665-6615 COUMATES), more powerful active 
site-directed inhibitors than EMATE and its analogues were found. The most potent 
compounds in this series, 669 COUMATE (119) and 6610 COUMATE (122) have 
ICso’s o f 2.4 and 1 nM, respectively in vitro and are non-estrogenic in vivo. 
Interestingly, 6615 COUMATE (131) proved to be the most active congener in vivo. 
The higher potencies observed for the alkyl series o f compounds can be due to their 
bicyclic system mimicking the A/B rings o f steroid backbone with their C-3 or C-4 
alkyl substituents interacting with the amino acid residues at the active site, which 
normally recognise the C/D rings o f steroid. The higher inhibition observed for the 
tricyclic COUMATEs could be attributed to the fact that the third cyclic rings might 
fold in such a way to mimic the C/D ring conformation o f the steroid and hence have 
better recognition for binding at the enzyme active site. In addition, the lipophilicity of 
the tricyclic compounds was studied by calculating the log P values by an HPLC 
technique and the X-ray crystal structures o f compounds 119 and 122 were determined.
2-Methoxyestradiol, a natural estradiol metabolite, is non-estrogenic, known to induce 
G2/M phase cell cycle arrest and apoptosis. The sulphamate derivatives o f this 
compound, 2-MeO/2-EthylEMATE and 2-MeO/2-EtE2MATE have previously been 
found to be more potent, irreversible and non-estrogenic inhibitors, and also shown to 
trigger apoptosis and inhibit tubulin polymerisation. It is therefore possible that the 
structurally similar derivatives o f these synthetic sulphamates, such as the 2 -substituted
3-sulphamide, 3-sulphonamide and 3-S-sulphamate, with nitrogen or sulphur bridging 
heteroatoms at the C-3 position would also inhibit tubulin polymerisation and 
angiogenesis. These compounds would provide an indication about the importance of 
the sulphamoyloxy group for potent activity in 2-MeOEMATE, which is thought to 
elicit effect by taken up into blood cells and released slowly. Therefore, presumably 
acting as a pro drug o f 2-M eOEl. There are certain sulphonamides, which are known 
to bind to carbonic anhydrase in the blood cells therefore the sulphonamides syntheised 
might also show similar inhibitory activities to that o f the sulphamates. Most 
importantly, these compounds would offer useful information about the site where the 
sulphamoyl group binds in tubulin and the mechanism o f binding for irreversible 
inhibition, which might be similar to that o f sulphamoylation o f sulphatase enzyme. 
This structure-activity study would also show how the stability o f the sulphamoyloxy 
group could be improved further. Therefore, novel sulphamate surrogates such as 2- 
methoxy and 2-ethyl 3-sulphamide, 3-sulphonamide and 3-^-sulphamates are 
synthesised in this work and their synthetic methods are reported.
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Steroids are derived from cholesterol, so they are highly lipophilic and readily enter 
most cells to access their intracellular receptors. Many of the important steroids, such 
as cholesterol, cholic acid and ergosterol were first isolated in the 19th century, but 
were not characterised until the beginning o f the 20th century. The early structural work 
was carried out in 1932 in Germany by Adolf Windaus and Heinrich Wieland, 
followed by Otto Rosenheim and Harold King of the National Institute o f Medical 
Research in England, for which they received the most prestigious Nobel Prize.1
Estrone (E l) was the first sex hormone to be recognised in 1929 by Edward Doisy in 
USA, followed by pregnanediol and estriol (E3) by G. F. Marion in 1930, androsterone 
by Adolf Butenandt in 1932 and testosterone by Ernst Laqueur in 1935. At the 
beginning of World War II, cortisone (E) was synthesised by Lewis Sarett in USA and 
found to have a remarkable effect in the treatment o f rheumatoid arthritis.1 This 
discovery set off a trend to synthesise steroidal and non-steroidal anti-inflammatories.
In 1932, Robert Robinson first attempted to propose routes for the synthesis o f steroids,
which later served as a reference point for the total synthesis o f estrogens, stilbestrol
and still later potent tumour-inhibiting compounds such as tamoxifen.2 Since then, R.
B. Woodward (total synthesis of Androgens), K. Ziegler (7-dehydrocholesterol), D. H.
R. Barton, E. R. H. Jones (ergosterol), B. Henbest and several others revealed elegant
• 2and historic synthetic methods for androgenic hormones and their derivatives.
The conformational analysis and the elucidation of steroid stereochemistry by Sir
Derek Barton in 1950 created a new turn in the fundamental investigation of steroids.
As a consequence o f this ongoing worldwide race, various other important steroids
were isolated, characterised and synthesised. The studies on steroids have become an
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1.1 Biosynthesis of steroid hormones
The biosynthetic pathway of steroids is very complex since they are derived from a 
single precursor, cholesterol. Cholesterol, besides being ingested in food, is synthesised 
in large amounts in the body. An adult human contains about 250 g of cholesterol 
although the steroids from which they are produced are at milligram level or lower.3 
The origin o f all the compounds involved in steroid synthesis are acetate, in the form o f 
acetyl co-enzyme A. In addition, the presence of oxygen, the reduced form of 
nicotinamide adinine dinucleotide phosphate (NADPH) and other co-factors are also 
required for the synthesis.3,4
Steroid hormones are synthesised by steroidogenic tissue of adrenal and gonads from 
cholesterol within the elements o f the endoplasmic reticulum (Er). Steroid-secreting 
cells are easily identified by the large amounts of smooth Er present in these cells. The 
complex multiple enzyme system required for the synthesis o f steroids is present 
within mitochondria as well as in the cytoplasm.
The adrenal steroidogenic tissue produces glucocorticoids such as cortisol (F), 
cortisone (E) and mineralocorticoids such as aldosterone4 (Figure 1.1). The 
steroidogenic tissue of the gonads produces a number o f sex steroids such as androgens 
(masculinising), estrogens (feminising) and progestins (related to pregnancy). The 
testes produce testosterone (1-1) and the ovaries produce estradiol (E2) (1-2) and 
progestrone (1-3) (Figure 1.2). During pregnancy, the placenta is an additional source 






Figure 1.2 : Structures o f steroid hormones from the gonads
3
The regulation of steroid biosynthesis is achieved by an intricate network o f peptide 
hormones, which are under neuro-endocrine influence, starting from the hypothalamus 
in the central nervous system (CNS). The hypothalamus produces a number o f small 
peptide hormones that act as releasing factors for the hormones synthesised from the 
pituitary gland. Adrenocorticotropic hormone (ACTH) regulates corticosteroid 
synthesis in the adrenal cortex, whereas luteinising hormone (LH) and follicle- 
stimulating hormone (FSH) act on the ovaries and testes. Gonodotropins induce the 
production of estrogens and gestagens in the female. In the male, LH and FSH regulate 
androgen formation. At the same time, the steroids have a feed back regulatory effect 
on the hypothalamo-pituitary axis, setting up an exquisitely tuned regulatory loop.4,3
Even though, many hormones are stored in the cells as granules, steroid hormones are 
not stored, to any extent, in vesicles. Being lipophilic and soluble in lipids, they are 
carried in plasma by carrier molecules and hence readily cross the plasma membrane of 
the cell. Therefore, their rate of release is directly related to their rate o f synthesis. 
Steroids are bound to various plasma proteins once released into the blood stream. The 
free form is usually only a small fraction of the total hormone in the blood. There is 
equilibrium between the bound and free form, but only the free form can penetrate the 
cell membrane and elicit an effect in the target cells. The concentration o f the active 
hormone in the blood is therefore, determined by the dynamic relationship between its 
rate o f secretion, the degree to which it is bound to plasma proteins and its rate of 
inactivation.4
Hormones in general affect the growth, development, metabolic activity and function 
o f tissues. The responses are often the result of a combination of the action o f several 
hormones. These actions may be stimulatory or inhibitory and additive or synergistic. 
Once inside the cell, the first step o f a steroid hormone is to bind to its specific 
receptor, which can be a monomeric or dimeric accepting one or two molecules of 
steroid hormones.5 The steroid-receptor complex is then translocates to the nucleus 
where it acts on a particular segment o f the chromosomal DNA. This results in an 
induction o f gene activation, which leads to transcription of new messenger RNA
4
species and consequently specific effector protein synthesis rendering cellular effect in 
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Figure 1.3 : Steroid hormone action at the cellular level/
Inactivation o f hormones may occur in the blood, liver, the kidneys, and in some cases 
the target tissues itself, by degradation, oxidation, reduction or methylation. The 
metabolites so formed often conjugate with glucuronic acid and are excreted in the 
urine or bile.3 The body’s endocrine system acts very slowly since it takes time for 
hormones to be synthesised, released and transported via the blood stream to some 
distant target organ. The concentrations o f hormones in the blood are extremely low in 
the range of 10‘6 to 10’9 mol/1.3 Although the onset is rather slow, the hormonal effects 
are longer acting than those o f the neurones from a matter of minutes to days. 
Hormones do not disappear from the body rapidly, nor do the intracellular effects turn 
off immediately as do the termination o f neuronal stimulation when the action 
potentials no longer reach their effector organ.4 This makes the whole endocrine 




1.2 Estrogens and their biosynthesis
Estrogens are the most important factors for the growth and maintenance o f the breast, 
vagina and uterus and also the development of the secondary sexual characteristics in 
women. Estrogens are characterised by an aromatic ring A with a phenolic hydroxyl 
group at the C-3 position. It is the unique nature of the A ring which distinguishes its 
chemistry from other steroids. About 20 different biologically active estrogens have 
been identified, but estrone (E l) (1-4), estradiol (E2) (1-2) and estriol (E3) (1-5) are the 
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Figure 1.4 : The natural estrogens
Out o f these three estrogens, E2 is the most biologically active and abundant in tissues, 
responsible for the onset o f heat in animals and the control o f menstrual cycle in 
women. In the liver, E2 is readily oxidised to El by 17/?-hydroxysteroid 
dehydrogenase (17/7-HSD) enzyme, which in turn can be converted to E3 in the liver 
itself.7 The metabolites o f these estrogens (particularly E3 and pregnanediol) are 
excreted by the kidney. E l and E2 exist in equilibrium at a ratio o f 1:2 to 1:4. E3 is an 
estrogen o f low estragenicity and has been regarded as only a partial agonist. However, 
the true situation is that E3 is short acting but if its concentration in the plasma is 
maintained under physiological conditions, E3 can be as potent as E2.
In premenopausal women, estrogens are produced predominantly in the granulosa cells 
o f the ovarian follicles from androgens by the stimulation o f FSH. After ovulation it is 
produced by the corpus luteum .8 The production of estrogens is stimulated during the 
first and second half o f the menstrual cycle, where LH combines with FSH in the 
second half.8 Upon binding o f FSH to its G-protein coupled receptor in the granulosa
6
cell membrane, the intracellular cyclic adenosine monophosphate (cAMP) levels rise 
and the binding of two critical transcription factors, i.e. steroidogenic factor-1 (SF-1) 
and cAMP response element binding protein (CREB), to the classically located 
proximal promoter II o f the aromatase (AR) gene is enhanced.9,10 This, in turn, 
activates AR expression and consequently causes estrogen production and secretion 
from the pre-ovulatory follicle.11
Estrogens are also synthesised by the placenta in large quantities during pregnancy, in 
small amounts by the testes in males and by the adrenal cortex in both sexes.12 Other 
tissues such as liver,13 muscle, 14 fat,14 brain15 and hair follicles16 can also convert 
steroid precursors into estrogens. The immediate precursors for estrogen synthesis are 
androstenedione or testosterone17 (Figure 1.1).
In postmenopausal women, when the ovaries cease to produce estrogens, adrenal 
glands take over the function of the ovaries and become the major source o f estrogens. 
The adrenals do not secrete estrogens directly.18 They secrete indirectly under the 
influence o f ACTH by a process called cortisol feedback control via the aromatisation 
o f androstenedione by the AR enzyme in non-ovarian tissues such as liver, muscle, fat, 
brain, and hair follicle.19 In contrast to cAMP regulation o f AR expression in the ovary 
in premenopausal women, the production of estrogens in postmenopausal women is 
controlled primarily by cytokines (IL6 , IL-11, TNFa) and glucocorticoids via the 
alternative use o f promotor 1.4 in adipose tissue and skin fibroblasts.11,18 The major 
substrate for AR in adipose and skin is androstenedione o f adrenal origin. In 
postmenopausal women, approximately 2% of circulating androstenedione is converted 
to E l, which is subsequently converted to the most biologically active E2 in the extra 
ovarian tissues by the enzyme 17/?-HSD.20,19
Apart from the natural estrogens such as E l, E2 and E3, there are several other 
synthetic estrogens such as ethinylestradiol21 (1-6), mestranol (1-7), hexestrol (1-8), 
diethylstilbestrol22 (1-9), dienestrol (1-10) and megestrol (1-11), which are widely 
available clinically (Figure 1.5). Equilin23 (1-12) (Figure 1.5) is another synthetic
7
estrogen currently being used in estrogen replacement therapy in the patients whose 























Figure 1.5 : Structures o f some widely used synthetic estrogens
Synthetic estrogens are orally administered in children aged between 11 and 13 with 
primary hypogonadism to stimulate the development o f secondary sexual 
characteristics and for accelerated growth. The main use o f synthetic estrogens in adult 
women is for oral contraception24 and also for primary amenorrhoea in which case they 
are used together with a progestogen to induce an artificial cycle. It is also useful to 
reduce menopausal symptoms associated with the decline in estrogen production, such 
as hot flushes, inappropriate sweating, palpitations, and atrophic vaginitis. 
Administration o f synthetic estrogens has also been shown to decrease postmenopausal 
osteoporosis. They maintain the scaffolding of the bone by decreasing the loss of
9 5 9 f scalcium phosphate complexes and protein matrix from the bone. ’
Estrogens that are administered orally as contraceptives have been shown to associate 
with an elevation in blood coagulation. This is directly related to an increase in platelet
aggregation as a result o f an increase in various clotting factor concentrations in the 
plasma rendering changes in the fibrinolytic system when the antithrombin III 
concentration is decreased. The coagulability o f blood is the basis of increased risk of 
thromboembolism, associated with contraceptive pills, in particular with those contain 
a high estrogen content.24
1.3 Estrogens and their role in breast cancer
The influence o f ovarian estrogens in the development o f breast cancer has long been 
recognised. Animal studies have repeatedly shown that estrogen administration can 
induce and promote mammary tumours in rodents.27,28 It is generally believed that 
estrogens act as promoters rather than as carcinogens in the development of breast 
tumours. Although, E2 is generally considered to be the major estrogen, which 
supports tumour growth there is now substantial evidence to show that in 
postmenopausal women another steroid, 5-androstenediol can also bind to the estrogen 
receptors (ER) and is equipotent to E2 in its ability to support tumour growth.
In postmenopausal women, in whom breast cancer most frequently occurs, 
approximately 30-40% of the tumours are hormone dependent.29 The concentrations of 
estrogens in particular E2, in breast tumours of these patents are higher than the 
estrogen levels in normal tissue and blood from the same individual.30
1.4 Incidence of breast cancer
Any development o f new therapies for the treatment o f breast cancer is an important 
target since the disease is the third most common cancer world-wide and also the most 
prevalent cancer in women. Breast cancer is the major cause o f death in Western
31women and it ranks third in developed countries and fifth in the developing countries. 
Breast cancer occurs most frequently in postmenopausal women at a time when the 
ovaries have ceased to produce estrogens.32 Incidence rates are high in most 
industrialised countries, except Japan and low in central and tropical South America, 
Africa and Asia. In Britain about 40,000 new cases o f breast cancer are diagnosed each
year and it is now identified to be the most prevalent cancer o f all. About 15,000 deaths
9
are reported each year to be related to this disease, and such death rate is the highest
'X ^amongst the European community. Therefore, it has been suggested that this 
international differences in the incidence rate of breast cancer is predominantly due to 
environmental rather than genetic factors.
The cause o f breast cancer, like that o f the other cancers, is yet to be fully understood. 
Research has shown that breast cancer frequently occurs in women aged between 30 
and 70 and indicates that reproductive and hormonal factors are the possible causes.34,35 
Breast cancer is found to be less common in women whose first pregnancy occurs 
before the age of 30.31 It is also less common in women with a late menarche (>12 
years) and who have a regular menses.36 A reduction in risk is also associated with 
women who are multiparous, whose ovaries are removed before the age o f 37, who 
breast-fed their babies,37 who have an early menopause (< 45 years)38 and who are 
from the lower socio-economic group and of non-Caucasian race.39,40
Factors that cause an increase risk o f breast cancer include, obesity in postmenopausal 
women,41 a prolonged use of oral contraceptives42,24 or hormone replacement therapy 
(HRT),43 high consumption o f unsaturated fats44 and alcohol45 and an exposure to high 
energy radiation .46 In addition, women who have blood relatives (mother or sisters) 
affected by this disease47 and who have a previous history of other cystic diseases, such 
as chronic mastitis and who have been treated with androgens have an increase risk of 
developing breast cancer at any one point of their life tim e .48 Epidemiological studies 
have shown that breast cancer is a heterogeneous disease with all women in general are 
randomly at risk of developing it at some stage o f their lives, but data are not available 
to suggest any alternatives to avoid any risk factors.
1.5 Estrogen and progestrone receptors
In the past decade, the discovery of the estrogen receptors (ER) within the hormone 
dependent primary breast tumour cells and the development o f effective, but relatively 
non-toxic hormonal drugs have revolutionised the treatment and understanding of 
breast cancer. The inability in the past to identify potential responders to endocrine
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therapy prior to treatment had offered a large proportion of breast cancer patients no 
alternative but invasive procedures. In seeking to improve the effectiveness of 
treatment as well as patient compliance, patients are now screened for their ER status 
and categorised according to the hormone dependency of their breast tumours.
Evidence to support the presence of ER within the target tissues was first shown in the 
early 1960’s. In order for estrogens to regulate cell growth and other functions in 
humans, a specific protein called the human estrogen receptor (hER) must be present.49 
Much o f the hER are initially found in the cytoplasm but, now it has been shown that 
these receptors are predominantly present in the nucleus and the initial observation was 
due to liberation o f free receptors from the nucleus during homogenisation.50
The hER gene has been cloned, sequenced and expressed and it was found to be 
composed of two non-overlapping functional domains, which have higher affinity for 
estrogens and DNA respectively.51 When estrogen binds to the first domain, a 
conformational change is triggered in the second domain, which allows the interaction 
with the specific DNA nucleotides known as a transcriptional enhancer region. As a 
result, an increased production of mRNA from selected genes that are essential for 
tumour growth occurs.
Patients are classified as estrogen-receptor positive (ER+) or estrogen-receptor negative 
(ER') according to the concentration of ER protein in the breast tissue. One with higher 
concentration of receptor protein than the average o f 10 fmol receptor protein/mg 
breast tissue is considered to be ER+ and one with less than this value is regarded as
c'i
ER'. Analysis of primary tumours has shown that 50-60% of all tumours contains 
measurable quantities o f ER+ tumours.54 Patients whose tumours expressed little or no 
ER rarely responded to endocrine therapy, whereas, 60% of patients with ER+ tumours 
responded. The remaining third o f patients with ER+ tumours that failed to respond to 
hormone manipulation may not contain a fully functional ER system. 60% of tumours 
in premenopausal women are ER+ and this rises to 80% in postmenopausal women. 
The frequency o f ER+ tumours in postmenopausal woman was found to be
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significantly higher than in premenopausal women. Age rather than menopausal status 
was found to be associated with this difference.55 The majority of patients with ER+ 
tumours and about 10% of ER' tumours respond to most types o f endocrine therapy.
In addition to ER, the presence of progesterone receptors (PR) has been identified in 
breast tumours. The frequency o f progesterone receptor positive (PR+) tumours was 
found to be significantly lower in postmenopausal woman than in the premenopausal 
women .55 However, unlike the situation in ER tumours, neither age nor the menopausal 
status alone could account for such difference but it appears to be due to a combined 
effect o f the two factors. The role of PR in breast cancer is yet to be fully understood 
but it is possible that PR acts as a mediator of hormonal response. The proliferation of 
tumour cells induced by estrogen is thought to be due to the presence o f both ER and 
PR .56 It has been identified that PR is present in the majority o f ER+ patients, but to a 
lesser extent in ER' patients. Patients who are PR+ and ER+ were found to respond to 
endocrine therapy much better (73%) than patients with other combinations of ER and 
PR status.57 Therefore, the ER and PR status of a breast tumour is a useful tool for
c o
predicting the response o f the patient to the endocrine therapy administered.
1.6 Primary treatment of breast cancer
Breast cancers can be broadly divided into two types: Hormone dependent breast 
cancer (HDBC) and non-hormone dependent breast cancer (NHDBC). In post 
menopausal women, about 1/3 o f the patients have hormone dependent breast tumour 
whose growth and development are supported by estrogens derived from 
extraglandular tissues such as the adipose, muscle, normal and malignant breast 
tissues.33
Breast cancer is one of only a few cancers (cancers o f the cervix, breast and mouth) 
whose incidence and prognosis could be altered by both primary and secondary 
preventive measures, which are practical enough to be implemented. In primary 
prevention, reproductive modification is not a practical one as it may be difficult in 
some cases due to social, cultural and economic reasons.39 Obesity is the main risk
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factor and has a significant effect in the incidence of breast cancer in postmenopausal 
women .41 Dietary modification is an important aspect as a high body fat content is a 
main component associated with breast cancer risk. A diet, which is high in animal fat, 
salt and free sugars but low in whole grains, vegetables and fruits increases the risk of 
cancer,44 as do to cardiovascular diseases, many other chronic diseases, together with 
alcohol consumption45 and cigarette smoking.59
For secondary prevention, early detection by breast self-examination and 
mammography followed by clinical examination reduces the rate o f mortality.31,47 
Once the mammographic findings point to suspicion o f carcinoma, a fine-needle 
aspiration and a more detailed histological biopsy are generally carried out to confirm 
malignancy.31,47 Factors such as the woman’s age, menopausal status, steroid hormone 
receptors status, tumour features, local spread, lymph node involvement and metastatic 
status in other parts of the body would determine the options of treatment 
employed.5,47,35,60 Decision will have to be made if the cancer can be surgically 
removed or will require multiple types o f treatment such as chemotherapy, hormonal 
treatment and/or radiation therapy.47,61
Once breast cancer is detected, the first-line treatment for the disease is the surgical 
removal of the tumour often followed by post-operative radiotherapy (exposure to 
ionising rays such as those emitted by an X-ray tube),31,35 which helps to prevent the 
recurrence o f the disease. The type of surgical procedure is often related to the size of 
the tumours with much emphasis on breast conservation and surgical techniques that 
are more cosmetically acceptable and also psychologically reassuring to the patients.
For small tumours with <2-3 cm diameter, lumpectomy, which is the removal o f the 
lump together with normal tissue from 1 cm surrounding, without removing the 
overlying skin, and quadrantectomy, which is the removal o f the entire quadrant o f the 
breast are the primary choice of treatment.47 Pre-operative radiation therapy is not
f\0preferred for small tumours with no skin involvement and metastasis.
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For larger tumours, mastectomy is the general choice of treatment, which is only 
performed, in exceptional cases o f extensive and regionally invasive tumours.31,5,47 For 
patients who have had surgery, postoperative treatment (adjuvant therapy) is often
f\~K f \  1recommended to improve the chance o f eliminating any remaining cancer cells. ’
1.7 Treatment of advanced breast cancer
In most patients in Western countries, their disease is often being diagnosed in its early 
stages, 0, I or II. In developing industrialised countries, disease at stages III and IV 
represent more than 50% of the newly diagnosed cases.64 Some patients who have a 
very aggressive form of the disease and do not respond to any form of treatment will 
die less than 6 months after the diagnosis of the metastatic disease. However, some 
patients survive for 10 years or even longer with indolent metastatic carcinoma, 
regardless of the therapy instituted.31,47
The two most important treatment modalities for advanced breast cancer are hormonal 
manipulation and chemotherapy. Before the type of treatment is decided, the patient’s
o c
hormone dependency status of the tumours has to be diagnosed. However, in 
advanced HDBC, where metastases o f the tumour have already taken place from its 
primary site to the lymph glands, peri-breast tissues, skin and bones and in more severe 
cases, the lungs, liver and brain have already taken place and the condition becomes 
incurable. Therefore further clinical interventions will have no significant impact on 
the development of the disease. Patients with visceral metastasis have the poorest 
prognosis, and a much shorter disease free interval.47 The aim o f the treatment for 
advanced breast cancer is therefore often not a curative measure but a palliative 
control.
1.7.1 Endocrine Ablation
Ovarian ablation by surgery or irradiation has been an effective treatment in providing 
tumour regression in around one-third o f premenopausal patients with recurrent breast 
cancer.47 ER+ patients show the best response to ovarian ablation. Amongst the non­
responders a further 10-20% of patients show remission following adrenalectomy
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and/or hypophysectomy.65 Because of the irreversible nature and unpleasant side 
effects of such surgical procedures it is preferred to delay ovarian ablation in 
premenopausal women until the patients show a positive relapse.35 However, in the 
management of early breast cancer, a revival call for a prophylactic use o f ovarian 
ablation after mastectomy has been raised in selected premenopausal patients with high 
risk o f relapse.35,66,60
In postmenopausal women, the ovaries have ceased to produce estrogens, and hence it 
would not be effective in carrying out ovarian ablation. Therefore, endocrine ablation 
therapy becomes the preferred mode of treatment.67,35 In patients whose tumours are 
ER+, adrenalectomy and/or hypophysectomy can be a form of treatment. However, 
these modes o f treatment have subsequently become obsolete because studies have 
revealed that such ablative treatment did not result in complete elimination o f estrogen
c o
production, and also due to the innovation of newer and more effective alternative 
endocrine therapies. (See later)
1.7.2 Chemotherapy
Cytotoxic chemotherapy is another regime widely used in the treatment o f patients 
with advanced breast carcinoma. Chemotherapy could offer substantial palliative 
benefits, in which large tumours are reduced to operable size tumours so that a breast 
conservational surgery can be carried out. However, it has the drawbacks o f high
o c
toxicity and side effects.
The quality o f life issues of patients undergoing chemotherapy remain crucially 
important. Chemotherapy appears to prolong the median survival duration o f patients, 
probably by approximately 1 year. Many single agents such as the anthrapyrazoles, 
antifolates, gemcitabine, miltefosine, taxanes and vinca-alkaloids are available for 
more than four decades as cytotoxic treatment.64 Until recently, doxorubicin was 
considered to be the most active single agent available for the treatment o f metastatic 
breast cancer, with response rates of 40% to 50% commonly reported. Other active 
agents widely used include cisplatin, cyclophosphamide, 5-fluorouracil, ifosfamide,
15
methotrexate, mitomycin- C, mitoxantrone, vinblastine and vincristine.64
Initial observation has shown that combination therapy (polychemotherapy) is more 
effective than single-agent treatment, in terms o f response rate, response duration and 
survival.69 Polychemotherapy as adjuvant treatment for early breast cancer has 
produced significant reductions in recurrence and mortality, with a statistically 
significant trend towards greater benefits in patients aged less than 50 years.70 FAC (5- 
Fluorouracil/doxorubicin/cyclophosphamide), FEC (5-Fluorouracil/epirubicin/ 
cyclophosphamide), AC (doxorubicin/cyclophosphamide), NFL (5-Fluorouracil/ 
mitoxantrone/leucovorin), MMM (mitozantrone/methotrexate/mitomycin C) and EP 
(etoposide/cisplatin) are some of the combination drugs used for this purpose, which 
produce a response rate of 40-80% in patients with no prior cytotoxic treatment.64,69 
These combination drugs are given every 3-4 weeks in several courses over a period of 
6 months. In resistant patients combination therapy may be followed by a course of 
vinblastine/methotrexate, paclitaxel or vinorelbine and then by a further course o f 5- 
Fluorouracil/folinic acid or vinblastine/mitomycin. The major disadvantage of 
polychemotherapy is that treated patients eventually develop tolerance due to an 
induction o f a Pi 70 membrane glycoprotein and the disease progresses even further.64
With the newer cytotoxic agents introduced lately show that anthracycline-containing 
regimens were found to be more effective than combinations without anthracyclines, 
but overall, it is not clear whether combinations are superior to high-dose single-agent 
anthracyclines.71 The addition of anthracyclin has extended disease-free interval and 
overall survival rates in both premenopausal and postmenopausal women, including 
those with ER+ tumours.70 Also, despite the development of the 
cyclophosphamide/doxorubicin/5-fluorouracil regimen, no major improvements on 
combination regimens have been achieved until the discovery o f the taxoids. These 
new agents have substantial activity against metastatic breast cancer. The results of 
phase II studies have suggested that o f these agents used at the recommended doses, 
docetaxel (Taxotere, Rhone-Poulenc Rorer) may be the most active. Docetaxel has 
been given at a standard dose o f 100 mg/m2 over 1 hour. Recent results from phase III
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studies in which individual studies with docetaxel and paclitaxel (Taxol; Bristol-Myers 
Squibb) have been compared with standard therapies, have indicated that docetaxel is 
the most active single agent against metastatic breast cancer.64,69
1.7.3 Endocrine Therapy
It is now over 100 years since it was first recognised that altering the endocrine 
environment can be valuable in patients with inoperable breast cancer. Endocrine 
therapy represents one of the most effective palliative and adjuvant treatments for 
breast cancer, in particular in postmenopausal patients.70 It aims to abolish or reduce 
the stimulatory effects o f estrogens on hormone dependent tumours. The choice of 
endocrine agent for breast cancer depends on the menopausal status of the patient, the 
stage o f disease, prognostic factors, and the toxicity profile of the agent. Endocrine 
therapies are typically given sequentially, with the least toxic therapy given first.70
The elucidation of the biosynthetic routes and mechanism of action of steroid 
hormones has helped to define the role o f hormones on tumour growth. The discovery 
o f ERs within the breast tumours has led to a greater understanding o f the disease and 
conferred selectivity on the administration of endocrine therapy. Also, new agents have 
been discovered, which offer effective and safer alternatives to the conventional 
methods o f treatment. Therefore, we are specifically interested in synthesising new 
drugs with a novel pharmacological action, which are effective and well tolerated by 
patients for use in the endocrine therapy.
In 1896, Beaston had laid the foundation for investigation into the role of endocrine 
treatment in breast cancer72 by demonstrating that oophorectomy/ovariectomy (surgical 
removal o f ovaries) could result in a significant regression o f tumour in premenopausal 
women with advanced breast cancer. Despite such demonstration ovariectomy had not 
been widely practised for some time since only about one-third o f the patients were 
found to respond to the surgery and the response was of a short duration, up to a year.
However, a renewed interest in endocrine therapy flourished in the early 1940’s, when
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Huggins showed the benefit of orchidectomy (surgical removal o f testis) in men with 
metastatic prostate carcinoma.73 As a consequence, oophorectomy conducted either by 
surgery or radiation had become a standard treatment for breast cancer in women. 
Unexpectedly, recurrence o f the disease was still common in these operated patients. 
The failure to cure the disease was subsequently attributed to the adrenals, where the 
precursor o f estrogens is produced after surgery. It is now known that the androgens 
synthesised by the adrenals are converted into estrogens in other tissues o f the body. 
Since synthetic glucocorticoids were not available at that time, the removal o f the 
adrenals was not practised, since such surgery would have led to Addisonian crisis due 
to insufficient adrenal hormones.
When synthetic glucocorticoids finally became available in 1952, adrenalectomy was 
shown to produce good remission in postmenopausal women. Among those non­
responders to oophorectomy, around 10-20% will show remission following 
adrenalectomy and/or hypophysectomy (surgical removal o f the pituitary glands).74,68 
Experiments, which were carried out in animals, have shown that the growth o f some 
mammary tumours may be dependent on pituitary hormones, growth hormones and/or 
prolactin. However, the clinical results achieved with hypophysectomy were similar to 
those with adrenalectomy.68
As an alternative to these ablative procedures, the administration o f pharmacological 
doses o f androgens such as testosterone were used in the 1940’s to antagonise the 
action or the biosynthesis of estrogens. Even though this kind of therapy showed 
tumour regression, long term use o f these hormones had led to virilising side effects. 
Administration o f antiestrogens75 and high doses of estrogens76 had also been tried and 
tested.
1.8 Drugs used for the treatment of breast cancer
Once Haddow and co-workers had shown paradoxically that large doses o f estrogens 
could cause tumour regression in 1944, several synthetic estrogens then became 
available.76 The most commonly used synthetic estrogen then was diethylstilbestrol
(DES) (1-9) (Figure 1.6). Although the mechanism of action is unclear, the most likely 
explanation for the clinical effects is that a large dose o f DES causes blockage of 
estrogen response, rather than stimulation as caused by smaller doses o f naturally 
occurring estrogens. The remission rates were around 35%, but prolonged use had led 
to uterine bleeding, cardiovascular toxicity, nausea and vomiting.
Nowadays, the most commonly used hormonal agents for treating advanced breast 
cancers are aminoglutethimide (AG) (Orimeten) (1-13), tamoxifen (Nolvadex) (1-14) 
and 3rd generation AR inhibitor anastrazole (Arimidex) (1-15) (Figure 1.6). Tamoxifen 
is an anti-estrogen and the other two inhibit the aromatase enzyme complex, which is 
responsible for the conversion of androgens into estrogens.70 AG inhibits several 
enzymes involved in the adrenal steroid synthesis and has been found to act as a 
“medical adrenalectomy” since its clinical results observed are similar to those 
achieved with surgical methods.77
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Figure 1.6 : Drugs used for the treatment o f breast cancer
The long-term clinical effects of AG and tamoxifen are of limited nature. The mean 
duration o f response is about 18 months for AG and about 20 months for tamoxifen. 
AG lacks selectivity for the AR enzyme and it is toxic .78 AG also inhibits other 
cytochrome P450 enzymes in particular cholesterol side chain cleavage enzyme. For this 
reason a corticosteroid is often administered concurrently with AG to counteract the 
resulting adrenal hypo function. The side effects o f tamoxifen are relatively mild and 
uncommon. Nausea, vomiting, lethargy, drowsiness, oedema, weight gain, vaginal
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bleeding, rash and hot flushes are occasionally encountered. Because o f its low 
toxicity, tamoxifen is used as the first-line treatment for women with advanced breast 
cancer. AG is being regarded as the second line therapy because a significant 
proportion of postmenopausal patients who developed tolerance to tamoxifen will 
respond to AG only if they have not been treated with AG beforehand.
The new drug anastrazole (1-15) is a comparatively simple, achiral derivative o f 
benzyltriazole (2,2’-[5-(lH-l,2,4-triazol-l-yl-methyl)-l,3-phenylene]bis(2-methyl 
propiononitrile), that inhibits human placental aromatase enzyme with an IC50 value o f 
15 nM .79 It is potent and selective with maximum activity elicited at about 0.1 mg/Kg. 
There are no other pharmacological effects or interference with the steroid hormones 
production by the adrenal glands being observed.80 It is extensively metabolised after
o  1
oral administration and the metabolites are excreted predominantly in urine. It has a 
half-life o f 30-60 hrs and is considered to be the best inhibitor available to date for the 
treatment of advanced breast cancer. 82
1.9 Antiestrogens or Selective Estrogen Receptor Modulators (SERMS)
Antiestrogens were first used as fertility drugs. This was based on the fact that E2 
inhibits the secretion o f gonodotrophic hormones LH and FSH by a feedback 
mechanism, which results in the production o f one single ovum in every menstrual 
cycle and hence prevents overlapping pregnancies. Antiestrogens block this inhibition 
o f E2 in infertile women by occupying ER in the hypothalamus resulting in an 
excessive LH and FSH production and hence facilitating multiple pregnancies.70
For the past 25 years antiestrogens have been used as the first line treatment for 
HDBC. Rather than relying on the removal of endocrine glands, which will ablate 
many important hormones in addition to estrogens, antiestrogens interfere with 
estrogen’s interaction with its target cells by antagonising E2 at its receptors. The 
triphenylethylenes and the aminoether derivatives of stilbene are the two classes of 
non-steroidal antiestrogens commonly used as anti-tumour agents in ER+ estrogen- 
dependent mammary carcinoma. These non-steroidal drugs have been shown to
2 0
83partially antagonise E l and E2 induced uterotrophic activity in mice.
Tamoxifen is the most widely prescribed endocrine therapy for breast cancer, which 
has both antiestrogenic and estrogenic activity. The antiestrogenic activity accounts for 
its efficacy against breast cancer, while the estrogenic activity is considered to be 
associated with positive effects on bone mineral density and lipid profiles and a 
proliferative effect on the endometrium in some women. Tamoxifen inhibits the 
synthesis of estrogen-regulated proteins by blocking the Gj phase of the cell cycle. 
This cis- isomer o f tamoxifen is estrogenic rather than being an estrogen antagonist.
Tamoxifen has a good tolerability profile. It benefits breast cancer patients by 
prolonging the overall disease-free survival and reducing the incidence o f contralateral 
breast cancer. These known benefits of tamoxifen far outweigh the risk o f endometrial 
cancer in tamoxifen-treated patients with breast cancer.84 Tamoxifen is currently being 
tested as a chemopreventive agent in patients with high risk o f developing breast 
cancer. However, a number of studies have shown genotoxic and carcinogenic effects, 
which are thought to be related to oxygen radical overproduction during tamoxifen 
metabolic activation.
In early breast cancer, tamoxifen can produce significant benefits, both statistically and 
clinically, in terms o f reduction in relative risk of relapse or death in all patient 
subgroups (i.e. ER status, aged < or > 50 years) except in premenopausal women with 
ER' negative tumours. The major benefit, however, is seen in women over 50 years old 
with ER+ tumours. The results of randomized trials have suggested that the optimum 
duration of tamoxifen therapy is at least 5 years. Recent data has also suggested a 
possible synergism between tamoxifen and chemotherapy in the treatment o f early 
breast cancer in post-menopausal women. Although, tamoxifen is the first choice 
endocrine therapy for all stages of breast cancer, the drug cannot be considered to be a 
cure, as drug resistance will eventually develop by the loss of ER.
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A number of pure antiestrogens (nonestrogenic) have been discovered that can either 
be administered orally [e.g., EM-800 (1-16)] or by injection [e.g., ICI 182,780 -  
Faslodex (1-17)]85 (Figure 1.7). In preliminary clinical studies, Faslodex has been 
shown to be an effective second-line therapy after tamoxifen failure.85
OH
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Figure 1.7 : Structures of some antiestrogens
It has now been discovered that antiestrogens also act as selective estrogen receptor 
modulators (SERMs). They are competitive inhibitors of estrogen binding at estrogen 
receptors a  and |3, and have become important weapons in the prevention and
q/:
treatment of HDBC. SERMs are also shown to represent a possible alternative to
87HRT, which is the first and probably the sole therapeutic approach for the prevention 
and treatment of medical postmenopausal disease.
A benzothiophene, raloxifene hydrochloride (LY -139481, Evista®) (1-18) (Figure 1.8) 
binds to the estrogen receptor and shows tissue-selective effects such as estrogen- 
agonist effects on bone and lipids and estrogen antagonist effects on the breast and 
uterus. In addition to its well-established effects on osteoporosis, it can also be used as 
a replacement to HRT. Recent preclinical and clinical findings suggest that raloxifene 
also possesses cardioprotective properties without an increased risk o f cancer or other 
side effects.88 Newer drugs, ERA-923 (1-19),89 the coumestrol derivative (1-20),90 the 




















Figure 1.8 : Structures o f some SERMS
1.10 Aromatase enzyme
The three key enzymes that are involved in the synthesis of estrogens in breast tumours 
are important targets for therapeutic intervention, such as aromatase (AR), estrone 
sulphatase (El-STS) and 17/?-hydroxysteroid dehydrogenase (17/?-HSD). AR is a 
membrane-bound enzyme complex consisting of a cytochrome P450 haemoprotein (a 
55-kDa protein of 503 amino acids) and a ubiquitous electron-donating flavoprotein,
Q9NADPH-cytochrome P450 reductase. The C-19 androgen substrates androstenedione 
and testosterone bind to the P450 and AR catalyses the aromatisation o f the androgen A 
ring and loss of the C l9 methyl group to yield E l and E293 extragladularly in 
peripheral tissues such as adipose, muscle, liver and skin94 (Figure 1.9). AR has also 
been described in other parts o f the body such as brain (hypothalamus, amygdala, 
hippocampus),95 ovary, testis, adrenal, breast, placenta and bone marrow .96
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F igure  1.9 : Aromatisation o f androgens to estrogens (I) Androstenedione or 
testosterone substrates (II) and (III) intermediates o f the reaction (IV) products o f  E l 
and E2.
AR represents the rate-limiting step in the production o f estrogen and expressed at a 
higher level in human breast cancer tissue than in normal breast tissue. This has been 
determined using enzyme activity measurement and immunocytochemistry. Cell 
culture, animal experiments using aromatase-transfected breast cancer cells, and 
transgenic mouse studies have demonstrated that in situ produced estrogen plays a 
more important role than circulating estrogens in breast tum our promotion. In addition, 
tum our AR has been shown to stimulate breast cancer growth in both an autocrine and 
a paracrine manner. Gene transcriptional studies have revealed that AR promoter 
switches from a glucocorticoid-stimulated promoter, 1.4, in normal tissue to cAMP- 
stimulated promoters, 1.3 and II, in cancerous tissue. Suppression o f in situ estrogen 
biosynthesis can be achieved by the prevention o f AR expression or by the inhibition 
o f AR activity in breast tumors.97 While the control mechanism o f AR expression in 
breast cancer tissue is not yet fully understood, AR-inhibitor therapy is considered for 
second-line treatment in patients who fail antiestrogen therapy. 20-30% o f the patients 
who fail antiestrogen treatment respond to AR-inhibitor treatment.
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1.11 Aromatase inhibitors
The benefits o f more recent therapies, such as the new generation o f AR inhibitors, 
appear to relate to better tolerability and more convenient administration. It is now 
recommended that the majority o f patients with advanced breast cancer should receive 
endocrine therapy and treated with an AR inhibitor as their first mode o f treatment, 
although it is postmenopausal patients who are likely to gain most benefit from this 
approach.
AG (1-13) (Figure 1.6) is the first AR inhibitor used clinically for HDBC. Because o f 
the similarity of the P450 enzymes, selectivity is important; nonselective AR inhibitors 
can affect enzymes controlling the production of other steroids and lead to significant
side effects. Since AG lacks selectivity to AR enzyme and inhibits several other P450
08enzymes, it is co administered together with a glucocorticoid. AG also possesses 
other side effects such as depression and rash, which limit its usefulness and hence 
came the second generation AR inhibitors such as rogletimide (1-22) and the most 






Figure 1.10 : 2nd Generation aromatase inhibitors
AR inhibitors represent a heterogeneous family of compounds able to provide more or 
less selective inhibition o f AR enzyme. Depending upon the way in which the inhibitor 
binds to the enzyme active site, AR inhibitors can be classified as Type I or suicide 
inhibitors, and type II inhibitors. The steroidal analogues compete rapidly with the 
substrate for the active site of the enzyme by initiating a time-dependent reactive 
process resulting in either covalent or very tight binding of the inhibitor to the enzyme
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and causing its inactivation. Because the reaction occurs at the enzyme active site, the 
inhibitors are quite specific and the compound also has lasting effects, since new 
enzyme synthesis is required to overcome this type of inhibition. Thus, the continued 
presence o f the drug to maintain inhibition is not necessary and the chance o f toxic side 
effects to the patient will therefore be reduced.
The steroidal derivatives plomestane (1-24), formestane (4-hydroxyandrostenedione) 
(1-25) and exemestane (6-methyleneandrosta-l,4-diene-3,17-dione) (1-26) are type I 
inhibitors, which bind to the steroid recognition site of the enzyme and hence activate 
the catalytic mechanism (Figure 1.11). The intermediate formed then covalently binds 
to the neighbouring amino acids leading to an irreversible inhibition o f the





Figure 1.11 : Type I aromatase inhibitors
Formestane is one of the first drugs on this type to be used clinically and has been 
demonstrated to be as effective as tamoxifen in first-line therapy, but reduces patient
i rn i mcomplience due to poor oral bioavailability. Due to its high first-pass metabolism, 
this drug is administered intramuscularly rather than orally. Formestane and 
exemestane have shown to reduce the circulating levels o f E l and E2 significantly, and 
have been shown to be active in 20% of patients pretreated with tamoxifen. Moreover, 
exemestane was also effective in patients pretreated with type II inhibitors, of which 
the parent drug is AG. Even though exemestane shown to be an effective AR inhibitor, 
the most commonly occurring adverse events such as nausea, hot flushes, fatigue, 
increased sweating and dizziness were observed.104 Formestane, the first selective AR
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inhibitor, has been shown to reduce serum estrogen concentrations and cause complete 
and partial responses in approximately 25% of patients with hormone responsive 
disease who have relapsed from previous endocrine treatment.105
The imidazole and triazole derivatives, anastrazole (Arimidex-Zeneca) (1-15), vorozole 
(1-27), letrozole106 (Femara-Novartis) (1-28), fadrozole (1-23) and miconazole are the 
third generation type II drugs, which are non-steroidal and compete reversibly with 
androestenedione for the enzyme active site (Figure 1.12). In these inhibitors, the basic 
nitrogen atom ligates with the iron atom at the centre o f the heam moiety o f the 
enzyme while the rest o f the structure o f the inhibitor aligns more or less closely with 











Figure 1.12 : Type II aromatase inhibitors
Anastrazole and letrozole are the first selective, oral and non-steroidal AR inhibitors, 
which are licensed for the treatment of advanced breast cancer in postmenopausal 
women, where tamoxifen or other antiestrogen therapy has failed. These inhibitors 
have recently been found to suppress plasma and urinary estrogens by more than 95% 
in breast cancer patients.101 Anastrazole and letrozole have both shown tolerability and 
efficacy advantages over standard treatments in postmenopausal women with advanced 
breast cancer. There are convincing reasons why the new generation o f AR inhibitors 
has advantages over tamoxifen. For instance, from their agonist properties, the effects 
on the endometrium and tumour stimulation seen with tamoxifen would not be 
expected, nor would the visual disturbances that have been associated with the 
triphenylethylene compounds, including tamoxifen. O f those AR inhibitors,
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anastrazole is now used widely in the UK, since it has been shown to be more
108effective, less toxic and better tolerated than the standard therapies used clinically.
1.12 Current Therapies in Development
The past decade has witnessed an accelerated phase in the development o f new drugs 
and strategies that have documented activity and/or a major interest in breast cancer. 
Apart from the conventional methods o f treatments employed, the newly emerged 
therapies have now broadly revolutionised. Researchers are concentrating more on the 
interception o f specific pathways of carcinogenesis and studying the various strategies 
associated with malignant-cell behaviors such as uncontrolled proliferation, 
unregulated cell division, cell survival/immortality, sustained angiogenesis, 
dissemination and metastasis.
1.12.1 Cyclin-Dependent Kinases and inhibitors
Recently, a cellular process has captured attention for therapeutic intervention. It is the 
inhibition of a key class of cell cycle proteins, cyclin-dependent kinases (CDKs) that 
control and drive the cell cycle and are present in the growing cell at constant 
concentration but much o f the time they are inactive. CDKs are enzymes that 
phosphorylate the serine and threonine amino acids using adinosine trisphosphate 
(ATP) and activate host proteins.109 For these kinases to be active they must first 
attached to a protein, cyclin.110 The progressions through the individual phases o f the 
cell cycle are indeed driven by CDKs.111 There are at least 9 CDKs and more than 
twelve different cyclin families have been identified so far.109 Normal cells undergo 
cell division at a controlled and limited rate. Malignant cells escape from the normal 
control mechanisms that regulate the rate and frequency at which they divide. It has 
been found that tumour cells appear to have unregulated CDKs, which trigger cell 
cycle progression and cell division. In addition, tumours have frequently lost the 
control over the prevention of replication o f defective cells.
The key CDK inhibitors are: (1) Tyrosine kinase inhibitors, such as the 3-substituted 
indolinone SU 5416 112 and the substituted anilinoquinazoline ZD 1839.109 (2) Fusudil,
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a diazepine developed as a vasodilator, which inhibits smooth muscle cell proliferation 
and DNA synthesis.109 (3) Staurosporine, a protein kinase C inhibitor.113 (4) 
Flavopiridol, a most advanced flavone currently in Phase II clinical trials.114 (5) 
Olomoucine, a dose-dependent inhibitor of the G l/S  phase and G2/M/G1 transitions in 
cell cycle.115 (6) Roscovitine, a second generation 2- and 9-substituted purine, which 
causes a complete cell cycle block116 and (7) Purvalanol B, which shows selectivity to 
CDK4/cyclin D1 in addition to other kinases.109
1.12.2 Oncogene targets and inhibitors
Cancer arises from the aberrant growth of cells that have sustained mutations in genes 
controlling cell proliferation and survival. The great majority of human breast cancers 
arises from epithelial cells and genetic analysis of tumour cells obtained from patients 
have revealed several commonly mutated genes. Determining the expression o f those 
genes and targeting and manipulating them is a new approach to the treatment.
1 I 7  1 I o
Mutations in the p53 tumour suppresser gene occur in majority o f the tumours. ’ 
Breast cancer also frequently carries mutations that deregulate the retinoblastoma 
protein (pRB) pathway including loss o f expression of pRBu9 or p ifi,NK4am 0r 
amplification or overexpression of cyclin D 1121’122>123 or cyclin E .124 Breast carcinoma 
cells also commonly acquire alterations in the ito.s'-signaling pathway,125 which may 
occur by several mechanisms, most notably amplification and overexpression o f the 
HER-2/neu gene.126 C-mycI18’127>128 and c-erbB-2u% genes are also frequently seen 
amplified or overexpressed. The deregulation o f Wnt expression patterns and
1 7 0  1 7 0
signaling, and bcl-2 expression also play a role in breast cancer
These individual genetic mutations have been catalogued in numerous breast 
carcinomas, none is involved universally in all human breast cancers, and the number 
o f mutant genes that coexist in the genome of a naturally arising breast tumour cell is 
unknown. As a consequence, it has been impossible to know how many mutant genes 
are required to convert a normal human mammary epithelial cell (HMEC) into a
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tumour cell. Therefore, extensive studies are being carried out at present to identify the
• • 130specific combinations of mutations required to form breast carcinoma cells.
It has been identified that 25% of patients with HER-2/neu-positive metastatic breast 
tumors respond favorably to trastuzamab (Herceptin) treatment.131 Weekly therapy 
with a combination o f trastuzumab and paclitaxel in women with HER-2-normal and 
//Ei?-2-overexpressing metastatic breast cancer showed significant activity. Although 
the therapy was relatively well tolerated, attention must be given to assess the cardiac 
function.132
1.12.3 Targeting telomerase enzyme and inhibitors
Telomeres are specialised DNA-protein structures consisting o f a large number of 
tandem repeats of TTAGGG at the end o f eukaryotic chromosomes; these are lost with 
each cell division and the telomere becomes short in length.133 In this way, the length 
o f the telomere indicates its age to the cell. The cell is programmed so that, after a 
certain number o f divisions and shortening o f telomeres causing chromosomal 
instability, it will enter apoptosis.134 Telomerase is a ribonucleoprotein complex with 
reverse transcriptase activity, which adds telomeric repeats to the 3’ end o f telomeric 
DNA. Tumour cells contain an abundance o f telomerase, which is specifically
1 35activated in most malignant tumours but is usually inactive in normal somatic cells. 
Telomerase enzyme causes the aging telomeres to re-grow. This telomere stabilisation 
by telomerase can lead to unlimited cell proliferation.136 Thus, the cell escapes the 
controls that regulate ageing and prevent defective cells from multiplying and dividing 
indefinitely.
Human telomerase reverse transcriptase (hTERT), which has been purified as human 
telomerase catalytic subunits, regulates telomerase activity. Recent observations 
support the notion that telomerase expression is essential for the formation o f human 
tumor cells. The expression pattern of hTERT is a rate-limiting determinant o f the 
enzymatic activity of human telomerase.138
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Retinoic acid and its analogues, such as all-trans retinoic acid, 9-cis retinoic acid and 
13-cis retinoic acid, were shown to be effective inhibitors of telomerase activity in 
human breast cancer MCF-7 cells in a wide range of concentrations investigated.139(a) 
The inhibition was preceded by a reduction of hTERT mRNA expression indicating 
that the anti-breast cancer activity of retinoic acid could be mediated by its ability to 
down-regulate the expression of hTERT telomerase gene.139,140 Also, a time-dependent 
and consistent decrease of telomerase activity in the tumours was observed with 4-
QO
(hydroxyphenyl)retinamide, a known inhibitor o f mammary carcinogenesis. A DNA- 
methylating prodrug, temozolomide, has also exhibited antitumour activity and has 
been selected for clinical trials.141 Therefore, in addition to the percentage of 
proliferating cells, telomerase activity could also be used as an endpoint in breast 
cancer chemotherapy.
1.12.4 Tumour vasculature as a target and inhibitors
Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been 
reported to be associated with a poor prognosis in primary breast cancer and in several 
other cancer types. Angiogenesis inhibition is an extremely promising novel approach 
in cancer prevention, because tumours are dependent on the formation o f new blood 
vessels to support growth and metastasis. Many tumours produce large amounts of 
VEGF, which signals normal blood vessels to grow. Binding of VEGF to its receptors 
activates signal-transduction pathways, which results in the formation o f new blood 
vessels that supply the tumour with nutrients and oxygen.
VEGF-C is a specific ligand that induces lymphangiogenesis and determines the 
progression of breast cancer. Immunohistochemical analysis revealed that VEGF-C 
was overexpressed in 40% of breast cancer specimens, but not in adjacent normal 
mammary glands.142 VEGF levels were not related to age or menopausal status but 
were negatively related to the cytosolic levels o f ER and PR.143 Patients with high or 
intermediate levels o f VEGF usually show a poor rate of response, compared with 
patients with low tumor-VEGF levels. Higher levels o f VEGF were also associated 
with a short progression-free survival and post-relapse overall survival.143 Therefore,
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tumor VEGF level in a patients is an important independent marker that helps selecting 
individual patients who may benefit from treatments with antiangiogenic agents 
combined with conventionally used drugs.
Recent studies have revealed that silymarin, a naturally occurring flavonoid 
antioxidant, exhibits anti-cancer effects against several epithelial cancers. Silymarin 
resulted in a dose-dependent decrease in the secreted VEGF level in conditioned media 
without any visible change in cell morphology.144 Vitamin E succinate, the most potent 
antitumour analogue of vitamin E, was found to inhibit VEGF gene expression in 
MDA-MB-231 cells and involves in the inhibition o f tumor angiogenesis hence inhibits 
the growth of breast cancer cells in vitro and in vivo.145 Thalidomide is another agent 
inhibited the processing o f mRNA encoding peptide molecules including tumour 
necrosis factor-alpha (TNF-alpha) and the angiogenic factor VEGF. 146 It has also been 
reported that tamoxifen could also be used since VEGF expression was significantly 
correlated with estrogen receptor status and inversely correlated with tumour grade.147 
These agents potentially possess antiangiogenic ability that may critically contribute to 
its cancer chemopreventive efficacy.
1.12.5 Cyclooxygenase 2 as a target and inhibitors
Cyclooxygenase-2 (COX-2) is the rate-limiting enzyme in the conversion o f 
arachidonic acid to prostaglandins and into several metabolites, some o f which have 
been identified as modulators o f mitogenesis and apoptosis.148 Elevated prostaglandin 
production is a common feature o f human malignancies. This activity has often been 
attributed to increased metabolic activity of the COX-1 and COX-2 enzymes. COX-2 is 
highly expressed in a number o f human cancers and cancer cell lines. COX-2 is only 
expressed in tumours resulting from the transplantation of metastatic cell lines whereas 
COX-1 is detected in both metastatic and nonmetastatic tumors.149
Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic 
mucosa, its activity increases dramatically following mutation of the APC 
(adenomatous polyposis coli) gene suggesting that beta-catenin/T-cell factor mediated
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Wnt-signaling activity may regulate COX-2 gene expression. In addition, hypoxic 
conditions and sodium butyrate exposure may also contribute to COX-2 gene 
transcription in human cancers.
The development of selective COX-2 inhibitors has made it possible to further evaluate 
the role of COX-2 activity in colorectal carcinogenesis. The recent marketing o f two 
selective COX-2 inhibitors, celecoxib and rofecoxib is remarkable considering that 
COX-2 was only discovered eight years ago as a growth factor- and cytokine- 
inducible gene.150 Studies indicate that the use of non-steroidal anti-inflammatory 
drugs (NSAIDs) may enhance the antitumour activity of cancer chemotherapeutic 
agents and reduce the risk o f many cancers. The best-known function o f NSAIDs is to 
block the COX-1 and COX-2 enzymes by altering the metabolism o f arachidonic acid 
and, subsequently, prostaglandins.151 Recent studies have revealed that nearly complete 
inhibition of prostaglandin synthesis and cell growth occurs in the presence of either 
indomethacin, which inhibits both COX-1 and COX-2 isoforms, or NS 398, which is 
selective for the COX-2 isoform .149 It is now anticipated that pre-treatment with 
selective COX-2 inhibitors may be useful in the prevention o f multi-drug resistance in 
response to cancer chemotherapy.
1.12.6 Immunotherapy of breast cancer
Triggering the immune system to attack malignant diseases, such as breast cancer, 
involves three main approaches. The first is the passive immunotherapy, which 
involves the administration of antibodies such as Herceptin or T-lymphocytes with 
defined specificity. A second approach is based on the transfusion of donor 
lymphocytes to patients in whom a chimerism has been obtained following a previous 
allogenic bone marrow transplantation; injection of T-lymphocytes may be capable of 
killing residual tumour cells. A third strategy attempts to induce an immune response 
against cancer cells in vivo using various immunogens, such as HER-2 or MUC-1 
peptides, dendritic cells loaded with tumour peptides, tumour lysates or RNA and 
autologous or allogenic tumour cells genetically modified to increase their 
immunogenicity.152
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The other recent therapeutic approaches behind uncontrolled proliferation, unregulated 






Sulphatases are a group o f hydrolytic enzymes that catalyse the conversion o f various 
sulphated compounds to their various unconjugated derivatives (Figure 2.1). To date, 
eleven different mammalian sulphatases, such as galactose-3-sulphatase 
(Arylsulphatase A or ASA), 7V-acetylgalactosamine-4-sulphatase (Arylsulphatase B or 
ASB or 4-S), steroid sulphatase (STS), arylsulphatase C, arylsulphatase D, 
arylsulphatase E, arylsulphatase F, A-acetyIgalactosamine-6-sulphatase (GAL6 S), N- 
acetylglucosamine-6-sulphatase (GLU6S), iduronate sulphatase and sulphamidase have 
been identified, eight o f which are in lysosomes and three are associated with 
microsomal membranes.153 Nine members o f this family o f enzymes have been isolated 
in the humans and the corresponding encoding genes have also been identified.
i? Sulphatases 
R O -S -O H  ------------------- ►  R -O Hii
O
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Figure 2.1 : General reaction catalysed by sulphatase family
The natural substrates of human sulphatases have varying degrees o f structural 
complexity, from simple aromatic molecules such as j^-nitrocatechol and 4- 
methylumbelliferyl sulphate to more complex molecules such as 3-hydroxysteroid 
sulphates and glycosaminoglycan sulphates. Sulphated glycosaminoglycans, 
glycolipids, glycoproteins and hydroxysteroids are hydrolysed by a group of 
sulphatases, each o f which has exquisite specificity towards its individual substrate in 
vivo. E l-STS is a microsomal enzyme, which removes the sulphate group from 
sulphate esters of phenol or 3/?-hydroxysteroids.154 All these sulphatases whose 
sequences have been determined so far show that the amino acid residues at their 
respective active sites are conserved. 155
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STS and aryl sulphatases A, B and C are from distinct subgroup of human sulphatases 
that possess similar hydrolytic activity toward aryl sulphates. Recently, many studies 
have focused on the study of STS, the enzyme that regulates the levels o f active 
estrogens and androgens in human target organs and steroidogenic tissues. STS has 
been suggested to play a key role in endocrine-related diseases such as breast, 
endometrium and prostate cancers. Aryl sulphatase A and B are lysosomal enzymes, 
hydrolysing cerebrozide sulphates and dermatan sulphates, respectively. Aryl 
sulphatase C and STS are located in microsomes and act on 3-hydroxysteroid 
sulphates.
Different inherited diseases are known to be caused by a deficiency o f distinct 
sulphatases leading to a tissue specific accumulation o f the non-degradable sulphuric 
acid ester. Deficiency of ASA leads to metachromatic leukodystrophy (MLD). A 
reduced level of ASB leads to Hunter syndrome (mucopolysaccharidosis II), a rare X- 
linked disorder of mucopolysaccharide metabolism that typically progresses to severe 
mental retardation.156 Mucopolysaccharidosis (MSP) type VI is a lysosomal storage 
disease with autosomal recessive inheritance involving degradation o f dermatan 
sulphate and chondroitin 4-sulphate.157 Morquio disease (MPS IVA) is an autosomal 
recessive disorder caused by a deficiency of V-acetylgalactosamine-6-sulphatase 
activity, where patients commonly present in early infancy with growth failure, but 
milder forms have also been described.158 Deficiency o f all known sulphatases leads to 
a rare disorder multiple sulphatase deficiency (MSD), which is caused by the failure of 
an essential post-transjational modification of a specific active site cysteine residue to 
oxo-alanine (formylglycine-FGly) 159,160 (Scheme 2.2).
Previous studies have indicated that aryl sulphatase C and STS are distinct enzymes 
encoded by different genes and have different electrophoretic mobilities.161 However, 
transfection of the cDNA encoding for the placental STS in to COS-1 cells resulted in a 
protein that hydrolyses both phenolic and 3/?-sulphated steroids suggesting that they 
are both the same enzymes, a transmembrane protein located in the endoplasmic
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reticulum (Er) and consisting of 587 amino acids.154,162
STS play a major role in steroid metabolism. They are involved in the regulation of
1
many physiological processes such as hypertension, immune response, some 
reproductive functions, the formation of neurosteroids in the CNS and memory 
enhancement.164 STS deficiency was found to associate with allergic diseases 
(bronchial asthma, allergic rhinitis, or atopic dermatitis) .165 STS is also suspected to be 
the cause o f the complex syndrome associating hypogonadotrophic hypogonadism, X- 
linked ichthyosis and renal malformation. The absence of the gene encoding STS 
accounts for the genetic disorder, X-linked ichthyosis, whereas the absence o f the 
Kallmann syndrome gene accounts for hypogonadism .166 X-linked ichthyosis causes 
the accumulation of STS in various organs and cells and causes early puberty. Serum 
STS levels start to increase in early infancy, peak at puberty, remain elevated in adults
1 f \ land decrease slightly in the elderly.
2.1 The role of steroid sulphatase in estrogen synthesis in breast cancer
In premenopausal women, the ovaries provide the major source of estrogens (E2 and 
E l). These hormones are synthesised in the granulosa cells o f the ovarian follicles from 
androgens (testosterone and androstenedione for E2 and E l, respectively). In 
postmenopausal women, with the cessation o f ovarian activity, estrogens continue to be 
produced from the adrenal glands via the aromatisation o f androstenedione to E l by the 
AR enzyme complex, which is present in the peripheral tissues such as muscle, adipose 
and in normal and malignant breast tissues.14,13,15 It is therefore anticipated that patients 
with HDBC should benefit from estrogen ablation elicited by an effective inhibition of 
the AR enzyme. As a result, a large number of AR inhibitors have been produced and 
some o f them are now in clinical use. However, anastrazole (1-15) (Figure 1.6, Chapter 
1), a potent AR inhibitor was recently evaluated in a phase III clinical trial in patients 
with ER+ tumours has shown a very disappointing 11% overall response rate.168 This 
raises the question if estrogen ablation by inhibiting AR alone will be sufficient.
It is known that much o f the E l formed is converted by estrone sulphotransferase (E l-
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ST) to the biologically inactive estrone sulphate (E1S), which circulates in blood at a 
much higher concentration (1 nmol/1)169 than the other unconjugated El or E2 (30-100 
pmol/1). The half-life o f  E1S (10-12 hrs) in blood is considerably longer than that o f  El 
(20-30 min).170 The concentration of  E1S in breast tissues is also higher than El or 
E2.171 Therefore, it is likely that E1S in plasma and tissues act as a reservoir for the 
formation of unconjugated estrogens after it has been hydrolysed by E l-S T S .172 The 
activity o f  this enzyme is much higher than that for AR in both normal and malignant 
breast tissues. Also, the formation of  El in breast tumours via the STS pathway 
provides at least 10 times as much El as that originates from the AR pathway. This 
constitutes the major source of breast tumour estrogens,173 accounting for the high 
concentrations of estrogens detected in such tissues (Figure 2.2).
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Figure 2.2 : The origins of  estrogenic steroids in postmenopausal women
In postmenopausal women it has now been recognised that another major circulating 
steroid, androstenediol (Adiol) has estrogenic properties. Although Adiol is an 
androgen, it can bind to the ER and can stimulate the growth of  ER+ breast cancer cells 
and also carcinogen-induced mammary tumours in the rat.174175 There is now strong 
evidence to suggest that Adiol may be of  even greater importance as a promoter of
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breast tumour growth.174 Therefore, stimulation of the AR alone is insufficient to 
destroy all estrogenic stimuli.
About 90% of Adiol produced in postmenopausal women originate from 
dehydroepiandrosterone sulphate (DHA-S), which is secreted in large amounts by the 
adrenal cortex. Two pathways can be envisaged (Figure 2.2). First, DHA-S is 
hydrolysed to DHA by DHA-sulphatase (DHA-STS), with subsequent metabolism o f 
DHA to Adiol. Alternatively, DHA-S is converted to androstenediol sulphate (Adiol-S) 
with subsequent hydrolysis to Adiol. Although the affinity o f Adiol for ER is lower 
than that of E2, plasma Adiol concentrations are 100-times higher than those o f E2,
176 177adding further evidence for DHA-S being the major source of plasma Adiol. ’ 
Therefore, estrogenic stimulation o f hormone dependent breast carcinoma can be 
reduced not only by inhibiting the hydrolysis o f E1S but also the production of Adiol 
from DHA-S. Since there is strong evidence to suggest that El-STS and DHA-STS are 
the same enzyme,162 inhibitors o f STS are potential agents for the treatment o f HDBCs 
when used alone or in conjunction with an AR inhibitor.
2.3 Development of steroid sulphatase inhibitors
Among all the identified functions o f STS enzymes, regulation o f estrogen synthesis in 
hormone-dependent tumours has been the main one for the development o f potent STS 
inhibitors. Danazol (2-1) (an isoxazole derivative of 17/?-ethinyltestosterone) (Figure
2.3), which was originally synthesised by Carlstrom178 as an inhibitor o f the conversion 
of E l to the more potent E2 by the 17/THSD, was one o f the first synthetic compounds 
shown to be able to inhibit STS activity weakly in human liver and breast tumour 
tissues (62% at 10 /jM  in MCF-7 cells) .179
Danazol
2-1
Figure 2.3 : Structure of Danazol
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Following the activity observed for Danazol, several steroidal and non-steroidal drugs
currently used clinically for endocrine disorders were tested for their ability to inhibit
STS enzyme. Antiestrogens, 180 such as tamoxifen and 4-hydroxytamoxifen, and
181 *progestogens and their derivatives such as demegestone, chlormadinone acetate, 
medroxyprogeterone and promegestone were found to be weak inhibitors o f STS. 
These findings and the recognition of the pivotal role o f STS enzyme in HDBC have 
encouraged the synthesis and development of other biologically active and potent 
inhibitors.
Initial studies in developing STS inhibitors revealed that steroid sulphates could not be
ideal candidates for sulphatase inhibition and a greater degree o f inhibition was
182observed with androstenediol-3-sulphate (2-2), which had a Kj value o f 2 //M 
(Figure 2.4). However, a major disadvantage with steroid sulphates is that they also act 
as substrates for the enzyme, though active in vitro, their sulphate group is liable to be 
hydrolysed in vivo releasing the biologically active unconjugated steroids as a
183consequence.
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Figure 2.4 : Structure o f androstenediol-3-sulphate
A series o f estrone-3-sulphonyI derivatives (2-3) was reported to inhibit STS enzyme 
with the sulphonyl chloride derivative being the best inhibitor achieving a 65% 
inhibition at 60 /uM in placental microsomes184 (Figure 2.5). Although 2-3 could have 
inactivated the enzyme via sulphonylation, preliminary results showed that other 
derivatives are only weak competitive inhibitors in this series.184,185 Cox et al in an 
attempt to generate antisera that are reactive towards E1S has observed that the 
antibodies, which recognise estrone-3-O-methylthiophosphonate (El-M TP) (2-4), also
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recognise E1S186 (Figure 2.5). When El-M TP was incubated with liver or placental 
tissues, El-M TP was found to be resistant to metabolism, whereas at least 50% of E1S 
incubated in a similar manner, was converted to E l. This observation suggested that 
El-M TP was not an alternative substrate for STS. Since it structurally mimics E1S and 
its MTP moiety acts as a sulphate group surrogate, and hence El-M TP is a competitive 
inhibitor.187 El-M TP was found to be 14 times more potent than Danazol in inhibiting 
El-STS activity in intact MCF-7 breast cancer cell with a Kj value of 37.5 /jM  (IC50 = 
43 juM in placental microsomes) .188
In vivo, E l-M TP was found to lower the plasma concentration o f E2 in treated rats by
188at least 50% suggesting that El-M TP is an active competitive inhibitor. When 
tissues are isolated and homogenised, the inhibitor concentration may be reduced at the 
enzyme active site. Thus it is quite difficult to demonstrate inhibition in tissues 
obtained from animals treated with El-M TP. However, some evidence was obtained to 
show inhibition in vivo. Plasma E2 concentrations were measured in samples obtained 
from treated (1 mg/Kg per day for 7 days s.c.) and untreated animals, which showed 
that the plasma E2 concentration was about 50% lower in treated animals, suggesting 
that El-M TP is active in vivo.
RO
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S 0 2C1 = Estrone-3-sulphonyl chloride 2-3
PS(Me)OH = Estrone-3-Omethylthiophosphonate (El-M TP) 2-4
Figure 2.5 : Structures o f the sulphate derivatives o f estrone
Since this finding, other E1S analogues with sulphate surrogates, such as, 
phosphates176,189,190 (2-5), phosphonates191 (2-6), sulphonates192 (2-7), estrone-3-0- 
methyl sulphonate189 (2-8), estrone-3-methylene sulphonate176 (2-9),
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thiophosphonates188,191 (2-10) and DHA-3-O-phosphate189 (2-13) were synthesised 
(Figure 2.6).
R
0 P 0 32- = Estrone-3-O-phosphate 2-5
OPO (H)0' = Estrone-3-(3-//-phosphonate 2 -6
0 S 0 2‘ = Estrone-3-O-sulphonate 2-7
OSO2CH3 = Estrone-3-O-methylsulphonate 2 -8
CH2S 0 3- = Estrone methylene sulphonate 2-9
SPO(H)0‘ = Estrone-3-S’-phosphonate 2 -1 0
Figure 2.6 : Structures o f the sulphate derivatives o f estrone
Estrone-3-O-phosphate189,176,190 (2-5) was found to be relatively potent with a Kj value 
o f 0.89 //M 189and 0.3 /zM176 at pH 7.0. Anderson and his colleagues synthesised several 
phosphorylated steroids with geometries closely related to El S .189 These phosphate 
esters are all good reversible inhibitors o f STS, binding with an affinity that is better 
than that o f the natural substrate E1S (2-11), but no hydrolysis o f the inhibitors was 
observed. In 2-11, a putative enzyme active site base acts to deprotonate an incoming 
water molecule (Figure 2.7 B). The peripheral OH group o f the phosphate monoanion 
o f 2-5 is probably well situated to mimic the incoming water molecule and makes a H- 
bond to the active site base (Figure 2.7 A). Such a combination results in a very strong 
H-bond and hence a strong inhibition o f the enzyme.
O f all the analogues synthesised in this series, the monoanions o f steroidal phosphates 
2-5 bind to the STS with exceptional affinity by engaging in H-bonding (Kj = 170 nM 
at pH = 6.0), whereas the singly charged estrone phosphofluoridate (2-12) has only H- 
bond accepting components. Unlike the phosphate ester monoanions, 2-12 cannot 
donate an H-bond to an enzyme active site amino acid residue. Therefore, it binds with
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180 •a much lower affinity than the-phosphate ester (Kj = 14.7 /jM  at pH = 6.0). This 
observation indicated that phosphates largely exist as monoanions at neutral pH and 
serve as better STS inhibitors than do sulphates.
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Figure 2.7 : Structures of the phosphate ester derivatives and the mechanisms of 
enzyme-catalysed reaction A and B.
Estrone-3-0-//-phosphonate189 (2-6) showed a 80% El-STS inhibition at 10 juM in 
MCF-7 cells.190 Estrone-3-methylene sulphonate176 (2-9) showed a 100 fold increase in 
inhibition than E1S indicating that the bridging O atom in E1S is essential for high 
affinity binding. Estrone-3-O-methyl sulphonate (2-8) and DHA-3-O-phosphate189 (2- 
13) (Figure 2.8) were found to be relatively weaker inhibitors than El-3-O-phosphate 
(2-5).
- 0 P 0 20 ’
Dehydroepiandrosterone-3-O-phosphate
2-13
Figure 2.8 : Structures o f dehydroepiandrosterone-3-O-phospahate
Other derivatives o f steroid sulphate have also been synthesised by various groups 
around the world and tested for their sulphatase inhibitory properties and some indeed 
showed interesting activities, which have been tabulated in Table 2.1.
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E 1 -3-0-phenylphosphoramidate (2-19) 32
Table 2.1 : Inhibition o f El-STS activity in MCF-7 cells by various derivatives of 
estrone sulphate.191,176
2.4 Development of steroid sulphamates
All the derivatives of E1S synthesised, including El-M TP, provided with some 
indication of the type of derivatives, which may be useful as steroid sulphatase 
inhibitors. The first steroid sulphatase inhibitor discovered with highly potent 
biological activity was estrone-3-O-sulphamate (2-20) (EMATE) (IC50 in MCF-7
1 87breast cancer cells = 65 pM and 25 nM in human placental microsomes) (Figure 
2.9).
EMATE inhibits over 99% of El-STS activity in intact MCF-7 cells at 0.1 //M and it is 
an active site-directed inhibitor showing time- and concentration-dependent 
inactivation of the enzyme. It is also highly potent in vivo against rat liver El-STS and 




Figure 2.9 : Structure o f estrone-3-O-suIphamate
Various analogues of EMATE were synthesised, where the NH2 protons were 
methylated and the bridging O atom was replaced with other heteroatoms such as 
sulphur or nitrogen. The V-monomethylated (2-21) and V.V-dimethylated (2-22) 
derivatives o f EMATE, whilst still more potent than El-M TP, are less potent than
EMATE in inhibiting sulphatase activity (79% and 52% inhibition at 0.1 /uM
1 0^respectively in MCF-7 cells). These compounds showed a weak, non-time dependent 
inhibition of E l-ST S.194 Derivatives such as estrone-3-sulphamide (2-23), estrone-3-S- 
sulphamate (2-24) and estrone-3-S-(V,V-dimethyl)sulphamate (2-25) were all found to 
be weak non-time dependent inhibitors194 (Figure 2.10). These weak inhibitory 
activities shown by these heteroatom containing derivatives o f EMATE have suggested 
that the bridging O atom in the sulphamate group might involve in the binding o f the 
inhibitor to the enzyme active site via H-bonding and that the leaving group ability of 
the parent steroid might play an important role in the inactivation of the enzyme.
Woo et al]95 acylated the N atom on the sulphamoyl group and also replaced all its 
protons with large alkyl groups. It was found that the V-acylated derivative (2-26) is an 
irreversible inhibitor, but less potent than EMATE, whereas the V-benzylated 
derivative, MA-dibenzyl sulphamate (2-27), 3-(?-AL(piperidino)sulphamate (2-28) and 
the 3-0-(V-benzoyl)sulphamate (2-29) are weakly reversible inhibitors (Figure 2.10).
Extensive structure-activity studies on EMATE and other related compounds have 
confirmed that the sulphamoyl group attached to an aryl ring is the active 
pharmacophore required for potent inhibition of steroid sulphatase activity.196 It has
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also been shown that the bridging O atom between the steroid nucleus and the 
sulphamoyl group is indispensable for the inhibitory activity o f EMATE and the NH2 
protons on the sulphamoyl group are also important for El-STS inhibition.
Even though EMATE is a potent sulphatase inhibitor, it has been shown recently to be 
highly estrogenic and hence EMATE in principle is unlikely to be developed for use in 
the clinical treatment o f hormone dependent cancers in women. It is about five-times 
more active than the synthetic estrogen, ethinylestradiol on oral administration to 
rats.197 Although the real reason is yet to be elucidated, current evidence suggests that 
in the body EMATE is acting as a prodrug o f estrone. Since the endocrine dependent 
tumours of the breast and endometrium are sensitive to E l, EMATE is unsuitable for 
use as an endocrine therapeutic agent.
R
o s o 2n h 2 = Estrone-3-O-sulphamate (EMATE) 2-20
0 S 0 2NHMe = Estrone-3-0-(7V-methyl)suIphamate 2-21
0 S 0 2NMe2 = Estrone-3-(9-(A(A-dimethyl)sulphamate 2-22
n h s o 2n h 2 =. Estrone-3-sulphamide 2-23
s s o 2n h 2 = Estrone-3-S-sulphamate 2-24
S S 0 2NMe2 = Estrone-3-S-(A,A/-dimethy])sulphamate 2-25
o s o 2n h c o c h 3 = Estrone-3-(3-(7V-acetyl)sulphamate 2-26
0 S 0 2N(CH2Ph)2 
/ --- \
= Estrone-3-0-(A(iV-dibenzyl)sulphamate 2-27
o s o 2n ^ J > = Estrone-3-0-7V-(piperidino)sulphamate 2-28
0 S 0 2N HC0Ph = Estrone-3-0-(A-benzoyl)sulphamate 2-29
Figure 2.10 : Derivatives of EMATE
Although, EMATE has been developed primarily for use in the treatment o f HDBC, it 
has also been shown to have memory-enhancing effects in rats by inhibiting the 
conversion of dehydroepiandrosterone sulphate (DHA-S) to dehydroepiandrosterone
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108  • • (DHA) suggesting an application in Alzheimer’s disease. It’s super-estrogemcity
can be further explored in therapeutic areas such as oral contraception and hormone
replacement therapy (HRT) .199,200 In addition, EMATE might have a role in regulating
the immune response since studies in mice have suggested a role o f DHA-STS activity
in regulation of part of the immune response • and such a relationship may also be
found in humans. Whilst agents clinically used for Alzheimer’s disease and HRT
targets elderly patients, STS inhibitors as regulators o f immune response may have to
be administered from an early age. It is thus anticipated that a potent orally active
irreversible non-steroidal El-STS inhibitor, which is metabolically stable and devoid
of estrogenic activity will have much wider clinical applications than their steroidal
counterparts.
Other estrone derivatives such as 3-aminoestrone (2-30) and 3-thioestrone (2-31) were 
synthesised by Selcer and L.i in order to investigate whether these STS inhibitors are 
converted in to any estrogenic metabolites in vivo203 (Figure 2.11). When tested in 
ovariectomised rats on growth o f the rat uterus, these compounds were found to be well 
tolerated in vivo at up to 100 //g/day and had no effect on uterine growth, indicating 
they are non-estrogenic. Also, they were found to be non-antiestrogenic, since they did 
not block the ability of E2 to stimulate uterine growth.
R -  NH2 2-30
SH 2-31
Figure 2.11 : Derivatives o f estrone
A large number o f A and D ring modified EMATE derivatives were also synthesised 
and tested for El-STS activity since it has been shown previously that C-2 and/or C-4 
substituted and D-ring modified estrogens are less estrogenic than their parent 
compounds.204,205 O f all the A-ring modified analogues synthesised, the 2/4-allyl- 
EMATEs (2-32, 2-33, 2-34) are more potent than the 2/4-alkyl analogues (2-35, 2-36, 
2-37), but they were all less potent than EMATE in placental microsome
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preparations.206 In contrast, the 4-nitro EMATE (2-39) was more potent than its 2-nitro 




2-Allyl EMATE (2-32) 2.5
4-Allyl EMATE (2-33) 9.0
2,4-Diallyl EMATE (2-34) >100
2-tt-Propyl EMATE (2-35) 29
4-rc-Propyl EMATE (2-36) > 100
2,4-Di-tt-propyl EMATE (2-37) >100
2-Nitro EMATE (2-38) 0.07
4-Nitro EMATE (2-39) 0.0008
2-MeOEMATE (2-40) 0.003
2-EthylEMATE (2-41) 2.4
2-BromoEMATE (2-42) 12.6x l 0"6
2-IodoEMATE (2-43) 0.0009
Table 2.2 : IC50 values of some A-ring modified EMATEs in placental microsomes
Earlier studies have also shown that an oxygen atom or at least a sterically or 
electronically similar link between the steroid ring and sulphonate moiety is essential 
for higher affinity towards the STS enzyme. Selcer et al designed and synthesized a 
series o f estrone-3-amino derivatives as potential El-STS inhibitors207 and tested their 
inhibitory potential using human placental microsomes, which contain a substantial 
amount of El-STS activity. Several compounds (Figure 2.12) in the series significantly 
inhibited El-STS activity of the human placental microsomes at 10 /uM. The IC50 of 
these compounds ranged from 8.7 to 14.6 juM, the most potent being compound 2-45. 
They also tested the ability of these amino derivatives to inhibit growth o f the estrogen-
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dependent MCF-7 breast cancer cell line, where they showed substantial proliferation 
in the presence of 100 nM E1S in estrogen-free media, indicating that the cells were 
capable o f converting E1S into E l .207
R = NHS02CF3 2-44 
N(CF3S 0 2)2 2-45
NHCOCFj 2-46 
NHCONH2 2-47
Figure 2.12 : Amino derivatives of estrone
There is currently a considerable interests in the role that 2-methoxyestrone (2- 
M eO El) (2-48) and its endogenous estrogen metabolite, 2-methoxyestradiol (2- 
MeOE2) (2-49) may have for development as a therapy for ER+ and ER' mammary 
tumours (Figure 2.13). 2-MeOE2 has been shown to inhibit in vitro angiogenesis and 
the growth of MDA-MB-435 ER- breast cancer cells in vivo, which may be due to its 
ability to inhibit tumour-induced angiogenesis. (See Chapter 6)
2-Methoxyestrone-3-(2-sulphamate (2-MeOEMATE) (2-40) and 2-methoxyestradiol-3- 
O-sulphamate (2-MeOE2MATE) (2-50) synthesised in our group were found to be 
potent non-estrogenic El-STS.inhibitors (Figure 2.13). 2-MeOEMATE was equipotent 
with EMATE as a steroid sulphatase inhibitor, but was found to posses potent anti­
mitotic properties, suggesting that it will be suitable not only for ER+/ER" breast 
cancers, but also for other types o f cancers.208 In addition, other 2-substituted 
compounds, such as 2-ethyl (2-41), 2-bromo (2-42) and 2-iodo (2-43) EMATEs were 
also found to be potent inhibitors of El-STS and also inhibited angiogenesis 
(Unpublished results) (Table 2.2). The most potent inhibitor being the 2-bromo 
analogue about 317 times more active than EMATE and the 2-iodo derivative was 

















Figure 2.13 : 2-Methoxy derivatives of estrone and EMATE
Apart from A ring modified derivatives, modifications at other positions of the estrone 
molecule have also been carried out. The estradiol derivatives with substituents at the 
17a-position, synthesised by Ciabanu et al were found to be potent STS inhibitors in 
vitro?09 Hence, 17a-benzylestradiol (2-51) and (4’-fer/-butylbenzyl)estradiol (2-52) 
inhibit STS activity with IC50 values of 0.39 nM and 0.15 nM respectively, probably 
due to interactions of their 17a-substituents with a hydrophobic pocket around the 
region o f the enzyme active site (Figure 2.14). Unlike EMATE, which is an active site
directed irreversible inhibitor o f El-STS these sulphamoylated derivatives of E2 are
210only reversible inhibitors. Further analogues in the series with an rc-octyl group (2- 
53), alkyl amide (2-54) and alkyn amide side chain (2-55) at the 17a position of 
estradiol were also found to be potent STS inhibitors with IC50 values of 0.44 //M, 0.08 
juM and 0.35 juM respectively.211 The increase in potency observed may be due to 
effective binding at the enzyme active site as a result o f an increase in hydrophobicity. 
The amide group is expected to block the activation o f the ER effectively.
h 2n s o 2o





h 2n s o 2Q'
R = -C O N H (C H 2)6CH3 2-56
2-54 -N H C O (C H 2)6CH3 2-57
2-55
Oct
Figure 2.14 : 17-Substituted derivatives o f estrone and EMATE
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17/?- substitued alkyl carbamoyl (2-56) and A-alkanoyl derivatives o f EMATE (2-57) 
synthesised by Li et al contains all the required structural features for a potent STS 
inhibitor were found to inhibit. El-STS with IC50 values in the range o f 0.5 nM (Figure 
2.14). These compounds were also shown to be devoid of estrogenicity when compared 
with EMATE .212
2.5 Development of non-steroidal sulphatase inhibitors
With the drawback o f EMATE being a ‘super-estrogen’, and the potential 
endocrinologically active metabolites o f steroidal inhibitors, much focus over the years 
has been on the development of non-steroidal sulphatase inhibitors which themselves 
or through their metabolites are unlikely to possess any undesirable endocrinological 
effects.
The first series of non-steroidal steroid sulphatase inhibitors was based upon 5- 
acetoxy-3-(4-acetoxyphenyl)-l-ethyl-3-methylindole, which was originally designed as 
a new class o f mammary tumour inhibitors. Birnbock and von Angerer synthesised 
mono- and bis- sulphate derivatives of 2-phenylindoles and one of the compounds 3- 
methyl-l-pentafluorophenylmethyl-6-sulphooxy-2-(4-sulphooxyphenyl)-4-trifluoro 
methylindole, disodium salt (2-58) was found to be a competitive sulphatase inhibitor 
with an IC50 value of 80 /uM in homogenate of calf uterus (Figure 2.15). However, this 
sulphate was shown to be hydrolysed to free phenols upon incubation with the steroid 
sulphatase.213
Cp3 c h 3
F F
2-58
Figure 2.15 : Structure o f 3-Methyl-l-pentafluorophenylmethyl-6-suIphooxy-2-(4- 
sulfooxyphenyl)-4-trifluoromethylindole, disodium salt
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Dibbelt and Kuss reported the sulphatase inhibitory activities o f several 4,4’- 
substituted stilbene-2,2’-disulphonate derivatives o f which 4,4’- 
dibenzoylaminostilbene-2,2’-disulphonate (2-59) was the most potent inhibitor with a 
Ki o f 3 n U 'si (Figure 2.16).
Figure 2.16 : Structure o f 4,4’-dibenzoylaminostilbene-2, 2 ’-disulphonate
The first series o f non-steroidal inhibitors synthesised in our group was based upon 
tetrahydronaphth-2-ol (THN) and diethylstilbestrol (DES) derivatives, which are 
presumably A/B- and A/D- ring mimics o f EMATE, respectively (Figure 2.17). Three 
sulphamate derivatives of THN were synthesised o f which the N,N- 
dimethylsulphamate (2-63) derivative was inactive in vitro when tested at 10 juM. The 
THN-sulphamate (2-61) was the best inhibitor in the series with an inhibitory activity 
o f 15-79% over the 0.1-10 /M  range in intact MCF-7 cells. Incubating MCF-7 cells 
with 2-61, as previously used to investigate the nature o f EMATE inhibition, revealed 
that El-STS activity only inhibited by 22% compared with the activity in untreated 
cells. This suggests that 2-61 may be acting as a weak irreversible inhibitor.214 The bis- 
sulphamate derivatives o f DES were found to be considerably more potent inhibitors 
than the THN derivatives. Like EMATE, DES bis-sulphamates appears to act as 
irreversible inhibitors. DES-bis-A/TV-dimethyl sulphamate (2-65) inhibited activity by 
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2-65 0 S 0 2NMe2
Diethylstilbestrol
Derivatives
Figure 2.17 : Derivatives of tetrahydronaphth-2-ol and diethylstilbestrol
Li et al developed a series of (p-O-sulphamoyl)-A^-alkanoyl tyramines (2-66), which
915 *were found to be potent El-STS inhibitors in human placental microsomes (Figure 
2.18). It was argued that the phenyl sulphamate portion of the inhibitors mimics the A 
ring whereas the TV-alkanoyl group provides a hydrophobic bulk mimicking the B, C 
and D rings and the carbonyl group mimics the C-17 C = 0 of EMATE.
h 2n s o 2o
0
CH2CH2N H - C -  (CH2)nCH3 
n =  5 - 13
2-66
Figure 2.18 : Structure o f (p-O-sulphamoy^-A^-alkanoyl tyramines
Li et al observed an increase in activity when they increased the alkanoyl chain length 
from n = 5 to 13. This is possibly due to increased hydrophobic interactions between 
the alkanoyl chain and the hydrophobic binding site of the enzyme. STS is a membrane 
bound enzyme therefore it has also been argued that these hydrophobic substituents 
might act as membrane inserters delivering the inhibitors to the enzyme. 215 The best 
inhibitor in this series, (/?-0-sulphamoyl)-7V-tetradecanoyl tyramine (2-66) with an 
alkanoyl chain length o f fourteen carbons was found to have an IC50 of 55.8 nM in
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human placental microsomes215 (Figure 2.18). Based on this observation their recent
series o f compounds (/?-0-sulphamoyl)-7^-alkanoylphenylalkylamines was shown to be 
potentially active El-STS inhibitors. The best compound in this series had an IC50 o f 
72 nM in human placental microsomes.216
Anderson et al have also reported a similar observation on extensive interaction 
between the enzyme and the hydrophobic side chain, by synthesising various non­
steroidal phosphate esters, such as aryl phosphates, tetrahydronaphthyl phosphates and 
phosphorylated tyramines.217
The best non-steroidal inhibitor in these series of compounds was found to be «-lauroyl 
tyramine phosphate (2-67) which inhibited El-STS with a Kj o f 520 nM at pH 7.0217 
(Figure 2.19). The increased hydrophobicity by the long alkyl chain enhances the 
partitioning in to a non-polar environment and presents the sulphatase enzyme with a 
locally higher inhibitor concentration, hence acting as membrane inserters.
In pursuit o f alternative non-steroidal mimics of EMATE after the modest success with 
the TFIN sulphamate (2-61) (Figure 2.17), the monohydroxylated coumarin structure 
was chosen by our group for modification, whose ring system is ubiquitous in nature 
and in many pharmaceuticals. The core coumarin, 7-hydroxycoumarin might mimic the 
A/B-ring o f EMATE and structurally it differs from THN at the B ring by possessing 
an a,/?-unsaturated lactone in place o f a saturated cyclic hydrocarbon. We reasoned 
that the extended conjugation o f such coumarin structures over THN should enhance 
the overall activity by lowering the relative pKa o f the leaving phenol released during 
enzyme inactivation. Also, having alkyl chain lengths increase the hydrophobicity o f
2-67
Figure 2.19 : Structure of /-z-lauroyl tyramine phosphate
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the compounds and hence enhances the interaction with the enzyme-binding site.214
7-(Sulphooxy)-4-methylcoumarin (2-69) was the first compound synthesised to 
examine if coumarin sulphates are substrates for El-STS. In a placental microsomal 
preparation, the hydrolysis o f 2-69 by El-STS was completely abolished when 
EMATE was included in the reaction mixture, indicating that the coumarin sulphate is 
a substrate for the sulphatase enzyme. Therefore the sulphamate derivatives of 
coumarin are expected to act as sulphatase inhibitors; hence a series of coumarin 
sulphamates were prepared (Table 2.3).
R3
X R i r 2 R 3
2-68 OH . H H H
2-69 0 S 0 3 c h 3 H H
2-70 o s o 2n h 2 H H H
2-71 o s o 2n h 2 c h 3 H H
2-72 o s o 2n h 2 c h 3 c h 3 c h 3
2-73 o s o 2n h 2 c f 3 H H
Table 2.3 : Some of the initial coumarin analogues synthesised
O f all the initial compounds synthesised, 4-methylcoumarin-7-0-sulphamate 
(COUMATE) (2-71) (Table 2.3) was found to be the most active with an IC50 value of 
380 nM in intact MCF-7. cells, exhibiting similar inhibitory profiles to those of 
EMATE. Although it is less potent and its duration o f inhibition in vivo is much 
shorter,214 like EMATE, 2-71 is orally active and acts in a time- and concentration- 
dependent manner, suggesting that it may have a similar mechanism o f action.196
55
However, in contrast to EMATE, 2-71 is non-estrogenic as shown by its lack o f 
stimulatory effect on the growth o f uterus in ovariectomised rats.218 The structure- 
activity relationships for 2-71 were studied recently, which have shown, inter alia, that 
the coumarin ring system is pivotal for its inhibitory activities.196
% Inhibition ± S.D. of E l-STS activity in 
placental microsomes MCF-7 breast cancer cells
10 fiM 1 fjM. 0.1 //M 1 0 /iM 1 juM 0.1 /JM.
2-70 C3-H, C4-H (COUMATE) 78 ± 1 * * * * *
2-71 C3-H, C4-CH3 93 ± 1 63 ± 1 < 10 93 ± 1 86 ± 1 43 ±1
2-74 C3-CH3, C4- CH3, 97 ± 4 88 ± 2 35 ± 1 98 ± 1 95 ±1 83 ± 1
2-75 C3-H, C4-CH3CH2 > 99 88 ± 1 35 ±1 92 ± 1 90 ±1 77 ± 1
2-76 C3-H, C4-CH3(CH2)2 96 ±1 94 ± 1 42 ± 1 94 ± 1 89 ±1 81 ± 1
2-77 C3-CH3CH2, C4-CH3, > 9 9 96 ± 1 57 ± 1 99 ± 1 97 ±1 92 ± 1
2-78 C3-CH3(CH2)2, C4-CH3, > 99 97 ± 1 83 ±1 99 ± 1 98 ± 1 94 ± 1
2-79 C3-CH3(CH2)3, C4-CH3, >99 >99 90 ± 1 99 ± 1 99 ± 1 97 ± 1
Table 2.4 : Inhibition of El-STS activity by 4-alkylated and 3-alkyl-4-methyl 
coumarin sulphamates. Compounds 2-70, 2-71 and 2-74 are included for comparison.
One o f the analogues of 2-71, 3,4-dimethylcoumarin-7-(9-sulphamate (2-74) (Table
2.4) was found to be about 12 times more potent than 2-71 (IC50 = 30 nM in MCF-7 
cells, c.f. IC50 = 380 nM for 2-71). It is evident that the higher potency o f 2-74 in 
comparison with 2-71 is attributed to its stronger binding to the enzyme active site as a 
result o f hydrophobic interactions with neighbouring amino acids provided by the 
methyl group at the 3-position. Therefore, it is reasonable to expect that the analogues 
o f 2-71 and 2-74 with substituents o f increased hydrophobicity at the C-3 and/or C-4 
positions would be even more effective sulphatase inhibitors. Such hydrophobicity- 
activity relationship is also implicated by Li and Anderson et al in their work on (p-O-
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sulphamoyl)-/V-alkanoyl tyramines215 and n-lauryl tyramine phosphate respectively.217
In order to test out such a prediction, several other coumarin sulphamates were 
synthesised (Table 2.4). As shown in table 2.4, all these coumarin sulphamates are 
potent El-STS inhibitors with the highest potency being observed for the 3-(rc-butyl)-4- 
methyl analogue 2-79 in MCF-7 cells and placental microsomes.219 2-75 is equipotent 
with 2-74 in placental microsomes at 0.1 /dVl, while, 2-75 and 2-76 are less potent than 
2-74 in MCF-7 cells. Compounds 2-77, 2-78 and 2-79 are all showed an increase in 
potency with chain length indicating that chain extension at the C-3 position is more 
effective than at C-4 position.
While the hydrophobicity of coumarin sulphamates is significantly increased by 
introducing linear alkyl chains at the C-3 and/or C-4 positions of the coumarin ring, it 
is reasonable to expect a similar effect could be achieved by incorporating an extra ring 
structure at the C3-C4 junctions of the coumarin ring. A series o f tricyclic coumarin 
sulphamates, whose third ring differ in size, were hence synthesised (Table 2.5).
X = o s o 2n h 2 % Inhibition ±S.D . of E l-STS activity
Ring size N 0.01 //M 0.1 juM 1 fJM IC50 (/M )
2-80 665 COUMATE 3 < 10 37 ± 1 91 ± 2 200
2-81 666 COUMATE 4 < 10 63 ± 1 93 ±1 70
2-82 667 COUMATE 5 48 ± 2 91 ± 1 99 ±1 8
2-83 668 COUMATE 6 17 ± 2 89 ±1 99 ± 2 30
2-84 6613 COUMATE 11 < 10 17 ± 2 77 ± 2 75
Table 2.5 : Inhibition of El-STS activity in placental microsomes by tricyclic















As predicted, this series of  tricyclic coumarin sulphamates were found to be highly 
effective STS inhibitors with the highest potency being observed for compound 2-82 
which has a 7-membered third ring (667 COUMATE) (Table 2.5). The IC50 value for 
667 COUMATE was found to be 8  nM 220 suggesting that this inhibitor is about three- 
times and 100-times more potent than EMATE (IC50 = 25 nM) and COUMATE (IC50 = 
800 nM) respectively. However, a jump from a cycloheptyl to a cyclotridecanyl third 
ring was found to be detrimental as shown by the poorer inhibitory activity of 
compound 2-84.220
The time- and concentration- dependent inactivation of  the El-STS activity by 667 
COUMATE (2-82) was found to be similar to those of  EMATE.221,196 As shown in 
figure 2.20 A,219 the inhibition by 667 COUMATE is biphasic, indicating that the 
inhibitor shares a similar mechanism of*action to that proposed for EMATE (Figure 
2.20 B) which, we have postulated that it acts via irreversible sulphamoylation o f  one 
or more essential amino acid residues in the enzyme active site.196
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Figure 2.20 : Time- and concentration- dependent inactivation of  El-STS activity in 
placental microsomes by 667 COUMATE (A)219 and EMATE (B).196










in vitro, which usually responds to low concentrations o f E2 and stimulates cell growth 
by 150% compared with the controls at 10'9 M. With 667 COUMATE, the cells 
showed no significant effects on the proliferation of MCF-7 cells over a range o f 10'11 
to 10'5 M, strongly indicating that 667 COUMATE is devoid o f estrogenicity.208
2.6 Initially proposed mechanism of steroid sulphatase inhibition by
EM ATE
The mechanism of aryl sulphate hydrolysis was first proposed by Purohit et al and they 
postulated that the mechanism may be analogous to the proposed mechanism of
OOO 000 nsulphuryl transfer by aryl steroid sulphotransferase. ’ They proposed that the 
mechanism involves a direct nucleophilic displacement of E l from E1S, either directly 
by water (A) or by a two step mechanism, which involves hydrolysis o f a sulphated 
enzyme intermediate to regenerate the active enzyme (Scheme 2.1). EMATE involves 
the essential amino acid residue, which is normally sulphated during catalysis or a 
neighbouring residue becomes irreversibly sulphamoylated, either by direct 
nucleophilic attack at the sulphur atom of EMATE by the enzyme or by the formation 
of a reactive aminosulphene intermediate by proton abstraction at nitrogen and








X -S -O -
No hydrolysis of 
sulfamoylated enzyme
- SO, 2 R e g e n e r a t e d  enzym e
A B
Scheme 2.1 : Initially proposed mechanism o f estrone sulphate hydrolysis by steroid 
steroid sulphatase and enzyme inactivation by EMATE. (A) Direct nucleophilic 
displacement of E l from the sulphate group o f E l S. (B) Involvement o f either the 
essential amino acid residue, or a neighbouring residue becomes irreversibly 
sulphamoylated.
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The catalytic sites of lysosomal sulphatase and human arylsulphatase A, identified 
from the crystal structures have now suggested new mechanisms for sulphatase ester
far, the active site amino acid residues are conserved. Bond et al showed that in ASB, 
hydrolysis takes place via post-translational modification o f a specific-active site 
cysteine residue to oxo-alanine (Scheme 2.2).
Scheme 2.2 : The post translational modification o f the essential active site cysteine
To understand the catalytic mechanism o f sulphatases, Bond et al determined the 
crystal structure o f ASB .159 The active site of ASB was readily located by the presence 
o f a cluster of conserved residues surrounding the post-translationally modified 
essential amino acid cysteine residue (Cys91), which is conserved by a sulphate adduct 
o f FGly [-CH(0 H)-S03 -]. The conserved residues that line the active site pocket are 
Asp53, Asp54, Cys91, Pro93, Ser94, Arg95, Lysl45, His 147, His242, Asp300, and 
Lys318 (Figure 2.21). The sulphate is bonded to a metal ion, which has been identified 
as calcium. It also has been identified that the electron density around the sulphate is 
due to the covalently bonded gem-diol sulphate ester 1 (Scheme 2.2). The sulphate










residue in A-acetylgalactosamine-4-sulphatase (ASB) (Adapted from Bond et al]59)
2.7 Mechanism of sulphate cleavage by sulphatase enzymes
61
ester observed in the crystals may have formed by the addition of  the sulphate to the 
aldehyde resulting from Cys91 modification. Schmidt et al proposed that this cysteine 
residue in sulphatase undergoes a conversion to oxo-alanine and the free aldehyde is 
stablised as enol or linked to an amino or hydroxyl group o f  the polypeptide forming a 
Sch iffs  base or a hemi-acetal respectively.223 The presence of the aldehyde group in 
the residue was demonstrated by reduction of  the enzyme with sodium borohydride 
under conditions specific for aldehyde reduction, and identification o f  a resultant serine 
residue in the sequence in place of  the encoded cysteine.223
L y s 3 l8  H is2 4 2
Figure 2.21 : Sketch view of  the catalytic site of  ASB showing H-bonding (dashed
2 j t m
lines) that stablises the sulphate ester. The seven-coordinated Ca metal ion is on the 
left. A salt bridge interaction between Lysl45 and the carboxyl O atom o f  Asp53, 
which is not coordinated to the metal ion and a number o f  charges and double bonds 
are omitted for clarity. (Adapted from Bond et a l159)
During the hydrolysis cycle of  the substrate ester by ASB, the sulphate ester 1 may be 
released possibly by an attack by a nucleophile such as water or it could be relatively 
weakly bound to the enzyme and in equilibrium with the free aldehyde form. When the
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substrate o f ASB, glycosaminoglycan binds to the enzyme, the sulphate group 
covalently binds to residue 91. A nucleophile such as water attacks the sulphur atom 
and makes a five co-ordinate intermediate that is stabilised by the calcium ion, which 
collapses by a breakage of the bond between the sulphur and the glycosidic oxygen, 
releasing the glycosaminoglycan and leaving the sulphate bound to residue 91159 
(Scheme 2.3).
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99 f \Scheme 2.3 : Proposed reaction of ester cleavage for ASB
Like ASB, ASA also shares the unique post-translational modification o f a conserved
cysteine residue. In this case cys69, which is converted to formylglycine, where the
226thiomethylene group o f the side chain is replaced by an aldehyde group. The 
conserved residues surrounding the active site pocket are Asn282, Asp281, Cys69, 
Asp29, Asp30, Lys302, His405, Val91, Arg73 and Lysl23.227
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Figure 2.22 : Sketch view o f the catalytic site o f ASA227 
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Figure 2.23 : Structures o f the adducts formed by ASB and ASA
In ASA the formylglycine residue is located in a positively charged substrate-binding 
pocket in which a Mg2+ is co-ordinated (Figure 2.22). In contrast to ASB, which is a 
sulphate adduct o f the aldehyde (A), the electron density at the formylglycine side 
chain o f ASA is shown to be an aldehyde hydrate (B) 153 (Figure 2.23).
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Using the crystal structures, two different catalytic mechanisms have been proposed for 
ASB and ASA. The sulphate sulphur atom undergoes a nucleophilic attack by one of 
the geminal oxygen atoms of the aldehyde. The Mg2+ increases the electrophilicity of 
the S atom and facilitates the nucleophilic attack of the hydrate O atom leading to the 
formation of a sulphated enzyme intermediate, which is the same covalent intermediate 
as the resting form observed for ASB (c.f. Scheme 2.2). The aldehyde is regenerated by 
the elimination o f the sulphate induced by the second non-esterified hydroxyl group o f 
the covalent intermediate (Scheme 2.4). These mechanisms provide a good model to 






























Scheme 2.4 : Hypothetical mechanism of sulphuric acid ester hydrolysis by ASA226
In order to discriminate the two mechanisms Recksiek et al constructed mutant 
proteins of ASA and ASB226 in which the active site formylglycine originated from a 
cysteine is replaced by a serine [-CH2-OH] by site-directed mutagenesis. This leads to 
a sulphatase protein that can no longer be modified to the formylglycine-containing 
form. The results showed that the serine mutants o f both ASA and ASB make one half­
cycle and as a consequence, it forms a sulphoserine-containing derivative by cleaving 
the sulphate ester o f the substrate.
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If the catalytic cycle is initiated by the addition of the sulphate ester to the 3-oxogroup 
o f the active site formylglycine as proposed for ASB, only the wild-type sulphatases 
but not the serine mutants should be able to cleave the sulphate ester and to form a 
sulphated intermediate. But, substitution of the formylglycine by serine abolished the 
reaction of sulphatases.226
If on the other hand the sulphate ester reacts with an active site aldehyde hydrate as 
proposed for ASA, the serine mutant could be able to form a covalently sulphated 
intermediate. But the results strongly suggests that the wild type sulphatases initiate 
sulphate ester cleavage by transesterification (Scheme 2.3), which requires a 
nucleophilic hydroxyl group at the catalytic residue, which in sulphatases can only be 
initiated by hydration o f the formylglycine residue.226
2.8 Steroid sulphatase inhibition by EMATE and related synthetic
sulphamates
Since it has been shown that the catalytic site amino acid residues for El-STS activity 
amongst sulphatase enzymes are conserved. It is anticipated that steroid sulphatase 
would share a similar mechanism of sulphate hydrolysis to those proposed for ASA 
and ASB. It is therefore reasonable to re-examine the previously proposed mechanisms 
for EMATE on reflection of the two recently proposed catalytic pathways for ASA and 
ASB. EMATE could have inactivated steroid sulphatase by one or a combination o f the 
following proposed mechanisms.
2.8.1 Involvement of the oxo-alanine residue
The first possible mechanism is analogous to that proposed by Bond et al, for sulphate 
hydrolysis.159 The resting sulphated derivative o f oxo-alanine could be in equilibrium 
with its free form and EMATE could be expected to attack the electrophilic aldehyde 
group.
As shown in scheme 2.5, initially, a nucleophilic attack by the amino o f the sulphamate 
group on the oxo-alanine takes place to give i. The next step involves the release o f E l,
6 6
possibly as a result o f displacement by a nucleophilic attack by water on the sulphur 
atom of the sulphamate to give the sulphamoylated residue ii and elimination of water 
takes place first to give the imino sulphamoylated form iii, which subsequently under 
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Scheme 2.5 : Proposed mechanism for EMATE-induced inhibition o f steroid 
sulphatases: Involvement of the oxo-alanine residue. The potential dead-end enzyme 
complexes are boxed. (Adapted from Woo et al2]9)
2.8.2 Involvement of the aldehyde hydrate residue
The second possible mechanism could be similar to that proposed by Recksiek et al for 
sulphate hydrolysis, i.e. a nucleophilic attack on the sulphamate group at the sulphur 
atom by one o f the hydroxyl group o f the aldehyde hydrate residue to give the







Scheme 2.6 : Proposed mechanism for EMATE-induced inhibition o f steroid 
sulphatases: Involvement o f the aldehyde hydrate residue. The potential dead-end 
enzyme complexes are boxed. (Adapted from Woo et al219)
2.8.3 A non-specific or random specific sulphamoylation
When EMATE binds to El-STS, the enzyme is inactivated when either an essential 
amino acid residue, which is normally sulphated during the catalysis or an important 
neighbouring residue, becomes irreversibly sulphamoylated. (Scheme 2.7)
estrone










Scheme 2.7 : Non-specific sulphamoylation o f sulphatase by EMATE. (Adapted from 
Woo et a /219)
6 8
Two mechanisms for this type of sulphamoylation are feasible : it may either be 
mediated by (A) the formation o f a reactive electrophilic aminosulphene intermediate, 
which rapidly sulphamoylates the active site, from the anion o f EMATE via a E/cb 
process possibly initiated by an enzyme catalysed proton abstraction from the amine on 
the sulphamate group (Scheme 2.7 A) and most likely stimulated by H-bonding to the 
bridging O-atom; or (B) a direct nucleophilic attack by an amino acid residue at the 
sulphur atom o f the sulphamate group (Scheme 2.7 B). Both mechanisms will rapidly 
lead to a sulphamoylated enzyme intermediate, which cannot be hydrolysed by water to 
regenerate the active form of the enzyme in the same manner or rapidly as the 
sulphoenzyme intermediate resulting from the hydrolysis o f estrone sulphate thus 
rendering the enzyme irreversibly inhibited.
Analysis o f pH dependence of enzyme activity shows that there are two ionisable 
groups with pKa values of 7.2 and 9.8 that are involved in the enzyme inactivation by 
EMATE. Initial studies using rose bengal inactivated the amino acid histidine and 
suggested that histidine may play a role in the catalytic mechanism. Another amino 
acid, tyrosine was also suspected to be involved in the transfer between a tyrosine- 
enzyme substrate and a phenolic acceptor substrate since the pKa o f tyrosine is 9.8 and 
correlates with the requirement for the inactivation o f EMATE. However the recent 
finding shows that tyrosine is not present in the conserved active site o f the enzyme, 
therefore some other amino acids with a similar pKa must be involved. The most likely 
candidate with a similar pKa would be lysine, which has a pKa of ~10 in proteins.228
2.9 Aims of this project
This project aims broadly (i) to design and synthesise a range o f non-steroidal 
inhibitors, which would be as potent as EMATE and 667 COUMATE, and (ii) to build 
up a more comprehensive structure-activity relationship (SAR) for these coumarin 
sulphamates. Therefore I focused on synthesising coumarin sulphamate derivatives 
with alkyl chains and other functionalities at the C-3 and/or C-4 positions and a 
complete series of tricyclic coumatin sulphamates as potentially effective inhibitors of 
El-STS. It is likely that other herterocyclic ring containing sulphamates would also
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show some interesting activities. Therefore several novel indole sulphamate derivatives 





C-3 or/and C-4 substituted coumarin sulphamates
3.0 Background
Coumarins are ubiquitous secondary metabolites isolated from medicinal plants. 
Natural coumarin (2H-l-benzopyran-2-one) can be effectively extracted from the
99Qplant Mikania glomerata in large quantities. Over the years, a number o f 
coumarin-containing natural and synthetic drugs have been discovered and shown 
to have useful biological activities. Apart from use as a food and fragrance 
ingredient, derivatives o f  coumarins are useful in photochemotherapy, antitumoural,
9 ^  A
anti-HIV therapy, CNS-active drugs and most importantly as anticoagulants. In 
addition, some o f the compounds containing the coumarin ring system were found 
to possess estrogenic and anti-estrogenic activities such as coumestrol90.
A large number o f  coumarin derivatives have shown to possess low toxicity and 
undesirable side effects, except in some cases. In 1988, synthetic coumarin was 
launched in France for the adjuvent therapy o f lymphoedema o f the upper limb 
following radio-surgical treatment o f breast cancer and shown to have a potential 
hepatotoxicity, which is probably due to the production o f a reactive metabolite in 
some patients exhibiting a coumarin 7-hydroxylation deficiency. Studies have 
shown that coumarin and 7-hydroxycoumarin were nearly equitoxic, whereras 4- 
hydroxycoumarin was nearly 2 -fold less toxic than coumarin on an equimolar 
basis .231
Our focus on the coumarin ring system was enhanced with the potent activities 
obtained for COUMATE (2-70) and 3,4-dimethylcoum arin-7-0-sulphamate (2-74) 
(Table 2.4, Chapter 2). Therefore, to understand any relationship between the 
potency and hydrophobicity in two ring compounds, we have further explored the 
concept o f  coumarins and related molecules as templates to design non-steroidal
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sulphatase inhibitors for the endocrine therapy of hormone dependent breast cancer 
by using COUM ATE as the lead compound.
3.1 Synthesis
The compounds synthesised in this project belong to three different series. (A) 
Alkyl groups of increasing carbon chain lengths and other functionalities at the C-4 
position of the coumarin ring and (B) alkyl groups of increasing carbon chain 
lengths and other functionalities at the C-3 position and a methyl group at the C-4 
position of the coumarin ring, and (C) alkyl groups or/and other functionalities at 
the C-4 and C-3 positions of the coumarin ring. They can be represented by the 
general structures as shown below: (Figure 3.1)
Figure 3.1 : The general structures of the compounds synthesised in this project. 
A: 4-Substituted series, B: 3-Substituted-4-methyl series, C: Other substituted 
series
Retrosynthetic analysis gives several possible synthetic routes to achieve these 
series of sulphamates as shown in Scheme 3.1. The coumarin ring can be 
disconnected conveniently in two ways, a and b as indicated. One highly used 
method is via route A, which involves a condensation of 2,4-dihydroxyphenyl 
ketones with alkylacetyl chloride. This method has been repeatedly reported to 
furnish the desired coumarins in high yields.232 Another possible approach was to 
go via route B, which involves the condensation of 2,4-dihydroxyphenyl ketones 
with the appropriate phenylacetic acid.
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Scheme 3.1 : Retrosynthesis o f hydroxy coumarins.
One other possible starting point was to synthesise the corresponding /J-keto esters 
followed by the Pechmann synthesis o f hydroxycoumarins via route C. For our 
purpose this route was primarily considered since the target coumarins can be 
relatively easily prepared from two similar-sized fragments and thus the forward 
synthesis would be convergent. The only synthetic problem would be the synthesis 
o f various /Tketo esters since most are not available commercially. The 7- 
hydroxycoumarins synthesised are subsequently sulphamoylated with freshly 
prepared sulphamoyl chloride to form the corresponding coumarin sulphamates. 
The Pechmann condensation reaction is now further discussed and explained in the 
context o f how it was used.
The alkanoylacetate esters required as starting material for the coumarins in the 4- 
alkyl series (A) (Figure 3.1) o f compounds are commercially unavailable and 
therefore, had to be synthesised. One o f the more general and useful approaches 
involves the acylation o f diethyl malonate followed by partial hydrolysis and 
subsequent decarboxylation o f only one o f the two ester groups in the acylated 
malonate intermediate. However, hydrolysis and decarboxylation o f  both ester 
groups may occur leading to an alkyl ketone by-product. Alternatively, both ester 
groups may be left unhydrolysed resulting in contamination by the acylated 
malonate intermediate. In some cases, retro-condensation takes place to regenerate 
the carboxylic acid starting material. In recent years, several more practical and
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• • 9 9 9reliable procedures using stronger acids such as malonic acid, Meldrum’s acid
9 9 A  9 9 ^  * 99S(pKa = 5) ’ and mixed malonate esters such as butyl ethyl malonate have
been developed, which attempt to avoid these problems (Scheme 3.2).
The most common ways to synthesise alkanoylacetates are by Claisen condensation 
reaction, which involves the condensation o f an ester enolate with an ester, crossed 
Claisen condensation, which involves esters with no ^-hydrogen and acylation o f  
enolate anions with an acyl chloride or an ester (Scheme 3.2). Irrespective o f  the 
poor yield noted in the Claisen condensation reaction, by self-condensation o f  the 
esters, it is a widely employed synthetic procedure. The yields can be improved by 
using fairly strong bases such as sodium hydride, sodium amide and lithium 
diisopropylamide (LDA) to make the formation o f the ester enolate anion 
essentially irreversible.
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Scheme 3.2 : Ways o f synthesising alkanoylacetates
The synthetic method used in this work to synthesise the required alkanoylacetates 
was by treating the inexpensive ethyl potassium malonate with the corresponding 
acid chloride in the presence o f magnesium chloride (MgCh), triethylamine (Et3N) 
and acetonitrile (CH3CN) as the solvent236 (Scheme 3.3). This method has the 
advantage o f being relatively safe, clean, economical, and suitable for scaling up 
with product produced in high yield and purity, which is free from any unnecessary 
side products. Rathke and Cowan have shown that the combination o f anhydrous
Acylation
O o
X  + 1
h 3c  O E t  R ^ a
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MgCh and EtsN provide a strong enough base system for metallating ethyl 
potassium malonate. They also found that the reactions failed when MgCh was 
replaced with other metal chlorides such as ZnC^, Q 1CI2, FeCl3, TiCE, LiCl and 
AICI3 .
0 0 (0 9 ?, , (”) ?,
loA A jE t R ' ^ ^ ' O E t  N2^ OEt
Scheme 3.3 : Synthesis o f alkanoyl acetoacetate for the preparation o f 4- 
alkylcoumarin sulphamate. (i) (a) MeCN, MgCl2, Et3N, 10-25°C, 2.5 h (b) RCOC1, 
Et3N, 0°C, 0.5 h, R.T. 12 h. (ii) RCOH, SnCl2, CH2C12, R.T. 3 h.
The number o f equivalents o f reagents used in the reaction determines the yield o f  
the product obtained. For aromatic acid chlorides which have electron-withdrawing 
substituents such as fluoro, chloro or nitro groups, 2 .1  equivalents o f potassium 
ethyl malonate, 2.5 equivalents o f MgCh and 2.2 equivalents o f  Et3N are optimal 
and the yield is around 90%. On the other hand, aliphatic acid chlorides or aromatic 
acid chlorides containing electron-donating substituents generate side products, 
which are minimised by employing extra equivalent o f  Et3N to obtain the 
alkanoylacetate in high yield. 1-Adamantaneacetic acid was converted to the 
corresponding acid chloride by reacting with thionyl chloride (SOCI2); reaction 
with potassium ethyl malonate gave 4-adamantan-l-yl 3-oxo-butanoate (54) 
(Scheme 3.4).
-  + Ad^ O E ,
53 5 4
Scheme 3.4 : Synthesis o f 4-adamantan-l-yl 3-oxo-butanoate (54) (i) SOCI2, DMF, 
reflux (ii) (a) MeCN, MgCl2, Et3N, 10-25°C, 2.5 h (b) Et3N, 0°C, 0.5 h, R.T. 12 h.
75
The mechanism o f the reaction is expected to be as shown in Figure 3.2. Et3N  
removes the a-hydrogen o f the ethyl potassium malonate and produces a carbanion, 
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Figure 3.2 : Metallation o f ethyl potassium malonate by MgCb to form the anion.
MgCb acts as a Lewis acid and assist the formation o f the anion. The Mg forms a 
complex co-ordination with the carbonyl O atoms (Figure. 3.2) and hence the 
abstraction o f the a-hydrogen by Et3N  to generate the anion is facilitated.
o o
Figure 3.3 : The resonance hybrid formed by the delocalisation o f electrons
The two flanking carbonyl groups o f malonate markedly increase the acidity o f  the 
a-hydrogen (pKa = 10 -  14) and the carbanion formed is highly stabilised due to 
delocalisation o f electrons (Figure 3.3). The /?-keto ester is the most acidic 
molecule in the sequence o f this reaction because o f the two carbonyl groups which 




anion again because o f its stability. In practice, the neutral ft-keto ester is recovered 
through acidification o f the reaction mixture. Upon acidification o f the reaction 
mixture, the resulting /?-keto- a-carboxy ester (I) readily undergoes 
decarboxylation (Figure 3.4) to yield CO2 and the desired alkanoylacetate (Figure 
3.4). W hen the acid decarboxylates, it goes through a six-membered transition state 
as shown in figure 3.4, which occurs at relatively low temperatures.
COOH
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F igure 3.4 : M echanism o f decarboxylation
/?-Ketoesters can also be prepared efficiently by reacting the corresponding 
aldehyde with ethyl diazoacetate in the presence o f a catalytic amount o f tin(II) 
chloride (S n C y  (Scheme 3.3). The two most noteworthy aspects o f this method are 
its selectivity and the mild conditions involved. The reaction is insensitive to 
atmosphere and is completed between 1-2 h at R.T. This reaction can be catalysed 
by various Lewis acids, such as BF3, ZnCl2, ZnBr2, AICI3, SnCb, G eC h and SnCU 
but the highest yield is obtained with SnC^ .239 Even though other common organic 
solvents can be used, CH2CI2 is often employed because it gives the best results and 
can be easily removed.
The mechanism o f the reaction is likely to have proceeded via a betaine 
intermediate, followed by a preferential migration o f the aldehyde hydrogen to the 
/ 2-carbon i.e. a 1,2 -hydride shift producing the required / 2-keto ester and N 2 as 
products. The possible mechanism o f this reaction is as follows : (Figure 3.5)
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F igure 3.5 : Proposed mechanism for the synthesis o f ethyl alkanoylacetates by 
SnCl2
Several efficient and convenient methods have been described for the alkylation o f 
ethyl acetoacetate, by alkylation o f sodium acetoacetic esters in by alkyl halides by 
using different solvents such as DMF and different alcohols.240,241 These reactions 
require long times and the use o f metallic sodium. Therefore, the or-alkyl acetates 
required for the synthesis o f coumarins in the 3-substituted-4-methyl series were 
prepared by a convenient method by treating a solution o f ethyl acetoacetate in 
CH2CI2 with the corresponding alkyl bromide in the presence o f potassium
94 9carbonate (K2CO3) and tetrabutylammonium chloride (B114NCI) (Scheme 3.5).
H-iC
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Schem e 3.5 : Synthesis o f cr-alkylacetoacetates for the 3-alkyl-4-methylcoumarin 
sulphamates. (i) RBr, K2CO3, H2O, B114NCI, CH2CI2, reflux, 40 h.
Alkyl bromides are chosen as the alkylating agent in place o f alkyl iodides, since 
they are readily available, relatively cheaper and the bromide ion is a better leaving
group than Cl but similar to I. The phase-transfer catalyst tetrabutylammonium 
iodide (B114NI) is insoluble in water but soluble in all common organic solvents. 
Great interest has now been developed in such phase transfer processes. The 
principle is to generate a carbanion by K2CO3, which is normally insoluble in 
organic solvents and use the phase-transfer catalyst to transport this anion into the 
organic phase, then allow this anion to react in the organic phase. The reactive 
anion generated in this experiment was the ethyl acetoacetate carbanion at the a- 
carbon. Once dissolved by the phase transfer catalyst in the organic solvent in this 
case CH2CI2, this anion reacts with the alkylating agent, which is the alkyl bromide 
to give the acetoacetic ester alkylated product.243 All the compounds were easily 
purified by flash chromatography with CHCI3.
All the parent coumarins were prepared under Pechmann conditions from the 
corresponding p -keto ester and resorcinol in the presence o f an equimolar mixture 
o f trifluoroacetic acid (CF3COOH) and concentrated sulphuric acid (H2SO4) 
(Scheme 3.6) warmed from ice-water temperature to R.T.
Scheme 3.6 : The Pechmann synthesis o f 4-alkyl and 3-alkyl-4-methyl substituted- 
7-hydroxycoumarin (i) C onc.f^SCV  CF3COOH, 3 h, 0°C to R.T.
The use o f  a 1 : 1 mixture o f conc. H2SO4 and conc. CF3COOH as the condensing
and in our hands such mixture has been found to be as effective as using conc. 
H2SO4 alone, which is playing a role as a catalyst. The role o f  CF3COOH in this
o o
agent for the Pechmann synthesis o f coumarins was first described by Hua et al244
reaction is not entirely clear, although it might be acting as an organic solvent and 
lowering the viscosity o f the reaction mixture rendering the stirring process more 
efficient.
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The synthesis o f  7-hydroxy-3-(4-methoxyphenyl)-4-methylcoumarin (115) was not 
possible using Pechmann conditions (Scheme 3.6) since the corresponding fi-keto 
ester cannot be prepared directly in the same manner described above (Scheme 3.4). 
In the literature several methods have been reported for the preparation o f 3- 
methyl-4-phenyl derivatives o f coumarin.245,246’247’248 Several similar 3-substituted 
coumarins have been reported to be prepared by various other methods. 2 - 
Hydroxyacetophenone with phenylacetyl chloride in acetone using anhydrous 
potassium carbonate as the base also appears to produce the required coumarins in 
high yields.232,249 This method is only viable for phenyl-containing compounds and
9^ 9found to be unsuccessful with alkyl coumarins. Direct condensation o f 2- 
hydroxybenzaldehydes with phenylacetic acid by the Perkin method does not give
9 50the products in good yields.
Therefore, an attempt was made to synthesise the desired 7-hydroxy-3-(4- 
methoxyphenyl)-4-methylcoumarin (115) by Hans et al using 2,4- 
dihydroxyacetophenone with phenylacetic acid in the presence o f 
dicyclohexylcarbodiimide (DCC) in dimethylsulphoxide (DMSO )251 (Scheme 3.7). 
Complex products were resulted when heated the reaction mixture at 100-110°C for 
24-28 h, which could not be separated into individual components and also the 
reaction did not take place when attempted at room temperature or at lower 
temperatures.
Alternatively, 115 was then synthesised using the general method described by 
Sabitha et al by condensation o f 2,4-dihydroxyacetophenone with 4- 
methoxyphenylacetyl chloride using aqueous potassium carbonate (K2CO3) (20%) 
as base and CH2CI2 as the solvent in the presence o f a phase-transfer catalyst, 
tetrabutylammonium sulphate (BU4N.HSO4), which furnished the desired hydroxy
959coumarin in good yield (Scheme 3.7).
2,4-Dihydroxyacetophenone was insoluble in CH2CI2 therefore it was first
8 0
dissolved in a small amount o f THF and then diluted with CH2CI2 . Aqueous K2CO3 
was used as a base instead o f potassium hydroxide because the stronger base ring 
opened the coumarin resulting in the formation o f  the potassium salt o f a substituted
2 -hydroxycinnamic acid derivative, which remains in the aqueous layer during the 
work-up. Although acidification o f the aqueous layer regenerates the desired 
coumarin, the use o f aqueous K2CO3 obviates this complication.
Scheme 3.7 : Synthesis o f 7-hydroxy-3-(4-methoxyphenyl)-4-methylcoumarin
(115) (i) K2CO3, CH2CI2, B114N.HSO4, 3-4 h, R.T.
Two pale yellow compounds were isolated from the brown crude suspension upon 
flash chromatography. When visualised under the UV light, one o f them was found 
to be fluorescent and the other was UV active but not fluorescent. The NMR  
spectral analysis indicated that the fluorescent compound isolated was without the
3-methoxyphenyl group (II) (Scheme 3.7) and the non-fluorescent compound was 
the desired product, which was supported by the mass spectral and combustion 
analyses.
The sulphamoyloxy group has been identified as an active pharmacophore for the 
inhibition o f E l -STS. Several different classes o f sulphamoylated drugs have been 
synthesised and have shown to be active inhibitors. In the earlier work, crude
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crystalline sulphamoyl chloride prepared according to the method described by 
Appel and Burger was used directly on phenolic compounds. Sulphamoyl 
chloride was prepared by treatment o f chlorosulphonyl isocyanate with freshly 
distilled formic acid (Scheme 3.8).
®
C1S02N = C = 0 + HCOOH ----------------- ► C1S02NH2 + C 0 2 + CO
Schem e 3.8 : Preparation o f sulphamoyl chloride (i) Anhy. toluene, N 2, 12 h, 0°C 
to R.T.
However, sulphamoyl chloride is very hygroscopic and decomposes readily even on 
storage at low temperature, which makes the continuous handling o f this compound 
very difficult. This problem was overcome by storing freshly prepared crude 
sulphamoyl chloride as a solution in freshly distilled anhydrous and sulphur-free 
toluene under nitrogen at low temperature.194 During the reaction carbon dioxide 
and carbon monoxide were formed. The mechanism for the synthesis o f sulphamoyl 
chloride reaction can be proposed as depicted in figure 3.6.
H+^
C k  N=C=0 O % H
° " °  V  m  CS ; n ‘h + 0=c=0 + CE0
o
F igure  3.6 : Proposed mechanism for the synthesis o f  sulphamoyl chloride from 
chlorosulphonyl isocyanate and formic acid.
No titration was attempted on this sulphamoyl chloride solution whose molarity 
was estimated according to the weight o f the original crude sulphamoyl chloride 
obtained after workup. An appropriate volume o f solution was freshly concentrated 
in vacuo immediately before use.
82
The sulphamoylation reaction was performed by treating the hydroxycoumarins 
with an excess o f (~ 5 equiv.) sulphamoyl chloride after treating with one 
equivalent o f NaH as described previously by Woo et al2U (Scheme 3.9).
Schem e 3.9 : The sulphamoylation reaction o f 7-hydroxylated coumarins (i) 
Anhydrous DMF, NaH, N2, 0°C and H2N S 0 2C1, 0°C to R.T.
The NaH deprotonates the 7-hydroxy group o f the coumarin to form the 
corresponding sodium phenolate. This reaction is accompanied by a colour change 
from a colourless mixture to a dark yellow suspension, due to the delocalisation o f 
electrons in the coumarin ring. Upon addition o f sulphamoyl chloride, the yellow 
colour disappears and a milky suspension results. The phenolate reacts with the 
sulphamoyl chloride to give the desired coumarin sulphamate and NaCl. The 
solvent DMF and NaCl were removed during the work-up and the organic products 
were extracted into ethyl acetate.
An A A'BB' relationship was observed for the four phenyl protons o f 3- 
methoxyphenyl group in the N M R spectra for the compounds 115 and 3-(4- 
m ethoxyphenyl)-4-m ethylcoumarin-7-0-sulphamate (116) (Figure 3.7). Two sets o f 
doublets corresponding to two protons each were observed at 6 6.93 ppm and 6 
7.31 ppm with coupling constants o f 8.6 Hz. This is characteristic o f the aromatic 
proton resonance for a para  substituted benzene ring. The two pairs o f protons, 
which are magnetically not equivalent are coupled together to appear as a doublet, 
but actually has a number o f extra lines, o f which the inside lines are the most 
noticeable.
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h 2n o 2s o
6.93 (d, 2H, Ph-2,6-H2, 7=8.6Hz) 
7.31 (d, 2H, Ph-3,5-H2, 7=8.6 H$)
7.35 (dd, 1H, C6-H, 7=1.9, 8.9 Hz)
7.48 (d, 1H, Cg-H, 7=1.9Hz) C
8.21 (d, 1H, C5-H,7=8.9Hz) 
< 2
O '
7 .5  7 . 4  7 .3  7 . Z
< c 3.75 (s, 3H, OCH3)
2.77 (s, 3H, CH3) 
< 2
Figure 3.7 : NMR of 3-(4-methoxyphenyl)-4-methylcoumarin-7-0-sulphamate
(116).
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For proton N M R spectral analysis, the compounds were dissolved in deuterated 
solvents such as chloroform and DMSO-d6. The keto esters and some 7- 
hydroxycoumarins are soluble in CDCI3 . The poorly soluble compounds and the 
sulphamates were dissolved in DMSO-d6. All the compounds were fully 
characterised by spectroscopic and combustion analysis. The yields o f  the 
sulphamates were generally poor therefore, improved significantly by using excess 
o f sulphamoyl chloride (> 5 equiv.). 40-50% o f the unreacted phenolic starting 
material was isolated.
The coumarin sulphamates prepared for this work are summarised as follows:
R
Compound R Compound R
3 CH3(CH2)3 32 'Pr
6 CH3(CH2)4 34 'Bu
9 CH3(CH2)5 36 CH2OCH3
1 2 CH3(CH2)6 38 c h 2c i
15 CH3(CH2)7 40 c 6h 5
18 CH3(CH2)8 43 CH2Ph
2 1 CH3(CH2)9 46 CH2CH2Ph
24 CH3(CH2) io 49 PhCH2CH3
27 CH3(CH2)„ 52 c 6h „
30 CH3(CH2) i2 56 CH2-adamantyl
Table 3.1 : Structures o f  4-substituted coumarin-7-O-sulphamates
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Compound R Compound R
59 CH3(CH2)4 89 CH3(CH2)14
62 CH3(CH2)5 91 Cl
65 CH3(CH2)6 93 Ph
6 8 c h 3(c h 2)7 95 CH2Ph
71 c h 3(c h 2)8 98 CH2CH2Ph
74 CH3(CH2)9 1 0 1 (CH2)3Ph
77 CH3(CH2)10 104 CH2C6H n
80 CH3(CH2) h 107 (CH2)2C6H n
83 CH3(CH2)12 116 Ph-OCH3
8 6 CH3(CH2)13
Table 3.2 : Structures o f 3-substituted-4-methylcoumarin-7-0-sulphamates
Ri r2 r3 R4 Rs
1 1 0 CH3(CH2)8 CH3(CH2)8 H H H
1 1 2 Ph(CH2)3 c h 3 H CH3CH2 H
114 Ph(CH2)3 c h 3 H H c h 3
Table 3.3 : Structures o f other substituted coumarin-7-O-sulphamates
8 6
3.2 Results
Biological testing o f the compounds are carried out by Dr. A. Purohit and Ms. B. 
Malini at the Department o f Endocrinology and Metabolic Medicine, St. M ary’s 
Hospital Medical School, Imperial College, London.
The biological evaluation o f the novel synthetic entities has shown that all the 
compounds synthesised in the coumarin series with alkyl groups o f increasing 
carbon chain lengths and other substituents at the C-3 and/or C4 positions o f  the 
coumarin rings are more potent E l-ST S  inhibitors than EM ATE (2-20) and 
COUMATE (2-70). All the compounds were tested in MCF-7 cells and placental 
microsomes at various concentrations. (Tables 3.4, 3.5, 3.6, 3.7, 3.8 and 3.9) The 
screening results o f some o f the inhibitors at lower concentrations such as 0.01 fiM 
and IC50 values are not yet available.
The available biological activity results can be summarised as follows: In the C-3 
alkyl series, all the compounds tested in intact MCF-7 breast cancer cells at 
concentrations o f 10 juM, \juM and 0.1 fJM. showed inhibitory activities >96% 
(Table 3.6). In placental microsomes, 4-methyl-3-pentylcoumarin-7-0-sulphamate 
(59), 3-hexyl-4-methylcoumarin-7-0-sulphamate (62) and 3-nonyl-4- 
methylcoumarin-7-O-sulphamate (71) showed inhibitory activities o f 94%, 88% 
and 85% respectively, at 0.1 juWl concentration. Compound 59 has an I C 5 0  value o f 
12 nM in placental microsomes and showed 41% inhibition at 0.01 jlM., whereas 
compound 62 was found to have an I C 5 0  o f 0.68 nM in MCF-7 cells (c.f. EM ATE = 
25 nM) (Table 3.7).
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% Inhibition on intact MCF-7 breast cancer cells
10//M 1 juM 0.1 //M 0.01 / M IC50mM
3 93 91 85 * He
6 95 92 88 52 10
9 93 90 87 He He
12 99 95 93 He He
15 99 97 90 He He
18 100 98 96 90 He
21 100 98 95 86 He
24 * * * He He
27 98 95 67 22 4.3
30 * * 96 72 3.2
32 * * * He He
34 * * * He He
36 83 52 17 He He
38 92 82 33 6 220
40 87 79 36 He He
43 84 70 55 8 75
46 98 95 84 39 18
49 84 73 24 6 350
52 93 80 72 37 23.5
56 * * * He He
Table 3.4 : Inhibition of the El-STS activity in intact MCF-7 breast cancer cells by
4-alkylcoumarin sulphamates at various concentrations. * = Results not available
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% Inhibition in placental microsomes
10 f i M 1 f M 0.1 f M 0.01 f M ICsowM
3 98 91 49 10 102
6 99 97 70 22 40
9 99 97 70 6 52
12 99 97 64 8 90
15 99 97 74 28 68
18 99 97 79 18 60
21 99 96 74 17 60
24 97 92 56 8 73
27 96 89 68 17 45
30 91 80 55 7 85
32 94 90 86 * *
34 * 97 19 * *
36 83 52 17 * 1000
38 94 59 19 10 600
40 * * * * 200
43 99 96 61 2 64
46 98 93 53 8 82
49 85 27 * * 2600
52 99 94 69 9 42
56 * 96 8 * *
Table 3.5 : Inhibition of the El-STS activity in placental microsomes by 4-
alkylcoumarin sulphamates at various concentrations. * = Results not yet available
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% Inhibition on intact MCF-7 breast cancer cells
10 f i M l f i M 0.1 /M 0.01 f i M IC50mM
59 100 99 97 * He
62 100 100 99 * 0.68
65 100 100 99 * He
68 100 100 99 * He
71 99 99 96 57 <10
74 97 99 97 80 <10
77 * * * * He
80 * * * * He
83 * * * * He
86 * * * * *
89 * * * * He
91 87 67 29 ♦ 600
93 * * 75 32 25
95 97 94 91 85 1
98 * 99 98 93 1.1
101 100 99 87 H« He
104 * * * He He
107 * * * He He
116 * * * He He
Table 3.6 : Inhibition of the El-STS activity in intact MCF-7 breast cancer cells by
3-alkyl-4-methylcoumarin sulphamates at various concentrations. * = Results not
yet available.
90
% Inhibition in placental microsomes
10 f M 1 f M 0.1 f M 0.01 f M IC50wM
59 100 99 94 41 12
62 99 99 88 13 32
65 99 91 65 23 *
68 99 98 71 21 *
71 98 97 85 21 320
74 94 79 33 3 250
77 * * * * 2000
80 * * * * *
83 * * * * *
86 * * * * 10000
89 * * * * *
91 * * * * *
93 99 95 65 8 54
95 * 99 94 53 8
98 100 99 91 45 33
101 * 99 47 * *
104 * 99 74 * *
107 * 99 37 * *
116 * * * * *
Table 3.7 : Inhibition of the El-STS activity in placental microsomes by 3-alkyl-4-
methylcoumarin sulphamates at various concentrations. * = Results not yet
available.
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% Inhibition on intact MCF-7 breast cancer cells
10 f M 1 f M 0.1 f M 0.01 f M IC50/1M
110 * * * * *
112 99 93 36 * *
114 * * * * *
Table 3.8 : Inhibition o f  the E l-ST S activity in intact MCF-7 breast cancer cells. 
* = Results not yet available.
% Inhibition in placental microsomes
10 f M 1 f M 0.1 f M 0.01 f M IC 50//M
110 * * * * *
112 * * * * He
114 * 13 6 * >10
Table 3.9 : Inhibition o f the E l-ST S activity in placental microsomes * = Results 
not yet available.
All the compounds in the 4-alkyl series (Table 3.4) inhibited E l-ST S  activity in 
intact MCF-7 breast cancer cells, where the inhibition ranges from 67% to 96% and 
in placental microsomes from 49% to 79% at 0.1 juM (Table 3.5). 4- 
Nonylcoumarin-7-O-sulphamate (18) and 4-decylcoum arin-7-0-sulpham ate (21) 
are found to be the most active compounds with inhibitory activities o f  90% and 
86% respectively, in MCF-7 cells at 0.01 fM  concentration (Table 3.4). 
Compounds 4-tridecylcoumarin-7-0-sulpham ate (30) and 4-dodecylcoum arin-7-0- 
sulphamate (27) were found to have I C 5 0  values o f  3.2 nM and 4.3 nM, respectively 
in MCF-7 cells. Compound 18 showed the highest inhibitory activity o f  79% at 0.1 
jlM  concentration whereas 4-octylcoumarin-7-0-sulphamate (15) exhibited potency
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at 0.01 //M  concentration with an inhibition o f 28% in placental microsomes 
preparation.
3-Benzyl-4-methylcoumarin-7-0-sulphamate (95), 4-methyl-3-(2-phenylethyl) 
coumarin-7-O-sulphamate (98) and 4-isopropylcoum arin-7-0-sulpham ate (32) were 
found to be the most potent in the series where other substituents at C-3 and/or C-4 
positions o f the coumarin ring with activities o f 96%, 91% and 86% respectively in 
placental microsomes at 0.1 /JM concentration (Tables 3.7 and 3.5). Compounds 95 
and 98 were found to have IC50 values o f 1 nM and 1.1 nM, respectively in MCF-7 
cells. Even though, all the compounds shown to be active it was found that in 
general the C-3 substituted sulphamates are more potent than the C-4 substituted 
compounds in particular, compound 95 was the m ost potent inhibitor o f all with an 
IC50 value o f  8 nM in placental microsomes.
The parent phenolic compounds were also evaluated side by side on the same assay 
system and found to be inactive for inhibition o f E l-ST S, indicating that the 
sulphamoyl group is the most important m otif to engender sulphatase inhibitory 
activity.
3.3 Discussion
Following COUMATE (2-70), its derivatives, 4-ethyl (2-75) and 4-propy 1-7-0- 
sulphamates (2-76) inhibited the E l-ST S enzyme by 77% and 81% in placental 
microsomes and in MCF-7 cells by 32% and 42% //M  respectively. Also, 3-ethyl 
(2-77), 3-propyl (2-78) and 3-butyl-7 -0 -sulphamates (2-79) inhibited the enzyme 
by 57%, 83% and 90% in placental microsomes, and in MCF-7 cells by 92%, 95% 
and 97% at 0.1 /uM respectively219 (Table 2.4, Chapter 2). This increase in 
inhibition with the increase in alkyl chain length was encouraging and prompted the 
approach o f  synthesising further analogues o f coumarin sulphamates with alkyl 
chains o f various lengths at the C-3 and/or C-4 positions o f the coumarin ring, 
which may lead to the development o f potential sulphatase inhibitors. Therefore, a
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number o f various different coumarin sulphamates have been synthesised and tested 
for their ability to inhibit E l-ST S enzyme. The majority o f the compounds in these 
series are more potent than EMATE and COUMATE.
Although time- and concentration-dependence studies have not yet been carried out 
to confirm the nature o f inhibition o f these compounds, we anticipate from our 
understanding o f the mechanism o f action for EMATE and related compounds, that 
the best compounds in the coumarin sulphamate series (Figure 3.8) are also acting 
in a similar manner to EMATE as active site-directed inhibitors.
n = 8 (18) n = 4 (59)
9 (21) 5(62)
8(71)
Figure 3.8 : Some potent inhibitors in the coumarin series o f compounds
The consequence o f having a long hydrophobic alkyl chain on the inhibition o f  E l-  
STS was shown by the TV-alkanoyl tyramines synthesised by Li et al, which showed 
an increase in activity as the length o f the alkyl chain was increased.254,255 This 
observation by Li et al was further justified by the biological activities observed 
with the long alkyl chain containing coumarin sulphamates. On comparison o f the 
results from both series have suggested that substitution with an unbranched alkyl 
group o f  the same chain length at the 3-position o f  the coumarin ring is more 
productive than that at the C-4 position as shown by the relatively higher potencies 
o f the inhibitors in the former series (e.g. ethyl 2-75 (35%) vs 2-77 (57%) (Tables 
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Figure 3.9 : The trend o f  inhibition by 4-alkyl series o f  com pounds in MCF-7 cells 
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The trend o f  inhibition by 3-alkyl-4-methyl series o f  com pounds in M CF-7 cells 
(C) and placental m icrosom es (D) at 10 fjM, — 1 /uM, — “ 0.1 /uM
concentrations. X- axis shows the num ber o f  carbon atoms in the alkyl chain and 
the num bers on Y-axis indicate the % inhibition o f  the corresponding com pound at 
a particular concentration.
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Even though the 4-alkyl series o f compounds is comparatively less potent than their 
corresponding 3-alkyl-4-methyl series o f compounds for the same alkyl chain 
length a steady increase in activity was observed in both series o f compounds 
(Figure 3.9). The % inhibition o f these compounds is very high at 10 //M  and 1 jlM  
concentrations. The difference in % inhibition is clearly visible at 0.1 /JM. 
concentration and mainly in placental microsomes preparation (Figure 3.9 B and 
D).
It is apparent that the hydrophobic interactions between the amino acids in the 
enzyme active site, which naturally recognise the steroid scaffold, and the alkyl 
substituents are more effective when these substituents are placed at the C-3 
position o f  the coumarin ring. Since, we have proposed that coumarin sulphamates 
are steroid sulphatase inhibitors by virtue o f  their structural mimicry o f  the A/B ring 
o f EMATE, it is conceivable that the positioning o f alkyl substituents with a high 
rotational degrees o f freedom at the C-4 position o f the coumarin ring may be 
counterproductive. The active site o f  steroid sulphatase, like many other enzymes 
with steroids as substrate, is expected to have limited accommodation for 
substituents at the C-l/C-1 l/C-12 edge o f the steroid scaffold. The coumarin ring 
system presumably mimics the steroid rings o f EMATE, and the long alkyl chains 
might be possessing similar hydrophobicity o f EMATE, which is required for extra 
binding to the enzyme and thus exhibit potent STS inhibitory activities. The long 
chains also may be generating the opitmal spacing and hence showing certain 
similarity to that o f the EMATE molecule. The structural comparison carried out 
for EMATE and the active compounds in the C-3 and C-4 alkyl series by computer 
modelling show the minimum energy conformation o f  these compounds (Figure
3.10). The flexible side chains in 18 and 71 enable these compounds to fold in such 
a way to create a steroid like structure, which is presumably highly preferred by the 
amino acid residues at the enzyme active site.
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EM ATE 18 71
Figure 3.10 : M olecular m odelling o f  the X-ray crystal structure o f EM ATE on 
Sybyl® and pictorial representation o f  some o f  the potent inhibitors in the alkyl 
series compounds, 4-nonylcoum arin-7-0-sulpham ate (18) and 3-nonyl-4- 
m ethylcoum arin-7-O-sulpham ate (71).
Com pounds with other functionalities at the C-3 and/or C-4 position o f  the 
coum arin ring showed varying degrees o f  potency. Com pounds 32 to 56 in the 4- 
substituted series (Table 3.4) showed good inhibitory activities at 10 //M , which 
range from 83% to 94% in MCF-7 cells and 83% to 98%  in placental microsomes. 
(Table 3.5) At 1 fj,M concentration, they still showed a good inhibition, ranging 
from 52% to 90% in M CF-7 cells and 52% to 96%  in placental microsomes. 
Testing at lower concentration such as 0.1 [iM distinguished 4-isopropylcoum arin- 
7-O-sulphamate (32) to be the best compound, which showed an inhibition o f  86% 
in placental microsomes. Interestingly, the activity drops trem endously for 4- 
tbutylcoum arin-7-0-sulpham ate (35) 19% at 0.1 juM concentration, even though 35 
was more active than 32 at 1 /iM . This indicates that a sterically hindering bulky 
group is preferred at the C-4 position for the com pound to fit perfectly at the 
enzyme active site and an isopropyl group seems to be possessing the optim al size. 
A sim ilar finding was also shown by Billich et al256 (Figure 3.11). Presence o f  
bulky tert-buty\ and adamantyl groups have shown to produce potent STS 
inhibitors, which was dem onstrated by the 2-'butyl or (l-adam antyl)-4H -chrom en-
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4-one-6-0-sulpham ate and 2-( 1 -adam antyl)-4H -thiochrom en-4-one-6-0-
sulpham ate synthesised by Billich et a l 256
x Relative IC50
04








Figure 3.11 : Sulphamates reported by Billich et al.
Similarly, com pounds 91 to 116 in the 3-substituted series also showed alm ost 
complete inhibition o f  > 99% at 1 /uM, in placental m icrosom es (Table 3.6). At 
lower concentrations such as 0.1 /JM  3-benzyl-4-m ethyl-7-0-sulpham ate (95) was 
found to be the most potent inhibitor with an IC50 o f  8 nM in placental microsomes, 
which is more active than EM ATE and equipotent to 667 COUM ATE, w hich is 
currently a phase 1 clinical trial candidate. At the enzyme active site the com pound 
95 is presum ably folding in such a way that it mimics the steroid scaffold and the 
flat benzene ring provides the necessary binding to the hydrophobic amino acid 
residues (Figure 3.12).
Figure 3.12 : A com puter m odelling pictorial representation o f  the other best 




The optimum size o f the substituent is an important factor in the inhibition o f E l-  
STS enzyme as well as the position o f the substituent, spacing o f atoms, and the 
presence and position o f the sulphamoyl group on the molecule. Koller et al 
synthesised several coumarin-based compounds with pKa values < 7 and suggested 
that the corresponding sulphates are substrates for aryl sulphatases. The best 
coumarin sulphate in their series o f compounds was sulphamoylated (3-1) by 
Bilban et al who found that it is 250 times less potent than EMATE (Figure
3.11). The most likely reason for this finding is that Koller et al tested their 
compounds on arylsulphatase A and B, which show only about 30% homology to 
STS and their natural substrates. Galactose sulphates in sulpholipids and 
glucosaminoglycans are structurally different from the natural substrate o f  steroid 
sulphatase, estrone sulphate. Also, the benzothiazolyl substituent in 3-1 may be 
sterically too demanding for tight binding to the enzyme active site. Therefore, the 
substituent at the C-3 position should be something that is hydrophobic, sterically 
not too hindering and rigid. The 3-benzyl substituent in compound 95 seems to be 
possessing the necessary hydrophobicity, ideal length and also sterically acceptable 
for the C-3 position for a tight binding at the enzyme active site. Since the I C 5 0  
values were rather large for 3-phenyl-4-m ethyl-7-0-sulphamate (93) (54 nM) and 
3-phenethyl-4-methyl-7-0-sulpham ate (98) (33 nM), which contains an extra CH2 
spacer group (Table 3.7). In vivo studies on compound 95 are currently in progress 
due to the highly promising I C 5 0  value o f 8 nM.
Bilban et al synthesised 3-phenyl derivatives with sulphamoyl groups at 7 and 6 
position o f the coumarin ring and found that the compounds with sulphamoyloxy
3-1 3-2
Figure 3.11 : Compounds reported by Bilban et al
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group at the 6 position (3-2) (Figure 3.11) is less potent than the corresponding 7- 
O-sulphamate.257 This proves that the bridging O atom at the 7 position o f the 
coumarin core is a prerequisite for potency.196
Compounds 110, 111 and 112 were synthesised in order to investigate the effects o f 
having substituents at different positions o f the coumarin ring in the enzyme 
activity (Tables 3.8 and 3.9). Since the nine-carbon containing compounds 15 and 
71 showed good biological activities, it was interesting to see the activity o f the 
compound, which contains a combination o f both drugs. Therefore, 3,4- 
dinonylcoumarin-7-O-sulphamate (110) was synthesised with two long nine carbon 
hydrophobic chains at the C-3 and C-4 positions o f  the coumarin ring. Such a 
feature presumably helps to increase the lipophilicity o f the compound to the 
optimum value, and to improve the binding ability at the enzyme active site. 
Activity results o f these compounds are not yet available to understand the binding 
mechanism and to make a clear comparison with the other coumarin analogues.
Overall, this study has revealed that coumarin sulphamates are potential STS 
inhibitors, which can potently inhibit E l-STS activity in MCF-7 cells as well as in 
placental microsomes. However, biological activity results o f all the compounds at 
even lower concentrations such as 0.001 /JM. and their corresponding IC50 values 
are required in order to get a clearer picture o f the nature o f the inhibition o f these 
compounds. Identification o f the most potent compound 95 produced a new lead 
and it may be a potential candidate for clinical evaluation.
3.4 Conclusion
We have further established in this work that coumarin sulphamates represent a key 
lead template for the optimaisation o f potential steroid sulphatase inhibitors and that 
highly potent derivatives could be designed by substituting at the C-3 and/or C-4 
positions o f the coumarin ring with hydrophobic moieties. Diagrammatically, we 
can compare the steroid backbone o f EMATE and the most active coumarin
10 0
sulphamates synthesised in this project (Figure 3.12).
(CH2)3CH3
Figure 3.12 : Diagrammatic comparison o f the best inhibitors, 4-nonylcoumarin-7- 
O-sulphamate (18), 3-nonyl-4-methylcoumarin-7-0-sulphamate (71) and 3-benzyl- 
4-m ethylcoum arin-7-0-sulpham ate (95) with EMATE.
It can be visualised that the coumarin ring mimics the A/B rings and the long 
hydrocarbon chain o f 18 and 71 and the benzyl group in 95 could be folded along 
the C/D rings o f EMATE as depicted. This could be used to explain the high 
potencies observed for these compounds and that they might be acting in a similar 
manner to that o f EMATE at the enzyme active site. In vitro studies have supported 
such a prediction as shown by the level o f potency observed for these compounds. 
Even though the compounds in the 4-alkyl series show a steady increase in 
inhibitory activity as the chain length o f alkyl group increase, the compounds in the 
3-alkyl-4-methyl series are more potent for the same alkyl chain length in placental 
microsomal preparation. Although the series o f compounds which have different 
substituents at the C-3 or C-4 positions showed good inhibitory activities, 
compound 95 was found to be the most potent compound with an I C 5 0  value o f 8 
nM in placental microsomes.
It is likely that the best inhibitors o f coumarin sulphamates are effective therapeutic 
agents and could be potentially development candidates for the treatment o f  HDBC,
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whose clinical use would allow the role and potential o f STS inhibitors in the 






A need for non-steroidal inhibitors emerged due to the highly estrogenic nature o f 
EMATE (2-20) (Figure 2.9, Chapter 2). The coumarin sulphamate derivatives with 
hydrophobic groups at the C-3 and/or C-4 position o f the coumarin ring have 
revealed the potential to design extremely potent E l-ST S inhibitors (Chapter 3). In 
addition, the encouraging biological activities obtained for the initial tricyclic 
COUMATEs (2.5, Chapter 2) has led to a further investigation on tricyclic 
coumarin sulphamates, which are presumably ABC ring mimics o f EMATE.
Our interest in the coumarin system as the core structure for the design o f  non­
steroidal STS inhibitors originated from the report o f coumestrol being an estrogen 
mimic. Coumestrol (4-1), which is a plant-derived tetracyclic coumarin compound 
initially isolated from alfalfa tree and red clover in high levels whose structure 
resembles that o f the natural estrogens. It interacts with the ER and has been 
demonstrated to produce estrogen-like effects in a number o f in vivo and in vitro 
models.90 Many coumestrol-type compounds containing a basic amine have been 
shown to be selective estrogen receptor modulators (SERMs). Therefore, it was 
reasoned that simple bicyclic coumarin sulphamates might exhibit steroid 
sulphatase inhibition, but they themselves or their starting coumarins are unlikely to 
be estrogenic. This reasoning was thus proved by the potency observed for 






Figure 4.1 : Structure o f  Coumestrol
The idea o f designing tricyclic COUMATEs as STS inhibitors emerged from the 
reasoning that the bicyclic coumarin moiety o f  COUMATE mimics the A/B ring 
system o f EMATE. Incorporation o f a third ring, which mimics the C/D ring o f  
EMATE would be beneficial. The initial tricyclic compounds synthesised, such as 
665 (2-80), 666 (2-81), 667 (2-82), 668 (2-83) and 6613 (2-84) COUMATEs 
supported such reasoning by exhibiting highly potent E l-ST S  inhibitory activity in 
human placental microsomal preparation (Table 2.5, Chapter 2). 667 COUMATE in 
particular was found to be even more potent than EM ATE in 'vitro w ith an IC50 
value o f 8 nM (c.f. IC50 = 25 nM for EMATE). 667 COUMATE is now being 
developed for Phase I clinical trials. To further improve the potency and also to 
investigate structure-activity relationship for this class o f  STS inhibitors several 
more tricyclic COUMATEs, with larger third ring sizes were synthesised in this 
project.
4.1 Synthesis
The starting cyclic y^-keto esters required for the synthesis o f tricyclic coumarin 
sulphamates beyond eight membered ring are unavailable commercially. Therefore, 
they were prepared by treating the corresponding cycloalkyl ketone with diethyl 
carbonate in the presence o f two equivalents o f sodium hydride (NaH) at room
9 SRtemperature (Scheme 4.1). This synthetic method exploits the reasonably high 
acidity o f  the or-protons o f a ketone, (pKa = 10-14), which can be removed by NaH 
and by NaOEt. The carbanion that forms undergoes a nucleophilic attack on the 
carbonyl carbon o f diethyl carbonate with the formation o f  the corresponding ethyl
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2-oxocycloalkyl carboxylic acid ester. Dieckmann condensation is another known 
method for the synthesis o f cyclic y^-keto esters, in which the a  carbon atom and the 
ester group for the condensation comes from the same molecule, i.e. intramolecular 
cyclisation. Though this is a valuable method, it is only useful for the preparation o f 
five or six membered rings.
Scheme 4.1 : Synthesis o f ethyl 2-oxocycloalkanecarboxylates (i) NaH, N2, 15 h,
Keto-enol tautomerism is a feature o f cyclic y^-keto esters (Figure 4.2). The 9- and 
10- membered ring containing ft-keto esters exist in the enol form as well as the 
keto form. When keto and enol forms are in equilibria, the tautomers are slowly 
inter-converted at R.T. Such tautomerism was not observed for the 11, 12 and 15 
carbon containing y#-keto esters. This is presumably due relatively fast interchange 
that is taking place between the keto and enol forms. The proton signals o f the 
individual isomers are clearly distinguishable in the NM R spectra o f  the 10 carbon 
containing p ~keto ester, ethyl 2-oxocyclodecanecarboxylate (120) (Figure 4.3). The 
two sets o f triplets corresponding to the CH3 protons at 8 1.24 ppm and 8 1.31 ppm, 
and a set o f quartets corresponding to the CH2 protons o f ethyl group at 8 4.13 ppm 




Figure 4.2 : Keto-enol tautomerism o f the y^-keto esters
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1.24 (t, 1.2H, keto CH2CH3) /=7.0Hz)
1.31 (t, 1.8H, enol CH2CH3,7=7.0Hz) , ^
4.22 (q, 1.5H, enol CH2CH3) 7=7.0Hz) =>
4.13 (q, 0.5H, keto CH2CH3) 7=7.0Hz) t >
12  10
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Figure 4.3 : NMR of ethyl 2-oxocyclodecanecarboxylate (120)
The strong deshielding effect o f internal hydrogen bonding in the enolic form is 
well recognised (Figure 4.2) and it is generally accepted that the magnitude o f the
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displacement o f  the OH signal to lower field is related to the strength o f  the 
hydrogen bond. The signal for the hydroxyl proton in the enol form was clearly 
visualised at 8 12.98 ppm for compound 120. The signal for the a-hydrogen o f  the 
keto species was observed as a multiplet at 8 3.82-3.85 ppm.
The 9, 10, 11, 12 and 15 ring containing parent coumarins were formed under 
Pechmann reactions by cyclising resorcinol and the corresponding ethyl 2- 
oxocycloalkanecarboxylates in the presence o f an equimolar mixture o f 
trifluoroacetic acid ( C F 3 C O O H )  and conc. sulphuric acid ( H 2 S O 4 )  as the 
condensing agent. The yields o f the tricyclic coumarins ranged from 14% to 33%. 
Such poor yields obtained were presumably due to the ring strain o f the large 
cycloalkane rings mainly the 9- and 11-membered ring, which undergoes severe 
ring strain during cyclisation o f the cyclic /?-keto esters with resorcinol. The parent 
hydroxycoumarins formed were subsequently sulphamoylated with freshly prepared 
sulphamoyl chloride (Scheme 4.2).
Scheme 4.2 : Synthesis o f tricyclic coumarin sulphamates (i)
Conc.H2S 0 4/Conc.CF3COOH, 3h, 0 °C to R.T. (ii) anhydrous DMF, NaH, N 2, 0 °C 
and H2N S 0 2C1, 0 °C to R.T.
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At the end o f the sulphamoylation reactions the pure products were obtained only in 
lower yields between 30-50%. This is possibly due to the instability o f the 
sulphamoylated compound. The weak O-S bond decomposes to its parent hydroxy 
compound. The unreacted starting materials were hence isolated. The COUM ATEs 
became more and more difficult to separate due to increased lipophilicity as the size 
o f  the third ring got bigger. This is because the difference in the polarity between 
the parent hydroxy compound and the sulphamates progressively becomes smaller 
as the size o f the third ring increases. As expected, recrystallisation o f 6615 
COUMATE proved to be difficult and it was obtained only as a waxy film.
Compounds
119 DG 237B 669 COUMATE
122 DG 161B 6610 COUMATE
125 DG 209B 6611 COUMATE
128 DG 163B 6612 COUMATE
131 D G 213D 6615 COUMATE
Table 4.1 : Structures o f the tricyclic coumarin-7-O-sulphamates 
4.2 Results
The ability o f  the tricyclic COUMATEs to inhibit STS activity was evaluated. All 
the compounds synthesised in this series are potent inhibitors o f E l-ST S  when 
tested in placental microsomes at various concentrations. (Table 4.2) The screening 
o f some o f the inhibitors at lower concentrations such as 0.01 /yM and I C 5 0  values 
are not yet available.
The biological activity o f the tricyclic COUMATEs can be summarised as follows:
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It was observed that the in vitro inhibitory activity was increased with the number 
o f carbon atom in the third ring up to 6610 COUMATE, and from there onwards 
gradually decreased (Figure 4.8). All the compounds synthesised were found to be 
very active with inhibitory activities o f >90% at 10 juM and 1 juM concentrations in 
placental microsomes. The inhibition ranges from 85% to 93% at 0.1 juM. It was 
found that 6610 COUMATE (122) is the most potent inhibitor in vitro with an IC50 
value o f 1 nM followed by 669 COUMATE (119) with an IC50 value o f 2.4 nM. 
Surprisingly, contrary to what was observed in vitro, 6615 COUMATE (131), 
which was the least active compound in vitro with an IC50 value o f  370 nM was 
found to be highly potent in vivo.
%  Inhibition in placental microsomes
10 juM 1 fJM. 0 .1 0.01 //M IC5 0 /1M
119 669COUMATE 93 ± 1 .5 91 ± 0 .9 85 ± 0.2 * 2.4
1 2 2 6 6 IOCOUMATE 95 ± 0 .8 92 ± 0.3 88 ± 0 .7 52 ± 5 .5 1
125 6611 COUMATE 93 ± 1 90 ±1 87 ± 1 * 13
128 6612COUMATE 99 ±0.1 95 ± 0 .6 93 ± 1 .5 * 60
131 6615 COUMATE 99 ±0.1 97 ± 0.4 90 ± 0.6 * 370
Table 4.2 : Inhibition o f E l-STS activity by the tricyclic COUM ATEs in placental 
microsomes. * = Results not available.
The sulphamates synthesised were observed to be increasingly lipophilic as the 
third ring got bigger. Therefore, to further understand the relationships between the 
inhibitory activities and the hydrophobicity o f tricyclic COUMATEs, log P values 
were determined using an HPLC analytical method and compared with those for the 
corresponding parent hydroxy compounds, estrone and EMATE (2-20).
1 1 0
4.3 Log P calculations for tricyclic COUMATEs
Quantitative structure-activity relationship studies have shown that there is a 
relationship between the hydrophobicity o f bioactive compounds and their 
biological activity. The absorption, distribution, metabolism and excretion (ADME) 
o f a compound are greatly influenced by its lipophilicity. It is a generally held view 
that very lipophilic compounds are the preferred targets for metabolism, often 
leading to high clearance values. In addition, lipophilicity positively correlates with 
a high plasma protein binding. A large volume o f distribution, probably due to a 
high fraction o f the compound bound to tissues, is often observed for lipophilic 
compounds.
Usually, the hydrophobic property o f a compound is expressed by the logarithmic 
value o f the partition coefficient o f the neutral form o f bioactive compounds 
between n-octanol and water (log Poct)- The partition coefficient o f  a bioactive 
compound can be obtained from the following equation:
P = Concentration o f bioactive compound in octanol
Concentration o f bioactive compound in aqueous solution
Hydrophobic molecules will prefer to dissolve in octanol and have higher P values, 
whereas hydrophilic molecules will prefer to be in the aqueous layer and have 
lower values. Log Poct is an indication that high lipophilicity (Log Poct > 4.5) causes 
poor solubility. The shake-flask method is the standard method for determining log 
Poct- However, determination by this method requires rigorous conditions to 
eliminate the effects o f  molecular association, acid dissociation and ion-pair 
formation between bioactive compounds and ions in the aqueous medium. This 
method forms emulsions that might produce false results. Therefore, centrifugation 
is necessary to separate the two phases and also this method requires relatively 
large amounts o f pure compounds and octanol. Furthermore, the exact 
determination o f  values below -2  and above 4 are very difficult and the whole
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0f\0process is time consuming. Therefore, a better and simple method for 
determining log Poct is highly desirable.
Since the latter half o f  the 1970s, many attempts have been reported using thin layer 
chromatography (TLC), high performance liquid chromatography (HPLC)261, 
dialysis261(a) and micro emulsion electro-kinetic chromatography260 for determining 
log Poct. As a result, chromatographic methods in particular have been regarded as a 
useful means for determining log Poct values, provided that they are employed 
carefully.
4.3.1 The procedure for determining the log Poct values of tricyclic 
COUMATEs and other compounds by HPLC
The HPLC procedure described by Lombardo et al261 was modified and used for the 
determination o f the log Poct values, which is now further discussed and explained 
in the context o f how it was used.
First, a standard regression line between log kw vs log Poct was obtained for several 
compounds with known log Poct values. For drug molecules, values calculated by 
the computer are often inaccurate and depending on the software used, they may 
differ by as much as two log Poct units. Log P for the test compounds were 
calculated using CS Chem Draw Pro 5.0 software to obtain approximate values. 
(Table 4.3)
Compounds Log P Compounds Log P
Estrone 4.40 6615 Coumarin 6.05
EMATE 3.73 COUMATE *
Coumarin * 665 COUMATE 1.21
665 Coumarin 1.88 666 COUMATE 1.63
666 Coumarin 2.30 667 COUMATE 2.04
667 Coumarin 2.71 668COUMATE 2.46
1 1 2
668 Coumarin 3.13 669COUMATE 2.88
669 Coumarin 3.55 6610COUMATE 3.29
6610 Coumarin 3.97 6611 COUMATE 3.71
6611 Coumarin 4.38 6612COUMATE 4.13
6612 Coumarin 4.80 6613 COUMATE 4.55
6613 Coumarin 5.22 6615 COUMATE 5.38
Table 4.3 : Estimated log P values using CS Chem Draw Pro 5.0 software.
* : Values not available on CS Chem Draw Pro 5.0 software.
According to the computed values the log P ranges roughly from 1.20 to 6.00. 
Using these values as guideline twelve different drug molecules with known log
*)f\ 1
Poct were selected from the literature to cover the same lipophilicity range.













Table 4.4 : Known log P oct, experimental log kw and log P hplc  values o f the 
standard drug molecules used for the regression line. (S.D ± 0.01 and n = 3)
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4.3.2 Experimental Procedure
In HPLC, the affinity o f a sample compound for the stationary phase is 
characterised by the capacity factor k o f the solute at a given mobile phase and kw is 
the capacity factor extrapolated to a 0% concentration o f the organic solvent in this 
case, methanol, k is expressed by Equation 1.
k = (tR -  to)/t0 (1)
to and tR are the retention times o f an unretained reference compound and sample 
compounds respectively. Pure methanol was regarded as the reference compound, 
which can be detected at a wavelength o f 210 nm. The retention time for pure 
methanol was determined to be 1.55 min. Injection o f compound was repeated three 
times at each mobile phase. As mobile phase, 90 : 10, 80 : 20 and 70 :30 methanol 
and water was used. An average value was taken for each mobile phase as tR and 
the corresponding k values were hence calculated from equation 1. The 
corresponding log k was calculated for each compound from the calculated k 
values. The log kw was generated from the extrapolated regression line between 
mobile phase vs log k (Figure 4.4), which was obtained from the regression 
equation generated for each regression line, which is the intercept on the curve.





Figure 4.4 : A typical graph o f mobile phase vs log k. 
log P o c t  = a + b logkw (2)
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A linear standard calibration curve (Figure 4.7) was generated between log kw and 
the known log P oct values o f the twelve drug molecules selected from the 
literature . A regression equation was produced for the treadline using M icrosoft 
Excel program, which is expressed by Equation 3.
y = 0.9495x + 0.8174 (3)
Where,
R2 = 0.9619
The estimated slope o f the final regression equation was within ± 0.05. R , which is 
the ‘coefficient o f determination’ was also within ± 0.05 and this value was also 
calculated using Microsoft Excel program. R is an indicator that ranges in value 
from 0 - 1 and reveals how closely the estimated values for the treadline
•y
corresponds to the actual data. The regression treadine is most reliable when its R 
value is at or near 1.
The same procedure was used for the tricyclic COUMATEs and the parent hydroxy 
coumarins together with estrone and EMATE. The corresponding log kw were 
calculated using the equations 1 and 2. Once the log kwwas calculated the log P hplc 
was obtained from the calibration curve generated for the standard drug molecules 
o f known log Poct either by directly reading o ff the regression line or calculated 
from the regression equation 3, where x = log kw o f the individual compounds 
(Table 4.5).
Calculated log k w and log P h pl c  values
Compounds Log kw Log P h plc
Estrone 2.97 3.64
EM ATE 3.28 3.92
Coumarin 1.01 1.82
665 Coumarin 1.66 2.39
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666 Coumarin 2.08 2.79
667 Coumarin 2.52 3.22
668 Coumarin 2.84 3.52
669 Coumarin 3.16 3.82
6610 Coumarin 3.62 4.26
6611 Coumarin 4.23 4.83
6612 Coumarin 5.08 5.64
6613 Coumarin 5.21 5.76
6615 Coumarin 5.71 6.24
COUMATE 1.01 1.77
665 COUMATE 1.61 2.34
666 COUMATE 1.99 2.71
667 COUMATE 2.46 3.15
668 COUMATE 2.79 3.46
669 COUMATE 3.09 3.75
6610 COUMATE 3.26 3.92
6611 COUMATE 4.19 4.80
6612 COUMATE 5.02 5.58
6613 COUMATE 5.18 5.74
6615 COUMATE 5.66 6.22
Table 4.5 : Experimental log kw and log P h p l c  values obtained for the tricyclic 
hydroxy coumarins and COUMATEs compared with estrone and EMATE. (SD ± 
0.02, n = 3)
1 mg o f each compound was dissolved in HPLC grade methanol and repeated three 
times at three different mobile phases, such as 90%, 80% and 70% methanol and 
the three points were extrapolated to the y-axis to give the kw for each compound. 
All the chromatographic measurements were taken on a Waters HPLC, which
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contains a reverse phase Waters Radialpak column (C l8.8 x 100 mm) at room 
temperature without the use o f octanol or any buffer. A number o f studies indicate 
that a monolayer o f  methanol molecules is adsorbed on to the alkyl bonded 
stationary phase from MeOH-FbO mobile phase, therefore it can be suggested that 
the stationary phase has a partial polar character and thus resembles n-octanol phase 
in octanol-H20 systems implying that it is not necessary to use an octanol-coated 
column.259
A diode array detector was used to monitor signals at 210, 230, 250 and 270 nm 
wavelengths and a flow rate o f 2 ml/min was used. At each mobile phase the entire 
sample set was run before the column is equilibrated to the next condition. All 
statistical analyses were performed by M icrosoft Excel program. Typical HPLC 
traces (Figures 4.5) and the graphs o f  mobile phase vs log kw (Figure 4.6) 
corresponding to EMATE and 6610 COUMATE are given below. Detailed 
calculations o f all o f the compounds are included in the Appendix C.
4 .3 .3  Factors that affect log P hplc
It should be noted that the log P determined by chromatographic methods is not the 
true partition coefficient o f a compound, but a parameter that is related to the true 
partition coefficient, and there is no theoretical relationship between log kw and log 
Poct- Therefore, the partition coefficient calculated in this work is hence called log 
P h p l c - However, this system is not suitable for determining high values o f log P h p l c  
because, increase o f  log Poct by one log unit requires about ten times increase in tR. 
The long elution times produce a broadening o f  the elution bands with inexact 







QSO 100 1.5) 200 250 300 33) 400 4.50 500 5SD
Mites
t ( D 2 D D 3 C D 4 C D 5 ( D 6 ( D 7 I D 8 a )
EM ATE 
(70:30 M ethanol:W ater)
6610 COUM ATE 
(70:30 M ethanol:W ater)
1 '( ' ' ' I > ' ' ' I"' ' 1 1 I '■ ' 1 1 I '
QB 100 ISO 2D  25D 3D 
Mite
EM ATE 
(80:20 M ethanohW ater)
6610 COUM ATE 
(80:20 M ethanol:W ater)
2 . 0 0 - i





0 . 5 0 -





0  0 0
o T“
J  v l - -- - - - - - - - -
CN
-  1
— --- — - - - - j--- i— 1— I--- ? | r ' - ' i '  i --- j--- I--- |--- i— i--- j--- 1--- i--- i— i— j-- - - |  --- i--- j--- i- - - - |--- j--- I--- j— i— 1





4 —  I -
2.50 3.00 3.50
EM ATE 
(90:10 M ethanol:W ater)
6610 COUM ATE 
(90:10 M ethanohW ater)
Figure 4.5 : Examples o f  typical HPLC traces o f  EM ATE and 6610 COUM ATE at 
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Figure 4.6 : Graphs o f  mobile phase vs log k o f EM ATE and 6610 COUM ATE at 
different methanol : water concentrations generated by M icrosoft Excel program.
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y = 0.9495x + 0.8174 
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Figure 4.7 : Calibration curve generated for log kw vs log P o f compounds with known log P values
Other major factors that affect the log P h p l c  are : (1) Temperature needs to be
constant at all times. Here we have regarded room temperature to be the constant
experimental temperature. (2) The nature o f the stationary phase : tR is directly
related to the affinity o f the test compound for the stationary phase, therefore the
right choice o f stationary phase is important. Generally, for a hydrophobic
stationary phase such as octadecyl silica (ODS), n-octanol or a buffer (MOPS
buffer)261 is eluted through the column and stabilised, before the use o f  the test
compound. Minick et al had used an MC-8 column coupled with octanol and a
small amount o f /7-decylamine in the aqueous phase.264,265 But, an electrostatically
coated silica phase might not require a modifier such as rc-decyl amine. On the other
hand, having octanol might be beneficial to reproduce the intermolecular
interactions experienced by a solute in the ‘shake-flask’ method and might reduce
1
the retention times slightly.
However, we have ignored this factor and assumed the column (Waters Radialpack 
column) as having an ‘octanol-like’ property. Since the data obtained by Lombard 
et al, with and without octanol did not show a vast difference in the correlation, and 
gave a slope, which is close to unity in both instances, however, the errors are 
slightly higher in the absence o f octanol. Equation 2 represents a linear free energy 
relationship in which the slope is an estimate o f how closely the free energies o f the 
processes compare. A slope close to 1 implies that the two processes have similar 
free energy changes. In this work, a slope o f 0.9495 was obtained without the use o f 
octanol. (3) The length and the diameter o f the column must be the same through 
out the course o f the measurements. We have used a fairly short column to enhance 
the throughput o f the method (4) The composition o f the mobile phase: In RP- 
HPLC, the mobile phase consists o f buffering aqueous solution and a water- 
miscible organic solvent such as methanol, acetonitrile or tetrahydrofuran. We have 
chosen methanol and water o f various concentrations to be the mobile phase. In 
general, log k decreases with increase in the concentration o f the organic solvent in 
the mobile phase (5) The flow rate, which must be constant for all injections and we 
have used 2 ml/min for all measurements.
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I have used a fairly acceptable number o f  standard compounds o f  12 for the 
calibration curve (Table 4.4) with a good degree o f accuracy across a wide range o f 
lipophilicity values and hydrogen bonding properties. Considering all the 
assumptions and modifications done to the procedure described by Lombardo et
O f  1al , the log P h p l c  values obtained are fairly accurate and within a range o f ± 1.0 
when compared to the computed values o f these tricyclic compounds. We have 
demonstrated that this is a fairly accurate and rapid method for determining log P 
values with minimal manual intervention. Log P value o f a compound is an 
important parameter to predict the solubility, permeability and clearance in the 
body. Therefore, the log P h p l c  values obtained could be used to explain the greater 
activity observed for the tricyclic compounds in vitro especially, the higher 
members o f the series.
4.4 X-ray crystallography
X-ray crystal structures o f 669 COUMATE and 6610 COUMATE were obtained in 
order to explore the conformation o f the third ring in the crystal lattice and also to 
understand how it might bind to the enzyme active site. Suitable crystals o f  these 
compounds were obtained by slowly recrystallising from THF : hexane = 3:2. 
Approximate dimensions are o f these crystals used for data collection are : 669 
COUM ATE (119) = 0.25 x 0.25 x 0.10 mm and 6610 COUMATE (122) = 0.30 x 
0.20 x 0.20 mm. Measurements were made on a Nonius Kappa CCD diffractometer 
(Figures 4.8 and 4.9).
All three rings and the key features are clearly visible in the structures obtained. 
The asymmetric units o f 669 COUMATE and 6610 COUM ATE are seen to consist 
o f a repeating unit o f two molecules together with half a molecule o f hexane is one 
o f the solvents used for the recrystallisation. The molecules are linked together by 
intra/intermolecular hydrogen bonding involving NH2 hydrogens. The geometric 
parameters for both molecules are similar within two estimated standard deviations.
1 2 2
Figure 4.8 : X-ray crystal structure o f 669 COUMATE (119)
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Figure 4.9 X-ray crystal structure of 6610 COUMATE (122)
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When looked through one o f the sides o f the crystals, it can be seen that the third 
cyclic ring folded in such a way that it exist in its lowest energy conformation. The 
aromatic ring is flat and rich in delocalised electrons, whereas the adjoining 
coumarin ring is relatively electron deficient due to the two electronegative oxygen 
atoms. Therefore, the two molecules form an interaction between their pi electron 
systems and hence stacked on top o f each other to form pi molecular complexes.
From these X-ray crystal structures, the absolute conformation o f 669 COUM ATE 
and 6610 COUMATE molecules can be reliably determined. For 669 COUMATE, 
all C-C bond lengths were between 1.353 -  1.552 A, all the C -0  bond lengths were 
between 1.207 -  1.409 A, all the S -0  bond lengths were between 1.418 - 1 .614A  
and the S-N bond lengths were 1.581 and 1.595 A. The bond angles are in the range 
o f 101.32 -  126.7 °. The symmetry transformation used to generate equivalent 
atoms : -x+1, -y, -z+1 through C(101). For 6610 COUMATE, all C-C bond lengths 
were between 1.361 -  1.597 A, all the C -0  bond lengths were between 1.215 -  
1.413 A, all the S -0  bond lengths were between 1.4146 - 1.6141 A and the S-N 
bond lengths were 1.576 and 1.587 A. The bond angles are in the range o f 102.43 -  
126.1 °. The symmetry transformation used to generate equivalent atoms : -x+1, - 
y+1, -z through C(103). For full details, see Appendix D (1) and (2).
4.5 Discussion
4-M ethylcoumarin-7-0-sulphamate (COUMATE) (2-70) was one o f the first potent 
non-steroid based inhibitors identified.196 It is possible that this 2-ringed compound 
might mimic the A and B rings o f  steroid based inhibitors, such as EM ATE (2-20) 
(Figure 4.10). Therefore, it is reasonable to expect that a compound that mimics the 
A, B and C or D rings o f EMATE or the steroid nucleus would be an even better 
inhibitor. Hence a series o f tricyclic COUMATES (665, 666, 667, 668 and 6613 
COUMATEs) were synthesised and tested. 665 COUMATE (2-80) was proved to 
be 4-times more potent than the 2-ringed COUMATE (2-71) with an I C 5 0  o f 200
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nM, (Table 2.4 and 2.5, Chapter 2) which suggested that such a strategy could 
lead to the developm ent o f  more potent STS inhibitors than EMATE. The best 
com pound was found to be 667 COUM ATE (2-82) (Figure 4.10), whose IC50 o f  8 
nM  in placental m icrosomes is some 3-fold better than EM ATE (c.f. 25 nM). Such 
findings further validated our reasoning that inhibitory activity o f  a bicyclic 
coum arin sulphamate against STS can be increased by the incorporation o f  a third 
ring, which mimics the C/D rings o f  EMATE.
EM ATE 667 COUM ATE
6611 COUM ATE 6612 COUM ATE
Figure 4.10 : X-ray crystal structures o f  EM ATE (2-20), 667 COUM ATE (2-82) 
and computer m odelling pictorial representation o f  6611 COUM ATE (125) and 
6612 COUM ATE (128) on Sybyl®.
O f all the compounds synthesised in this series, 6610 COUM ATE proved to 
possess the optim al size o f  the third ring for the binding to the enzyme active site
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and hence was found to be the most potent STS inhibitor in vitro. 6610 COUMATE 
has an IC50 value o f 1 nM, which is some 8-times and 25-times more potent than 
667 COUMATE (c.f. IC50 = 8 nM) and EMATE (IC50 = 25 nM) in vitro. One 
possibility for the most potent STS inhibition observed with 6610 COUMATE 
might be that its third, 10-membered carbon ring folds in such a way that the 
interactions o f the ring with those amino acid residues at the active site, which 
normally interact with the C and D rings o f the steroid nucleus. The relatively sharp 
decline in potencies observed for 665 and 6615 COUMATEs has suggested that the 
interactions o f their third ring with the amino acid residues in the enzyme active site 
are the least effective, either because it is too small or bulky. On the contrary, 669, 
6610 and 6611 COUMATEs were all potent inhibitors with IC50S of 2.4 nM, 1 nM 
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Figure 4.11 : Effects o f the number o f carbon atoms in the third ring o f tricyclic 
coumarin sulphamates (665-6615 COUMATEs) on inhibition o f STS activity in 
placental microsome preparation. The I C 5 0  value for each individual inhibitor is 
shown on the X-axis.
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Figure 4.12 : In vivo inhibition of rat liver E l-S T S  activity by 665-, 667-, 6610- 
and 6615 COUM ATEs. Female W istar rats were treated with a single dose o f 
vehicle, propylene glycol as control or the inhibitors at 0.1 mg/Kg and 1.0 mg/Kg. 
E l-S T S activity was measured in samples of liver hom ogenate obtained 24 h after 
administration of the oral dose. Results are expressed as the percentage of 
remaining E l-S T S  activity compared with that in control animals (mean ± SD, n = 
3). (a) 0.1 mg/Kg; a, p<0.05 compared with controls, (b) l.Omg/Kg; a, p<0.001 
versus 667 COUM ATE; b, p<0.001 versus 6610 COUM ATE.
From the in vitro results, 6610 and 6615 COUM ATEs were selected for in vivo 
studies. A single dose o f 0.1 mg/Kg or 1.0 mg/Kg, p.o was administered to fem ale 
rats. Unexpectedly, 6615 COUM ATE with an in vitro IC50 value 370-times lower 
than that for 6610 CO UM ATE proved to be the m ost potent inhibitor in vivo. O f the 
series of compounds tested at 0.1 mg/Kg dose, 6615 CO UM ATE (131) was the 
only com pound produced a small, but statistically significant (p<0.05) decrease 
(23%) in liver E l-S T S  activity. However, at 1.0 m g/Kg all the compounds tested 
significantly inhibited liver E l-S T S  activity (Figure 4.12). 667 CO UM A TE 
resulted in an 86% inhibition of E l-S T S  activity com pared with that for anim als 
receiving vehicle only. 665 COUM ATE was less potent, achieving 75% inhibition
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with 6610 COUMATE having a similar inhibitory potency to that of 667 
COUMATE. Surprisingly, in view o f its in vitro activity, the most potent 
compound in vivo was 6615 COUMATE inhibiting El-STS activity by 94%. This 
is significantly (p<0.001) greater than the 86% inhibition achieved by 667 
COUMATE at 1.0 mg/Kg. It is obvious that further studies are required to account 
for this apparent contradictory in vitro and in vivo inhibitory profile o f 6610 and 
6615 COUMATEs. Such findings are possibly due to species difference in STS 
since in vitro studies were carried out using human placental microsomes whereas 
for in vivo studies rat model was used (Figure 4.13). Also, the high lipophilicity of 
6615 COUMATE as a result o f its larger third ring might have profoundly affected 
the pharmacokinetics o f the inhibitor in vivo.
Figure 4.13 : In vitro inhibition of rat liver El-STS activity by 667- and 6615 
COUMATEs. (mean ± SD, n = 3). Figures in parentheses represent the percent 
inhibition compared with control animals.
There is now much evidence that in addition to the potential therapeutic roles in 
oncology and immunology, STS inhibitors may be o f value in the treatment of
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some disorders o f cognitive function such as Alzheimer’s disease. Hence the 
ability o f 6610 COUMATE, the best in vitro inhibitor in the series to inhibit brain 
STS activity in vivo was studied (Figure 4.14). Similar to what was seen previously 
for EMATE,221 6610 COUMATE also effectively inhibited STS activity by 76% in 
brain tissues at an oral dose o f 0.1 mg/Kg. However, at a lower dose no significant 
inhibition o f brain STS activity was detected.
5 r
E 1 -STS 
( nmol /  h / 
mg p r o t e i n ) 3
Control 8610 6610
Q. 1 1 -0
Figure 4.14 : Effect o f 6610 COUMATE on rat brain sulphatase (in vivo). At the 
higher dose brain El-STS activity was inhibited by 76% (means ± SD, n = 3). Dose 
: 0.1 and 1 mg/kg body weight, oral dose, 3 rats/dose, sacrificed after 24 hrs o f 
treatments.
The inhibition o f STS activity in white blood cells (WBC) was also examined with 
6610- and 6615 COUMATEs (Figure 4.15) using the method developed 
previously266 in which the extent and duration of STS inhibition was monitored. At 
0.1 mg/Kg 6615 COUMATE inhibited WBC-STS activity by 45% whereas, 6610 
COUMATE showed no effect. However, at a higher dose o f 1.0 mg/Kg both 
compounds almost completely inhibited WBC-STS activity.
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Figure 4.15 : Effect o f 6610 COUMATE and 6615 COUMATE on El-STS 
activity in white blood cells 24 h after administration (p.o.) o f a single 0.1 mg/Kg or
1.0 kg/Kg dose (means ± SD, n = 3). Figures in parentheses represent the percent 
inhibition compared with control animals.
The log P values o f these tricyclic COUMATEs have been determined by HPLC in 
order to establish if  there is a correlation between the hydrophobicity o f an inhibitor 
and its observed biological activity. According to the computed values the log P 
ranges from 1.88 to 6.05 for coumarins and 1.21 to 5.58 for COUMATEs. It can be 
observed that the log P values increase steadily as the third ring gets bigger and the 
log P value o f the parent hydroxycoumarins are reduced when they are 
sulphamoylated. This trend was clearly observed from the log P values calculated 
for the corresponding parent compounds and the sulphamates (c.f. 6610 Coumarin 
= 3.97, whereas 6610 COUAMTE = 3.29) (Table 4.5).
The experimental log P h p l c  values ranges between 1.82 to 6.24 for the coumarins 
and 1.77 to 6.22 for COUMATEs. At least for the in vitro results, it appears that 
inhibitors whose potencies are better than or similar to that o f EMATE have
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experimental log P values in the range from 3.15 to 4.81 (Table 4.5). In particular, 
the log P h p l c  value obtained for 6610 COUM ATE and EMATE are 3.92. W ith the 
experimental log P h p l c  value o f 6610 COUMATE being similar to EMATE, 
despite the fact that the non-steroidal inhibitor is 25-fold more active, it is possible 
that the improved potency observed for 6610 COUMATE might be attributed to 
other contributory factors in addition to the hydrophobicity o f the molecule, such as 
a greater sulphamoyl group transfer potential, i.e. lower pKa o f 6610 coumarin with 
respect to estrone.
The contradicting in vitro and in vivo activities o f 6615 COUMATE (Calculated log 
P = 6.22, Table 4.5) are rather difficult to explain, since one would expect that a 
compound, which has a log P value greater than 5 to be less active. One o f 
Lipinski’s ‘rule o f 5 ’ states that a highly lipophilic drug (log P > 5) is more likely to 
have poor solubility, absorption or permeability and would not be an active drug. 
However, there are other factors, which contribute to the activity o f a drug 
molecule, such as the nature o f binding o f the drug at the enzyme active site. 6615 
COUMATE was assayed in vitro, in human placental microsomes preparation, 
whereas in vivo an animal model was used. Therefore, this difference in biological 
testing could be playing a major part in the observed difference in potencies in vivo. 
However, a definite explanation cannot be established unless further work is carried 
out.
The conformation in which the cyclodecene ring o f 6610 COUM ATE adopts upon 
binding to the enzyme active site might be such that it renders a very efficient 
interaction with those amino acid residues, which normally recognise the backbone 
o f EMATE. The same reasoning can be applied to rationalise the relatively higher 
potency observed in vitro for 669 COUMATE ( I C 5 0  = 2.4 nM). Although the X-ray 
crystal structures o f these compounds cannot show clearly the conformations these 
cycloalkene rings adopt on the enzyme, diagrammatically, it can be shown that the 
third ring in tricyclic coumarins could fold in such a way at the enzyme active site 
as to mimic the C/D rings o f EM ATE as depicted (Figure 4.16). The lower
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potencies observed for 6611 and 6612 COUMATE are presumably due to their 
highly strained third ring, which might experience difficulty in forming the 
conformation like the steroid C/D ring at the enzyme active site hence, poor binding 
to the active site amino acids.
o
EMATE 669 COUMATE 6610 COUMATE
Figure 4.16 : Diagrammatic comparison o f the folding pattern o f  the third ring in 
669, 6610 and 6615 COUMATEs with EMATE.
The 17/?-substituted carbamoyl (2-56) and the 7V-alkanoyl derivatives (2-57) o f 
EM ATE synthesised by Li et al are more potent inhibitors in vitro, but yet more 
lipophilic than EMATE (Figure 2.13, Chapter 2). This could perhaps be because, 
Li et aVs compounds are exploiting an active site’s hydrophobic pocket in the 
region o f  C-17 o f EMATE and hence an increase in log P causes an increase in in 
vitro activitiy. However with the tricyclic COUMATEs, which are presumably 
ABCD ring mimics o f EMATE, the log P values should be as close to that o f 
EM ATE as possible for them to be as potent as EMATE. This is exhibited by the 
calculated log P value o f 6610 COUMATE (log P = 3.82), which is found to be 
similar to that o f EMATE (Table 4.5).
4.6 C onclusion
We have further established in this work that tricyclic coumarin sulphamates 
represent a key lead template for the optimisation o f  potential STS inhibitors and 
highly potent non-steroidal, non-estrogenic derivatives can be produced by 
enlarging the third ring. In summary, the optimal size o f the third ring for achieving 
the highest potency in a placental microsomes preparation is 10 as shown by the 
I C 5 0  value for 6610 COUMATE, which was found to be 800-, 8- and 370 times
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more potent than COUMATE, 667 and 6615 COUMATEs respectively. In the 
same assay, 6615 COUMATE was found to be the least potent inhibitor o f the 
series (IC50 = 370 nM). However, upon evaluation o f 665-, 667- and 6615 
COUMATEs in vivo for the inhibition o f rat liver E l-ST S  activity, 6615 
COUMATE was found to be more potent (94% inhibition at 1 mg/kg dose) than 
667 COUMATE (86%) (Figure 4.9), which is contrary to what would be expected 
from their in vitro activities. It is possible that the in vivo finding o f 6615 
COUM ATE being the most potent inhibitor o f STS activity could be due to the 
entry o f 6615 COUMATE into tissues being facilitated by its higher lipophilicity, 
even though the log P o f a bioactive drug should optimally be < 5. However, further 
studies are required to account for the differential in vitro and in vivo activities 
observed for 6615 COUMATE.
W hilst the most potent inhibition o f STS in vitro was achieved with 6610 
COUMATE, this inhibitor was found to be not as potent as its higher congener 
6615 COUM ATE in vivo. The X-ray crystal structures have revealed some 
interesting conformations o f these non-steroidal compounds (Figures 4.8 and 4.9). 
The log P values o f tricyclic COUMATEs might influence their biological activity, 
although it is unlikely that such property is the only contributory factor. These 







W hilst all steroidal inhibitors o f STS are primarily derivatives o f EM ATE (2-20) 
(Figure 2.9, Chapter 2),187,221,224 and non-steroidal inhibitors apparently have more 
structural diversity than their steroidal counterparts. Sulphamates o f single ring 
compounds, such as (p-O-sulphamoyl)-A-alkanoyltyramines (2-66) and DES 
derivatives190 (5-1), bicyclic compounds such as THN sulpham ates190 (5-2) and
1 Qf \  91 Q 9 9 0coumarin sulphamates, ’ ’ (5-3) tricyclic compounds such tricyclic
COUM ATEs220,219 (5-4) (Chapter 4) and flavonoids268 (5-5) are all STS inhibitors 
albeit to a different levels o f potency (Figure 5.1).
N y ( C H 2)nCH3
h 2n s o 2o '  ^  0  x
2-66 5-2
(/?-0-Sulphamoyl)-./V-alkanoyltyramine Diethylstilbestrol Tetrahydronaphthol
n = 5 - 13 Derivatives Derivatives
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Figure 5.1 : Structures o f the non-steroidal compounds explored so far
These compounds all share a common pharmacophore, which is a phenolic ring 
structure, another adjacent ring, a hydrophobic moiety attached to it and most 
importantly, the sulphamoyloxy group.196 Although much success and progress
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have been with coumarin sulphamates, it would be interesting to explore 
sulphamates o f other structural moieties, which could also potentially be active 
against the STS enzyme.
Indole is an important heterocyclic system because it is built into proteins in the 
form o f the amino acid tryptophan and also it provides the skeleton for many 
biologically active compounds and alkaloids. The incorporation o f an indole moiety 
in biologically active compounds intended for endocrine therapy is not 
unprecedented. But, several indole containing compounds have been reported
9AQ 9 7 0previously possessing antiestrogenic activities against mammary carcinomas ’
971 979and also inducing angiogenesis and apoptosis. ’
The work carried out by von Angerer et al identified a new class o f mammary
9 * 0  7 7 0
tum our inhibitors, the 2-(hydroxyphenyl)indoles. ’ The most promising 
compound o f this class, 5-acetoxy-2-(4-acetoxyphenyl)-l-ethyl-3-methylindole 
(Zindoxifene) (5-6), was shown to be metabolised substantially to its hydroxy 
conjugate (5-7) in vivo, which acts as a potential antiestrogen for the treatment o f
970
hormone dependent malignancies (Figure 5.2). l-Ethyl-4-chloro-2-(2,6-dichloro-
4-hydroxyphenyl)-6-hydroxy indole (5-8) was found to have high affinity for the 
estrogen receptors and inhibit the growth o f the 9 ,10-dimethyl-1,2- 
benz[a]anthracene (DMBA) induced mammary carcinoma o f the Sprague-Dawley 




5-6 R = COCH3 (Zindoxifene) 5 . 3 R = OH
5-7 R = H 5 . 9  R = 0 S 0 3‘ 5-10
F igure 5.2 : Structures o f indole containing compounds with anti-tumour activities
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In subsequent work, Bimbock et al synthesised a number o f mono- and disulphated 
derivatives o f 2-(hydroxyphenyl)indoles to determine their sulphatase inhibitory
9 7 4activities. O f all the derivatives synthesised, compounds 5-9 and 5-10 were the 
most potent, with IC50 values o f 210 //M  and 80 /JM. respectively (Figure 5.2). In 
these compounds, the presence o f the two S O 4 '  groups at positions C-6 and C-4’ 
and the bulky hydrophobic group at the indole nitrogen are expected to be the 
features responsible for this marked increase in enzyme inhibitory activities.274
Extensive studies carried out by von Angerer et al on heterocyclic structures have 
demonstrated that side chains, characterised by a polar function such as an amide, 
or sulphoxide group linked by a polymethylene spacer group to the receptor binding 
moiety, determine the endocrine profile in respect to antagonism and potency. A 
number o f l-benzyl-2-phenylindoles and 1,2-diphenylindoles were synthesised and 
5 -hydroxy-2-(4-hydroxypheny l)-3 -m ethyl-1 - [3 - [3 -(pentylsulphonylmethyl)benzyl
97 5oxy]benzyl] indole (5-11) has now been identified as a potent antiestrogen 
(Figure 5.3). It has been deduced that the existence o f two hydroxyl groups in the 
molecule are prerequisite for a strong binding interaction with the estrogen receptor 
site. It is feasible that the methylene group, which acts as a hinge between the 
indole nitrogen and the phenyl group in the 1 -benzyl-2-phenylindoles, mimics one 
o f  the tetrahedral carbon atoms in the steroid, giving rise to an orientation o f  the 
side chain similar to that o f the steroidal pure antiestrogens.
O C H j - m - C f i ^ - C H j - S O z - C s H , ,
5-11
Figure 5.3 : Structure o f  5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-l-[3-[3- 
(pentylsulphonylmethyl)benzyloxy]benzyl]indole
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W hen compared with the most popular antiestrogen tamoxifen, the indole 
compounds are superior at higher doses and are capable o f reducing the initial 
tumour size while tamoxifen only delays the average tumour growth. The reduction 
o f the average tumour size caused by the indole derivatives is due to the large 
fraction o f the tumours regressing after administration.270 W hen given in large 
doses, indoles accumulate in the target cells by binding to the ER and develop their 
antineoplastic activity via an estrogenic mechanism and non-specific cytostatic 
effects on hormone-independent mammary tum our cells. These indoles were also 
tested for their estrogenicity and antestrogenic activity in vivo and estimated in 
immature mice uterine weight test. It was found that the position o f the oxygen 
functions and the size o f the alkyl residues influence the character o f  the phenyl 
indoles and any minute alterations such as replacing the ethyl group with any other 
alkyl chain changes the biological profile o f that compound. This is presumably due 
to the difference in conformational changes that occur in the drug-receptor 
complex.270
The finding that compound 5-10 is a substrate for the STS enzyme,213’274 has 
suggested that its mono- or bis-sulphamate might potentially be an irreversible 
inhibitor o f  the enzyme. We observed a similar property with coumarin sulphate, 
which is a substrate for STS, and went on to develop coumarin sulphamates as 
time- and concentration dependent inhibitors o f  STS. Our initial approaches to the 
design o f indole sulphamates as STS inhibitors were to sulphamoylate the indole 
ring at various positions, and investigate the inhibitory activities against STS. These 
investigations should provide a way for designing polycyclic indole sulphamates, 
with either fused or non-fused ring system in much the same manner as the 
development o f coumarin sulphamates.
Therefore, to identify a new lead for a non-steroidal inhibitor and also as part o f the 
on going programme to develop nonsteroidal inhibitors o f E l-ST S, indole ring 
system was chosen to explore further. Various indole sulphamate derivatives were 
hence synthesised with sulphamoyl group at the C-4, C-5 or C-6 positions o f the
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indole ring (Figure 5.4).
Figure  5.4 : General structure o f the indole sulphamates synthesised. X = Xi = X2 
=002SNH2, R = Alkyl chain and Ri = H, alkyl or benzoyl group.
5.1 Synthesis
Since its first isolation in 1866 by A dolf Baeyer as a result o f  his studies on the
7 7  f \degradation o f indigo, the synthesis o f the indole ring system has captured the 
interest o f organic chemists. Because o f the potent biological activities exhibited by 
various indole derivatives, the methods o f construction o f this heterocyclic system 
have been subjected to considerable attention. Building an indole ring is well 
known. However, in this work, commercially available indoles were utilised to 
prepare the required indole sulphamates. The corresponding hydroxyindoles were 
deprotonated with NaH followed by an excess o f sulphamoyl chloride furnished the 
desired indole-4-O-sulphamate (132), indole-5-O-sulphamate (133) and 2- 
indolecarboxylic acid-5-O-sulphamates (134) in 39%, 32% and 49% yields, 
respectively (Scheme 5.1).
132 X! = OH Y, = 0 0 2SNH2 
x 2 = h  y 2= h
R = H  R = H
133 X, = H Yj = H
X2 = OH y 2= o o 2sn h 2 
R =H R =H
134 Xj = H Y, = H
X2 = OH y 2= oo2sn h 2
R = C02H R = C02H
Schem e 5.1 : Synthesis o f indole sulphamates (i) Anhydrous DMF, NaH, N 2, 0°C 
and H2NSO2CI, 0°C to R.T.
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2-M ethyl-5-methoxyindole was demethylated with aluminium chloride (AICI3) to 
form the corresponding 5-hydroxyindole (140) in 35% yield. W hen compound 140 
was sulphamoylated with an excess o f sulphamoyl chloride using the usual 
procedure (Scheme 5.2), it was observed from the N M R spectra that the C-3 





Scheme 5.2 : Synthesis o f compound 141 (i) AICI3, dry toluene, reflux, N 2, 3 h (ii) 
anhydrous DMF, NaH, N 2, 0°C and H2N S 0 2C1, 0°C to R.T.
Indoles in general are very weak bases due to delocalisation o f the nitrogen lone 
pair into the aromatic ring system. In a hydroxylated indole, the hydroxyl group at 
C-5 is more acidic (pKa ~ 10) than the N-proton (pKa ~ 17) therefore, deprotonation 
by 1 equivalent o f NaH occurs almost exclusively at the hydroxyl group. Hence, the 
nucleophilic substitution by the sulphamoyl group readily takes place at the 
hydroxyl position first. Although Af-sulphamoylation was not observed, it is 
possible that some deprotonation o f the N-H also takes place. But, the resulting N- 
sulphamoylated compound is very unstable to isolate.
In addition to the desired sulphamoylation at the C-5 hydroxyl group o f  140, it was 
observed that sulphamoylation had also occurred at the indole C-3 position. 
Although this was disappointing it was not entirely surprising, because the C-3 
position is the most highly electron-rich position in the indole system. Generating 
the oxyanion would also seriously activate the C-3 position and hence it easily 
undergoes electrophilic substitution at C-3 position to form a stable product
140
(Scheme 5.2).
c ij- s o 2n h 2
s o 2n hh 2n o 2s  h
F igure  5.5 : Electrophilic substitution by the sulphamoyl group at the C-3 carbon.
Sulphamoylation at the C-3 and C-5 positions o f the indole ring was observed in the 
corresponding NM R spectrum o f compound 141. The N-proton was clearly visible 
at 8 11.86 ppm, indicating that sulphamoylation had not occurred at this position. 
Deuteration causes a rapid exchange o f the N-proton at neutral pH and also the four 
sulphamoyl protons, which were observed at 8 7.84 ppm. In the N M R spectrum o f 
141, the C-3 proton signal, which appeared at 8 5.97 ppm for the compound 140 
was absent. Such out come was not observed with compounds 132 and 133 which 
are unsubstituted at C-2 and C-3 positions, and also with compound 134, which has 
a carboxylic acid group at the C-2 position. The presence o f the electron-donating 
methyl group at the C-2 position o f 141 must presumably be activating the C-3 
carbon towards a nucleophile such as a sulphamoyl group.
Deprotonation o f the indole nitrogen allows the introduction o f a variety o f alkyl 
groups by simple nucleophilic substitution reactions. To synthesise further 
derivatives o f indole sulphamates, the N-proton was alkylated with methyl and 
ethyl groups. According to von Angerer, having a lipophilic side chain at the indole 
nitrogen shows a moderate to strong binding affinity for the estrogen receptor 
protein.269 Therefore, the sodium salt formed from commercially available 5- 
methoxy-2-methylindole and NaH was alkylated with the corresponding alkyl 
iodide to produce l,2-dimethyl-5-methoxyindole (142) and l-ethyl-2-methyl-5- 
methoxyindole (145) in 22% and 68% yields, respectively (Scheme 5.3).
141
Although compounds 142 and 145 were the major products isolated, a small 
fraction o f 1,3-alkylation product was also obtained during the synthesis o f 
compound 145. This probably due to subsequent alkylation o f  the highly electron- 
rich C-3 position o f the N-alkylated indole with excess electrophile. The same 
could have taken place in the synthesis o f compound 142, which may explain the 
poor yield obtained for this reaction. Unfortunately, this cannot be confirmed since 
the impurities from this reaction could not be separated.
HO.
142 R = C H 3 143 R = C H 3
145 R = CH2CH3 146 R = CH2CH3
( i i i )( iv )
(v )  h 3c o .
c h 3
148 R = CH3 144 R = CH3 
147 R = CH2CH3
HO.
R R
150 R = C H 3 149 R = CH3
Schem e 5.3 : Synthesis o f 2-m ethyl-l-alkylindole-5-O-sulphamate derivatives (i) 
NaH, DMF, RI, R.T. N 2, 3 h (ii) AICI3, dry toluene, reflux, N2, 3 h (iii) anhydrous 
DMF, NaH, N 2, 0°C and H2N S 0 2C1, 0°C to R.T. (iv) A1C13, CH2C12, benzoyl 
chloride, 3 h, R.T. (v) NaBH4/CF3COOH, CH2C12, 0°C to R.T., N 2, 12 h.
The A-alkylated indole derivatives were subsequently O-demethylated with AICI3 
(Scheme 5.3) to form the corresponding 5-hydroxy derivatives l,2-dim ethyl-5-
142
hydroxyindole (143) and l-ethyl-2-methyl-5-hydroxyindole (146) in 56% and 52% 
yields, respectively, before sulphamoylated with an excess o f sulphamoyl chloride 
by the usual procedure. Clean reactions were observed and produced the desired 
l,2-dim ethylindole-5-0-sulpham ate (144) and l-ethyl-2-m ethylindole-5-0  
sulphamate (147) as crystalline products in rather poor yields o f 14% and 10%, 
respectively. Like what was observed with the compound 141, sulphamoylation at 
the C-3 position was not noticed in these A-alkylated derivatives. This could be due 
to the fact that the alkylation at the N-H makes the C-3 carbon to be less reactive 
towards electrophiles. Hence, sulphamoylation takes place only at the deprotonated 
C-5 hydroxyl group.
Although the presence o f alkyl substituents on the indole ring system has been 
reported to be useful for biological activity, having a group that could provide an 
enhanced binding to the enzyme active site would be highly desirable. From earlier 
investigations with coumarin sulphamates (Chapter 3), it was identified that having 
a phenyl or a benzyl group in the molecule is highly advantageous in terms o f 
potent biological activity. It is also equally important to have these groups at the 
correct location on the ring. Therefore, it is likely that a similar approach to indoles 
also could provide an active compound. In the attempt to produce such compounds, 
approaches to the introduction o f an acyl or benzyl groups at the C-3 position o f the 
indole ring system were investigated.
Even though the addition o f electrophiles to the C-3 position o f  the indole is the 
most characteristic reaction o f this class o f heterocycles and has been studied 
extensively, the synthesis o f 3-acylindoles is often complicated by the fact that the 
indole displays ambident reactivity leading to competing substitution at the indole 
nitrogen. A previous attempt by Saxton mainly afforded 1,3-diacetylindole when a
977mixture o f acetic anhydride and acetic acid was heated. Reaction o f  indole
7 7 8magnesium salts with acid chlorides or o f Vilsmeier-Haack conditions involving
7 7 0  •dialkylamides and phosphorus oxychloride produced only moderate yields o f the 
desired products. These shortcomings can be defeated by acylation o f  the N-
143
protected compound using the Friedel-Crafts acylation procedure described by 
Ketcha and Gribble, where they have used phenylsulphonyl group to protect the 
indole nitrogen before acylating the 3-position with acetic anhydride or acid 
chlorides280 (Scheme 5.4).
Scheme 5.4 : Friedel-Crafts acylation procedure described for indoles by Ketcha 
and Gribble using phenylsulphonyl protecting group. (i) Benzenesulphonyl 
chloride (ii) AICI3, CH2CI2, benzoyl chloride, 2 h, R.T.
Compound 142 was hence acylated at the 3 position o f the indole ring using the 
Friedel-Craft acylation procedure. N-Protected indoles react readily with acid 
chlorides, therefore benzoyl chloride reacted at the C-3 position to yield 1,2- 
dimethyl-3-benzoyl-5-methoxyindole (148) in a poor yield o f  13% (Scheme 5.3). 
Subsequent demethylation o f compound 148 with AICI3 gave the 5-hydroxyindole 
(149), which was sulphamoylated with excess sulphamoyl chloride to furnish 1 ,2 - 
dimethyl-3-benzoylindole-5-0-sulphamate (150) in moderate yield o f 32% 
(Scheme 5.3).
The reduction o f the carbonyl group in the benzoyl substituent o f  compound 148 to 
the corresponding benzyl derivative III was found to be unsuccessful with the 
reagent, sodium tris(trifluoroacetoxy)borohydride (I) that formed between NaBH4 
and CF3COOH (Figure 5.6). The product obtained contained a lot o f  byproducts, 
which were inseparable by flash chromatography. Plausible explanations could be 
that the highly electrophilic indole (II) formed (Figure 5.6) after the reduction with 
I is susceptible to attack by any surrounding nucleophilic species and hence 
forming several by-products.
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Figure 5.6 : Proposed reduction o f compound 148 with I to form the product III
Having synthesised compounds with a sulphamoyloxy group at the C-5 position o f 
the indole, the next task was to develop a method to synthesise compounds, with 
sulphamoyloxy group at C-6 position. This is to investigate the change in biological 
activity by placing the sulphamoyl group in a different position o f the indole 
system. It has been reported that 6 -hydroxyindoles possess a range o f interesting 
pharmacological activities and are valuable precursor to some important indoles 
and indole alkaloids.281
Substituted 6-hydroxyindoles have been synthesised previously by various 
methods, from alkyl tyrosinates and N-bromosuccinimide, and from 4-
9 81hydroxybenzaldehyde and methyl a-azidoacetate. There are also several other
984.reactions, such as M eerwein arylation, which was reported by Raucher et al, 
involving a diazonium salt derived from an appropriate 2-nitroaniline. Other 
methods postulated by Feldman et al using 4-methoxy-2-nitrotoluene, condensed
• 9 or # 9RA
with N, A^-dimethylformamide dimethyl acetal, Reissert indole synthesis and,
97£more recently, the Leimgruber-Batcho method are also possible routes to
145
synthesise 6 -hydroxyindoles. But they are comparatively lengthy, involve 
cyclisation from simple starting materials, cumbersome and gave poor yields.
Direct hydroxylation o f the benzene ring o f indole derivatives was reported to occur 
in the reaction with hydrogen peroxide in super-acids, but regioselectivity is
9 8 7poor. Therefore, the reaction described by Teranishi et al was chosen to carry out 
because the desired 6-hydroxyindole is relatively easily prepared from 
corresponding commercially available indoles in rather good yields281 (Scheme 
5.5). Also, this elegant regioselective oxidation o f substituted indoles is reported























Scheme 5.5 : Synthesis o f 3-methyl-l-pivaloylindole-6-O-sulphamate (139) (i) 
NaH, (CH3)3CC0C1, DMF, 0°C, 1 h (ii) A1C13, C1CH2C0C1, CH2C1CH2C1, R.T. 3 
h (iii) w-CPBA, Na2H P 0 4, CH2C12, R.T. 1 h (iv) NaSCH3, CH3OH, R.T. 1 h (v) 
anhy. DMF, NaH, N2, 0°C and H2N S 0 2C1, 0°C to R.T.
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The anion formed by the deprotonation o f  the NH proton o f 3-methylindole with 
NaH was acylated with pivaloyl chloride to produce the 3-methyl-1-pivaloylindole 
(135) in 77% yield (Scheme 5.5). The bulky pivaloyl group hence sterically 
protects the C-2 position from any unwanted subsequent reactions. The 
regioselective acylation o f compound 135 at the C -6 position with AICI3 and 
chloroacetyl chloride gave 6-chloroacetyl-3-methyl-1-pivaloylindole (136) in 48% 
yield, without the formation o f  2-chloroacylated product (Scheme 5.5). Only 
disadvantage o f this reaction however was the use o f a large excess o f  AICI3 (4.5 
equivalents) and chloroacetyl chloride (4.7 equivalents) in 1,2-dichloroethane was 
used, which was a very rigorous reaction to do when carried out in a large scale. 
Also, 135 must be added slowly to the AlCh/chloroacetyl chloride complex in order 
to minimise any by-product formation.
■100 9RQ
In the literature, oxidation o f indole derivatives with peracid, or singlet oxygen 
has always taken place at the pyrrole ring o f indole. The reason being that the 
pyrrole ring is more nucleophilic than the benzene ring, which prevents the direct 
oxidation on the benzene part. Therefore, a regioselective method to introduce an 
oxygen function at the C-6 position is highly desirable. Baeyer-Villiger oxidation 
with m-chloroperbenzoic acid (m-CPBA) was chosen for our purpose since it has 
been reported to furnish selective oxidation at the C-6 position o f the indole in high 
yield in a similar reaction .281 Hence, compound 136 was treated with m-CPBA in 
CH2CI2 at R.T. in the presence o f anhydrous sodium hydrogen phosphate 
(NaHPC>4), which acts as a base to obtain 6-chloroacetoxy-3-m ethyl-1- 
pivaloylindole (137) in 72% yield (Scheme 5.5). There were no reaction observed 
when NaHPC>4 was omitted or non-anhydrous NaHPCU was employed with the 
recovery o f the starting material 136 as a result.
The hydrolysis o f the 6 -chloroacetate group o f 137 to its phenolic derivative and the 
deacylation o f the N-atom can be carried out simultaneously using different basic 
reagents, such as, potassium carbonate/methanol or sodium hydride/methanol, but 
these reagents have reported to be very low yielding .281 Therefore, the hydrolysis
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and deacylaton reactions were carried out by stirring 137 for 2 h with sodium 
thiomethoxide in methanol at R.T. and under a N 2 atmosphere (Scheme 5.5). 
Unfortunately, the main product obtained was 6-hydroxy-3-methyl- 1-pivaloylindole 
(138 A) in a very low yield and had the pivaloyl group still attached to the nitrogen 
atom (Scheme 5.5). The desired product (138 B) was only a little fraction, which 
was recognised in the crude product isolated from flash chromatography and was 
not attempted to purify any further. Since the pivaloyl group is more hindered for 
the thiomethoxide anion to attack at R.T., optimising the conditions o f this reaction 
such as, having an excess o f sodium thiomethoxide or stirring the reaction mixture 
for longer or raising the temperature could produce the desired product as the major 
compound. The major (138 A) and the minor (138 B) products were identified from 
the N M R spectra, where the peak corresponding to the nine protons o f the pivaloyl 
group remained at 81.51 ppm, which was also supported by mass spectral analysis. 
Compound 138 A was subsequently sulphamoylated by the usual procedure using 
an excess o f  sulphamoyl chloride to furnish 3-m ethyl-1-pivaloylindole-6-O- 
sulphamate (139) in 24% yield.
The following compounds were synthesised in the indole sulphamate series:
R Ri r 2 X Xi x 2
132 H H H OO2SNH2 H H
133 H H H H OO2SNH2 H
134 H C 0 2H H H OO2SNH2 H
139 COC(CH3)3 H c h 3 H H OO2SNH2
141 H c h 3 H H OO2SNH2 H
144 c h 3 c h 3 H H OO2SNH2 H
147 c h 2c h 3 c h 3 H H OO2SNH2 H
150 c h 3 c h 3 H H OO2SNH2 H
Table 5.1 : Structures o f the indole sulphamates
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5.2 R esults
The ability o f the indole sulphamate derivatives to inhibit E l-ST S  activity was 
examined in MCF-7 breast cancer cells and in placental microsomes (Table 5.2). 
The biological activity data for all the compounds are not available at present.
5.3 Discussion
During the course o f this work, substituted and unsubstituted indole sulphamates 
with the sulphamoyloxy group at the C-4, C-5 and C -6 were synthesised.
An alkyl substituent at the indole nitrogen helps for a strong binding with the ER 
protein. Derivatives with hydrogen in position 1 o f the indole ring do not bind to 
the receptor, presumably because they form hydrogen bridges with water 
molecules. Therefore, the polar moieties formed prevent the necessary hydrophobic 
interaction with the receptor site. The most favourable structures are those with a 
methyl or ethyl group at 3-position o f the indole nucleus and an ethyl or propyl 
group on the nitrogen. Two contrary effects can rationalize this maximum affinity: 
the favourable increase in lipophilicity in the centre o f  the molecule and the steric 
hindrance by larger groups.270
Recently, it has been reported that some indole-containing derivatives play a crucial
771 77 7role in cell proliferation, differentiation, transformation and apoptosis. ’ (See 
Chapter 6 for detail) Malignant tumour cells can be clearly distinguished from 
normal cells by their chaotic proliferation, due to a serious disorder in their cell 
cycle regulatory mechanism. Cell cycle inhibitors or modulators that halt 
uncontrollable tumour growth are regarded as highly promising new therapeutic 
agents against human cancers. Tryprotatins A (5-12) and B (5-13), which were first 
isolated as secondary metabolites o f a fungal marine strain BM939 were shown to 
inhibit completely the cell cycle progression o f tsFT210 cells in the G2/M phase at
7 7 7a concentration o f 50 pg/mL o f 5-12 and 12.5 pg/mL o f 5-13 respectively 
(Figure 7.5, Chapter 7).
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5-12 Tryprostatin A R = OCH3 
5-13 Tryprostatin B R = H
yV-(3-chloro-7-indolyl)-l,4-benzenedisulphonamide
5-14
Figure 5.7 : Structures o f  some promising indole derivatives with clinical potential
Another promising drug that has been recently reported is A-(3-chloro-7-indolyl)- 
1,4-benzenedisulphonamide (5-14), the indole derivative o f  previously known 
antimitotic agent E7010 (Figure 7.5). This drug inhibited the cell cycle progression 
o f P388 murine leukemic cells in the G1 phase unlike its lead compound, which 
blocked the G l/M  phase. This indole sulphonamide showed a significant 
antitumour activity against HCT116 human colon carcinoma in both in-vitro (IC50 
= 0.11 (ig/mL in cell proliferation assay) and in vivo also showed a marked 
reduction o f tumour size in nude mice. Because o f this excellent activity, this
771compound is currently undergoing Phase I clinical trials in Europe. Therefore, as 
well as exhibiting E l-ST S inhibitory activities, it is very much likely that the indole 
derivatives synthesised in this project would also likely to possess antimitotic or 
apoptotic properties. Unfortunately, the nature o f these o f inhibition o f  these 
compounds can only be validated once the biological activity results are made 
available, which is currently underway.
5.4 Conclusion
In conclusion, a series o f  indole sulphamate analogues have been prepared and their 
biological evaluation is ongoing at present. Indole sulphamates may presumably be 
effective therapeutic agents in the treatment o f  estrogen-dependent breast cancer as 
well as possessing potential antimitotic and apoptotic activities. These results 
would lead also to further studies to design and maximise the activity o f
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metabolically stable and potent E l-ST S inhibitors and to make the compounds 







Following heart disease, cancer is the biggest cause o f death in the West. Cancer is 
a generic term for over 200  diseases, which share a number o f  characteristics 
including uncontrolled cellular proliferation. This uncontrolled growth can impinge 
on surrounding organs, causing disruption o f normal bodily functioning, which in 
turn can lead to death. Another feature o f cancer is the ability o f  tum our cells to 
migrate to other sites in the body. This process (metastasis) also increases the 
difficulty in treating these diseases as those secondary tumours can also disrupt 
bodily functions. Under these conditions, the removal o f tumours by surgery 
becomes less practicable and other methods o f treatment are needed such as 
chemotherapy.
Cancer chemotherapy is designed to exploit the differences between normal and 
malignant cells. Thus the ultimate goal o f chemotherapy is to produce a drug, which 
will specifically destroy, or otherwise render benign, cancer cells without having a 
significant effect on the normal cells. Cancer cells differ from their normal 
counterparts in a number o f biochemical processes, particularly in the control o f 
cell growth and cell division. Inhibiting such key cellular processes in the tumour 
can cause the cancer cells to regress. Angiogenesis and apoptosis are some o f these 
processes in cancer that can be exploited in controlling tumour cell proliferation. 
However, these differences can be small as a result o f alterations or damage to only 
a minute proportion o f normal cellular processes and hence the design and synthesis 
o f  a truly selective anticancer drug to target specifically these cellular processes o f 
the cancer has yet to be accomplished.
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6.1 Angiogenesis and diseases
Angiogenesis is a process by which new blood vessels are formed. In healthy 
adults, angiogenesis occurs during menstrual cycle, wound healing, fetal 
development and numerous pathological processes. Disrupting the angiogenesis 
cascade is a novel approach to the treatment o f cancer, heart disease, several forms 
o f blindness, psoriasis, and many chronic inflammatory diseases. The market for 
this approach is significant to date, since the existing therapies are largely 
inadequate. It is forecasted that angiogenic therapeutics could represent a vast 
pharmaceutical market with sales in excess o f $3,770 M by the year 2005 and the 
value o f the angiogenic oncology market alone is estimated to be $3 billion in the 
same time frame.290
6.2 Angiogenesis and cancer
Under homeostatic conditions, angiogenesis is a highly regulated process and is 
essential for tumour progression and the formation o f metastases. The endothelial 
lining o f a blood vessel is normally quiescent. The vascular endothelial cells that 
form blood vessels rarely proliferate. In cancer the switch from resting state to the 
angiogenic state occurs when homeostasis is altered by pathological processes, such 
as tum our growth. Under such conditions, angiogenesis is stimulated by a change in 
the net balance between pro- and anti-angiogenic factors. The angiogenic switch 
can be triggered by an increase in pro-angiogenic factors or a decrease in anti- 
angiogenic factors. Additionally, several studies have further indicated that up- 
regulation o f angiogenic stimulators is often accompanied by a down-regulation o f 
local tissue inhibitors o f  angiogenesis.
6.3 Tumour growth and metastasis
All solid tumours are composed o f two distinct but inter-related compartments: the 
malignant cells themselves and the tissue framework or stroma, in which the 
tumour cells grow. A major compartment o f this stroma is the vascular supply, 
which is required for the malignant progression. Rapid and exponential tumour 
growth requires ongoing angiogenesis. It appears that rapidly growing tumours
153
actively influence the angiogenic switch to sustain continuous cell proliferation. In 
the absence o f  angiogenesis, tumour growth is limited to 1-2 mm . Growth beyond 
this size requires the angiogenic phenotype. Expansion o f tumour mass is made 
possible not only through perfusion o f blood but also through paracrine stimulation 
o f tumour cells by numerous growth factors and matrix proteins produced by the 
new capillary endothelium.
Angiogenesis is also an essential component o f the metastatic pathway. These 
vessels provide the principle route by which tumour cells exit the primary tumour 
site and enter the circulation. It has been shown that highly vascularised malignant 
tumours have a higher incidence o f metastasis than poorly vascularised malignant 
tumours. Moreover, once tumour cells have metastasised, their sustained growth is 
once again dependent upon establishing a new blood supply.
6.4 Angiogenesis therapeutic strategy
Tumour angiogenesis is essential for tumour progression and the formation o f 
metastasis. In the adult, -0 .01%  o f endothelial cells undergo cell division. By 
contrast, the fraction o f proliferating endothelial cells in tumours is proposed to be
901 • •50-fold higher. These differences between proliferating endothelial cells in 
tumour tissue vs normal tissue can be exploited through the use o f angiogenesis 
inhibitors. Furthermore, a single tumour vessel may supply as many as 104 tumour
901cells, thereby amplifying the anti tumour effects o f antiangiogenic compounds. 
Importantly, tumour endothelium is derived from normal host cells and in contrast 
to tumour cells, is genetically stable, which suggests that tumour endothelium is
9 0 9
unlikely to develop resistance to cytotoxic agents. Recent investigations have 
focused on the development o f  antiangiogenic agents, particularly those that can be 
administered p.o. and for prolonged period, as alternatives to standard cytotoxic 
anticancer therapies.
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Angiogenic therapies may act either directly by interfering specifically with the 
ability o f endothelial cells to form new capillary blood vessels or indirectly by 
influencing the microenvironments that regulate tumour angiogenesis. There are 
multiple pharmacological targets in this process currently under evaluation for 
therapeutic potential. Investigations o f antiangiogenic compounds have been 
conducted preclinical and clinical trials. Strategies to inhibit angiogenesis have 
included the use o f neutralising antibodies to angiogenic proteins, integrin
A A A ^
molecules and growth factor receptors. Also, kinase inhibitors, natural 
products such as TNP-470 and antibiotic derivatives such as minocyclin have been
9 0 Sused. Angiostatin and endostatin, enzymatic degradation products o f 
plasminogen and type XVIII collagen respectively, are reported to induce tumour 
regression and prolong tumour dormancy in murine model systems. However, in
9 0  f \most cases, tumour re-growth ensues after cessation o f treatment. Tumour cures 
have been limited when most angiogenesis inhibitors are used as a sole method o f 
treatment. Angiogenesis inhibitors represent a promising cancer therapy for several 
reasons: Effective angiogenic agents should have wide applicability as a general 
anticancer therapy as tumours o f many diverse histological types must induce 
angiogenesis to grow beyond a size o f 1 to 2 mm and the angiogenic pathway used 
is generally independent o f tumour type.
Drug resistance is a severe limitation o f conventional chemotherapy. The 
emergence o f  acquired drug resistance depends in part on the genetic instability, 
heterogeneity and high mutational rate o f tumour cells. In contrast, endothelial cells 
are genetically stable, homogeneous and have a low mutational rate. Angiogenic 
therapy directed against tumour-associated endothelial cells should induce little or 
no drug resistance. To date, studies with angiogenesis inhibitors, such as 
rhAngiostatin, have shown no drug resistance in animal studies. In addition to the 
potential in the monotherapy o f  cancer, angiogenic agents can be used in 
combination with traditional chemotherapy and radiotherapy. To date, promising 




The control o f cell number and the removal o f inappropriate or damaged and 
potentially dangerous cells are critical both in development and for adult tissue 
homeostasis. This regulation occurs via coordinated control o f cellular proliferation, 
cellular differentiation and cell death. Apoptosis or programmed cell death is a 
widespread physiological process that has steadily gained recognition due to its 
clearly established roles in tissue development, tissue homeostasis and disease 
pathogenesis. This is an active mode o f cellular suicide, which is encountered 
among normal as well as tumour cells in physiological and pathological situations. 
W hen there is an abnormal proliferation o f cells taking place in the body, apoptosis 
is induced by specific cellular processes, and those abnormal cells are effectively 
removed from the body to protect from any harmful effects. Therefore, a drug that 
could induce apoptosis would be useful as an anticancer agent.
Cell death was understood to be an element in normal development as early as 
195 1 297 and good experimental evidence that it was integrated into developmental 
programmes was provided by Saunders298 in 1966 and Lockshin and Beaulaton299 
in 1974. In 1971, John Kerr first introduced the concept o f apoptosis during his 
studies to define the role o f lysosomes in lethal hepatocyte injury.300 Kerr observed 
single cells that appeared to be dying, but he saw no evidence o f dispersion o f their 
lysosomal enzymes. Extensive studies revealed this unique process o f cellular cell
on, ‘2/Y}
death and in 1972 they named this process apoptosis. ’
The apoptotic process involves an orchestrated cleavage o f DNA and organelles 
including the nucleus and mitochondria, together with an activation o f  signals for 
phagocytic engulfment and destruction. The damaged cells with mutated DNA are 
removed from the body by apoptosis. This prevents the proliferation o f malignant 
clones or the propagation o f cells containing viral DNA.303 In vivo, apoptotic cells 
are phagocytosed by macrophages. In vitro, however, they are not phagocytosed, so 
that they can last until the apoptotic process is completed.
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The morphology o f apoptosis is well characterised. Deregulation o f  the apoptotic 
pathway can lead to diseases, most notably cancers, autoimmune diseases304 and 
neurodegenerative disorders such as A lzheimer’s disease. In breast cancer, an 
altered balance between the rate o f survival and proliferation contributes to the 
increased cell number seen in neoplasia. In the breast, secretory epithelial cells are 
removed extremely rapidly by apoptosis and in rodents mammary glands can 
completely be remodeled within a few days. The role o f  apoptosis in a wide 
variety o f diseases, together with its highly regulated nature, has m ade it an 
attractive new target for therapeutic intervention in diseases previously considered 
incurable.
6.6 Mechanism of cell division
In 1903, Boveri suggested that cancer might arise as a consequence o f  chromosome 
gain or loss. Many subsequent studies have backed up this insightful proposal and 
put this theory in the centre stage.307 The microtubule system plays an im portant 
role in eukaryotic cells and is an attractive target for the development o f anticancer 
agents. A cancer can be viewed, as a condition where the delicate balance between 
cell production and cell death is lost, resulting in an overproduction o f cells. This 
increase in cell growth and division presents an attractive and achievable target for 
drug design.
A typical cell cycle is divided into two phases: M itosis and Interphase. M itosis is 
the stage in the process o f cell division where segregation o f chromosomes occurs 
prior to cell replication. It has been recognised for a century as the mechanism in 
eukaryotes for partitioning the genetic material (DNA) equally at cell division. This 
process occurs in a normal cell undergoing division and thus does not represent a 
truly specific target. This division o f  the nucleus is usually followed immediately 
by cytokinesis, the division o f cytoplasm. The basic sequence leading to cell 
division is well established. Microtubules, dynamic pipe-like protein fibres, are 
highly dynamic organelles that are essential in mitosis.308 Chemicals that attack 
microtubules through tubulin, their major structural component, disrupt or suppress
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both microtubule structure and normal functions by inhibition or promotion o f 
microtubule assembly. This action results in cell arrest at mitosis.309
The microtubules function vitally for cell support, by acting as a form o f internal 
scaffold, giving the cell both shape and an organised structure, cellular transport by 
moving the cell around its environment and transporting organelles around the 
cellular interior. However, arguably the most important role o f  the microtubules is 
the formation o f the mitotic spindle, which is intimately involved in cell replication,
T t  A
one o f the most complex and demanding processes undertaken by the body 
(Figure 6.1).
During cell division, the cell must completely duplicate its internal components, 
including the whole o f its DNA, so that it can form two identical daughter cells. 
The cell then orders the DNA to split into two identical sets o f  chromosomes and 
separate them into two distinct parcels at opposite ends o f the cell, ready to form 
the two nuclei in the daughter cells. This ordering and relocation o f the genetic 
material, which takes about an hour, is known as mitosis. Thus a gap o f time occurs 
after DNA synthesis and before cell division and another gap was found to occur 
after cell division and before the next round o f DNA synthesis. This analysis led to 
the conclusion that the eukaryotic cell cycle consists o f 4 phases: an M (mitotic) 
phase, a G1 phase (the first gap), the S phase (DNA synthesis), a G2 phase (the 
second gap), and back to M. The phases between mitoses (G l, S and G2) are 
collectively known as the interphase (Figure 6.2).
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Figure 6.1 : Stage o f mitosis110
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M phase includes both mitosis and cytokinesis, is usually the shortest part o f cell 
cycle. Successive mitotic cell divisions alternate with a much longer interphase, 
which often accounts for about 90% of the cell cycle. It is during interphase that the 
cells grows and copies its chromosomes in preparation o f cell division. During G l, 
S and G2 phases, the cell grows by producing proteins and cytoplasmic organelles. 
Thus the cell grows (G l), continues to grow as it copies its chromosomes (S), 
grows more as it completes preparations for cell division (G2), and divides (M). 
The daughter cells formed may then repeat the cycle. Typically, a cell completes its 
cycle in about 24 h, but some cells like those in human liver, have a cycle lasting 
more than a year. Many non-dividing cells (all quiescent fibroblasts) in tissues 
suspend the cycle after mitosis and just prior to DNA synthesis. Such resting cells 
are said to have exited from the cell cycle and to be in the GO state.109 At any one 
time most o f the cells in an animal’s body are in GO phase. Some, such as muscle 
and nerve cells, remain there permanently and others such as liver cells can resume 
G l phase in response to factors released during injury.
T ngger m itosis
M -phase-prom oting factor
Mitotic
cyclin
G2 C heck  point
G1 C heck  point
Start k in ase
Trigger DNA replication
Figure 6.2 : Different phases o f interphase110
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Microtubules, therefore are intimately involved with the replication o f cells. If  the 
microtubules in a tumour cell can be prevented from forming or decaying, the 
chromosomes cannot separate, the cell cannot reproduce and hence the tum our 
cannot grow. Thus agents, which interfere with the dynamics o f tubulin may also 
act as inhibitors o f cell division. Indeed, a number o f these agents have shown to act 
as clinically useful anticancer agents.
6.7 Angiogenic, apoptotic indicing and antimicrotubular drugs
Three different small-molecule binding sites are known to date for the tubulin 
system. These are the colchicine site and the vinca alkaloid domain, both located on 
monomeric unpolymerised a , p-tubulin, and the taxoid site on the polym erised 
microtubule. Drugs, which bind to tubulin can be subdivided into separate
Tilclasses. The class into which a particular drug fits depends upon the effect, which 
that exerts on the binding o f five well-characterised agents to tubulin. These agents 
are colchicine, the two vinca alkaloids, vincristine and vinblastine and the two 
macrocyclic natural products rhizoxin and maytansine. However, some drugs do 
not have any effects o f the binding o f  these drugs, having affinity instead for a 
separate, distinct region o f tubulin. Some o f them may bind covalently to certain 
reactive groups on the protein, particularly the tubulin sulphydryl group. Ligands, 
which interact at the taxoid site stablise the microtubule, while ligands interacting at 
the vinca domain or the colchicine site disrupt the formation o f microtubules.
31]Treating the cells with these drugs can completely halt their replication.
6.8 Inhibitors of tubulin-binding sites
Inhibitors o f tubulin polymerisation interacting at the colchicine-binding site are 
potential anti-cancer agents. Colchicine (6-1) has long been associated with 
microtubules and it is indeed the classic tubulin binding agent (Figure 6.3). 
Colchicine is a highly soluble alkaloid first isolated from the m eadow saffron, 
colchicum autumnale.3U It has been initially used for the treatment for gout but due 
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Figure 6.3 : Inhibitors binding to the colchicine-binding site o f tubulin
Colchicine induces a partial unfolding in the secondary structure o f  the protein 
caused by binding to a high affinity site on the tubulin, which hinders tubulin 
assembly,314 It has been suggested that it is this unfolding which disrupts the 
protein regions necessary for microtubule formation. Other drugs such as 
amphethinile (6-2), a synthetic agent, which gained interest when it was shown to 
terminate pregnancy in rats316 and later shown that it competitively binds to 
colchicine-binding site o f tubulin effectively and hence entered Phase 1 clinical trial
• 0 1 7
in the mid-80’s. The natural flavone centauriedin (6-3), which is isolated from 
Polymnia fruticosa prevents the binding o f colchicine to tubulin and prevents the 
formation o f microtubules with an IC50 o f 3 //M .318 Although there are several other 
natural flavones have been isolated, centauriedin was the first flavone to cause 
mitotic arrest in cells stablising the mitotic spindle (Figure 6.3). For many hundreds 
o f years, podophyllotoxin (6-4) was used to treat patients with conditions ranging 
from sclerosis o f the liver through constipation, rheumatism and cancer. More 
recently, it has been shown to bind quickly and reversibly to at least part o f the
• 'X1Q
colchicine-binding site o f  tubulin. This ease o f  reversibility and the low 
temperature dependence o f binding, however, indicate that the binding does not 
occur at a completely identical site to that o f colchicine. It is now thought that the 
predominant function is by inhibition o f DNA topoisomerase II, an enzyme 
involved in the folding and unfolding o f DNA during cell replication rather than by 
microtubular interactions.320
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Combretastatin A-4 (6-5) is a naturally occurring stilbene first isolated in 1973 
from the South African Bush Willow, Combretum caffrum. ’ It has been used 
by the Zulu as a charm to ward o ff enemies and in traditional medical practice 
(Figure 6.4). In 1979 some anti-cancer activity by this compound was found in the 
U.S. National Cancer Institute’s astrocyte reversal (9ASK) system and the P388 
lymphocytic leukimia cell line. In 1982, Pettit and co-workers reported the 
structure o f Combretastatin and later the synthesis.321
h3co^ ^ .
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F igure 6.4: Structure o f  Combretastatin A
By far Combretastatin is one o f the simpler and most potent inhibitors to show 
antimitotic effects by interacting with the colchicine-binding site o f  tubulin.324 
Combretastatin A-4 is not recognized by the multidrug resistance pump, a cellular 
pump, which rapidly rejects foreign molecules, including many anti-cancer drugs 
and it is also reported to inhibit angiogenesis. Because o f the low w ater solubility
and poor bioavailability o f this drug, it has limited in vivo efficacy, the progress 
into clinical trials was haltered. But, recent studies have shown that in 
combination with radiation or chemotherapy it could form an effective therapy. 
Combretastatin A-4 is now being developed by the Cancer Research Cam paign and 
the biotechnology company, Oxigene and believed to be available in the next five 
years. This drug is effective against all solid tumours but the tum our must be at 
least 1 mm in diameter, about the size o f a grain o f rice and m ust have its own 
blood supply, since combretastatin acts by inhibiting the blood supply to the tum our 
cells and as a consequence the tumour cells are killed by lack o f  oxygen supply 
(Figure 6.5).
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ATTACKING A TUMOUR’S BLOOD SUPPLY
Tum our
Capillaries
As the tumour cells divide
capillaries proliferate bringing oxygen and
Figure 6.5 : Reduction o f tumour size by drugs such as Combretastatin A-4, which 
attacks cells lining blood vessels to the tumour, cutting off the blood supply and 
causing the tumour to shrink.
Despite the vast number o f colchicine-binding drugs available, several groups are 
now engaged in the synthesis o f new potent combretastatin analogues with 
enhanced solubility, such as benzylaniline hydrochloride (6-6) (IC50 = 3.5 fiM), 
diphenylselenides (6-7), diphenylsulphides (6-8).329 Combretastatin glucuronide (6-
3309) with attached sugar moieties, and its phosphate prodrug CA4P (6-10), which is 
water soluble and cause the disintegration of the vasculature o f solid tumours and is 
currently in Phase I/II clinical trials (Figure 6.6). The new class o f drugs 
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Figure 6.6 : Derivatives o f Combretastatin A
6.9 2-M ethoxyestradioI (2-M eOE2)
In 1957 Kraychy and Gallagher first reported the presence o f  2-methoxyestrone in 
human urine after the administration o f E2 or E l .331 The naturally occurring 
metabolite o f the mammalian hormone estradiol, 2-methoxyestradiol (2-M eOE2) 
(6-12) (Figure 6.7) is formed in the body by oxidation in the liver followed by O- 
methylation by catachol-O-methyltransferase (COMT), an enzyme present in large
^^ 9 111amounts in many organs and cells such as liver, kidney, brain, placenta, uterus, 
mammary glands and red blood cells (RBCs).334,335.
2-MeOE2 is cytotoxic to several tumour cell lines, binds to colchicine-binding site 
o f tubulin and induces the formation o f abnormal microtubules. Interestingly, 2- 
MeOE2 does not appear to cause destabilisation o f microtubules at concentrations 
sufficient for tubulin binding and mitotic block and cause little noticeable change in 
the morphology o f assembled microtubules. It is thought that 2-MeOE2 exerts its 
effects by altering the dynamics o f tubulin polymerisation. Many breast tumours 
initially show a response to commonly used anti-estrogens or aromatase inhibitors,
and most o f them eventually become resistant to the therapy. 2-MeOE2, once 
considered an inactive end metabolite o f E2 has recently emerged as a very
• • . • 336promising agent for cancer treatment. It has shown to inhibit angiogenesis and 
the growth o f solid tumours. Knowledge o f angiogenesis process provides 
opportunities for developing therapeutic agents such as 2-MeOE2, which can 
directly inhibit key stages o f the angiogenesis cascade by selectively targeting 





F igure 6.7 : Structure o f 2-methoxyestradiol
Extensive studies have shown that methylated catachol estrogens have little or no 
binding affinities for the classical ER (<0.1% compared with E2), and lack
'X'in
estrogenic activity in the uterus. Hence this raises the question o f  why the body 
makes such a large amount o f this hormonally inactive, lipophilic estrogen 
metabolite. Studies have led to the suggestion that metabolic O-methylation may be 
a rapid inactivation or detoxification process for those estrogen derived catechols 
and mainly that 2MeOE2 is not just an inactive metabolite o f E2 but, it has a unique 
protective role against estrogen induced carcinogenesis in estrogen target 
organs.338,339,340'336
Decreased formation o f 2-MeOE2 in the body increases the risk o f  estrogen- 
induced cancers. However, the growth inhibitory and pro-apoptotic 
mechanism(s) o f action o f 2-MeOE2 compounds is not fully resolved. Several 
mechanisms have been suggested to explain the antiproliferative activity o f  2- 
MeOE2 such as: tubulin binding, up-regulation o f p5 3341 and deregulation o f  cell
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cycle kinases and regulators, such as p34cdc2 and cyclin B.342 2-MeOE2 has been 
shown to induce changes in the levels and activities o f various proteins involved in 
the progression o f the cell cycle and these include, cofactors o f DNA replication 
and repair, inhibition o f mitosis, uneven chromosome distribution, faulty spindle 
formation and an increase in the number o f abnormal metaphases.340’339 Their is 
evidence to indicate that these effects are the results o f inhibition o f  tubulin 
polymerisation by 2-MeOE2 to the colchicine binding site.336 2-MeOE2 binds 
relatively weakly to the colchicine binding site on tubulin, and inhibits the 
polymerisation o f tubulin dimers to give microtubules.
Other possible mechanisms that have been suggested are those involving 
transcription factor modulators, (SAPK/JNK)343 the regulators o f cell arrest and 
apoptosis (tubulin,336,344 p21, bcl-2 and FAS), proliferating cell nuclear antigen 
(PCNA),345 nitric oxide synthase346 and stress activated protein kinase.347 2-MeOE2 
arrests cells in mitosis and induction o f apoptosis is associated with 
phosphorylation o f  the anti-apoptotic bcl-2 protein. However, there is no evidence 
for any o f  these being part o f a common mechanism operating in different systems. 
Recently, it has been found that 2-MeOE2 upregulates the KILLER/Death Receptor 
5 (DR5) and activates the downstream caspases, caspase 8 and caspase 3 in 
endothelial and tumour cells. The antiproliferative activity o f 2-MeOE2 is thought 
to be associated with the induction o f apoptosis, which is independent o f the 
estrogen receptor.348
W hatever the structural identity o f the putative intracellular effector or receptor for 
2-MeOE2, the interaction o f 2-MeOE2 with its specific effector or receptor in target 
cells is an initial step leading to the expression o f its growth-inhibitory effects in 
sensitive cells. Hence an understanding o f  the mechanism o f action o f 2-MeOE2 
should further enhance our understanding o f its unique physiological and its 
antitumourigenic functions.
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6.10 Derivatives of 2-MeOE2
To further enhance the activity o f 2-MeOE2, several groups extensively studied the 
Structure-Activity o f A, B and C ring modified analogues o f 2MeOE2 and some 
were more potent inhibitors o f tubulin polymerisation and/or cytotoxic agents than 
the parent compound.348,349,350’351 D ’Amato et al proposed that A-ring o f 2M eOE2 is 
functionally equivalent to the C ring o f colchicine and that the CD rings o f the 
steroid correspond to the trimethoxybenzene A ring o f  colchicine. On the basis o f
this hypothesis, several A ring expanded analogue o f 2MeOE2 (estratropones) (6- 
13) were synthesised by Miller et al and demonstrated to be more potent inhibitors 




Figure 6.8 : A ring expanded analoges o f 2-MeOE2
In an effort to investigate the structural parameters associated with the biological 
activities o f 2-MeOE2, Cushman and his colleagues synthesised some structurally 
similar compounds with different substituents at the C-2 position o f  the 2-MeOE2. 
M ost potent o f these new analogues was proved to be 2-ethoxyestradiol (6-14), 
which was found to be more potent than 2MeOE2 as a cytotoxic agent in cancer
O CA
cell cultures as well as tubulin polymerisation inhibitor. They also identified 
several 2EtOE2 analogues such as 2-EtO-6-oximinoE2 (6-15), 2-(2’,2’,2’- 
trifluoroethoxy)-6-oximinoE2 (6-16) and 2-EtO-6-methoxyiminoE2 (6-17) to be
-jr 1
potent inhibitors o f tubulin polymerisation (Figure 6.9). This observation o f 
variability o f the C-6 substituents suggests that the A ring o f 2M eOE2 interacts 
with the same portion o f the tubulin molecule as the C ring o f colchicine and the C- 














Figure 6.9 : Analogues o f 2-ethoxyestradiol
6.11 Taxol
The m ost well known o f these anti-tubulin agents are taxol (paclitaxel) (6-18) and 
taxotere (docetaxel) (6-19), which are currently used in the clinic effectively 
(Figure 6.10). Taxol was first isolated from Taxus brevifolia bark extracts in 1962 
as part o f  the American National Cancer Institute (ANCI) natural product screen o f 
over 35,000 plant extracts in 22 years. Taxol was like every antitubulin compound 
known at that time was considered a microtubule stabilizer rather than a 
destabilizer, but it was largely ignored due to low availability and poor water 
solubility. Over the years the level o f interest in this compound has increased, 
resulting in four groups have successfully completed the total synthesis and now 
one o f the most popular areas o f pharmaceutical interests. Taxol is now clinically 
used to treat a wide spectrum o f malignancies including lung, head, neck, Kaposi 
sarcoma,354 ovarian and advanced breast cancers together with ceramide-enhancing 
agents (ceramide is a known messenger o f apoptosis) to maximise its cytotoxic
- i f f
potential. W hen taxol was combined with doxorubicin, 90% response rate was 
observed, but shown to be cardiotoxic, which was reduced when doxorubicin was
■ir/'
replaced with epirubicin. Also various other combination o f drugs with taxol
'icn





F igure 6.10 : Structures o f Taxol and Taxotorel
The effect o f taxol on microtubules is well established. Taxol induces tubulin to 
assemble into microtubules under normally prohibitive conditions and stabilises 
these polymers against disassembly. It binds to the single site o f  the p-tubulin and 
suppresses the dynamic behaviour o f microtubules i.e. the cell proliferation in a
-ICO
concentration-dependent manner. Incubation o f cells with taxol leads to the 
formation o f abnormal bundles o f microtubules and results in the arrest o f cells in 
the G2/M phase o f the cell cycle.359
The discovery o f several other natural or synthetic analogues o f taxol, which 
structurally deviate from the taxoid platform and superficially do not resemble each 
other, has proven o f great significance in the field. Baccatin III (6-20) is one such 
compound isolated from the needles o f  yew and a synthetic side chain was attached
o co
to the baccatin core. and its analogue ABT-271 (6-21), which posses an a -  
hydroxyl group at C-9 instead o f the carbonyl in Taxol or taxotere. These 
compounds are identified to be promising anti cancer agents with activities similar 
or better than Taxol360 (Figure 6.11).
The discovery o f the second receptor for taxol361 has added further layer o f 
complexity to the understanding o f the structural requirements for cytotoxic 
activity, since little is known about the interaction o f the taxol analogues with the 
receptor. Bcl-2 family proteins play a crucial role in the regulation o f apoptosis. 
Recent findings show that taxol indued apoptosis and Bcl-2 protein phosphorylation
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when treated with human hepatocellular carcinoma cell line, QGY-7703.
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Figure 6.11 : Analogues o f Taxotorel
Taxotere was discovered as a late-stage intermediate in a synthesis o f taxol and now 
it has been obtained semi-synthetically from a precursor readily obtained from the 
needles o f the yew tree. Taxotere shows similar spectrum o f  action to taxol 
however, it reduces the complexity and side effects o f adm inistration in comparison 
to taxol because it is four-fold more potent than taxol and shows improved water 
solubility. It has now been licensed for the treatment o f ovarian, advanced breast 
cancer and non-small cell lung cancers. The fluorinated CF2 analogues (6-22) 
synthesised by Ojima et al showed higher potency against drug sensitive cell line 
LCC6-W T and 40-70 times potent against drug resistant cell line LCC6-M DR and 
induce apoptosis as compared to that o f taxol.364 Another analogue, IDN 5109365 (6- 
23) is active on multidrug resistant cells and found to be easier to administer, orally 
active and endowed with better profile o f side effects.
Therefore it can be clearly seen than the concept o f inhibiting a number o f key 
biochemical processes, in particular the cell division and cell growth hold 
considerable potential for future therapeutic development.366 Angiogenesis and 
apoptosis are some o f these processes in cancer that can be exploited in controlling 
tum our cell proliferation. However, the differences in such processes can be small 
as a result o f  alterations or damage to only a minute proportion o f  normal cellular
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processes and hence the design and synthesis o f a selective anticancer drug to target 




7.0 Aims of this work
It can be very clearly seen from the different types o f drugs that are reported, that 2- 
methoxyestrogens are an important class o f new drugs that can be used to inhibit 
tumour growth and angiogenesis. Although the identification o f 2-methoxyestradiol (2- 
MeOE2) (6-12) (Figure 6.7, Chapter 6) as a new therapy for cancer is a remarkable 
advance, the bioavailability o f orally administered estrogens is generally poor and also 
they can undergo extensive metabolism when they pass through the liver. This problem 
could be overcome by designing a prodrug of the active agent, which would reach the 
target effectively before it can be cleaved off to release the drug molecule to elicit the 
desired effect. From previous investigations it has been identified that EMATE (2-20) 
(Figure 2.9, Chapter 2), a synthetic drug, which was initially synthesised as a steroid 
sulphatase inhibitor for breast cancer therapy, is also a super estrogen. Its oral 
uterotrophic activity in rats has been found to be about 100-times greater than that of 
E2 .197 Its enhanced estrogenicity is thought to be the result o f the drug being 
sequestered into the red blood cells after absorption and hence protected from
inactivation during its passage through the liver and possibly act as a reservoir for its
• 266subsequent slow release from the erythrocytes for a prolonged period o f time. 
Although the mechanism for the desulphamoylation of EMATE remains to be 
established, it can be envisaged that EMATE is acting as a prodrug o f E l, with its 
sulphamate group cleaving off in vivo to release El possibly after its inactivation of 
steroid sulphatase.
With the super-estrogenicity o f EMATE being a disadvantage, a number o f A-ring 
modified analogues o f EMATE were synthesised and tested. Among these, 2- 
methoxyestrone-3-(9-sulphamate (2-MeOEMATE) (2-40) was found to be equipotent 
to EMATE as a steroid sulphatase inhibitor but devoid o f estrogenicity206,367 (Figure 
7.1). In addition to all the compounds that are known to possess antimitotic activity, 2- 
MeOEMATE has demonstrated some superior qualities that lacked in others. From the 
DNA analysis it was apparent that 2-MeOEMATE like 2-MeOE2 and taxol, induces
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G2/M arrest of the cell cycle. In an experiment carried out by Purohit and co-workers it 
was shown that cells that are treated with 2-MeOEMATE remained arrested in the 
G2/M phase for at least 24 h, even after washing off the drug .206 When a similar 
experiment was carried out with 2-MeOE2, a significant proportion o f the cells went 
back to G l/S  phase after the removal of the drug368 providing further evidence that 2- 
MeOEMATE is possessing potent and prolonged antiproliferative effects.
R = OCH3 2-MethoxyEMATE 2-40
CH2CH3 2-EthylEMATE 2-42
Figure 7.1 : 2-Substituted analogues of EMATE
h 2n s o 2o
The inhibition o f the growth of MCF-7 cells as a result o f the induction o f apoptosis by 
2-MeOEMATE was shown by Purohit et al.208 In untreated cells, only a few rounded 
and detached cells were visible per field whereas, for cells treated with 2-MeOEMATE 
(1 //M) for 24 h there was a significant increase in the number o f both rounded and 
detached cells. As the stromal compartment constitutes a major proportion o f the 
volume o f breast tumours, the effect o f 2-MeOEMATE on the morphology o f breast 
tumour-derived fibroblasts was examined by Purohit et al?08 At 1 /uM, little effect on 
cell morphology was detected, whereas at 5 /JM rounding o f a significant proportion of 
fibroblasts was observed. In contrast to its effects on epithelial cells, 2-MeOEMATE 
did not reduce the number of fibroblasts. After an exposure to 2-MeOEMATE, a 
significant increase of 27% of the total cells was in the sub-Gl/S phase o f the cell cycle 
fraction, and represented apoptosis.369 This is likely due to the increase in the 
phosphorylation of the Bcl-2 oncoprotein (antiapoptotic).343 Phosphorylation o f Bcl-2 
occurs during the arrest o f cells in the G2/M phase of the cell cycle370 and blocks its 
ability to dimerise with Bax (proapoptotic protein) and hence causing the induction of 
apoptosis.
2-MeOEMATE, unlike other compounds is found to be active against both ER+ and 
ER' breast tumours and also a number of other types of tumour cell lines. A marked
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effect on the growth and the morphology of ER+ MCF-7 cells and ER- M DA-M B-231 
breast cancer cells was observed with 2-MeOEMATE.206 The effect o f the 
sulphamoyloxy group in 2-MeOEMATE is studied and it was found that 2- 
MeOEMATE inhibited MCF-7 cells proliferation by 52% at 1 fJ,M, whereas the
371precursor 2-M eOEl had only a little effect. This clearly indicates that the potency 
observed for 2-MeOEMATE was due to the presence of the sulphamoyloxy group, 
which may be acting as a prodrug o f 2-MeOEl or may be exhibiting enhanced binding 
to the colchicine-binding site o f tubulin.
In vivo, 2-MeOEMATE also inhibited the growth of some nitrosomethylurea-induced 
mammary tumours in intact rats.369 The tumour regression due to 2-MeOEMATE was 
compared with that o f 2-MeOEl and found that the tumours receiving 2-MeOEMATE 
regressed almost completely, whereas 2-MeOEl receiving tumours only showed a 
modest regression, indicating that the sulphamate is much more potent than its parent 
compound. In addition, 2-MeOEMATE has been recognized to be non-toxic as the 
body weight o f the animals were found to be unchanged.
2-MeOEMATE 2-EthylEMATE
Figure 7.2 : Pictorial representation o f 2-MeOEMATE (2-40) and 2-ethylEMATE (2- 
42) by Sybyl®
Cancer cells do not have the ability to store glucose therefore they depend upon 
constant uptake to sustain growth. Glucose enters cells via Na /glucose co-transporters 
such as GLUT 1-7.372 Transfection o f cells with oncogenes ras or src increases the rate
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of glucose uptake and hence the expression of glucose transporter mRNA. Inhibiting 
the glucose uptake and metabolism by cancer cells is another attractive new therapeutic 
target. A number o f compounds such as the isoflavone genistein and cytocholasin B 
have been shown to inhibit the process of glucose uptake374 as well as disruption o f cell 
actin cytoskeleton by dismpting the actions o f the glucose transporters.375 MCF-7 cells 
have a high capacity to take up a glucose analogue, deoxyglucose. 2-MeOEMATE has 
been shown to possess the ability to inhibit this insulin-stimulated uptake and hence 
inhibit cell proliferation better than the non-sulphamoylated parent compound. It is 
anticipated that alterations in microtubule stability interfere with the recruitment o f
375glucose transporters to the cell membrane.
control   2-EthylEM ATE




Figure 7.3 : Apoptosis caused by 2-ethylEMATE. (A) Control (B) cells treated with 2- 
ethylEMATE.
Like 2-MeOEMATE, another 2-substituted derivative 2-EtEMATE (2-42) (Figure 7.2) 
was also found to promote the inhibition o f tubulin polymerisation and induce 
apoptosis. (Unpublished) Apoptosis caused by 2-ethylEMATE is shown in figure 7.3. 
The advantages o f 2-MeOEMATE and 2-EtEMATE over other compounds are that 
they are orally bioavailable and it is possible that these sulphamates are acting as 
prodrugs o f their parent compounds. Like EMATE, it is possible that they also may be
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taken up by red blood cells and released slowly to give a protracted increase in blood 
steroid concentration and hence a reduction in cell proliferation. This concept is still to 
be validated but if this is the case, relatively high levels o f drug could be delivered over 
a prolonged period o f time to attack tumour growth and these drugs therefore hold 
considerable potential for therapeutic development.366
In view o f the exciting results obtained for the sulphamates, it is indeed interesting to 
establish some degree o f structure-activity relationship for the 2-MeOEMATE class of 
compounds by synthesising derivatives with surrogates of the sulphamate group. The 
obvious modification is to replace the bridging O atom in the sulphamoyloxy group 
(H2NSO2O-) with other heteroatoms. Therefore 2-substituted estrone-3-sulphamide 
(Figure 7.4) and 3-S-sulphamates were synthesised in this project.
2-MeOestrone-3-suIphamide 2-Ethylestrone-3-sulphamide
Figure 7.4 : Pictorial representation o f 2-MeOestrone-3-sulphamide and 2- 
ethylestrone-3-sulphamide by Sybyl®
These surrogates are resistant to hydrolysis than the sulphamate group. Hence, their 
biological activities would help to establish if  the increase in potency observed for 2- 
MeOEMATE over 2-MeOEl is the result o f sulphamoylation of essential amino acid 
residues at the receptor-binding site. If these surrogates shared similar biological 
activities to 2-MeO or 2-ethylEMATEs, it is possible that the enhanced potency 
observed for 2-MeOEMATE could well be due to the result o f better binding affinity 
than 2-M eOEl to the receptor possibly through hydrogen bonding provided by its 
sulphamate group.
177
It has been recently reported that a series o f sulphamido antimitotic agents of which 
compound E7010 (7-1) (Figure 7.5) has been shown to inhibit microtubule formation 
by binding to the colchicine-binding site.377 In vivo, tests have shown good oral activity 
across a wide range o f tumour types and good activity against vinca alkaloid resistant 
solid tumours. Results from animal studies carried on E7010 have indicated that this 
agent is active against gastric, colorectal, breast and lung cancer tissues. The clinical 




Figure 7.5 : Structure of E7010
E7010 contains a sulphamido group although its not clear if such a moiety is crucial for 
its biological activities. Since the sulphonamide and the sulphamoyloxy groups are 
similar in structure, an obvious target modification to 2MeOEMATE and 2-EtEMATE 
is to synthesise their 3-sulphamido derivatives.
In addition, these compounds chosen to synthesise would further provide an indication 
about the importance or need o f the sulphamoyloxy group for the potent activity 
observed in the sulphamates. Certain sulphonamides such as acetazolamide (7-2), 
methazolomide (7-3), dorzolomide (7-4) and brinzolomide (7-5) are known inhibitors
379o f carbonic anhydrase, which catalyses the interconversion o f CO2 and HCO3' 
(Figure 7.6). Their clinical use has been in the reduction o f the formation o f aqueous 
humour for the treatment o f glaucoma, which is a chronic ophthalmic condition 
affecting approximately 15 million people.379 The binding mechanism of
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trifluromethane sulphonamide inhibitor (7-6) (Figure 7.6) to carbonic anhydrase II is 
well established by the help of X-ray crystallography. It has been shown that the N- 
atom of the sulphonamide tetrahedrally coordinates directly to the active site zinc ion 
o f the enzyme, a small hydrophobic moiety placed in the hydrophobic part o f the active 
site and the hydrogen bonds provided by the oxygens are the factors making 7-6 high 
affinity for carbonic anhydrase.380
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Figure 7.6 : Structures o f some known carbonic anhydrase inhibitors.
It has been hypothesised that EMATE’s super-estrogenicity might be the result o f it 
being sequestered into erythrocytes, hence evading ‘first-pass’ metabolism.371 It is 
possible that the same mechanism is also operable for 2-MeOEMATE rendering the 
compound more effective than 2MeOEl in inducing tumour regression in vivo as well 
as possibly causing enhanced binding to the colchicine site. Since the sulphonamido 
and sulphamoyloxy groups are similar in structure and that there is a high level of 
carbonic anhydrase in red blood cells, it is possible that the sequestration of EMATE 
and related compounds such as 2-MeOEMATE into red blood cells operates in the 
same manner as that for sulphonamides. In order to assess this hypothesis, the 3- 
sulphonamido derivatives o f 2-substituted estrones were prepared (Figure 7.7).
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2-MeOestrone-3-sulphonamide 2-Ethylestrone-3-sulphonamide
Figure 7.7 : Pictorial representation o f 2-MeOestrone-3-sulphonamide and 2- 
ethylestrone-3-sulphonamide by Sybyl®
It is reasonable to expect that the 2-substituted sulphonamide derivatives would also 
show similar inhibitory activities to that o f the sulphamates as a result o f being taken 
up into the blood cells possibly with minimal metabolism. Most importantly, these 
compounds would offer useful information about the nature o f the site where the 
sulphamoyl group binds in tubulin. This site might be one o f the five binding sites that 
have been previously identified such as colchicine site or might be a new sulphamate- 
binding site unique to the sulphamoyl group, which is possible but unlikely. It might 
also indicate how the sulphamoyloxy group binds to tubulin to produce the irreversible 
inhibition as observed, which might be similar to that o f sulphamoylation o f sulphatase 
enzyme. Therefore several important aspects of inhibition by sulphamoylated 
compounds are likely to be revealed as a result o f this study.
7.1 Synthesis
The 2-substituted estrogen derivatives synthesised in this project can be represented by 
the general structures as shown below in Figure 7.8: 2-Substituted estrone (A) 




Figure 7.8 : General structures o f the 2-substituted derivatives synthesised in this 
project. R = H, O C H 3  or Et.
In view o f the established promising biological activity with 2-MeOEMATE and 2- 
MeOE2MATE, multi-gram quantities o f 2-MeOEl were required in order to prepare 
the corresponding sulphamides and sulphonamides. An efficient synthetic method for 
the preparation of 2-MeOEl was required, which could provide the target compounds 
rapidly in large quantities. The ideal method should also provide flexibility for 
incorporating other alkyl or alkoxy groups to the C-2 position without too much 
difficulty.
A literature search has revealed several different approaches to the synthesis o f 2MeO 
estrogens but most lacked selectivity and gave low yields. A practical synthesis was 
first reported by Fishman et alm  starting by condensation o f estriol with 2-chloro-5- 
nitrobenzophenone. This method has been proved to be cumbersome. Since the 
publication o f Fishman’s method, many synthetic procedures have been reported. Rao 
et al demonstrated a two step synthesis382 via the formation of 2-bromoestradiol from 
estradiol itself. This procedure however requires long reaction time of 22 h and the 
yield is not satisfactory. Numazawa et aV s approach to obtain 2-MeO estrogens from
2-iodo estrone supposedly furnished a good yield (65%) and gave good 
regioselectivity.383 The four-step method by Nambara et al was reported to be a viable 
one for the synthesis o f 2 -methoxy estrogens, although it was found to be inefficient in 
practice.384
Direct hydroxylation at the C-2 position is another approach, which could also be 
employed to synthesise 2MeO estrogens. Taylor et al have reported the use o f thallium
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(Ill) trifluoroacetate (TTFA), which is an efficient and simple method for phenol 
preparation. ’ Many other methods focused on the introduction of an acyl or formyl 
group at the C-2 position350,384,387 followed by an oxidation with m-
chloroperoxybenzoic acid (wCPBA) to give the 2-hydroxyl, which can eventually be 
alkylated. To carry out this approach the 3-hydroxyl group must be protected with a 
suitable protecting group, which would not be cleaved under acidic conditions such as 
that o f Baeyer-Villiger oxidation.
One probable approach is to carry out or/Zzo-lithiation selectively at the C-2 position of 
C-3 hydroxy- and C -17 carbonyl- protected estrone. Pert et al have shown that ortho- 
lithiation can be selectively carried out at the C-2 position by protecting the C-3 
hydroxyl group with a MOM group (CH3OCH2-).443 A similar procedure was 
effectively utilised by Cushman et al, in their multi-step synthesis o f 2- 
alkyloxyestradiols where they used benzyl ether as the protecting group o f the 3- and 
17-hydroxyl, which was removed with palladium ( 10% or black)/palladium hydroxide 
on charcoal in ethanol/THF mixture.350,351 However this method is lengthy and too 
many by-products are produced due to cleavage o f the benzyl protecting groups at 
various stages of the whole synthesis. Therefore, to overcome some o f the 
disadvantages of Cushman’s method, a modified procedure developed in Bath by 
Leese et a /388 was employed, where estrone instead of estradiol has been used as the 
starting material with its C-17 carbonyl protected with ethylene ketal (Scheme 7.1).
A mixture of estrone, ethylene glycol (HOCH2CH2OH) and a catalytic amount o f p- 
toluenesulphonic acid (pTsOH) in toluene was refluxed under boiling using Dean-Stark 
conditions to gave the C-17 acetal- protected compound 160 in 96% crude yield 
(Scheme 7.1). Several similar methods have been reported previously for the protection 
o f the C-17 carbonyl group of steroids with an acetal group.389 Cyclic ketals are stable 
to bases and basic nucleophiles and formed by the reaction o f two molecules o f alcohol 
with one molecule of ketone. Ethylene glycol is a single molecule with two terminal 
hydroxyl groups (diol) and has been effectively used for protecting the C-17 carbonyl. 
Cyclic ketals are more resistant to acid hydrolysis than acyclic ones and are also easier 
to synthesise.
182
Scheme 7.1 : Synthesis o f 2-methoxyestrone (182). (i) HOCH2CH2OH, toluene, 
/?TsOH, A, 14 h (ii) NaH, 0°C, CH30C H 2C1, DMF, R.T., 12 h, N2 (iii) THF, -78°C , 
N2, secBuLi, DMF, 12 h (iv) wCPBA, CH2C12, N aH P04, N2, 3 h, R.T., NaOH/MeOH, 
HC1 (v) wCPBA, CHCI3 : CH2C12 = 1:3, 24 h, R.T. (vi) DMF, CH3I, tetra Bu4NI, N2 
(vii) CH3OH, 0°C, N2> acetyl chloride (viii) THF, KOBu1, MePPh3I, R.T., 2h.
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Methyl chloromethyl ether (MOMC1 - CH3OCH2CI), which was synthesised from a 
mixture o f dimethoxymethane (CH3OCH2OCH3), decanoyl chloride and concentrated 
sulphuric acid and was used for the subsequent protection of C-3 hydroxyl group. The 
phenolic ion formed by the deprotonation o f C-3 hydroxyl with NaH, reacts with 
MOMC1 to give the acetal, which is stable to bases and can be subsequently cleaved 
easily by mild acid treatment. The pure product 162 (Scheme 7.1) was obtained as a 
thick clear syrup in 95% yield, which solidified on standing.
Upon treatment with secbutyl lithium, compound 162 was selectively or/7*o-lithiated at 
the C-2 position.443 MOM group in 162 effectively directs the lithiation at the C-2 
position, a finding exploited by Cushman et al in their synthesis o f 2- 
alkoxyestradiol.350,351 The flexibility o f this synthetic approach to 2-substituted 
estrones is illustrated further when alternative electrophiles are used to quench the 
lithiated estrone intermediate A (Figure 7.9). The use of freshly distilled DMF afforded 
the aldehyde 178 in an excellent yield of 98% (Scheme 7.1).
The aldehyde 178 formed was oxidised using Baeyer-Villiger oxidation by two 
different methods. One approach was where mCPBA was used in the presence of 
NaHP04  buffer in CH2CI2. The subsequent acid hydrolysis of the resulting formate, 
yielded the phenol 179 in good yield (80%) (Scheme 7.1, Path A). Similar to Path A, 
the purified wCPBA was added to a solution o f 178 in a 1:3 mixture o f CHCI3 : CH2CI2 
at R.T. to give compound 180 in 61% yield (Scheme 7.1, Path B). The ratio of the two 
solvents employed seemed to be a key factor for this reaction since the slightly acidic 
nature o f this mixture of solvents seems to be important. Although the yield is 
relatively low and the reaction time is longer, method B gave a cleaner reaction than
A
Figure 7.9 : Orr/zo-lithiation o f compound 162.
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method A with an easier purification process. However, the proton NMR spectrum of 
the product obtained revealed the absence of the C-17 ketal group. This is presumably 
due the presence of acidic impurities in the mixture o f chlorinated solvents or the p- 
chlorobenzoic acid, which formed after the oxidation of mCPBA might be responsible 
for the cleavage o f the C-17 ketal group. Therefore, method B is not suitable for any 
reactions that may require C-17 carbonyl protection as a ketal. In this particular 
sequence o f reactions, the presence of this C-17 ketal group is not vital for the 
subsequent reactions. Therefore, method B can also be employed to syntheise the 2- 
hydroxylated compound. Compound 179 in DMF was then alkylated with methyl 
iodide using anhydrous K2CO3 as base to give compound 181 in 90% yield. The C-3 
and C-17 protecting groups in compound 181 were subsequently cleaved with HC1, 
which was generated in situ from acetyl chloride in methanol to give the desired 2 - 
methoxyestrone 182 in an excellent yield of 70% (Scheme 7.1).
In an attempt to convert the aldehyde 178 into a vinyl group at the C-2 position, a 
Wittig reaction was employed. The Wittig reaction is extremely useful and a versatile 
method for the synthesis of alkenes from aldehydes. The aldehyde 178 was added to a 
THF solution of methyltriphenylphosphonium iodide containing potassium tertbutoxide 
base at R.T. The ylide, formed by the abstraction of a proton from the methyl group o f 
the phosphonium salt by the base, acting as a carbanion attacks the aldehyde carbon of 
the C-2 formyl group to give an oxophosphatane intermediate, which decomposes to 
give the required alkene 188. Compound 188 however failed to give the desired 2- 
alkenyl-3-hydroxyestrone upon acidification, where HC1 was generated in situ from 
acetyl chloride in methanol. A mixture o f products was obtained, which proved 












Scheme 7.2 : Synthesis of 2-ethylestrone (164) (i) HOCH2CH2OH, toluene, TsOH, A, 
14 h (ii) NaH, 0°C, CH30C H 2C1, DMF, R.T.,12 h, N2 (iii) THF, -78°C, secBuLi, EtI, 
R.T., 12 h, N2 (iv) CH3OH, 0°C, N2, acetyl chloride.
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This highly flexible synthetic approach to 2-substituted estrones by Leese et al gave 
way to the synthesis of 2-alkylated derivatives of estrone using the method shown in 
Scheme 7.2. Different electrophiles can be employed to alkylate the 2-lithiated 
derivative. In this case, iodoethane was used to obtain the C-3 and C-17 protected 2- 
ethylestrone 163 in 91% yield. This intermediate was subsequently acid hydrolysed to 
re-generate the desired 2-ethylestrone 164 in an excellent yield o f 95%. The method 
reported by Cushman et al also provides an effective way to synthesise 2- 
alkylestradiols where they have prepared a series o f 2-alkylated estradiols by reaction
o c r \
of 2-formylestradiol with a series o f Wittig reagents.
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R = H 191 
Et 195 
OCH3 200
Scheme 7.3 : Synthesis of 2-substituted estronesulphamides (i) diglyme, NaH, N2, 4- 
chloro-2-phenylquinazoline, A, 3 h (ii) mineral oil, N2, A (iii) ethanol, NaOH/H20 , A, 7 
h, N2, HC1 (iv) DMF, NaH, N2, 0°C, H2N S 0 2C1, 0°C to R.T. (v) isopropanol /THF, 
NaBH4, 30 min., 0°C.
Once the parent 2-MeOEl and 2-EtEl were made in adequate quantities, they were 
utilised for the subsequent reactions to make the desired sulphamides and 
sulphonamides. Several other methods have been described in the literature for the 
synthesis o f 3-amino derivatives starting from phenols and estrone. Most were by the 
conversion o f simple phenols to anilines, since phenols generally are more widely 
available than the corresponding anilines. One o f the possible reactions is the Bucherer 
reaction, which works well with naphthalenes and related heterocycles, whereas 
benzene derivatives are much less reactive.390 Smiles rearrangement is another useful 
method reported and could be carried out in one pot.391 Unlike these procedures, Gold 
and Schwenk postulated a method by the condensation o f steroidal quinol acetate and
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benzylamine. However, the resulting product proved to be difficult to dissolve and 
purify.392
The method described by Morrow and Hoffer for the synthesis o f 3-aminoestrone was 
adopted here for the synthesis of 2-substituted estrone sulphamides.393 Even though the 
reactions involve rearrangement of atoms at extremely high temperatures and require 
basic conditions, this method seems to be more practical than the others and is 
expected to provide a relatively higher yield. The sodium salts o f E l derivatives were 
condensed with 4-chloro-2-phenylquinazoline to give the corresponding 2-substituted
3-(2’-phenyl-4’-quinazolinyloxy)estrone (I) (Scheme 7.3). As well as using 4-chloro-2- 
phenylquinazoline, estrone can also be activated by diethyl chlorophosphate to give a 
similar product to that of I (aryl diethylphosphate esters).394 But it is not desirable since 
diethyl chlorophosphate is toxic and also involves the usage o f potassium metal in 
liquid ammonia. Bis(2-methoxyethyl) ether (Diglyme) was used as the solvent, which 
is water soluble and removed easily during the aqueous work-up procedure. The 
corresponding products were obtained as crystalline solids in excellent yields (189, 193 
and 198 = 80%, 70% and 83%, respectively) (Scheme 7.3).
The derivatives of I were thermally rearranged to yield the corresponding 3-[4’-oxo-2’- 
phenyl-3’(4H)-quinazolinyl]estrone (II). For this thermal rearrangement, very high 
temperatures were attained by melting the compounds in heavy mineral oil (bp = > 
400°C). The rearrangement temperatures varied from compound to compound. For the 
unsubstituted estrone derivative (190) the temperature required was found to be 
between 3 00 -310°C and for the 2-ethyl (194) and 2-methoxy (199) derivatives the 
temperatures required were higher at 320-330°C and 310-320°C respectively (Scheme 
7.3). These temperatures were found to be crucial for the rearrangements to take place. 
No reaction took place at a few degrees below the optimum temperature range whereas 
charring and decomposition took place at few degrees above these specific temperature 
ranges. It took several attempts before the correct temperatures for the rearrangement 
o f an ether to an amide was optimised. Another practical problem encountered with 
this reaction was that the 2-methoxy derivative o f II gave a suspension in mineral oil
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and was soluble in all the common organic solvents used to remove the mineral oil 
such as hexane and petroleum spirit. Therefore, the product was extracted into acetone 
and purified by flash chromatography or recrystallisation with hot isopropanol to 
obtain the products in good yields (190, 194 and 199 = 79%, 67% and 60% 
respectively). The relatively lower yield observed for the 2-methoxy derivatives was 
due partly to the cleavage o f the 2-methoxy group at high temperature to give 
compound 190. This fraction has been isolated and identified by proton NMR analysis, 
and found to be corresponding to the El derivative of II. i.e. 190. The relatively poor 
yield o f 199 could also be due to decomposition of compound and the production of a 
few unisolatable byproducts.
3-Aminoestrone (III) and its 2-substituted derivatives were obtained upon basic 
hydrolysis o f II. The product III was purified either by flash chromatography or direct 
recrystallisation from hot isopropanol [191 (16%), 195 (36%) and 200 (66%)]. 
(Scheme 7.3). In contrast to the literature method,393 in which 3-aminoestone was 
purified by sublimation followed by recrystallisation with a benzene-cyclohexane 
mixture. Treating III with sulphamoyl chloride by the usual method yielded the 
corresponding 2-substituted sulphamides (IV). The yield o f sulphamides obtained was 
rather poor [192 (17%), 196 (29%) and 201 (14%)] (Scheme 7.3). It was observed that 
the sulphamoylation reaction did not go to completion as anticipated even with a large 
excess o f sulphamoyl chloride (>5 eq.) as confirmed by the retrieval o f the unreacted 
III in a significant amount.
The natural metabolite 2MeO estradiol and the synthetic agent 2MeOE2MATE were 
proven to be highly potent antitubulin agents.369 Therefore, the C-17 carbonyl group of 
compound 196 was reduced stereoselectively to a 17/2-OH group with NaBELt to give 
compound 197 as white crystals (Scheme 7.3). The C-17 proton was observed as a 
triplet at 8 3.73 ppm with a J  value o f 8.6 Hz. Even though the OH signal was not 
visible it was confirmed by the presence o f the broad peak present at 3446 cm ' 1 in the 
corresponding IR spectrum. The sharp C = 0 stretch present in the spectrum of 




Scheme 7.4 : Synthesis of 2-methoxybenzenesulphonamide (177). (i) NaH/DMF, N2. 
dimethylthiocarbamyl chloride, A, 80°C, 1 h (ii) mineral oil, A, N2 (iii) NaOH, 
EtOH/H20 , A, N2, 4 h (iv) NaH/DMF, N2, BnBr, R.T., 4 h (v) AcOH/H20 , Cl2, 15 min. 
(vi) NH4OH, acetone, R.T., 15 min.
For the preparation o f 2-substituted sulphonamides, the modified method described by 
Li et al was employed.184 This procedure was similar to that o f the synthetic route 
designed by Holt et al for the synthesis of 5cr-reductase inhibitors.395 This method was 
previously demonstrated by Woo et al in their synthesis of unsubstituted estrone-S'- 
sulphamate194 and also by Newman et al in their synthesis of various 
arylthiocarbamates.396 A similar procedure was used to synthesise 2-methoxy 
benzenesulphonamide, (Scheme 7.4) which was made as a model for the target 
compound, 2-methoxyestronesulphonamide (Scheme 7.5). The desired 2- 
methoxybenzenesulphonamide (177) was obtained in an excellent yield o f 80%. The 
same method was employed for the synthesis of 2-methoxy and 2 -ethylsulphonamide 
by treating the corresponding estrone derivatives with NaH and N,N- 
dimethylthiocarbamoyl chloride in DMF to form the corresponding O-aryl 
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Scheme 7.5 : Synthesis o f estrone sulphonamide (158) and its 2 -substituted 
derivatives, (i) NaH/DMF, N2. dimethylthiocarbamoyl chloride, A, 80 °C,1 h (ii) 
mineral oil, A, N2 (iii) NaOH, EtOH/H20 , A, N2, 4 h (iv) NaH/DMF, N2, 0°C, 
H2N S 0 2C1, 0°C to R.T. (v) NaH/DMF, N2, BnBr, R.T., 4 h (vi) AcOH/H20 , Cl2, 15 
min. (vii) 1,4-Dioxane, KF/ H20 , A 50 - 55°C, 24 h (viii) NH4OH, acetone, R.T., 15 
min. (ix) isopropanol/THF, NaBH4, 30 min., 0°C.
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The O-aryl thiocarbamates were then thermally isomerised to the corresponding S-aryl 
thiocarbamates (VII) through Newman-Kwart rearrangement by heating in heavy 
mineral oil396 (Figure 7.9). The temperatures for the rearrangement of atoms were 
rather high and varied for each compound. For the unsubstituted estrone derivative 
(152) the temperature required was between 280-290°C whereas for the 2-ethyl (166),
2-methoxy (184) and 2-methoxybenzene (173), derivatives the temperatures were 
found to be 250-260°C, 270°C and 280°C, respectively. The yields of the 2-methoxy 
derivatives 173 and 184 were found to be relatively poor (48% and 45% respectively). 
It is possible that the extremely high temperature employed for the rearrangement 
reaction cleaved the 2 -methoxy moiety resulting in a reduction of the isolated yield of 
the products 173 and 184 compared to the unsubstituted and 2-ethyl derivatives [152 
(76%) and 166 (92%)] (Scheme 7.5). The mechanism of the rearrangement reaction 
presumably involves a nucleophilic attack o f the sulphur atom on the carbon at which 
the oxygen atom is attached as depicted in Figure 7.10. The dialkylamino group of the 
carbamate assists the desired polarisation.
Figure 7.10 : Proposed mechanism of the thermal rearrangement of O- 
arylthiocarbamates to S-arylthiocarbamates
In the subsequent reaction, the thiophenol (VIII) was obtained by alkaline hydrolysis 
o f VII with NaOH in aqueous ethanol in good yields except for the 2-methoxy 
derivative 185, which again gave a rather low yield o f 25% [153 (86%), 174 (74%), 
167 (89%)] (Scheme 7.5). There are not many practically applicable methods available 
for the synthesis o f thiophenols. Although the yield o f thiophenols via the formation of 
thiocarbamate is not very impressive, this is a fairly reasonable method to follow in the 
laboratory with ease.
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Sulphamoylation o f V III with an excess o f sulphamoyl chloride by the usual method 
gave the corresponding ^-sulphamate (IX) in low yields o f the desired products [154 
(56%), 168 (28%) and 186 (14%)] (Scheme 7.5). Once again, it was observed that the 
reaction does not go to completion and hence most o f the starting materials were 
recovered. These compounds were identified by *H NMR analysis and difficulties were 
encountered in obtaining good mass spectroscopy data since the S-sulphamates are 
very unstable for the conditions used for FAB+ and E.I. Very soft techniques such as 
electrospray (e.s.) were required to detect their molecular ions. Stability of these 
compounds is an important factor since it determines whether these compounds are 
indeed stable in the bioassay conditions. Chemical stability studies carried out in assay 
conditions by Woo et alm  for the unsubstituted estrone derivative o f IX, compound 
154 and also for compound 192 (Scheme 7.3) on HPLC showed that these sulphamates 
do not degrade to form the corresponding parent steroid, indicating most likely these 
compounds are also stable under the biological assay conditions used to test these 
compounds.
The thiophenol derivatives (VIII) were deprotonated with NaH in DMF, followed by 
alkylation of the resulting thiolate anion, which acts as a nucleophile in an Sn2 
reaction, with benzyl bromide to obtain the corresponding thiobenzyl derivatives (X) in 
good yields except for the 2-methoxy derivative 187 which gave the lowest yield of 
21% [155 (82%), 175 (88%) and 169 (65%)]. The sulphonyl chloride derivatives (XI) 
were obtained by oxidation with chlorine in acetic acid-water [156 (78%), 176 (94%) 
and 170 (55%)]. As well as the desired sulphonyl chloride, such oxidation is expected 
to furnish the benzyl acetate and benzyl chloride as by-products (Figure 7.11).
AcO.AcOH
Figure 7.11 : Reaction o f thiobenzyl derivatives with CI2
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Unfortunately, when this reaction was carried out with the 2-methoxy derivatives, the 
desired product was not formed. The reaction cleaved off the 2-methoxy group and 
also a lot o f inseparable byproducts were obtained. This is presumably due to the 
formation o f the cation (B), which undergoes further reactions with the surrounding 
anionic species to produce a mixture o f compounds (Figure 7.12) or the 2-methoxy 
group could be cleaved as depicted in figure 7.13, to form the stable product C. 
Disappointingly, repeating the reaction at various different conditions such as lower 
temperatures, a reduction o f the reaction time with CI2 or the use o f highly diluted 
reaction mixture did not yield the desired product. Although the same reaction worked 
well before for the transformation o f 175 to 176, (Scheme 7.4) somehow it proved to 
be difficult with the 2-methoxyestrone derivatives. This observed difference in 
reactivity with the estrone derivative may be due to the formation o f chloride radicals 
during light reaction, attack at the benzylic positions (Shown with * in Figure 7.12) of 
the estrone molecule and hence producing a mixture o f products. Therefore, conducting 
the experiment in the dark could provide a solution to the difficulty encountered in the 
process. Direct oxidation of the thiophenol 185 did not give the product either. The 
synthetic utility of benzylic sulphides as the intermediates in the synthesis o f sulphonyl 
chloride is superior to that o f from thiophenol since a benzylic group is selectively 




Figure 7.12 : Reaction o f CI2 with the 2-methoxy containing compound
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cFigure 7.13 : Possible demethylation mechanism o f the 2-methoxy derivative
The sulphonyl fluoride derivative (XII) was obtained in 60% yield with the 
unsubstituted estrogen derivative 157 by halogen exchange reaction using potassium 
fluoride. (Scheme 7.5) Treatment of XI with ammonium hydroxide yielded the desired 
sulphonamides (XIII) in excellent yields [158 (82%), 177 (80%) and 171 (61%)]. The 
estradiol derivative of unsubstituted estrone-3-sulphonamide 159 was prepared in 26% 
yield by reduction o f 158 with excess NaBfLi in THF/isopropanaol (1:1) mixture 
(Scheme 7.5). The C-17 proton appeared as a triplet at 8 3.53 ppm with J=  8.6 Hz. The 
C-17 OH group peak was observed as a singlet at 8 4.54 ppm, which was exchanged 
with D2O.
The following key compounds were synthesised during the course o f this project:
R
X
R X R X R X
154 H s s o 2n h 2 168 c h 2c h 3 s s o 2n h 2 186 o c h 3 s s o 2n h 2
158 H s o 2n h 2 171 c h 2c h 3 s o 2n h 2 201 o c h 3 n h s o 2n h 2
192 H n h s o 2n h 2 196 c h 2c h 3 n h s o 2n h 2
Table 7.1 : Compounds synthesised in the sulphamides, sulphonamide and S- 
sulphamate series
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In addition, the estradiol derivatives, estra-l,3,5(10)-trien-17-ol-3-sulphanamide 
(159), 2-ethylestra-l,3,5(10)-trien-17-ol-3-sulphamide (197) and 2-methoxy 
benzylsulphonamide derivatives, DGS01142B (177) were also synthesised.
7.2 Results
In this work, several A-ring modified novel 2-substituted estrone-3-sulphamides, 3- 
sulphonamides and 3->S'-sulphamates derivatives were designed and synthesised. The 
studies on the ability o f these compounds to inhibit El-STS activity and to cause 
tubulin polymeristion, angiogenesis and apoptosis are currently underway. Therefore, 
the biological activity data for these compounds are not available at present.
7.3 Conclusion
The vast amount of natural and synthetic drugs that are available as potential 
microtubule disrupters highlights the importance of tubulin as a target for anticancer 
agents and the structural diversity in compounds that interact at various sites o f tubulin. 
Any compound in this category may be suitable for the treatment of cancers such as 
breast, ovarian, endometrial, pancreatic, prostate cancers, sarcomas, melanomas and 
other solid tumours.
The identification of 2-methoxyestradiol (2-MeOE2) (6-12) (Figure 6.5, Chapter 6) as 
an antitumourigenic and antiangiogenic agent led to the synthesis of 2 -methoxyestrone-
3-0-sulphamate (2-MeOEMATE) (2-40) and related sulphamoyloxy analogues such as 
2-methoxyestradiol-3-0-sulphamate (2-MeOE2MATE) (2-50) and 2-ethylEMATE (2- 
42) (Figure 6.10, Chapter 6). It has been well established that the sulphamoyloxy group 
is indispensable for potent irreversible inhibition o f STS activity. 2-MeOEMATE was 
found to induce G2/M cell cycle arrest and modest levels of apoptosis in breast cancer 
cells in vitro, and also induced tumour regression in vivo in intact rats whereas, the 
parent compound 2-MeOEl failed.
The role o f 2-MeOEMATE in the observed enhancement o f the antiproliferative 
activity o f 2-MeOE2 and its derivatives remains unclear. This raised questions as to
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whether the sulphamoyloxy group may be the key structural factor for the observed 
activity. The rationale for this work is to find solutions to several unaswered questions 
resulted from the previous findings. It has been shown that 2-MeOE2 has a very low 
affinity for ER, and its activity comes from the binding to the colchicine binding site of 
tubulin resulting in either inhibition o f tubulin polymerisation or formation o f a 
polymer with altered stability, properties and morphology depending on the reaction 
conditions. Therefore it is interesting to investigate the exact mechanism and the site of 
binding o f 2-MeOE2 to tubulin. The observation shows that 2-MeOEMATE, 2- 
MeOE2MATE and 2-ethylEMATE are more potent than 2-MeOE2 itself and they also 
might be acting in a similar manner indicating that the sulphamate group may be 
involved in an increased binding to tubulin. The irreversible inhibition of the tubulin 
polymerisation observed in the sulphamoylated compounds might be the result of 
sulphamoylation of tubulin in a similar way to that o f sulphatase.
EMATE is a prodrug o f E l, in which the sulphamate group is cleaved off in vivo to 
elicit effect at the target. Similarly, it is possible that 2-MeOEMATE and 2- 
MeOE2MATE may be acting as prodrugs o f 2-MeOEl and 2-MeOE2 respectively. It 
is also important to find out the binding mechanism of 2-MeOE2 and 2-MeOEMATE 
to the tubulin site. Therefore, the ultimate objective o f this work became the 
modification of the sulphamoyloxy group, in order to establish some degree of 
structure-activity relationships for the 2-MeOEMATE class o f compounds. Hence, a 
series o f stable sulphamate surrogates such as 2-substituted estrone-3-sulphamides, 3- 
sulphonamides and 3-<S'-sulphamates were synthesised in this project as potential 
microtubule disruptors and antiangiogenesis agents.
The biological evaluation of these 2-substituted analogues is in progress at present. 
These results might lead to a greater understanding o f the binding mechanism o f these 
compounds to tubulin. It would also enable further studies to design and maximise the 
activity o f metabolically stable and potent El-STS inhibitors devoid of estrogenicity, 
since it is known that 2-MeOE2 and 2-MeOEMATE are non-estrogenic.269 
Unfortunately, the nature of these of inhibition o f these compounds can only be
197






8.0 Chemicals and analyses
All reagents and solvents used were of general purpose or analytical grade unless 
otherwise stated and were obtained commercially either from Aldrich Chemicals, 
Lancaster synthesis or Maybridge.
Analysis by thin layer chromatography (TLC) was carried out using commercially 
available aluminium plates (Merck Kieselgel 60 F254, 20x20 cm, layer thickness 0.25 
mm, Art. No. 5554). Products and starting material spots were visualised either under 
UV light at 254 nm (hydroxycoumarins are brightly fluorescent) or by using 
anisaldehyde solution (for /?-keto esters) or by treating with a methanolic solution of 
phosphomolybic acid (PMA) followed by heating (for steroids) or by a combination of 
these methods. Preparative TLC was performed on pre-coated glass plates (Merk TLC 
Silica gel 60 F254, 20x20 cm, layer thickness 2 mm, Art. No. 5717). Flash 
chromatography was performed using BDH Kieselgel 60, flash silica (Si02 ), of particle 
size, 70-230 /uM as stationary phase and different solvents systems, such as 
chloroform, dichloromethane, acetone, methanol, ethyl acetate and hexane of varying 
ratios as the mobile phase.
Melting points of solid, crystalline compounds were determined using Reichert-Jung 
Kofler block melting point apparatus and were uncorrected. Boiling points of oils are 
reported in Torr. unless otherwise stated. Fast atom bombardment (FAB), electron 
ionisation (E.I.) or electrospray (e.s.) mass spectra and accurate mass spectra were 
recorded at the University of Bath Mass Spectrometry service on a VG 7070H Double 
Focusing Mass Spectrometer and VG Autospec instruments. m-Nitrobenzyl alcohol
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(w-NBA) was used as the matrix for FAB experiments. For e.s. experiments, samples 
were prepared in 1:1 water/methanol with 1% acetic acid.
IR spectra were recorded on a Perkin-Elmer 782 FT-IR spectrometer, using KBr discs 
or Nujol mulls between NaCl plates. Elemental analysis was carried out at the 
University o f Bath Microanalysis service.
The Proton ( !H) and DEPT-edited. carbon (13C) spectra were recorded as a solution in 
deuterated chloroform (CDCI3) or methylsulfoxide (DMSO-d6) with tetramethylsilane 
(TMS) as internal standard at the University o f Bath NMR Service, using a Jeol EX 
400 (400 MHz) NMR spectrometer. The chemical shifts (5) are reported in ppm and 
the chemical shift of the proton of residual undeuterated CHCI3 in CDCI3 is -7.27 ppm, 
acetone is -2.05 ppm and those o f DMSO is -2 .49 ppm. The peaks corresponding to 
OH and NH2 are visualised by exchanging with D2O.
The log P calculations, analytical and preparative high performance liquid 
chromatography (HPLC) are carried out on a Waters 600E analytical and semi Prep 
systems. A Waters Radialpak column (RP18, 8 x 100 mm) was used at a flow rate o f 1 
or 2 ml/min. Methanol and water was used at different proportions as the mobile phase. 
All the spectra were determined at wavelengths (^max) o f 190 -  400 nm, using a Photo 
Diode Array (PDA) and visualised at 254 nm. The retention times (tR) of the 
compounds were expressed in minutes. Full details of the log P calculations are given 
in the Appendix C.
X-ray Crystal structures o f the tricyclic coumarin sulphamates were determined by Dr. 
M. F. Mahon at the Dept, of Chemistry of University of Bath. Full details are given in 
the Appendix D. Molecular modelling was carried out by Mr. K. Smith at the 
Department of Pharmacy and Pharmacology of University o f Bath.
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All reagents and solvents used were stored away from moisture and light and dried 
before use. All experiments were carried out at room temperature (R.T.), unless 
otherwise stated. Low temperature experiments were conducted in a Dewar flask 
containing either ice-water with NaCl for 0°C and carbon dioxide pellets with acetone 
for -78°C. Magnesium sulphate (MgSCL) was used as the drying agent. The solvents 
used in the reactions were removed with a rotary evaporator at reduced pressure (water 
pump) and on stated occasions, under a high vacuum. Samples for analysis were dried 
beforehand in a drying pistol at low temperature (~40-50°C) in vacuo.
8.1 Preparation of sulphamoyl chloride
Sulphamoyl chloride was prepared according to the method described by Appel and 
Berger253 and stored as a standard solution as described by Woo et al.m  To 
chlorosulphonyl isocyanate (25.0 g; 177 mmol; 1.1 eq.) in freshly distilled, anhydrous 
and sulphur impurities-free toluene (150 ml) at 0°C and under N2, freshly distilled 
formic acid (7.20 g; 156 mmol; 1 eq.) was added dropwise at such a rate so that the 
reaction did not become too violent. The resulting white gel was warmed gradually to 
R.T. and stirred overnight under N2. Evaporation under high vacuum gave a pale 
yellow residue o f crude sulphamoyl chloride (ca. 19-21 g). A standard solution was 
prepared by dissolving the crude in anhydrous, sulphur-free toluene and stored under a 
positive pressure o f N 2, in the refrigerator. No titration was attempted on this 
sulphamoyl chloride solution whose molarity was {ca. 0.5-0.7 M) estimated according 
to the crude sulphamoyl chloride obtained after work up. An appropriate volume o f this 
solution was freshly concentrated in vacuo before use.
Toluene and formic acid were purified according to the method previously 
described.397 Toluene (1 litre) was cooled to 2-4°C and placed in a separating funnel. 
Any sulphur impurities present in the cold toluene were removed by washing with cold 
conc. H 2 S O 4  (3x100 ml). Then washed with water (2x100 ml) followed by aqueous 5% 
NaOH and again with water until neutral, dried and stirred in sodium metal overnight
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at R.T. and then fractionally distilled under N 2 (bp = 110°C) and stored in dark place 
under N2. Formic acid, after being stirred overnight at R.T. with dried and finely 
powdered boron oxide was fractionally distilled under N2 (bp = 100-101°C) and stored 
in a refrigerator under N2.
8.2 Experimental Procedures
8.2.1 General methods for the synthesis of ethyl 3-oxo-alkanoates for the
preparation of 4-alkylcoumarin sulphamates
Method A236
To ethyl potassium malonate (2.1 eq.) in MeCN (100 ml/5 g o f acid chloride) at 10- 
15°C and under N2 was added Et3N (3.2 eq.), followed by M gCb (2.5 eq.). The 
mixture was stirred at 20-25°C for 2.5 h and then at 0°C for 0.5 h before the 
corresponding acid chloride (1 eq.) was added dropwise during 25 min. The mixture 
was further treated with EtaN (5 ml) and stirred overnight at 20°C. The evaporation 
residue was dissolved in toluene and re-concentrated. More toluene was added, stirred 
and cooled to 10-15°C before aq. HC1 (1M, 50 ml) was added cautiously while keeping 
the temperature <25°C. The organic layer was washed with 1M aq. HC1 (50 ml) and 
water. Drying, evaporation and distillation or chromatography (CHCI3 or 
CHC^/acetone, 10:1) gave the corresponding ethyl alkanoylacetate.
Method B239
To anhydrous SnCh (0.1 eq.) was added CH2CI2 (-100  ml/5g of aldehyde), followed 
by ethyl diazoacetate (1.05 eq.). The reaction was initiated by adding a few drops of 
the corresponding aldehyde in CH2CI2. When N2 evolution began, the remaining 
solution o f aldehyde (1 eq.) was added dropwise over 30 min. After the evolution o f N2 
had stopped (-1-3 h), the mixture was washed with brine (50 ml) and extracted twice
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(Et2 0 ). Drying, evaporation and chromatography (CHCI3 or CHC^/acetone, 10:1) or 
distillation gave the corresponding ethyl alkanoylacetate.
8.2.2 General method for the synthesis of ethyl a-alkylacetoacetates for the 
preparation of 3-alkyl-4-methyIcoumarin sulphamates242
K 2 C O 3  (2.4 eq.), water (50 ml), the alkyl bromide (1 eq.), ethyl acetoacetate (1 eq.), 
CH2CI2 (50 ml/5g o f alkyl bromide) and BU4NCI (1 or 2 eq.) were boiled under reflux 
for 3 d. After cooling, the separated organic layer was washed with 5M aq. HC1 (30 
ml). The mixture was extracted twice with Et2 0 . The combined ethereal extracts were 
dried, filtered and concentrated in vacuo. Chromatography (CHCI3 or CHC^/acetone 
10:1) or distillation gave the corresponding ethyl a-alkylacetoacetate.
8.2.3 General method for the synthesis of ethyl 2-oxocycloalkylcarboxylates for
the preparation of tricyclic coumarin sulphamates
To a suspension of sodium hydride (60% dispersion in mineral oil) (NaH) (2 eq.) and 
diethyl carbonate (80 ml/5 g of cyclic ketone) under N2 was added dropwise a solution 
o f the corresponding cyclic ketone (1 eq.) in diethyl carbonate (20 ml) over a period of 
0.5 h. When the evolution of H2 had ceased (~15 h), the pale yellow solid residue was 
treated with H2O and aq. HC1 (20 ml). The mixture was extracted twice with Et20  and 
H2O. The combined ethereal extracts were dried and concentrated in vacuo. 
Chromatography (CHCI3 or CHC^/acetone, 10:1) or distillation gave the corresponding 
ethyl 2 -oxocycloalkyl carboxylates as oils.
8.2.4 General method for the synthesis of tricyclic, 3- or 4-alkyl or 3,4-
2 1 0
dialkyl-7-hydroxycoumarms
Resorcinol (1 eq.) was dissolved in the corresponding hot /?-keto ester (1 eq.). The 
resulting syrup was cooled to 0°C and treated drop-wise with a mixture of CF3COOH 
(2 eq.) and conc. H2SO4 (2 eq.) while keeping the temperature <10°C. After stirring for 
3 h at R.T., the mixture was cautiously quenched with ice-water. The brightly coloured
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gluey mass formed was stirred for further 1 h. The bright yellow/brown precipitate 
resulted was collected by suction filtration, washed exhaustively with water and re­
dissolved in acetone. The yellow/brown solid obtained upon evaporation, was purified 
by flash chromatography (CHC^/acetone, 8:1 to 4:1 gradient) and/or recrystallised 
from hot absolute ethanol, acetone/hexane (4:1) or THF/hexane (2:0.5) to give the 
corresponding coumarin as a crystalline solid.
8.2.5 General methods for the sulphamoylation reaction 
Method A 196
To a solution o f the compound (1 eq.) in anhydrous DMF (5 ml) at 0°C under N2 was 
added NaH (1 eq.). When the evolution o f H2 had ceased, previously prepared 
sulphamoyl chloride (-3-5 eq.) was introduced. After stirring at R.T. under N 2 
overnight, the mixture was quenched with ice-water. The organic fractions were 
extracted into ethyl acetate (-150 ml) and washed with brine (4x100 ml). Drying, 
evaporation, chromatography (CHC^/ethyl acetate, 8:1 to 2:1 gradient) and/or 
recrystallaisation with either ethyl acetate/hexane (5:2) or THF/hexane (2:1) gave the 
corresponding crystalline sulphamate.
Method B
To a solution o f sulphamoyl chloride (-3-5 eq.) in toluene and A/A'-dimethylacetamide 
(DMA) (1.5 eq.), the corresponding compound (1 eq.), was added at 0°C. After stirring 
at R.T. under N2 overnight, the mixture was quenched with ice-water. The organic 
fractions were extracted into ethyl acetate (-150 ml) and washed with brine (4x100 
ml). Drying, evaporation, chromatography (CHC^/ethyl acetate, 8:1 to 2:1 gradient) 
and/or recrystal laisation with either ethyl acetate/hexane (5:2) or THF/hexane (2:1) 
gave the corresponding crystalline sulphamate.
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8.3 Synthesis of compounds with varying lengths of alkyl chain at the C-4
position of the coumarin ring
8.3.1 Ethyl 3-oxoheptanoate (1)
Prepared by method A (8.2.1) using potassium ethylmalonate (12.6 g; 74.0 mmol), 
CH3CN (110 ml), EtsN (11.6 g; 115 mmol), MgCl2 (8.39 g; 88.1 mmol) and pentanoyl 
chloride (4.34 g; 36.0 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 1 as a pale yellow oil (4.65 g; 78%). 398Lit. bpg 97- 
101 °C); Rf. 0.92 (CHCl3:acetone, 10:1); MS (FAB+) m/z: 173.1 [100, (M+H)+]; MS 
(FAB') m/z: 171.1 [100, (M-H)']; Acc. MS (FAB+): 173.1089, C9Hi70 3 requires 
173.1099; ‘H N M R  (400 MHz; CDC13) 6H: 0.91 (t, 3H, 7-CH3, J = 7 .3  Hz), 1.28 (t, 3H, 
CH2CH3, J=  7.0 Hz), 1.29-1.37 (m, 2H, CH2), 1.54-1.62 (m, 2H, CH2), 2.55 (t, 2H, 4- 
CH2, J=  7.3 Hz), 3.44 (s, 2H, 2-CH2) and 4.19 (q, 2H, CH2CH3, J=  7.3 Hz).
8.3.2 4-ButyI-7-hydroxycoumarin (2)
Prepared by method 8.2.4, using resorcinol (2.0 g; 18 mmol), 1 (3.13 g; 18.2 mmol) 
and a mixture o f CF3COOH (2.77 ml; 36.3 mmol) and conc. H2S 0 4 (1.83 ml; 36.3 
mmol). The crude yellow/brown solid was recrystallised from acetone/hexane to give 2 
as cream crystals (1.87 g; 47%). R / 0.63 (CHCl3/acetone, 3:1); mp 135-138°C (399Lit. 
mp 139-140°C-ethanol); vmax (KBr) cm '1: 3440 (OH), 1650 (C=0); MS (FAB+) m/z:
437.2 [15, (2M+H)+], 219.2 [100, (M+H)+]; MS (FAB') m/z: 435.3 [20, (2M-H)'],
217.2 [100, (M -H); Acc. MS (FAB+): 219.1034, C 13H ,503 requires 219.1021; ]H 
NMR (400 MHz; DMSO-d6) 5H: 0.92 (t, 3H, CH3, J =  7.3 Hz), 1.34-1.43 (m, 2H, 
CH2), 1.54-1.62 (m, 2H, CH2), 2.73 (t, 2H, l ’-CH2, J  = 7.6 Hz), 6.08 (s, 1H, C3-H),
6.71 (d, 1H, Cg-H, J=  2.4 Hz), 6.80 (dd, 1H, C6-H, J=  8 .6 , 2.4 Hz), 7.6 (d, 1H, C5-H, J  




Compound 2 (700 mg; 3.21 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was fractionated by flash chromatography (CHC^/ethyl acetate, 8:1 
to 2:1 gradient) and the white solid isolated was recrystallised from ethyl 
acetate/hexane to give 3 as white crystals (98 mg; 10%). R / 0.36 (CHCI3 .ethyl acetate, 
4:1); mp 147-150°C; vmax (KBr) cm '1: 3400-3100 (N-H), 1750 (C=0), 1450-1300 
(S 0 20 ), 1100-1150 (S 0 2); MS (FAB+) m/r. 595.2 [70. (2M+H)+], 298.1 [100, 
(M+H)+], 219.1 [10, (M +H-HNS02)+]; MS (FAB') m/z: 593.2 [15, (2M-H)'], 296.2 
[100, (M-H)-], 217.2 [60, (M-H2N S 0 2)']; Acc. MS (FAB+): 298.0742, C |3H 16N 0 5S 
requires 298.0749; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.93 (t, 3H, CH3, J =  7.3 Hz), 
1.36-1.45 (m, 2H, CH2), 1.57-1.64 (m, 2H, CH2), 2.82 (t, 2H, l ’-CH2, J =  7.6 Hz), 6.38 
(s, 1H, C3-H), 7.29 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.33 (d, 1H, Cs-H, J =  2.4 Hz), 7.94 
(d, 1H, C5-H, J  = 8.8 Hz) and 8.24 (s, 2H, NH2); Found C, 52.00; H, 5.00; N, 4.61; 
C i3Hi5N 0 5S requires C, 52.52; H, 5.09; N, 4.71%.
8.3.4 Ethyl 3-oxooctanoate (4)
Prepared by method A (8.2.1), using potassium ethylmalonate (13.0 g; 74.4 mmol), 
CH3CN (120 ml), Et3N (16.2 ml; 116 mmol), MgCl2 (8.66 g; 90.1 mmol) and hexanoyl 
chloride (5.31 g; 38.2 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 4 as pale yellow oil (6.58 g; 93%). (400Lit. bp4 90- 
96°C); R / 0.88 (CHC13); MS (FAB+) m/z: 187.2 [100, (M+H)+]; MS (FAB") m/z: 185.2 
[100, (M-H)"]; Acc. MS (FAB+): 187.1342, C 10H 19O3 requires 187.1334; ]H NMR (400 
MHz; CDCI3) 5h : 0.89 (t, 3H, CH3, J =  7.1 Hz), 1.29 (t, 3H, OCH2CH3, J =  7.3 Hz), 
1.31-1.37 (m, 4H, CH2CH2), 1.56-1.63 (m, 2H, CH2), 2.54 (t, 2H, 4-CH2, J =  7.3 Hz),
3.43 (s, 2H, 2-CH2) and 4.19 (q, 2H, OCH2CH3, J=  7.3 Hz).
8.3.5 7-Hydroxy-4-pentylcoumarin (5)
Prepared by method 8.2.4, using resorcinol (2.0 g; 18 mmol), 4 (3.4 g; 18 mmol) and a 
mixture o f CF3COOH (2.8 ml; 36 mmol) and conc. H2SC>4 (1.8 ml; 36 mmol). The 
crude yellow/brown solid was recrystallised from acetone/hexane to give 5 as pale
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yellow crystals (2.32 g; 56%). R / 0.86 (CHCl3/acetone, 3:1); mp 148-150°C (401Lit. 
mp 145-146°C); MS (FAB4) m/z: 465.3 [15, (2M+H)4], 233.2 [100, (M+H)4]; MS 
(FAB ) m/z: 463.4 [10, (2M-H)'], 231.2 [100, (M-H) ]; Acc. MS (FAB4): 233.1181, 
C 14H 17O3 requires 233.1178; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.87 (t, 3H, 5 ’-CH3, 
J =  7.1 Hz), 1.33-1.34 (m, 4H, CH2CH2), 1.58-1.61 (m, 2H, CH2), 2.72 (t, 2H, l ’-CH2, 
J=  7.6 Hz), 6.08 (s, 1H, C3-H), 6.71 (d, 1H, C8-H, J=  2.4 Hz), 6.80 (dd, 1H, C6-H, J  = 
2.4, 8.8 Hz), 7.64 (d, 1H, C5-H, J=  8.8 Hz) and 10.53 (s, 1H, OH); Found C, 72.33; H, 
6.96; C 14H 16O3 requires C, 72.39; H, 6.94%.
8.3.6 4-PentyIcoum arin-7-0-sulpham ate (6)
Compound 5 (700 mg; 3.01 mmol) was sulphamoylated by method A (8.2.5). The 
crude white sold (893 mg) was fractionated by flash chromatography (CHCl3/ethyl 
acetate, 8:1 to 2:1 gradient) to get a white solid, which was recrystallised from ethyl 
acetate/hexane to give 6 as white crystals (251 mg; 27%). R / 0.36 (CHCl3/ethyl 
acetate, 4:1); mp 128-132°C; MS (FAB4) m/z: 623.2 [70, (2M+H)4], 312.1 [100, 
(M+H)4], 233.1 [20, (M +H-HNS02)4]; MS (FAB') m/z: 621.2 [20, (2M-H)'], 310.2 
[100, (M-H)'], 231.2 [100, (M-H2N S 0 2)']; Acc. MS (FAB4): 312.0908, Ci4H |8N 0 5S 
requires 312.0906; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.88 (t, 3H, 5 ’-CH3, J  = 7.1 
Hz), 1.31-1.39 (m, 4H, CH2CH2), 1.59-1.64 (m, 2H, CH2), 2.81 (t, 2H, l ’-CH2, J  = 7.6 
Hz), 6.37 (s, 1H, C3-H), 7.28 (dd, 1H, C6-H ,J =  1.5, 8.5 Hz), 7.33 (d, 1H, C8-H, J=  1.5 
Hz), 7.93 (d, 1H, C5-H, J=  8.5 Hz) and 8.23 (s, 2H, NH2); Found C, 54.70; H, 5.56; N, 
4.50; C ,4H |7N 0 5S requires C, 54.01; H, 5.50; N, 4.50%.
8.3.7 Ethyl 3-oxononanoate (7)
Prepared by method A (8.2.1), using ethyl potassium malonate (13 g; 74 mmol), 
CH3CN (120 ml), Et3N (16.2 g; 116 mmol), MgCl2 (8.7 g; 91 mmol) and heptanoyl 
chloride (5.91 g; 36.2 mmol). The crude oily residue was purified by flash 
chromatography (CHC13) to give 7 as a pale yellow oil (4.51 g; 62%). (402Lit. bpg 
87°C); R/. 0.64 (CHC13); MS (FAB+) m/z: 201.2 [100, (M+H)+]; Acc. MS (FAB+):
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201.1492, C hH 210 3 requires 201.1491; 'H  NMR (400 MHz; CDC13) 5H: 0.88 (t, 3H, 9- 
CH3, J  = 7.3 Hz), 1.26-1.32 (m, 9H, CH2CH3 and 3xCH2), 1.59 (m, 2H, 5-CH2), 2.35 
(t, 2H, 4-CH2,J =  7.3 Hz), 3.43 (s, 2H, 2-CH2) and 4.19 (q, 2H, CflhCH;,, J=  7.1 Hz).
8.3.8 4-HexyI-7-hydroxycoumarin (8)
Prepared by method 8.2.4, using resorcinol (2.20 g; 19.9 mmol), 7 (4.0 g; 20 mmol) 
and a mixture of CF3COOH (3.1 ml; 40 mmol) and conc. H2SO4 (2.04 ml; 39.9 mmol). 
The crude orange solid obtained was recrystallised from acetone/hexane to 8 as off- 
white crystals (2.95 g; 60%). R / 0.72 (CHCl3/acetone, 3:1); mp 124-126°C; MS 
(FAB+) m/z: 493.4 [10, (2M+H)+], 247.2 [100, (M+H)+]; MS (FAB") m/z: 491.3 [15, 
(2M-H)"], 245.2 [100, (M-H)"]; Acc. MS (FAB+): 247.1334, C 15H i90 3 requires
247.1334; *H NMR (400 MHz; DMSO-d6) 8H: 0.86 (t, 3H, 6 ’-CH3, J  = 7.1 Hz), 1.27-
1.37 (m, 6H, 3xCH2), 1.55-1.63 (m, 2H, CH2), 2.72 (t, 2H, l ’-CH2, J =  7.6 Hz), 6.08 
(s, 1H, C3-H), 6.71 (d, 1H, C8-H, J =  2.4 Hz), 6.80 (dd, 1H, C6-H, J =  2.4, 8.8 Hz), 7.64 
(d, 1H, C5-H, J  = 8.8 Hz) and 10.53 (s, 1H, OH); Found C, 73.30; H, 7.40; C ,5H 180 3 
requires C, 73.15; H, 7.37%.
8.3.9 4-Hexylcoumarin-7-0-sulphamate (9)
Compound 8 (700 mg; 2.84 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 9 as fine white crystals (441 mg; 48%). R/ 0.24 (CHCl3/ethyl acetate, 4:1); mp
126-128°C; MS (FAB+) m/z: 651.3 [10, (2M+H)+], 326.2 [100, (M+H)+], 247.2 [10, 
(M +H-HNS02)+]; MS (FAET) m/z: 649.3 [15, (2M -H)], 324.2 [100, (M-H)'], 245.2 
[60, (M-H2N S 0 2)']; Acc. MS (FAB+): 326.1079, Ci5H20NO5S requires 326.1062; ]H 
NMR (400 MHz; DMSO-d6) 8H: 0.87 (t, 3H, 6 ’-CH3, J =  6.7 Hz), 1.29-1.39 (m, 6H, 
3xCH2), 1.58-1.66 (m, 2H, CH2), 2.81 (t, 2H, l ’-CH2, J  = 7.9 Hz), 6.37 (s, 1H, C3-H),
7.29 (dd, 1H, C6-H, J =  2.4, 8.6 Hz), 7.33 (d, 1H, C8-H, J =  2.4 Hz), 7.93 (d, 1H, Cs-H,
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J =  8.6 Hz) and 8.24 (s, 2H, NH2); Found C, 55.20; H, 5.88; N, 4.25; C i5H 19N 0 5S 
requires C, 55.37; H, 5.89; N, 4.30%.
8.3.10 Ethyl 3-oxodecanoate (10)
Prepared by method A (8.2.1), using potassium ethylmalonate (10.5 g; 61.5 mmol), 
CH3CN (120 ml), Et3N (13.1 ml; 93.8 mmol), MgCl2 (7.0 g; 73 mmol) and octanoyl 
chloride (5.0 ml g; 29 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 10 as a pale yellow oil (3.86 g; 61%). (403Lit. b p o .3  87- 
88°C); R / 0.76 (CHC13); MS (FAB+) m/z: 215.2 [100, (M+H)+]; MS (FAB") m/z: 213.2 
[100, (M-H)']; Acc. MS (FAB+): 215.1652, C 12H230 3 requires 215.1647); *H NMR 
(400 MHz; CDC13) 5H: 0.88 (t, 3H, 10-CH3, J =  7.3 Hz), 1.26-1.29 (m, 11H, CH2CH3 
and 4xCH2), 1.57-1.61 (m, 2H, CH2), 2.53 (t, 2H, 4-CH2, J  = 6.8 Hz), 3.43 (s, 2H, 2- 
CH2) and 4.19 (q, 2H, CH2CH3, J=  7.3 Hz).
8.3.11 4-H eptyl-7-hydroxycoum arin (11)
Prepared according by method 8.2.4, using resorcinol (1.8 g; 16 mmol), 10 (3.5 g; 16 
mmol) and a mixture o f CF3COOH (2.52 ml; 32.7 mmol) and conc. H2S04  (1.67 ml; 
32.7 mmol). The crude yellow solid was recrystallised from acetone/hexane to give 11 
as yellow crystals (2.32 g; 55%). R / 0.78 (CHCl3/acetone, 3:1); mp 106-107°C; MS 
(FAB+) m/z: 261.2 [100, (M+H)+j; MS (FAB') m/z: 519.3 [60, (2M-H)"], 259.2 [100, 
(M-H)']; Acc. MS (FAB+): 261.1501, C ,6H2i0 3 requires 261.1491; 'H  NMR (400 
MHz; DMSO-d6) 8H; 0.86 (t, 3H, 7 ’-CH3, J=  7.1 Hz), 1.24-1.36 (m, 8H, 4xCH2), 1.55- 
1.63 (m, 2H, CH2), 2.72 (t, 2H, l ’-CH2, J =  7.6 Hz), 6.08 (s, 1H, C3-H), 6.71 (d, 1H, 
Cs-H, J =  2.4 Hz), 6.80 (dd, 1H, C6-H, J =  2.4, 8.8 Hz), 7.64 (d, 1H, Cs-H, J =  8.8 Hz) 




Compound 11 (700 mg; 2.69 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) to get a white solid, which was recrystallised from ethyl acetate/hexane to 
give 12 as fine white crystals (503 mg; 55%). R / 0.42 (CHCl3/ethyl acetate, 4:1); mp 
137-139°C; MS (FAB+) m/z\ 679.3 [60, (2M+H)+], 340.1 [100, (M+H)+], 261.1 [10, 
(M +H-HNS02)+]; MS (FAB-) m/z: 611A [20, (2M-H)'], 338.1 [100, (M-H)'], 259.1 
[60, (M-H2N S 0 2)']; Acc. MS (FAB+): 340.1215, C 16H22NO5S requires 340.1218; *H 
NMR (400 MHz; DMSO-d6) 6H: 0.86 (t, 3H, 7’-CH3, J =  7.1 Hz), 1.27-1.39 (m, 8H, 
4xCH2), 1.58-1.64 (m, 2H, CH2), 2.81 (t, 2H, l ’-CH2, J =  7.3 Hz), 6.37 (s, 1H, C3-H),
7.27-7.33 (m, 2H, C6-H and C8-H), 7.39 (d, 1H, C5-H, J  = 8.8 Hz) and 8.22 (s, 2H, 
NH2); Found C, 56.90; H, 6.31; N, 4.15; C 16H2iN 0 5S requires C, 56.62; H, 6.24; N, 
4.13%.
8.3.13 Ethyl 3-oxoundecanoate (13)
Prepared by method A (8.2.1), using potassium ethylmalonate (13.0 g; 76.4 mmol), 
CH3CN (120 ml), Et3N (16.2 ml; 116 mmol), MgCl2 (8.7 g; 91 mmol) and nonanoyl 
chloride (6.69 ml; 37.8 mmol). The crude oily residue was purified by flash 
chromatography (CHC13) to give 13 as pale yellow oil (6.73 g; 78%). (404Lit. bpo.6 
116°C); R / 0.65 (CHC13); MS (FAB+) m/z: 229.2 [100, (M+H)+]; MS (FAB') m/z:
227.2 [100, (M-H)']; Acc. MS (FAB+): 229.1794, C 13H25O3 requires 229.1725; 'H 
NMR (400 MHz; CDCI3); 8H: 0.88 (t, 3H, II-C H 3, J =  7.3 Hz); 1.26-1.61 (m, 15H, 
CH2CH3 and 6xCH2), 2.53 (t, 2H, 4-CH2, J  = 7.6 Hz), 3.43 (s, 2H, 2-CH2) and 4.19 (q, 
2H, CH2CH3, J=  7.3 Hz).
8.3.14 7-Hydroxy-4-octyIcoumarin (14)
Prepared by method 8.2.4, using resorcinol (1.93 g; 17.5 mmol), 13 (4.0 g; 18 mmol) 
and a mixture o f CF3COOH (2.7 ml; 35 mmol) and conc. H2SO4 (1.8 ml; 35 mmol). 
The crude yellow solid was recrystallised from acetone/hexane to give 14 as yellow
2 1 0
crystals (2.31 g; 48%). R / 0.71 (CHCl3/acetone, 3:1); mp 90-92°C; MS (FAB+) m/z:
549.5 [80, (2M+H)+], 275.2 [100, (M+H)+]; MS (FAB-) m/z: 547.4 [75, (2M-H)'],
273.2 [100, (M-H)']; Acc. MS (FAB+): 275.1647, C 17H23O3 requires 275.1647; 'H 
NMR (400 MHz; DMSO-d6) 8H: 0.85 (t, 3H, 8 ’-CH3, J  = 7.1 Hz), 1.25-1.36 (m, 10H, 
5xCH2), 1.55-1.62 (m, 2H, CH2), 2.51 (t, 2H, l ’-H2, J =  7.3 Hz), 6.08 (s, 1H, C3-H),
6.71 (d, 1H, C8-H, J=  2.4 Hz), 6.80 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.64 (d, 1H, Cs-H, 
J  = 8.8 Hz) and 10.53 (s, 1H, OH); Found C, 74.70; H, 8.18; C |7H220 3 requires C, 
74.42; H, 8.08%.
8.3.15 4-O ctylcoum arin-7-0-suIpham ate (15)
Compound 14 (400 mg; 1.46 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) to get a white solid, which was recrystallised from ethyl acetate/hexane to 
give 15 as white fine crystals (279 mg; 53%). R / 0.37 (CHCf/ethyl acetate, 4:1); mp 
124-125°C; MS (FAB+) m/z: 707.0 [80, (2M+H)+], 354.0 [100, (M+H)+], 275.0 [20, 
(M +H-HNS02)+]; MS (FAB') m/z: 705.2 [20, (2M-H)'], 352.1 [100, (M-H)'], 273.1 
[70, (M-H2N S 0 2)"]; A cc. MS (FAB+): 354.1375, C l7H24N 0 5S requires 354.1375; 'H 
NMR (400 MHz; DMSO-d6) 8H: 0.85 (t, 3H, 8 ’-CH3, J =  6.7 Hz), 1.25-1.39 (m, 10H, 
5xCH2), 1.58-1.63 (m, 2H, CH2), 2.81 (t, 2H, l ’-H2, J  = 7.3 Hz), 6.37 (s, 1H, C3-H),
7.28 (dd, 1H, C6-H, J=  2.4, 8.5 Hz), 7.32 (d, 1H, Cr H, J=  2.4 Hz), 7.93 (d, 1H, C5-H, 
J  = 8.5 Hz) and 8.24 (s, 2H, NH2); Found C, 58.00; H, 6.50; N, 3.75; Ci7H23N 0 5S 
requires C, 57.77; H, 6.56; N, 3.96%.
8.3.16 Ethyl 3-oxododecanoate (16)
Prepared by method A (8.2.1), using potassium ethylmalonate (13.0 g; 76.4 mmol), 
CH3CN (120 ml), Et3N (16.2 ml; 116 mmol), MgCl2 (8.7 g; 91 mmol) and decanoyl 
chloride (7.5 ml; 36 mol). The crude oily residue was purified by flash chromatography 
(CHC13) to give 16 as a pale yellow oil (7.79 g; 89%). (405Lit. bpo.15 100-102°C); R / 
0.75 (CHC13); MS (FAB+) m/z: 243.1 [100, (M+H)+]; MS (FAB') m/z: 241.1 [100, (M-
21 1
H)']; Acc. MS (FAB+): 243.1959, C 14H27O3 requires 243.1960; 'H NMR (400 MHz; 
CDCI3) 6h : 0.82 (t, 3H, 12-CH3, J=  5.5 Hz), 1.19-1.55 (m, 17H, CH2CH3 and 7xCH2), 
2.48 (t, 2H, 4-CH2, J -  7.3 Hz), 3.37 (s, 2H, 2-CH2) and 4.13 (q, 2H, CH2CH3, J=  7.3 
Hz).
8.3.17 7-Hydroxy-4-nonyIcoumarin (17)
Prepared by method 8.2.4, using resorcinol (1.14 g; 10.3 mmol), 16 (2.5 g; 10 mmol) 
and a mixture of CF3COOH (1.6 ml; 21 mmol) and conc. H2S04 (1.05 ml; 20.6 mmol). 
The crude yellow solid was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane 
to give 17 as off-white fine crystals (532 mg; 18%). R / 0.71 (CHC^/acetone, 3:1); mp
91-93°C; MS (FAB+) m/z: 577.2 [80, (2M+H)+], 289.1 [100, (M+H)+]; MS (FAB')
m/z: 575.2 [20, (2M-H)'], 287.1 [100, (M-H)']; Acc. MS (FAB+): 289.1807, C i8H250 3 
requires 289.1804; !H NMR (400 MHz; CDC13) 5H: 0.88 (t, 3H, 9 ’-CH3, J =  7.1 Hz),
1.27-1.44 (m, 12H, 6xCH2), 1.64-1.72 (m, 2H, CH2), 2.73 (t, 2H, l ’-CH2, J =  7.3 Hz),
6.14 (s, 1H, C3-H), 6.88 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.08 (d, 1H, C8-H, J=  2.4 Hz),
7.52 (d, 1H, C5-H, J  = 8.8 Hz) and 10.54 (s, 1H, OH); Found C, 75.10; H, 8.39; 
C i8H2403 requires C, 74.97; H, 8.39%.
8.3.18 4-Nonylcoumarin-7-0-suIphamate (18)
Compound 17 (400 mg; 1.39 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 18 as white fine crystals (36 mg; 7%). R / 0.40 (CHC^/ethyl acetate, 4:1); mp 
101—103°C; MS (FAB+) m/z: 735.3 [90, (2M+H)"], 368.1 [100, (M+H)+]; MS (FAB') 
m/z: 733.1 [80, (2M-H)'], 366.0 [100, (M-H)'], 287.1 [90, (M-H2N S 0 2)']; Acc. MS 
(FAB+): 368.1539, Ci8H26N 0 5S requires 368.1532; ‘H NMR (400 MHz; DMSO-d6) 
8h: 0.85 (t, 3H, 9 ’-CH3, . / =  7.1 Hz), 1.18-1.43 (m, 12H, 6 xCH2), 1.57-1.65 (m, 2H, 
CH2), 2.81 (t, 2H, l ’-CH2, J=  7.3 Hz), 6.37 (s, 1H, Cr H), 7.28 (dd, 1H, C6-H, J =  2.4,
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8.5 Hz), 7.33 (d, 1H, C8-H, J=  2.4 Hz), 7.93 (d, 1H, C5-H, J=  8.5 Hz) and 8.24 (s, 2H, 
NH2); Found C, 59.05; H, 6.91; N, 3.74; C i8H25N0 5S requires C, 58.84; H, 6 .86 ; N, 
3.81%.
8.3.19 Ethyl 3-oxotridecanoate (19)
Prepared by method B (8.2.1), using CH2C12 (80 ml), ethyl diazoacetate (3.52 g; 30.8 
mmol), SnCl2 (556 mg; 2.9 mmol) and undecanal (5.0 g; 29 mmol) in CH2C12. The 
crude oily residue was purified by fractional distillation under reduced pressure to give 
19 as a pale yellow oil (4.34 g; 58%). R / 0.72 (CHC13); bp0.,5 135-139°C. (406Lit. bp0 ,5 
130-135°C); MS (FAB"") m/z: 257.2 [100, (M+H)+J; MS (FAB') m/z: 255.2 [100, (M- 
H)']; Acc. MS (FAB+): 257.2129, C 15H29O3 requires 257.2117; 'H  NMR (400 MHz; 
CDCI3) SH: 0.88 (t, 3H, 13-CH3, J=  6.9 Hz), 1.26-1.61 (m, 19H, CH2CH3 and 8xCH2),
2.53 (t, 2H, 4 -CH2, J =  7.2 Hz), 3.43 (s, 2H, 2-CH2) and 4.19 (q, 2H, CFbCTFs, J =  7.2 
Hz).
8.3.20 4-Decyl-7-hydroxycoum arin (20)
Prepared according to method 8.2.4, using resorcinol (1.07 g; 9.76 mmol), 19 (2.5 g;
9.8 mmol) and a mixture of CF3COOH (1.5 ml; 20 mmol) and conc. H2SC>4 (1.0 ml; 20 
mmol). The crude yellow solid was purified by flash chromatography (CHCl3/acetone, 
8:1 to 4:1 gradient) and the pale yellow solid isolated was recrystallisation from 
acetone/hexane to give 20 as off-white fine crystals (1.66 g; 54%). R / 0.73 
(CHCl3/acetone, 3:1); mp 98-99°C; MS (FAB+) m/z: 303.1 [100, (M+H)+]; MS (FAB') 
m/z: 301.1 [100, (M-H)']; Acc. MS (FAB+): 303.1973, C i9H2703  requires 303.1960; ]H 
NMR (400 MHz; CDC13) 6H: 0.88 (t, 3H, 10’-CH3, J =  7.0 Hz), 1.27-1.42 (m, 14H, 
7xCH2), 1.64-1.72 (m, 2H, CH2), 2.73 (t, 2H, l ’-CH2, J=  7.6 Hz), 6.14 (s, 1H, C3-H), 
6.89 (dd, 1H, C6-H, J — 2.4, 8.8 Hz), 7.11 (d, 1H, C8-H, 7 = 2 .4  Hz), 7.52 (d, 1H, C5-H, 




Compound 20 (400 mg; 1.32 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was fractionated by flash chromatography (CHCl3/ethyl acetate, 8:1 
to 2:1 gradient) and the white solid isolated was recrystallised from ethyl 
acetate/hexane to give 21 as white fine needles (288 mg; 57%). R / 0.55 (CHCl3/ethyl 
acetate, 4:1); mp 112—115°C; MS (FAB+) m/z: 763.2 [65, (2M+H)+], 382.0 [100, 
(M+H)+], 303.1 [20, (M +H-HNS02)+]; MS (FAB') m/z: 761.0 [80, (2M-H)'], 380.0 
[100, (M-H)'], 301.1 [9 0 , (M-H2N S 0 2)']; A c c . MS (FAB+): 382.1696, C 19H28N 0 5S 
requires 382.1688, 'H  NMR (400 MHz; DMSO-d6) 5H: 0.85 (t, 3H, 10’-CH3, J =  7.1 
Hz), 1.16-1.38 (m, 14H, 7xCH2), 1.58-1.63 (m, 2H, CH2), 2.81 (t, 2H, l ’-CH2, J =  7.6 
Hz), 6.37 (s, 1H, C3-H), 7.28 (dd, 1H, C6-H, 7 =  2.1, 8.8 Hz), 7.33 (d, 1H, C8-H, 7 =  2.1 
Hz), 7.93 (d, 1H, C5-H, 7  = 8.8 Hz) and 8.24 (s, 2H, NH2); Found C, 60.15; H, 7.12; N, 
3.54; C 19H27N 0 5S requires C, 59.82; H, 7.13; N, 3.67%.
8.3.22 Ethyl 3-oxotetradecanoate (22)
Prepared by method B (8.2.1), using CH2C12 (80 ml), ethyl diazoacetate (3.25 g; 28.5 
mmol), SnCl2 (514 mg; 2.7 mmol) and dodecyl aldehyde (5.0 g; 27 mmol) in CH2C12 
(20 ml). The crude oily residue was purified by fractional distillation under reduced 
pressure to give 22 as a colourless oil (5.3 g; 72%). R/. 0.74 (CHC13); b p o .1 5  122— 
123°C. (407Lit. bpo.i 123-125°C); MS (FAB+) m/z: 271.1 [100, (M+H)+]; MS (FAB') 
m/z: 269.2 [100, (M-H)']; Acc. MS (FAB+): 271.2285, Ci6H310 3 requires 271.2273; *H 
NMR (400 MHz; CDC13) 5H: 0.88 (t, 3H, 14-CH3, 7  = 7.0 Hz), 1.25-1.61 (m, 21H, 
CH2CH3 and 9xCH2), 2.53 (t, 2H, 4-CH2, 7  = 7.3 Hz), 3.43 (s, 2H, 2-CH2) and 4.19 (q, 
2H, CH2CH3, 7 = 7 .3  Hz).
8.3.23 7-Hydroxy-4-undecylcoumarin (23)
Prepared by method 8.2.4, using resorcinol (1.22 g; 11.1 mmol), 22 (3.0 g; 11 mmol) 
and a mixture o f CF3COOH (2.0 ml; 22 mmol) and conc. H2SC>4 (2.0 ml; 22 mmol). 
The crude yellow solid was purified by flash chromatography (CHCl3/acetone, 8:1 to
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4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane 
to give 23 as white crystals (1.92 g; 55%). R / 0.86 (CHCl3/acetone, 3:1); mp 102- 
105°C; MS (FAB+) m/z: 317.2 [100, (M+H)+]; MS (FAB') m/z\ 631.4 [10, (2M-H)'],
315.3 [100, (M-H)']; Acc. MS (FAB+): 317.2121, C20H29O3 requires 317.2117; 'H  
NMR (400 MHz; DMSO-d6) 5H: 0.85 (t, 3H, i r - C H 3, 7 = 6 .2  Hz), 1.23-1.36 (m, 16H, 
8xCH2), 1.54-1.60 (m, 2H, CH2), 2.72 (t, 2H, l ’-CH2, J =  7.6 Hz), 6.07 (s, 1H, C3-H),
6.71 (d, 1H, Cg-H, .7=2.1 Hz), 6.79 (dd, 1H, C6-H, J =2 . l ,  8.5 Hz), 7.63 (d, 1H, C5-H, 
J =  8.5 Hz) and 10.52 (s, 1H, OH); Found C, 75.50; H, 8.97; C2oH2803 requires C, 
75.91; H, 8.92%.
8.3.24 4-U ndecyIcoum arin-7-0-sulpham ate (24)
Compound 23 (400 mg; 1.27 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was fractionated by flash chromatography (CHCl3/ethyl acetate, 8:1 
to 2:1 gradient) and the white solid isolated was recrystallised from ethyl 
acetate/hexane to give 24 as white fine fluffy crystals (88 mg; 18%). R / 0.54 
(CHCl3/ethyl acetate, 4:1); mp 114-116°C; MS (FAB+) m/z: 396.1 [100, (M+H)+],
317.2 [20, ( M + H - H N S O 2 ) ' ] ;  M S  (FAB') m/z: 394.3 [100, ( M - H ) ' ] ,  315.3 70, ( M -  
H 2 N S O 2 ) ' ] ;  Acc. MS (FAB+): 396.1843, C 2 o H 3 o N 05 S  requires 396.1845; ’H NMR 
(400 MHz; DMSO-d6) 6H: 0.85 (t, 3H, l l ’-CH3, J =  7.0 Hz), 1.24-1.38 (m, 16H, 
8xCH2), 1.58-1.65 (m, 2H, CH2), 2.81 (t, 2H, r -C H 2, 7  = 7.4 Hz), 6.37 (s, 1H, C3-H),
7.28 (dd, 1H, C6-H, J6 = 2.3, 8.9 Hz), 7.33 (d, 1H, C8-H, J=  2.3 Hz), 7.93 (d, 1H, C5- 
H, J =  8.6 Hz) and 8.24 (s, 2H, NH2); Found C ,  61.00; H, 7.44; N, 3.52; C20H29NO5S 
requires C, 60.74; H, 7.39; N, 3.54%.
8.3.25 Ethyl 3-oxopentadecanoate (25)
Prepared by method B (8.2.1), using CH2CI2 (80 ml), ethyl diazoacetate (3.02 g; 26.5 
mmol), SnCb (478 mg; 2.5 mmol) and tridecanal (5.0 g; 25 mmol) in CH2CI2 (20 ml). 
The crude oily residue was purified by flash chromatography (CHC13) to give 25 as a 
colourless oil, which solidified to a white soft solid on standing (6.98 g; 97%). R / 0.65
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(CHC13); mp 28°C (406Lit. mp <20°C); MS (FAB+) m/z-. 285.2 [100, (M+H)+[; MS 
(FAB') m/z\ 283.2 [100, (M-H)']; Acc. MS (FAB+): 285.2426, Ci7H330 3 requires 
285.2429; 'H  NMR (400 MHz; CDC13) 8H: 0.88 (t, 3H, 15-CH3, / =  6.4 Hz), 1.25-1.64 
(m, 23H, CH2CH3 and 10xCH2), 2.53 (t, 2H, 4-CH2, J =  7.3 Hz), 3.43 (s, 2H, 2-CH2) 
and 4.19 (q, 2H, CHjCHj, J=  7.3 Hz).
8.3.26 4-Dodecyl-7-hydroxycoumarin (26)
Prepared by method 8.2.4, using resorcinol (1.16 g; 10.5 mmol), 25 (3.0 g; 11 mmol) 
and a mixture o f CF3COOH (2.0 ml; 21 mmol) and cone. H2SO4 (1.5 ml; 21 mmol). 
The crude brown solid was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) and the yellow solid isolated was recrystallised from acetone/hexane to 
give 26 as fine yellow crystals (747 mg; 22%). R / 0.77 (CHC^/acetone, 3:1); mp 101- 
103°C; MS (FAB+) m/z: 331.2 [100, (M+H)+]; MS (FAB') m/z: 329.3 [100, (M-H)+]; 
Acc. MS (FAB+): 331.2279, C21H31O3 requires 330.2273; 'H N M R  (400 MHz; DMSO- 
d6) 5h: 0.85 (t, 3H, 12’-CH3, J  = 7.0 Hz), 1.17-1.36 (m, 18H, 9xCH2), 1.55-1.60 (m, 
2H, CH2), 2.72 (t, 2H, l ’-CH2, J =  7.4 Hz), 6.08 (s, 1H, C3-H), 6.71 (d, 1H, C8-H, J  =
2.3 Hz), 6.79 (dd, 1H, C6-H, J=  2.3, 8.6 Hz), 7.64 (d, 1H, C5-H, J=  8.9 Hz) and 10.54 
(s, 1H, OH); Found C, 76.80; H, 8.80; C21H30O3 requires C, 76.33; H, 9.15%.
8.3.27 4-Dodecylcoumarin-7-<?-sulphamate (27)
Compound 26 (400 mg; 1.21 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 27 as white fine crystals (91 mg; 18%). R / 0.55 (CHC^/ethyl acetate, 4:1); mp 
104-106°C; MS (FAB+) m/z: 410.2 [100, (M+H)+], 331.2 [20, (M +H-HNS02)+]; MS 
(FAB') m/z: 817.3 [20, (2M-H)'], 408.3 [100, (M-H)'], 329.3 [70, (M-H2N S 0 2)']; Acc. 
MS (FAB+): 410.2006, C21H32NO5S requires 410.2001; 'H  NMR (400 MHz; DMSO- 
d6) 5H: 0.85 (t, 3H, 12’-CH3, J =  7.0 Hz), 1.24-1.34 (m, 18H, 9xCH2), 1.58-1.63 (m, 
2H, CH2), 2.81 (t, 2H, l ’-CH2, J=  7.6 Hz), 6.37 (s, 1H, C3-H), 7.28 (dd, 1H, C6-H, J  =
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2.3, 8.9 Hz), 7.33 (d, 1H, C8-H, J=  2.3 Hz), 7.93 (d, 1H, C5-H, J=  8.6 Hz) and 8.23 (s, 
2H, NH2); Found C, 61.90; H, 7.65; N, 3.34; C2iH3iN 0 5S requires C, 61.59; H, 7.63; 
N, 3.42%.
8.3.28 Ethyl 3-oxohexadecanoate (28)
Prepared by method B (8.2.1), using CH2C12 (80 ml), ethyl diazoacetate (2.82 g; 24.7 
mmol), SnCl2 (446 mg; 2.35 mmol) and tetradecanal (5.0 g; 24 mmol) in CH2C12 (20 
ml). The crude oily residue was purified by flash chromatography (CHC13) to give 28 
as a colourless oil, which solidified to an off-white soft solid on standing (5.45 g; 
78%). R / 0.71 (CHCI3); mp 45-47°C (408Lit. mp 41-42°C); MS (FAB+) m/z: 299.2 
[100, (M+H)+]; MS (FAB') m/z: 297.2 [100, (M-H)']; Acc. MS (FAB+): 299.2599, 
C 18H35O3 requires 299.2586; 'H  NMR (400 MHz; CDCI3) 8H: 0.88 (t, 3H, I6-CH3, /  = 
6.67 Hz), 1.20-1.69 (m, 25H, CH2CH3 and 11xCH2), 2.53 (t, 2H, 4-cH2, J =  7.3 Hz),
3.43 (s, 2H, 2-CH2) and 4.19 (q, 2H, CH2CH3, J=  7.3 Hz).
8.3.29 7-H ydroxy-4-tridecylcoum arin (29)
Prepared by method 8.2.4, using resorcinol (1.11 g; 10.1 mmol), 28 (3.0 g; 10 mmol) 
and a mixture of CF3COOH (2.0 ml; 20 mmol) and conc. H2S04  (1.5 ml; 20 mmol). 
The crude brown solid was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) and the beige solid isolated was recrystallised from acetone/hexane to 
give 29 as fine cream-coloured crystals (757 mg; 22%). R / 0.72 (CHC^/acetone, 3:1); 
mp 95-97°C; MS (FAB+) m/z: 345.2 [100, (M+H)+]; MS (FAB') m/z: 343.3 [100, (M- 
H)']; Acc. MS (FAB+): 345.2438, C22H330 3 requires 345.2429; ]H NMR (400 MHz; 
DMSO-d6) SH: 0.85 (t, 3H, 13’-CH3, J =  7.0 Hz), 1.19-1.36 (m, 20H, 10xCH2), 1.54- 
1.62 (m, 2H, CH2), 2.72 (t, 2H, l ’-CH2, J =  7.4 Hz), 6.08 (s, 1H, C3-H), 6.71 (d, 1H, 
C8-H, J =  2.3 Hz), 6.79 (dd, 1H, C6-H, J =  2.3, 8.9 Hz), 7.64 (d, 1H, C5-H, J =  8.6 Hz) 




Compound 29 (350 mg; 1.01 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 30 as white crystals (101 mg; 23%). R / 0.53 (CHCl3/ethyl acetate, 4:1); mp 
120-121°C; MS (FAB+) m/z: 424.3 [100, (M+H)+], 345.3 [25, (M +H-HNS02)+]; MS 
(FAB') m/z: 422.3 [60, (M-H)'], 343.3 [100, (M-H2N S 0 2)']; Acc. MS (FAB+): 
424.2168, C22H34N 0 5S requires 424.2158; ]H NMR (400 MHz; DMSO-d6) 5H: 0.86 (t, 
3H, 13’-CH3, J  = 7.0 Hz), 1.20-1.39 (m, 20H, 10xCH2), 1.58-1.66 (m, 2H, CH2), 2.81 
(t, 2H, P-C H 2, J  = 7.8 Hz), 6.38 (s, 1H, C3-H), 7.29 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 
7.33 (d, 1H, C8-H, J =  2.3 Hz), 7.93 (d, 1H, C5-H, J =  8.9 Hz) and 8.24 (s, 2H, NH2); 
Found C, 62.60; H, 7.90; N, 3.46; C22H33N 0 5S requires C, 62.38; H, 7.85; N, 3.31%.
8.4 Synthesis of compounds with other functionalities at the C-4 position of
the coumarin ring
8.4.1 7-Hydroxy-4-(prop-2-yl)coumarin (31)
Prepared by method 8.2.4, using resorcinol (1.21 g; 11.1 mmol), ethyl 4-methyl-3- 
oxopentanoate (1.6 g; 10 mmol) and a mixture o f CF3COOH (1.7 ml; 22 mmol) and 
conc. H2SC>4 (2.2 ml; 22 mmol). The crude yellow solid was purified by 
recrystallisation from acetone/hexane to give 31 as pale white fine crystals (420 mg; 
21%). R / 0.42 (CHCl3/acetone 3:1); mp 120-122°C (409Lit. mp 62-64°C); MS (FAB+) 
m/z: 409.2 [20, (2M+H)+], 205.2 [100, (M+H)+]; MS (FAB') m/z: 407.2 [20, (2M-H)'],
203.1 [100, (M-H)']; Acc. MS (FAB+): 205.0874, Ci2H i30 3 requires 205.0865; ]H 
NMR (400 MHz; DMSO-d6) 5H: 1.24 (d, 6H, CH(CH3)2, J =  6.7 Hz), 3.28-3.35 (m, 
1H, CH(CH3)2), 6.08 (s, 1H, C3-H), 6.72 (d, 1H, Cg-H, J=  2.1 Hz), 6.81 (dd, 1H, C6-H, 
J=  2.1, 8.8 Hz), 7.71 (d, 1H, C5-H, J=  8.8 Hz) and 10.54 (s, 1H, OH); Found C, 70.60; 
H, 6.00; C 12H i20 3 requires C, 70.57; H, 5.92%.
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8.4.2 4-(Prop-2-yl)coumarin-7-0-sulphamate (32)
Compound 31 (400 mg; 1.96 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 32 as white fine crystals (150 mg; 30%). R / 0.22 (CHCl3/ethyl acetate, 4:1); mp 
164-167°C; MS (FAB+) m/z: 567.1 [70, (2M+H)+], 284.1 [100, (M+H)+]; MS (FAB') 
m/z: 565.2 [30, (2M-H)'], 282.1 [100, (M-H)'], 203.1 [60, (M-H2N S 0 2)']; Acc. MS 
(FAB+): 284.0599, Ci2Hi4N 0 5S requires 284.0593; !H NMR (400 MHz; DMSO-d6) 
6h : 1-26 (d, 6H, CH(CH3)2, J=  6.7 Hz), 3.31-3.34 (m, 1H, CH(CH3)2), 6.35 (s, 1H, C3- 
H), 7.29 (dd, 1H, C6-H, J =  2.4, 8.8 Hz), 7.33 (d, 1H, Cg-H, J  = 2.4 Hz), 7.99 (d, 1H, 
Cs-H, J  = 8.8 Hz) and 8.23 (s, 2H, NH2); Found C, 50.80; H, 4.62; N, 4.97 
Ci2H 13N 0 5S requires C, 50.88; H, 4.63; N, 4.94%.
8.4.3 7-Hydroxy-4-tbutylcoumarin (33)
Prepared by method 8.2.4, using resorcinol (7.0 g; 63 mmol), methyl 4,4-dimethyl-3- 
oxopentanoate (10.0 g; 63.2 mmol) and a mixture o f CF3COOH (10 ml; 0.2 mol) and 
conc. H2S 0 4 (6.5 ml; 0.2 mol). The crude brown residue was purified by flash 
chromatography (CHCl3/acetone, 8:1 to 4:1 gradient) and the pale yellow solid isolated 
was recrystallised from THF/hexane to give 33 as pale yellow crystals (380 mg; 
0.03%). Rf  0.61 (CHCl3/acetone, 3:1); mp 159-161°C; MS (FAB+) m/z: 219.1 [100, 
(M+H)+]; MS (FAB') m/z: 217.1 [100, (M-H)']; Acc. MS (FAB+): 219.1029, Ci3H ]50 3 
requires 219.1021; 'H NMR (400 MHz; CDC13) 8H: 1.49 (s, 9H, C(CH3)3), 6.28 (s, 1H, 
C3-H), 6.85 (dd, 1H, C6-H, J=  2.7, 8.9 Hz), 7.11 (d, 1H, C8-H, J= 2.7  Hz), 7.13 (s, 1H, 
OH) and 7.91 (d, 1H, Cs-H, J6,s = 8.9 Hz); Found C, 71.90; H, 6.49; C ,3H 140 3 requires 




Compound 33 (310 mg; 1.43 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl THF/hexane to 
give 34 as white fine crystals (43 mg; 10%). R / 0.48 (CHCl3/ethyl acetate, 4:1); mp 
187-189°C; MS (FAB+) m/z: 298.0 [100, (M+H)+], 219.1 [15, (M +H-HNS02)+]; MS 
(FAB') m/z: 296.0 [100, (M-H)'], 217.0 [40, (M-H2N S 0 2)']; Acc. MS (FAB+): 
298.0746, C 13H]6N 0 5S requires 298.0749; ’H NMR (400 MHz; DMSO-d6) 6H: 1-45 (s, 
9H, C(CH3)3), 6.33 (s, 1H, C3-H), 7.27 (dd, 1H, C6-H, J -  2.3, 8.9 Hz), 7.34 (d, 1H, C8- 
H, J=  2.3 Hz), 8.26 (s, 2H, NH2) and 8.28 (d, 1H, C5-H, J=  8.9 Hz); Found C, 52.40; 
H, 4.91; N, 4.76; C i3H 150 5NS requires C, 52.51; H, 5.08; N, 4.71%; HPLC: 
MeOH:H20  (70:30); Flow rate = 2 ml/min, A,max = 273.4 and 310.1 nm; tR= 1.6 min.
8.4.5 7-Hydroxy-4-(methoxymethyl)coumarin (35)
Prepared by method 8.2.4, using resorcinol (3.1 g; 28 mmol), methyl 4-methoxy-3- 
oxobutanoate (4.0 g; 28 mmol) and a mixture of CF3COOH (4.34 ml; 56.3 mmol) and 
conc. H2S 0 4 (2.85 ml; 56.3 mmol). The crude brown solid was purified by 
recrystallisation from acetone/hexane to give 35 as pale pink fine crystals (1.52 g; 
27%). R / 0.54 (CHCl3/acetone, 3:1); mp 210-212°C; MS (FAB+) m/z: 413.2 [10, 
(2M+H)+], 207.2 [100, (M+H)+]; MS (FAB') m/z: 512.2 [10, (2M-H)'], 205.1 [100, (M- 
H)']; Acc. MS (FAB+): 207.0641, C n H ii0 4 requires 207.0657; 'H  NMR (400 MHz; 
DMSO-d6) 8h: 3.41 (s, 3H, CH3), 4.63 (s, 2H, CH20), 6.17 (s, 1H, C3-H), 6.73 (d, 1H, 
Cg-H, J=  2.4 Hz), 6.79 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.53 (d, 1H, C5-H, J=  8.8 Hz) 
and 10.57 (s, 1H, OH); Found C, 64.30; H, 4.90; C nH i0O4 requires C, 64.07; H, 
4.89%.
8.4.6 4-(Methoxymethyl)coumarin-7-0-sulphainate (36)
Compound 35 (was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 2:1 
gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane to
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give 36 as fine fluffy white crystals (301 mg; 31%). R / 0.14 (CHC^/ethyl acetate, 4:1); 
mp 151—153°C; MS (FAB+) m/z: 571.2 [10, (2M+H)+], 286.1 [100, (M+H)4]; MS 
(FAB') m/r. 284.1 [100, (M-H)'], 205.1 [50, (M-H2N S 0 2)']; Acc. MS (FAB+): 
286.0384, C nH ,2N 0 6S requires 286.0385; 'H  NMR (400 MHz; DMSO-d6) 8H: 3.43 (s, 
3H, CH3), 4.71 (s, 2H, CH20 ), 6.45 (s, 1H, C3-H), 7.28 (dd, 1H, C6-H, .7=2.1 , 8.7 Hz), 
7.35 (d, 1H, C8-H, / =  2.1 Hz), 7.81 (d, 1H, C5-H, J =  8.5 Hz) and 8.25 (s, 2H, NH2); 
Found C, 46.40; H, 3.84; N, 4.88; C ,|H nN 0 6S requires C, 46.31; H, 3.89; N, 4.91%.
8.4.7 4-ChloromethyI-7-hydroxycoumarin (37)
Prepared by method 8.2.4, using resorcinol (2.93 g; 29.6 mmol), methyl 4-chloro-3- 
oxobutanoate (4.0 g; 29 mmol) and a mixture o f CF3COOH (4.1 ml; 53 mmol) and 
conc. H2SO4 (2.7 ml; 53 mmol). The crude orange solid was purified by 
recrystallisation from acetone/hexane to give 37 as off-white fine crystals (1.31 g; 
23%). R / 0.73 (CHCl3/acetone, 3:1) mp 183-185°C (4l0Lit. mp 181°C); MS (FAB4) 
m/z: 421.2 [15, (2M+H)4], 211.1 [100, (M(C135)+H)+]; MS (FAB') m/z: 419.1 [15, (2M- 
H)'], 209.1 [100, (M(C135)-H)']; A cc. MS m/z (FAB+): 213.0127, C ,0H837ClO3 requires 
213.0132 and 211.0151, C |0H835ClO3 requires 211.0162; ‘H N M R  (400 MHz; DMSO- 
d6) SH: 4.96 (s, 2H, CH2), 6.42 (s, 1H, C3-H), 6.76 (d, 1H, C8-H, J =  2.4 Hz), 6.85 (dd, 
1H, C6-H, J  = 2.4, 8.7 Hz), 7.69 (d, 1H, C5-H, J  = 8.8 Hz) and 10.69 (s, 1H, OH); 
Found C, 57.00; H, 3.20; C 10H7CIO3 requires C, 57.03; H, 3.35%.
8.4.8 4-Chloromethylcoumarin-7-0-sulphamate (38)
Compound 37 (400 mg; 1.9 mmol) was sulphamoylated by method A (8.2.5). The 
crude yellow solid was purified by flash chromatography (CHCf/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 38 as pale green fine crystals (59 mg; 11%). R / 0.44 (CHCb/ethyl acetate, 4:1); 
mp 172-175°C; MS (FAB+) m/z: 289.9 [95, (M(CI3S)+H)+], 210.9 [100, (M+H- 
H N S02)+]; MS (FAB') m/z: 287.9 [100, (M(C135)-H)]', 208.9 [90, (M-H2N S 0 2)']; Acc. 
MS m/z (FAB+): 289.9893, Ci0H935C1NO5S requires 289.9889 and 291.9862, 
C 10H937ClNO5S requires 291.9860; 'H  NMR (400 MHz; DMSO-d6) 8H: 5.05 (s, 2H,
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CH2), 6.72 (s, 1H, C3-H), 7.34 (dd, 1H, C6-H, J  = 2.4, 8.8 Hz), 7.38 (d, 1H, Cg-H, J  =
2.4 Hz), 7.96 (d, 1H, C5-H, J  = 8.8 Hz) and 8.28 (s, 2H, NH2); Found C, 41.50; H, 
2.79; N, 3.48; C 10H8ClNO5S requires C, 41.46; H, 2.78; N, 4.84%.
8.4.9 7-Hydroxy-4-phenylcoum arin (39)
Prepared by method 8.2.4, using resorcinol (2.0 g; 18 mmol), ethyl 3-oxo-3- 
phenylpropanoate (2.0 g; 18 mmol) and a mixture o f CF3COOH (2.8 ml; 36 mmol) and 
conc. H2SO4 (1.85 ml; 36.3 mmol). The crude orange solid was purified by 
recrystallisation from hot absolute ethanol to give 39 as yellow crystals (1.85 g; 43%). 
R / 0.71 (CHCl3/acetone, 3:1); mp 248-252°C (411Lit. mp 247-248°C); MS (FAB+) 
m/z: 239.1 [100, (M+H)+]; MS (FAB') m/z: 237.1 [100, (M-H)']; Acc. MS (FAB+): 
239.0634 (M+H) (C i5H n 0 3 requires 239.0629); 'H  NMR (400 MHz; DMSO-d6) SH:
6.15 (s, 1H, C3-H), 6.79 (dd, 1H, C6-H ,J =  1.2, 8.8 Hz), 6.81 (d, 1H, C8- H ,J =  1.2 Hz),
7.27 (d, 1H, C5-H, J =  8.8 Hz), 7.51-7.57 (m, 5H, Ph-H) and 10.67 (s, 1H, OH); Found 
C, 75.40; H, 4.13; C i5H |0O3 requires C, 75.62; H, 4.23%.
8.4.10 4-Phenylcoum arin-7-0-sulpham ate (40)
Compound 39 (700 mg; 2.94 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 40 as white fine fluffy crystals (304 mg; 33%). R / 0.60 (CHC^/ethyl acetate, 
4:1); mp 185-190°C; MS (FAB+) m/z: 318.1 [100, (M+H)+]; MS (FAB ) m/z: 316.2 
[100, (M-H)'], 237.2 [65, (M-H2N S 0 2)']; Acc. MS (FAB+): 318.0379 (M+H) 
(C 15H l2N 0 5S requires 318.0357); 'H  NMR (400 MHz; DMSO-d6) 8H: 6.36 (s, 1H, C3- 
H), 7.28 (dd, 1H, C6-H, J =  2.1, 8.7 Hz), 7.39 (d, 1H, Cr H, J =  2.1 Hz), 7.58 (d, 1H, 
Cs-H, J  = 8.7 Hz) and 7.59-7.62 (m, 7H, Ph-H and NH2 -  reduced to 5H when 
exchanged with D20 ); Found C, 56.70; H, 3.53; N, 4.48; C15H 11NO5S requires C, 
56.78; H, 3.49; N, 4.41%.
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8.4.11 Ethyl 3-oxo-4-phenyIbutanoate (41)
Prepared by method B (8.2.1), using CH2CI2 (80 ml), ethyl diazoacetate (4.99 g; 43.7 
mmol), SnCh (790 mg; 3.73 mmol) and phenylacetaldehyde (5.0 g; 42 mmol) in 
CH2CI2. The crude oily residue was purified by distillation under reduced pressure to 
give 41 as a pale yellow oil (5.27 g; 61%). bp0j  185-189°C. (412Lit. bp9 154-156°C); 
R / 0.62 (CHC13); MS (FAB+) m/z: 207.1 [100, (M+H)+], 91.1 [40, (PhCH2)+]; MS 
(FAB') m/z: 205.1 [100, (M-H)']; Acc. MS (FAB+): 207.1014, C ,2H |50 3 requires 
207.1021; 'H  NMR (400 MHz; DMSO-d6) 8H: 2.16 (t, 3H, CH2CH3, J  = 7.3 Hz), 3.45 
(s, 2H, Ph-CFb), 3.83 (s, 2H, 2-CH2), 4.17 (q, 2H, CfchCH:,, J=  7.3 Hz) and 7.20-7.36 
(m, 5H, Ph-H).
8.4.12 4-Benzyl-7-hydroxycoumarin (42)
Prepared by method 8.2.4, using resorcinol (1.6 g; 15 mmol), 41 (3.0 g; 15 mmol) and 
a mixture of CF3COOH (2.5 ml; 29 mmol) and conc. H2SO4 (1.5 ml; 29 mmol). The 
crude yellow solid was purified by recrystallisation from hot absolute ethanol to give 
42 as pale yellow crystals (2.19 g; 60%). R / 0.80 (CHCh/acetone, 3:1); mp 209-212°C 
(413Lit. mp 214-215°C); MS (FAB+) m/z: 505.1 [10, (2M+H)+], 253.1 [100, (M+H)+]; 
MS (FAB') m/z: 503.2 [15, (2M-H)'], 251.2 [100, (M-H)']; Acc. MS (FAB+): 253.0863, 
C |6H ,30 3 requires 253.0865; 'H  NMR (400 MHz; CDC13) 8H: 4.38 (s, 2H, CFF-Ph), 
5.98 (s, 1H, C3-H), 6.71 (d, 1H, Cs-H ,/ =  2.3 Hz), 6.76 (dd, 1H, C6-H ,./=  2.3, 8.6 Hz), 
7.23-7.36 (m, 5H, Ph-H), 7.67 (d, 1H, C5-H, J =  8.6 Hz) and 10.57 (s, 1H, OH); Found 
C, 75.60; H, 4.88; C |6H ,20 3 requires C, 76.18; H, 4.79%.
8.4.13 4-B enzylcoum arin-7-0-sulpham ate (43)
Compound 42 (400 mg; 1.6 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 43 as white fine crystals (135 mg; 26%). R / 0.39 (CHC^/ethyl acetate, 4:1); mp 
180-182°C; MS (FAB+) m/z: 663.4 [30, (2M+H)+], 332.1 [100, (M+H)4]; MS (FAB )
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m/z: 330.2 [100, (M-H)'], 251.2 [50, (M-H2N S 0 2)] ; Acc. MS (FAB+): 332.0590 
(M+H) (Ci6H |4N 0 5S requires 332.0593); 'H  NMR (400 MHz; DMSO-d6) SH: 4.23 (s, 
2H, Cfch-Ph), 6.32 (s, 1H, C3-H), 7.23-7.26 (m, 2H, C8-H and C6-H), 7.26-7.37 (m, 5H, 
Ph-H), 7.92 (d, 1H, C5-H, J =  8.9 Hz) and 8.22 (s, 2H, NH2); Found C, 57.70; H, 3.97; 
N, 4.21; C 16Hi3N 0 5S requires C, 58.00; H, 3.95; N, 4.23%.
8.4.14 Ethyl 3-oxo-5-phenylpentanoate (44)
Prepared by method B (8.2.1), using CH2CI2 (80 ml), ethyl diazoacetate (4.5 g; 39 
mmol), SnCl2 (700 mg; 3.73 mmol) and hydrocinnamaldehyde (5.0 g; 37 mmol) in 
CH2CI2. The crude oily residue was purified by flash chromatography (CHCI3) to give 
44 as a pale yellow oil (5.38 g; 66%). (414Lit. bp0.i 114-122°C); R / 0.63 (CHCI3); MS 
(FAB+) m/z\ 221.1 [100, (M+H)+], 91.0 [55, (PhCH2)+]; MS (FAB') m/z: 219.1 [100, 
(M-H)']; Acc. MS (FAB4): 221.1181 (M+H) (C |3H ,70 3 requires 221.1178); 'H  NMR 
(400 MHz; DMSO-d6) 8H: 1.17 (t, 3H, CH2CH3, J =  7.3 Hz), 2.79 (t, 2H, 4-CH2, J  =
7.5 Hz), 2.87 (t, 2H, 5-CH2, J =  7.5 Hz), 3.60 (s, 2H, 2-H2), 4.08 (q, 2H, CH2CH3, J  =
7.3 Hz) and 7.13-7.29 (m, 5H, Ph-H).
8.4.15 7-Hydroxy-4-(2-phenylethyl)coumarin (45)
Prepared by method 8.2.4, using resorcinol (1.25 g; 11.4 mmol), 44 (2.5 g; 11 mmol) 
and a mixture o f CF3COOH (1.75 ml; 22.7 mmol) and conc. H2SO4 (1.16 ml; 22.7 
mmol). The crude yellow solid was purified by recrystallisation from hot absolute 
ethanol to give 45 as pale white crystals (1.06 g; 35%). R / 0.65 (CHC^/acetone, 3:1); 
mp 175-177°C (415Lit. mp 175-176°C); MS (FAB+) m/z: 533.2 [40, (2M+H)+], 267.1 
[100, (M+H)+], 91.1 [20, (CH2Ph)+]; MS (FAB') m/z: 531.2 [30, (2M-H)'], 265.0 [100, 
(M-H)']; Acc. MS (FAB+): 267.1018, C 17H 1503 requires 267.1021; 'H  NMR (400 
MHz; CDCI3) 6h: 2.98-3.06 (m, 4H, CH2CH2), 6.12 (s, 1H, C3-H), 6.59 (s, 1H, OH), 
6.84 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.11 (d, 1H, Cg-H, J=  2.4 Hz), 7.20-7.34 (m, 5H, 
Ph-H) and 7.53 (d, 1H, C5-H, J =  8.8 Hz); Found C, 76.70; H, 5.20; Ci7H 1403 requires 
C, 76.68; H, 5.30%.
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8.4.16 4-(2-Phenylethyl)coumarin-7-0-sulphainate (46)
Compound 45 (400 mg; 1.5 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from THF/hexane to give 
46 as white fine crystals (395 mg; 76%). R / 0.27 (CHCl3/ethyl acetate, 4:1); mp 89- 
93°C; MS (FAB+) m/z: 346.0 [100, (M+H)+], 91.0 [50, (CH2Ph)+]; MS (FAB ) m/z:
344.0 [100, (M-H)'], 265.0 [60, (M-H2N S 0 2)']; Acc. MS (FAB+): 346.0754, 
C i7Hi6N 0 5S requires 346.0749; 'H NMR (400 MHz; DMSO-d6) 5H: 2.96 (t, 2H, 
CH2CH2Ph, J  = 8.8 Hz), 3.14 (t, 2H, CH2Ph, J=  8.5 Hz), 6.36 (s, 1H, C3-H), 7.22-7.34 
(m, 7H, Ph-H, Cg-H and C6-H), 8.03 (d, 1H, C5-H, J =  7.9 Hz) and 8.25 (s, 2H, NH2); 
Found C, 59.30; H, 4.89; N, 3.86; CnH ^N OsS requires C, 59.12; H, 4.38; N, 4.06%.
8.4.17 Ethyl 3-(4-ethylphenyl)-3-oxopropanoate (47)
Prepared by method A (8.2.1), using ethyl potassium malonate (6.07 g; 35.7 mmol), 
CH3CN (120 ml), Et3N (7.58 ml; 54.4 mmol), MgCl2 (4.05 g; 42.5 mmol) and 4- 
ethylbenzoyl chloride (2.5 ml; 17 mmol). The crude oily residue was purified by 
distillation under reduced pressure to give 47 as colourless oil (3.74 g; 78%). R / 0.64 
(CH2C12); bpo,23 131-135°C. (4l6Lit. bp0.oo4 105-112°C); MS (FAB+) m/z: 221.0 [100, 
(M+H)+]; MS (FAB") m/z: 219.0 [100, (M-H)']; Acc. MS (FAB+): 221.1177, Ci3Hi70 3 
requires 221.1178; 'H  NMR (400 MHz; CDC13) 8H: 1.22-1.33 (m, 6H, CH3CH2Ph and 
CH2CH3), 2.70 (q, 2H, CH2Ph, J=  7.8 Hz), 3.97 (s, 2H, 2-H2), 4.21 (q, 2H, CH2CH3, J  
= 6.8 Hz), 7.29 (d, 2H, Ar-H2, J =  8.3 Hz) and 7.87 (d, 2H, Ar-H2, J=  8.3 Hz).
8.4.18 4-(4-EthylphenyI)-7-hydroxycoumarin (48)
Prepared by method 8.2.4, using resorcinol (1.5 g; 14 mmol), 47 (3.0 g; 14 mmol) and 
a mixture of CF3COOH (2.5 ml; 27 mmol) and conc. H2SC>4 (1.5 ml; 27 mmol). The 
crude orange solid was purified by recrystallisation from hot ethanol to give 48 as 
white needles (1.66 g; 46%). R / 0.72 (CHCl3/acetone, 4:1); mp 176-180°C; MS 
(FAB+) m/z\ 533.1 [10, (2M+H)+], 267.0 [100, (M+H)+]; MS (FAB') m/z: 531.1 [20,
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(2M-H)'], 265.1 [100, (M-H)']; Acc. MS (FAB+): 267.1018, C 17H 150 3 requires 
267.1021; *H NMR (400 MHz; DMSO-d6) 6H: 1.23 (t, 3H, CH3CH2, J=  7.6 Hz), 2.69 
(q, 2H, CH3CH2, J=  7.6 Hz), 6.13 (s, 1H, C3-H), 6.77 (m, 2H, C6-H and C8-H), 7.31 (d, 
1H, C5-H, J =  8.5 Hz), 7.38-7.44 (m, 4H, Ph-H) and 10.64 (s, 1H, OH); Found C, 
76.30; H, 5.30; Ci7Hi40 3 requires C, 76.68; H, 5.30%.
8.4.19 4-(4-Ethylphenyl)coumarin-7-0-sulphamate (49)
Compound 48 (400 mg; 1.5 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from THF/hexane to give 
49 as white fine crystals (114 mg; 22%). R / 0.35 (CHCl3/ethyl acetate, 4:1); mp 170— 
173°C; MS (FAB+) m/z: 691.0 [30, (2M+H)+], 346.1 [100, (M+H)+]; MS (FAB') m/z:
689.3 [10, (2M-H)'], 344.2 [100, (M-H)'], 265.2 [60, (M-H2N S 0 2)']; Acc. MS (FAB+): 
346.0749, C 17H]6N 0 5S requires 345.0749; ]H NMR (400 MHz; DMSO-d6) 6H: 1.25 (t, 
3H, CH3CH2, J=  7.4 Hz), 2.71 (q, 2H, CH3CH2, J=  7.4 Hz), 6.44 (s, 1H, C3-H), 7.26 
(dd, 1H, C6-H, J=  2.3, 8.9 Hz), 7.42-7.49 (m, 5H, Ph-H and C8-H), 7.57 (d, 1H, C5-H, 
J  = 8.6 Hz) and 8.28 (s, 2H, NH2); Found C, 59.00; H, 4.36; N, 4.03; C ]7H ,5N 0 5S 
requires C, 59.12; H, 4.38; N, 4.06%.
8.4.20 Ethyl 3-cyclohexyl-3-oxopropanoate (50)
Prepared by method B (8.2.1), using CH2C12 (80 ml), ethyl diazoacetate (5.34 g; 46.8 
mmol), SnCl2 (85 mg; 4.5 mmol) and cyclohexanecarboxaldehyde (5.0 g; 45 mmol) in 
CH2C12 (20 ml). The crude oily residue was purified by fractional distillation under 
reduced pressure to give 50 as a pale yellow oil (5.38 g; 66%). R / 0.63 (CHC13); bpo.3 
135-139°C. (4,2Lit. bp,8: 146-150°C); MS (FAB+) m/z: 199.0 [100, (M+H)+[; MS 
(FAB') m/z: 197.0 [100, (M-H)']; Acc. MS (FAB+): 199.1341, C n Hi9 0 3 requires 
199.1334; 'H N M R  (400 MHz; CDC13) SH: 1.28 (t, 3H, CH2CH3> J=  7.2 Hz), 1.39-2.49 
(m, 11H, cyclohexyl H), 3.48 (s, 2H, 2-CH2) and 4.19 (q, 2H, CFhCHj, J=  7.2 Hz).
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8.4.21 4-Cyclohexyl-7-hydroxycoumarin (51)
Prepared by method 8.2.4, using resorcinol (1.67 g; 15.1 mmol), 50 (3.0 g; 15 mmol) 
and a mixture of CF3COOH (2.33 ml; 30.3 mmol) and conc. H2SO4 (1.5 ml; 30 mmol). 
The crude yellow solid was purified flash chromatography (CHCb/acetone, 8:1 to 4:1 
gradient) and the pale yellow solid isolated was recrystallised from hot acetone to give
51 as white crystals (1.45 g; 39%). R / 0.80 (CHC^/acetone, 4:1); mp 191-192°C 
(230Lit mp 176-178°C); MS (FAB+) m/z-. 489.1 [15, (2M+H)+], 245.1 [100, (M+H)+[; 
MS (FAB') m/z: 487.3 [15, (2M-H)'], 243.2 [100, (M-H)']; Acc. MS (FAB+): 245.1179, 
C I5H i70 3 requires 245.1178; 'H  NMR (400 MHz; DMSO-d6) 8H: 1.38-1.87 (m, 11H, 
cyclohexyl H), 6.04 (s, 1H, C3-H), 6.71 (d, 1H, Cg-H, J =  2.3 Hz), 6.81 (dd, 1H, C6-H, 
J=  2.4, 8.8 Hz), 7.70 (d, 1H, Cs-H, J=  8.8 Hz) and 10.56 (s, 1H, OH); Found C, 73.90; 
H, 6.60; C 15H 16O3 requires C, 73.75; H, 6.60.
8.4.22 4-C yclohexylcoum arin-7-0-sulpham ate (52)
Compound 51 (400 mg; 1.6 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCh/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from THF/hexane to give
52 as white fine crystals (192 mg; 36%). R / 0.45 (CHC^/ethyl acetate, 4:1); mp 187- 
190°C; MS (FAB+) m/z: 324.1 [100, (M+H)+], 245.1 [15, (M +H-HNS02)+]; MS (FAB‘ 
) m/z: 323.2 [100, (M-H)'], 243.2 [50, (M-H2N S 0 2)] ; Acc. MS (FAB+): 324.0902, 
C 15Hi8N05S requires 324.0906; 'H  NMR (400 MHz; DMSO-d6) 8H: 1.23-2.06 (m, 
11H, cyclohexyl H), 6.32 (s, 1H, C3-H), 7.32 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 7.36 (d, 
1H, Cg-H, J=  2.3 Hz), 8.01 (d, 1H, C5-H, J =  8.9 Hz) and 8.31 (s, 2H, NH2); Found C, 
55.70; H, 5.28; N, 4.17; C 15H 17NO5S requires C, 55.72; H, 5.30; N, 4.33%.
8.4.23 (A dam antan-l-yl)acetyl chloride (53)
1-Adamantaneacetic acid (5.0 g; 25.7 mmol) in an excess of thionyl chloride (20 ml;
77.2 mmol) and THF (5 ml) was boiled under reflux overnight under N2. Thionyl 
chloride was removed under vacuum to get the crude 53 as a brown oil (5.5 g; 101%
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crude), which was used for the next reaction without purification. R / 0.91 
(CHCl3/MeOH, 8:1); (417Lit. bp3 107-109°C); MS (FAB+) m/z: 213.1 [100, 
(M(35C1)+H)+]; MS (FAB') m/z: 211.1 [100, (M(35C1)-H)']; Acc. MS m/z (FAB+): 
213.1097, C i2H 1835C10 requires 213.1081 and 215.1006, C 12H 1837CIO requires 
215.1012; 'H NMR (400 MHz; CDC13) 6h: 1.11-1.76 (m, 15H, adamantane H) and 
2.69 (s, 2H, CH2CO).
8.4.24 4-(A dam antan-l-yl)-3“Oxobutanoate (54)
Prepared by method A (8.2.1), using ethyl potassium malonate (8.4 g; 49 mmol), 
CH3CN (150 ml), Et3N (11 ml; 75 mmol), MgCl2 (5.6 g; 59 mmol) and 53 (5.0 g; 24 
mmol). The crude oily residue was purified by flash chromatography (CHC13) to give 
54 as brown oil (4.5 g; 72%). R / 0.77 (CHC13/Hexane, 9:1); (4l8U t. bpo.o? 105-106°C); 
MS (FAB4) m/r. 265.2 [100, (M+H)+], 135 [85, (Ci0H 15+H)+]; MS (FAB') m/z: 263.3 
[100, (M-H)']; Acc. MS (FAB+): 265.1697, C 16H25O3 requires 265.1705; ‘H N M R  (400 
MHz; CDCI3) 8h: 1.24-1.58 (m, 15H, adamantane H), 1.28 (t, 3H, CH2CH3), 2.28 (s, 
2H, CH2CO), 3.41 (s, 2H, 2 -CH2) and 4.21 (q, 2H, CH2CH3, J =  7.0 Hz),
8.4.25 4-(l-A dam antanem ethyl)-7-hydroxycoum arin (55)
Prepared by method 8.2.4, using resorcinol (834 mg; 7.6 mmol), 54 (2.0 g; 7.6 mmol) 
and a mixture o f CF3COOH (1.2 ml; 15 mmol) and conc. H2SC>4 (1.5 ml; 15 mmol). 
The crude yellow solid was purified by recrystallisation from THF:hexane to give 55 as 
yellow crystals (1.82 g; 77%). R / 0.72 (CHCl3/acetone, 4:1); mp 211-214°C; MS 
(FAB+) m/z: 311.1 [100, (M+H)+]; MS (FAB') m/z: 309.2 [100, (M-H)']; Acc. MS 
(FAB+): 311.1568, C20H23O3 requires 311.1569); ’H NMR (400 MHz; CDC13) 5H: 
1.52-2.09 (m, 15H, adamantane H), 1.90 (s, 2H, CH2), 5.95 (s, 1H, C3-H), 6.69 (d, 1H, 
C8-H, J=  2.3 Hz), 6.78 (dd, 1H, C6-H, J=  2.3, 8.6 Hz), 7.75 (d, 1H, C5-H, J =  8.9 Hz) 




Compound 55 (400 mg; 1.3 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from THF/hexane to give 
56 as white fine crystals (88 mg; 18%). R / 0.57 (CHC^/ethyl acetate, 4:1); mp: 218- 
221°C; MS (FAB+) m/z: 390.0 [100, (M+H)+]; MS (FAB') m/z: 388.1 [100, (M-H)']; 
Acc. MS (FAB+): 390.1301, C20H24NO5S requires 390.1297; ]H NMR (400 MHz; 
DMSO-d6) 5h: 1.54-1.64 (m, 15H, adamantane H), 1.91 (s, 2H, CH2), 6.24 (s, 1H, C3-
H), 7.24-7.31 (m, 2H, C6-H and Cg-H), 8.04 (d, 1H, C5-H, J=  8.9 Hz) and 8.25 (s, 2H,
NH2); Found C, 61.40; H, 5.75; N, 3.22; C20H23NO5S requires C, 61.68; H, 5.95; N, 
3.60%.
8.5 Synthesis of compounds with a methyl group at the C-4 position and
varying lengths of alkyl chain at the C-3 position of the coumarin ring
8.5.1 Ethyl 2-acetylheptanoate (57)
Prepared by method 8.2.2, using K2CO3 (11.09 g; 79.2 mmol), water (50 ml), 1- 
bromopentane (4.09 ml; 33 mmol), ethyl 3-oxobutanoate (4.29 ml; 33 mmol), CH2CI2 
(50 ml) and BU4NCI (~10 g; 33 mmol). The crude oily residue (4.68 g) was purified by 
flash chromatography (CHCI3) to give 57 as a pale yellow oil. (4.03 g; 61%). (240Lit. 
bp8 101-105°C); R / 0.69 (CHC13); MS (FAB+) m/z: 201.2 [100, (M+H)+]; Acc. MS 
(FAB+): 201.1492, C nH 2i0 3 requires 201.1491; ]H NMR (400 MHz; DMSO-d6) 5h: 
0.85 (t, 3H, CH3, J =  7.3 Hz), 1.19 (t, 3H, CH2CH3, J =  7.3 Hz), 1.23-1.27 (m, 6H, 
3xCH2), 1.68-1.72 (q, 2H, 3-CH2, J=  6.1 Hz), 2.17 (s, 3H, CH3CO), 3.57 (t, 1H,2-H, J  
= 7.3 Hz) and 4.12 (q, 2H, CH2CH3, J=  7.3 Hz).
8.5.2 7-Hydroxy-4-methyl-3-pentyIcoumarin (58)
Prepared by method 8.2.4, using resorcinol (2.2 g; 20 mmol), 57 (4.0 g; 20 mmol) and 
a mixture o f CF3COOH (3.08 ml; 40 mmol) and conc. H 2 S O 4  (2.04 ml; 40 mmol). The 
crude pale yellow solid was purified by flash chromatography (CHC^/acetone, 8:1 to
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4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane 
to give 58 as white crystals (2.03 g; 38%). R / 0.80 (CHC^/acetone, 3:1); mp 101- 
102°C (401Lit. mp 111-113°C); MS (FAB"1)  m/z: 493.4 [15, (2M+H)+], 247.3 [100, 
(M+H)+]; MS (FAB') m/z: 491.3 [10, (2M-H)'], 245.2 [100, (M-H)']; Acc. MS (FAB+): 
247.1327, C i5H 190 3 requires 247.1334; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.87 (t, 
3H, 5 ’-CH3, J =  6.8 Hz), 1.29-1.44 (m, 6H, 3xCH2), 2.35 (s, 3H, C4-CH3), 2.51 (t, 2H, 
l ’-CH2, J =  7.3 Hz), 6.71 (d, 1H, C8-H, J =  2.4 Hz), 6.78 (dd, 1H, C6-H, J =  2.4, 8.8 
Hz), 7.59 (d, 1H, C5-H, J =  8.8 Hz) and 10.36 (s, 1H, OH); Found C, 72.90; H, 7.29; 
C 15H 18O3 requires C, 73.15; H, 7.37%.
8.5.3 4-M ethyI-3-pentylcoum arin-7-0-sulpham ate (59)
Compound 58 (700 mg; 2.84 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 59 as white fine crystals (479 mg; 52%). R / 0.82 (CHC^/ethyl acetate, 4:1); mp 
133-135°C; MS (FAB+) m/z: 326.2 [100, (M+H)+], 245.2 [50, (M +H-HNS02)+]; MS 
(FAB') m/z: 326.2 [100, (M-H)']; Acc. MS (FAB+): Acc. MS (FAB+): 326.1076, 
Ci5H20NO5S requires 326.1062; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.87 (t, 3H, 5 ’- 
CH3, J =  6.7 Hz), 1.31-1.49 (m, 6H, 3xCH2), 2.43 (s, 3H, C4-CH3), 2.58 (t, 2H, l ’-CH2, 
J =  8.2 Hz), 7.26-7.29 (m, 2H, C6-H and Cs-H), 7.88 (d, 1H, Cs-H ,./ = 7.9 Hz) and
8.19 (s, 2H, NH2); Found C, 55.20; H, 5.88; N, 4.27; C 15H 19NO5S requires C, 55.37; H, 
5.89; N, 4.30%.
8.5.4 Ethyl 2-acetyIoctanoate (60)
Prepared by method 8.2.2, using K2CO3 (11.1 g; 79.2 mmol), water (50 ml), 1- 
bromohexane (4.63 ml; 33 mmol), ethyl 3-oxobutanoate (4.29 ml; 33 mmol), CH2CI2 
(50 ml) and BU4NCI (-10  g; 33 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 60 as a pale yellow oil (3.05 g; 43%). (241Lit. bp 10
127-129°C); R / 0.66 (CHC13);M S (FAB+) m/z: 215.2 [100, (M+H)+]; MS (FAB') m/z:
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213.1 [100, (M-H)’]; Acc. MS (FAB+): 215.1600, Ci2H2303 requires 215.1639; *H 
NMR (400 MHz; DMSO-d6) 6H: 0.85 (t, 3H, CH3, J=  6.1 Hz), 1.18 (t, 3H, CH2CH3, J  
= 7.1 Hz), 1.22-1.36 (m, 8H, 4xCH2), 1.71 (q, 2H, 3-CH2, J =  6.4 Hz), 2.17 (s, 3H, 
CH3CO), 3.57 (t, 1H, 2-H, J=  6.7 Hz) and 4.12 (q, 2H, CH2CH3, J=  7.3 Hz).
8.5.5 3-Hexyl-7-hydroxy-4-methyIcoumarin (61)
Prepared by method 8.2.4, using resorcinol (1.28 g; 11.7 mmol), 60 (2.5 g; 12 mmol) 
and a mixture of CF3COOH (1.8 ml; 23 mmol) and conc. H2S 0 4 (1.19 ml; 23.3 mmol). 
The crude pale white solid was recrystallised from acetone/hexane to give 61 as white 
fine crystals (2.12 g; 70%). R / 0.81 (CHCl3/acetone, 3:1); mp 112-114°C (401Lit. mp 
111-112°C); MS (FAB+) m/z: 521.1 [100, (2M+H)+], 261.2 [100, (M+H)+]; MS (FAB') 
m/z: 259.2 [100, (M-H)’]; Acc. MS (FAB+): 261.1421, C ]6H210 3 requires 261.1412; ]H 
NMR (400 MHz; DMSO-d6) 8H: 0.88 (t, 3H, 6 ’-CH3, J  = 7.1 Hz), 1.25-1.55 (m, 8H, 
4xCH2), 2.39 (s, 3H, C4-CH3), 2.63 (t, 2H, l ’-CHi , J =  1.6 Hz), 6.83 (dd, 1H, C6-H ,J  =
2.4, 8.8 Hz), 6.96 (d, 1H, C8-H, 2.4 Hz), 7.49 (d, 1H, C5-H, 8.8 Hz) and 10.41
(s, 1H, OH); Found C, 73.90; H, 7.78; C ,6H20O3 requires C, 73.82; H, 7.74%.
8.5.6 3-Hexyl-4-methylcoumarin-7-0-sulphamate (62)
Compound 61 (700 mg; 2.69 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid that isolated was recrystallised from ethyl 
acetate/hexane to give 62 as white fine fluffy crystals (449 mg; 49%). R / 0.41 
(CHCl3/ethyI acetate, 4:1); mp 132-133°C; MS (FAB+) m/r  679.4 [15, (2M+H)+],
340.2 [100, (M+H)+]; MS (FAB') m/r  338.2 [100, (M-H)'], 259.2 [45, (M-H2N S 0 2)']; 
Acc. MS (FAB+): 340.1230, C |6H22N 0 5S requires 340.1219; 'H  NMR (400 MHz; 
DMSO-d6) SH: 0.86 (t, 3H, CH3, 7  = 5.5 Hz), 1.25-1.48 (m, 8H, 4xCH2), 2.43 (s, 3H, 
C4-H3), 2.59 (t, 2H, l ’-CH2, 7 =  7.1 Hz), 7.26 (d, 1H, Cr H, 7 =  2.1 Hz), 7.28 (m, 1H, 
C6-H), 7.88 (d, 1H, Cs-H, 7 =  7.3 Hz) and 8.19 (s, 2H, NH2); Found C, 56.90; H, 6.22; 
N, 4.12; C ,6H2|N 0 5S requires C, 56.62; H, 6.24; N, 4.13%.
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8.5.7 Ethyl 2-acetylnonanoate (63)
Prepared by method 8.2.2, using K2CO3 (11.11 g; 80.39 mmol), water (50 ml), 1- 
bromoheptane (6 ml; 34 mmol), ethyl acetoacetate (4.27 ml; 33.5 mmol), CH2CI2 (50 
ml) and BU4NCI (-10 g; 34 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 63 as a pale yellow oil (2.45 g; 33%). (419Lit. bpo.4 80- 
85°C); R / 0.9 (CHC13); MS (FAB+) m/z: 229.2 [100, (M+H)+]; MS (FAB') m/z: 227.2 
[100, (M-H)']; Acc. MS (FAB+): 229.1804, C 13H2503 requires 229.1803; 'H NMR (400 
MHz; CDCI3) 5h: 0.85 (t, 3H, CH3, J = 7 .1  Hz), 1.18 (t,3H , CH2CH3 J = l . \  Hz), 1.23-
1.73 (m, 12H, 6xCH2), 2.17 (s, 3H, CH3CO), 3.56 (t, 1H, 2-H, J =  7.1 Hz) and 4.19 (q, 
2H, CH2CH3, J = l . \  Hz).
8.5.8 3-Heptyl-7-hydroxy-4-methyIcoumarin (64)
Prepared by method 8.2.4, using resorcinol (965 mg; 8.76 mmol), 63 (2.0 g; 8.8 mmol) 
and a mixture o f CF3COOH (1.55 ml; 20.2 mmol) and conc. H2SO4 (1.03 ml; 20.2 
mmol). The crude pale yellow solid was recrystallised from acetone/hexane to give 64 
as pale yellow crystals (730 mg; 30%). R / 0.78 (CHC^/acetone, 3:1); mp 96-98°C; 
MS (FAB+) m/z: 549.4 [15, (2M+H)+], 275.2 [100, (M+H)+j; MS (FAB') m/z: 547.4 
[10, (2M-H)’], 273.2 [100, (M-H)']; Acc. MS (FAB+): 275.1641, C 17H2303 requires 
275.1647; 'H N M R  (400 MHz; CDC13) 6H: 0.88 (t, 3H, CH3, J=  7.3 Hz), 1.26-1.53 (m, 
10H, 5xCH2), 2.39 (s, 3H, C4-CH3), 2.63 (t, 2H, l ’-CH2), 7.01 (d, 1H, Cg-H, J =  2.4 
Hz), 6.85 (dd, 1H, C6-H, J =  2.4, 8.7 Hz), 7.49 (d, 1H, C5-H, J=  8.85 Hz) and 10.37 (s, 
1H, OH); Found C, 74.08; H, 8.03; C 17H220 3 requires C, 74.42; H, 8.08%.
8.5.9 3-Heptyl-4-methyIcoumarin-7-0-suIphainate (65)
Compound 64 (400 mg; 1.46 mmol) was sulphamoylated by method 8.2.5. The crude 
white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 2:1 
gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane to 
give 65 as white fine crystals (75 mg; 14%). R/. 0.51 (CHC^/ethyl acetate 4:1); mp 
138-140°C; MS (FAB+) m/z: 707.2 [40, (2M+H)+], 354.1 [100, (M+H)+]; MS (FAB')
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m/z: 705.2 [40, (2M-H)'], 352.1 [100, (M-H)'], 273.2 [90, (M-H2N S 0 2)']; Acc. MS 
(FAB+): 354.1391, Ci7H24N 0 5S requires 354.1375; 'H  NMR (400 MHz; DMSO-d6) 
8h : 0.86 (t, 3H, CH3, J =  6.7 Hz), 1.26-1.49 (m, 10H, 5xCH2), 2.43 (s, 3H, C4-CH3),
2.58 (t, 2H, l ’-CH2, J=  7.1 Hz), 7.25-7.29 (m, 2H, C6-H and Cs-H), 7.88 (d, 1H, C5-H, 
J =  8.8 Hz) and 8.18 (s, 2H, NH2); Found C, 57.80; H, 6.58; N, 3.92; C 17H23N 0 5S 
requires C, 57.77; H, 6.56; N, 3.96%.
8.5.10 Ethyl 2-acetyldecanoate (66)
Prepared by method 8.2.2, using K2CO3 (11.47 g; 82.98 mmol), water (50 ml), 1- 
bromooctane (6.0 ml; 35 mmol), ethyl 3-oxobutanoate (4.41 ml; 34.6 mmol), CH2CI2 
(50 ml) and B U 4 N C I  (~10 g; 35 mmol). The crude oily residue was purified by flash 
chromatography (CHCB/acetone) to give 66 as a pale yellow oil (3.1 g; 37%). (420Lit. 
bpo.4 79-83°C); R / 0.68 (CHC13); MS (FAB+) m/z: 243.2 [100, (M+H)+]; MS (FAB') 
m/z: 241.2 [100, (M-H)']; Acc. MS (FAB+): 243.1968, C 14H27O3 requires 243.1960; 'H 
NMR (400 MHz; DMSO-d6) 5H: 0.86 (t, 3H, CH3, J =  6.7 Hz), 1.18 (t, 3H, CH2CH3, J  
= 7.3 Hz), 1.23-1.75 (m, 12H, 6xCH2), 2.06 (s, 3H, CH3CO), 2.39 (q, 2H, 3-CH2, J  =
7.3 Hz), 3.61 (t, 1H, 2-H, J=  6.7 Hz) and 4.12 (q, 2H, CH2CH3, J=  7.1 Hz).
8.5.11 7-Hydroxy-4-methyl-3-octylcoumarin (67)
Prepared by method 8.2.4, using resorcinol (910 mg; 8.26 mmol), 66 (2.0 g; 8.3 mmol) 
and a mixture o f CF3COOH (1.27 ml; 16.3 mmol) and conc. H2SO4 (0.84 ml; 16.3 
mmol). The crude brown solid was recrystallised from acetone/hexane to give 67 as 
white crystals (405 mg; 17%). R / 0.72 (CHC^/acetone, 3:1); mp 98-100°C; MS 
(FAB+) m/z: 511A  [40, (2M+H)+], 289.2 [100, (M+H)+]; MS (FAB') m/z\ 575.3 [35, 
(2M-H)'], 287.2 [100, (M-H)']; Acc. MS (FAB+): 289.1801, C18H25O3 requires
289.1801; ]H NMR (400 MHz; DMSO-d6) 5H: 0.88 (t, 3H, CH3, J=  7.3 Hz), 1.27-1.46
(m, 12H, 6xCH2), 2.38 (s, 3H, C4-CH3), 2.54 (t, 2H, l ’-CH2, J =  6.4 Hz), 6.69 (d, 1H, 
Cg-H, J=  2.1 Hz), 6.81 (dd, 1H, C6-H, J=  2.1, 8.8 Hz), 7.62 (d, 1H, C5-H, J =  8.8 Hz)
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and 10.52 (s, 1H, OH); Found C, 74.90; H, 8.40; C I8H240 3 requires C, 74.97; H, 
8.39%.
8.5.12 4-Methyl-3-octyIcoumarin-7-0-sulphamate (68)
Compound 67 (400 mg; 1.39 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyI acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 68 as white fine crystals (69 mg; 15%), R/: 0.43 (CHCl3/ethyl acetate, 4:1); mp 
135-138°C; MS (FAB+) m/z: 735.2 [35, (2M+H)+], 368.1 [100, (M+H)+]; MS (FAB') 
m/z: 733.3 [40, (2M-H)'], 366.2 [100, (M-H)'], 287.2 [60, (M-H2N S 0 2)']; Acc. MS 
(FAB+): 368.1529, C ,8H26N05S requires 368.1532; ‘H NMR (400 MHz; DMSO-d6) 
5H: 0.86 (t, 3H, CH3, J =  7.3 Hz), 1.25-1.49 (m, 12H, 6xCH2), 2.43 (s, 3H, C4-CH3),
2.58 (t, 2H, l ’-CH2, 7  = 7.1 Hz), 7.26-7.29 (m, 2H, C6-H and Cg-H), 7.88 (d, 1H, Cs-H, 
7  = 8.8 Hz) and 8.18 (s, 2H, NH2); Found C, 58.70; H, 6.72; N, 3.68; C 18H25N 0 5S 
requires C, 58.84; H, 6 .86 ; N, 3.81%.
8.5.13 Ethyl 2-acetylundecanoate (69)
Prepared by method 8.2.2, using K2C 0 3 (7.4 g; 58 mmol), water (50 ml), 1- 
bromononane (5.0 ml; 24 mmol), ethyl 3-oxobutanoate (3.1 ml; 24 mmol), CH2C12 (50 
ml) and BU4NCI (-10 g; 49 mmol). The crude oily residue was purified by flash 
chromatography (CHC13) to give 69 as a pale yellow oil (2.76 g; 45%). (421Lit. bp4.2 
191°C); R / 0.65 (CHC13); MS (FAB+) m/z: 257.2 [100, (M+H)+]; MS (FAB') m/z:
255.2 [100, (M-H)']; Acc. MS (FAB+): 257.2126, C 15H290 3 requires 257.2170; 'H 
NMR (400 MHz; CDC13) 8H: 0.88 (t, 3H, CH3, 7  = 6.8 Hz), 1.26-1.91 (m, 19H, 
CH2CH3 and 8xCH2), 2.22 (s, 3H, CH3CO), 3.39 (t, 1H, 2-H, 7  = 7.3 Hz) and 4.19 (q, 
2H, CHhCHs, 7 = 7 .3  Hz).
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8.5.14 7-Hydroxy-4-methyl-3-nonylcoumarin (70)
Prepared by method 8.2.4, using resorcinol (1.07 g; 9.76 mmol), 69 (2.5 g; 9.8 mmol) 
and a mixture of CF3COOH (1.5 ml; 20 mmol) and conc. H2SO4 (1.0 ml; 20 mmol). 
The crude yellow solid was purified by flash chromatography (CHCB/acetone, 8:1 to 
4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane 
to give 70 as white crystals (797 mg; 27%). R / 0.69 (CHC^/acetone, 3:1); mp 78- 
80°C; MS (FAB+) m/z\ 605.3 [35, ( 2M + H ) 4 ] ,  303.1 [100, (M+H)+]; MS (FAB') m/z:
603.1 [40, ( 2M - H ) ' ] ,  301.1 [100, (M-H)']; Acc. MS (FAB+): 303.1964, C 19H27O3 
requires 303.1960; ]H NMR (400 MHz; DMSO-d6) 5H: 0.87 (t, 3H, CH3, J =  7.1 Hz), 
1.26-1.55 (m, 14H, 7xCH2), 2.39 (s, 3H, C4-CH3), 2.63 (t, 2H, l ’-CH2, J  = 7.6 Hz),
6.86 (dd, 1H, C6-H, J=  2.4, 8.8 Hz), 7.05 (d, 1H, Cg-H, J=  2.4 Hz), 7.49 (d, 1H, C5-H, 
J =  8.8 Hz) and 7.55 (s, 1H, OH); Found C, 75.35; H, 8.65; C 19H26O3 requires C, 
75.46; H, 8.67%.
8.5.15 4-Methyl-3-nonyIcoumarin-7-0-sulphamate (71)
Compound 70 (400 mg; 1.32 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 71 as white fine crystals (184 mg; 37%). R / 0.82 (CHC^/ethyl acetate, 4:1); mp 
125-129°C; MS (FAB+) m/z: 763.3 [45, (2M+H)+], 382.1 [100, (M+H)+]; MS (FAB') 
m/z: 761.2 [45, (2M-H)'], 380.1 [100, (M-H)'], 301.1 [75, (M-H2N S 0 2)']; Acc. MS 
(FAB+): 382.1679, C 19H28NO5S requires 382.1688; *H NMR (400 MHz; DMSO-d6) 
5h : 0.85 (t, 3H, CH3, J =  6.7 Hz), 1.24-1.48 (m, 14H, 7xCH2), 2.42 (s, 3H, C4-CH3),
2.58 (t, 2H, l ’-CH2, J =  7.3 Hz), 7.25 (d, 1H, C8-H, J -  2.4 Hz), 7.28 (dd, 1H, C6-H, J  
= 2.1, 8.5 Hz), 7.88 (d, 1H, C5-H, J  = 8.5 Hz) and 8.19 (s, 2H, NH2); Found C, 59.50; 
H, 7.08; N, 3.59; C 1 9 H 2 7 N O 5 S  requires C, 59.82; H, 7.13; N, 3.67%.
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8.5.16 Ethyl 2-acetyldodecanoate (72)
Prepared by method 8.2.2, using K2CO3 (7.5 g; 54 mmol), water (50 ml), 1- 
bromodecane (5.0 ml; 23 mmol), ethyl 3-oxobutanoate (2.88 ml; 22.6 mmol), CH2CI2 
(50 ml) and BU4NCI (-10 g; 45 mmol). The crude oily residue was purified by flash 
chromatography (CHCI3) to give 72 as a pale yellow oil (2.95 g; 48%). (422Lit. bp2 140- 
150°C); R / 0.76 (CHC13); MS (FAB+) m/z: 271.2 [100, (M+H)+]; MS (FAB’) m/z:
269.2 [100, (M-H)']; Acc. MS (FAB+): 271.2275, C 16H3i 0 3 requires 271.2273; *H 
NMR (400 MHz; CDC13) 6H: 0.88 (t, 3H, CH3, J  = 7.3 Hz), 1.25-2.00 (m, 21H, 
CH2CH3 and 9xCH2), 2.22 (s, 3H, CH3CO), 3.39 (t, 1H, 2-H, J =  7.3 Hz) and 4.19 (q, 
2H, CH2CH3, J =  7.3 Hz).
8.5.17 7-Hydroxy-3-decyl-4-methylcoumarin (73)
Prepared by method 8.2.4, using resorcinol (1.02 g; 9.25 mmol), 72 (2.5g; 9.3 mmol) 
and a mixture o f CF3COOH (1.42 ml; 18.5 mmol) and conc. H2SO4 (0.94 ml; 18.5 
mmol). The crude brown solid was purified by flash chromatography (CHC^/acetone, 
8:1 to 4:1 gradient) and the pale yellow solid isolated was recrystallised from 
acetone/hexane to give 73 as white crystals (807 mg; 28%). R / 0.81 (CHC^/acetone, 
3:1); mp 96-100°C; MS (FAB+) m/z: 633.3 [50, (2M+H)+], 317.1 [100, (M+H)+]; MS 
(FAB') m/z: 631.2 [10, (2M-H)'], 315.1 [100, (M-H)']; Acc. MS (FAB+): 317.2117, 
C20H29O3 requires 317.2117; *H NMR (400 MHz; CDC13) 5H: 0.88 (t, 3H, CH3, J=  7.3 
Hz), 1.26-1.55 (m, 16H, 8xCH2), 2.39 (s, 3H, C4-CH3), 2.63 (t, 2H, l ’-CH2, J =  7.6 
Hz), 6.85 (dd, 1H, C6-H, J =  2.4, 8.7 Hz), 7.02 (d, 1H, C8-H, J =  2.4 Hz), 7.32 (s, 1H, 
OH) and 7.49 (d, 1H, C5-H, J=  8.5 Hz); Found C, 75.65; H, 8.99 C2oH280 3 requires C, 
75.91; H, 8.92%.
8.5.18 3-DecyI-4-methylcoumarin-7-0-sulphamate (74)
Compound 73 (400 mg; 1.27 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane
236
to give 74 as white fine crystals (101 mg; 27%). R/. 0.55 (CHCl3/ethyl acetate, 4:1); mp
118-121°C; MS (FAB+) m/z\ 791.3 [20, (2M+H)+], 396.1 [100, (M+H)+], 317.1 [30, 
(M +H-HNS02)+]; MS (FAB') m/z: 394.1 [100, (M-H)'], 315.1 [60, (M-H2N S 0 2)"]; 
Acc. MS (FAB+): 396.1850, C2oH3oN05S requires 396.1845; ]H NMR (400 MHz; 
DMSO-d6) 6h: 0.85 (t, 3H, CH3, J =  7.6 Hz), 1.24-1.47 (m, 16H, 8xCH2), 2.43 (s, 3H, 
C4-CH3), 2.58 (t, 2H, l ’-CH2, J =  7.3 Hz), 7.25 (d, 1H, C8-H, J =  2.4 Hz), 7.27 (m, 1H, 
C6-H); 7.87 (d, 1H, C5-H, J =  8.5 Hz) and 8.13 (s, 2H, NH2); Found C, 60.65; H, 7.42; 
N, 3.12 C2oH29N 0 5S requires C, 60.74; H, 7.39; N, 3.54%.
8.5.19 Ethyl 2-acetyltridecanoate (75)
Prepared by method 8.2.2, using K2C 0 3 (7.1 g; 51 mmol), water (50 ml), 1- 
bromoundecane (5.0 ml; 21 mmol), ethyl 3-oxobutanoate (2.71 ml; 21.3 mmol), 
CH2C12 (50 ml) and Bu4NC1 (-10 g; 43 mmol). The crude oily residue was purified by 
flash chromatography (CHCl3/hexane, 8:1 to 2:1 gradient) to give 75 as a pale yellow 
oil (3.25 g; 54%). R / 0.69 (CHCl3/hexane, 2:1); (423Lit. bp, 145-150°C); MS (FAB+) 
m/z: 285.2 [100, (M+H)+]; MS (FAB') m/z: 283.2 [100, (M-H)']; Acc. MS (FAB+): 
285.2422, C 17H33O3 requires 285.2429; 'H  NMR (400 MHz; CDClj) 5H: 0.88 (t, 3H, 
CH3, J =  7.3 Hz), 1.25-1.85 (m, 23H, CH2CH3 and 10xCH2), 2.22 (s, 3H, CH3CO),
3.39 (t, 1H, 2-H, J =  7.3 Hz) and 4.15 (q, 2H, CH jCfy, J =  7.3 Hz).
8.5.20 7-Hydroxy-4-m ethyl-3-undecylcoum arin (76)
Prepared by method 8.2.4, using resorcinol (968 mg; 8.8 mmol) and 75 (2.5 g; 8.8 
mmol) in the presence of CF3COOH (1.4 ml; 18 mmol) and conc. H2S 0 4 (0.9 ml; 18 
mmol). The crude brown solid was purified by flash chromatography (CHCl3/acetone, 
8:1 to 4:1 gradient) and the pale brown solid isolated was recrystallised from 
acetone/hexane to give 76 as white crystals (722 mg; 29%). R/. 0.88 (CHCl3/acetone, 
3:1); mp 74-76°C; MS (FAB+) m/z: 660.9 [35, (2M+H)+], 331.1 [100, (M+H)+]; MS 
(FAB') m/z: 659.0 [10, (2M-H)'], 329.2 [100, (M-H)']; Acc. MS (FAB+): 331.2268, 
C2iH3]0 3 requires 331.2273; 'H  NMR (400 MHz; CDC13) 8H: 0.85 (t, 3H, CH3, J=  7.0
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Hz), 1.23-1.41 (m, 18H, 9xCH2), 2.35 (s, 3H, C4-CH3), 2.51 (t, 2H, V-CU2, J =  7.4 
Hz), 6.67 (d, 1H, Cg-H, J=  2.3 Hz), 6.78 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 7.59 (d, 1H, 
Cs-H, J =  8.9 Hz) and 10.39 (s, 1H, OH); Found C, 76.10; H, 8.96 C21H30O3 requires 
C, 76.33; H, 9.15%.
8.5.21 4-M ethyl-3-undecylcoum arin-7-0-sulpham ate (77)
Compound 76 (200 mg; 0.71 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified flash chromatography (CHC^/ethyl acetate, 8:1 to 2:1 
gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane to 
give 77 as white fine crystals (11 mg; 4%). R / 0.49 (CHC^/ethyl acetate, 4:1); mp 
117-119°C; MS (FAB+) m/z: 410.3 [100, (M+H)+]; MS (FAB') m/z: 408.3 [100, (M-H)' 
]; Acc. MS (FAB+): 410.1992, C21H32NO5S requires 410.2001; lU NMR (400 MHz; 
DMSO-d6) 8H: 0.87 (t, 3H, CH3, J =  7.2 Hz), 1.22-1.45 (m, 18H, 9xCH2), 2.34 (s, 3H, 
C4-CH3), 2.59 (t, 2H, V-CU2, J  = 7.3 Hz), 6.89 (d, 1H, Cg-H, J  -  2.3 Hz), 7.19 (dd, 1H, 
C6-H, J=  2.3, 8.8 Hz); 7.59 (d, 1H, Cs-H, J=  8.9 Hz) and 8.18 (s, 2H, NH2); Found C, 
61.40; H, 7.75; N, 3.16, C21H31NO5S requires C, 61.59; H, 7.63; N, 3.42%.
8.5.22 Ethyl 2-acetyltetradecanoate (78)
Prepared by method 8.2.2, using K2CO3 (7.99 g; 57.8 mmol), water (60 ml), 1- 
bromododecane (6.0 ml; 24 mmol), ethyl 3-oxobutanoate (3.1 ml; 24 mmol), CH2CI2 
(60 ml) and B U 4 N C I  (-10 g; 48 mmol). The crude oily residue was purified by 
distillation under reduced pressure to give 78 as a pale yellow oil (3.65 g; 51%). R / 
0.66 (CH2CI2); b p o ,3  159-160°C. (424Lit. b p u  149-152°C); MS (FAB+) m/r  299.2 [100, 
(M+H)+]; MS (FAB') m/r  297.2 [100, (M-H)']; Acc. MS (FAB+): 299.2594, C i8H350 3 
requires 299.2586; 'H  NMR (400 MHz; CDC13) 8H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 
1.12-1.89 (m, 25H, CH2CH3 and 11xCH2), 2.22 (s, 3H, CH3CO), 3.53 (t, 1H, 2-H, J  =
7.0 Hz) and 4.19 (q, 2H, CHzCHs, J=  7.0 Hz).
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8.5.23 3-Dodecyl-7-hydroxy-4-methylcoumarin (79)
Prepared by method 8.2.4, using resorcinol (553 mg; 5.02 mmol), 78 (1.5 g; 5.0 mmol) 
and a mixture o f CF3COOH (0.8 ml; 10 mmol) and conc. H2SO4 (0.6 ml; 10 mmol). 
The crude brown solid was purified by flash chromatography (CHCl3/acetone, 8:1 to 
4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane
to give 79 as off-white crystals (146 mg; 9%). R / 0.74 (CHCl3/acetone, 3:1); mp 94-
96°C; MS (FAB+) m/z: 689.4 [20, (2M+H)+], 345.4 [100, (M+H)+]; MS (FAB') m/z:
343.3 [100, (M-H)']; Acc. MS (FAS'1): 345.2435, C22H33O3 requires 345.2429; ‘H 
NMR (400 MHz; CDCI3) 5H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 1.25-1.63 (m, 20H, 
10xCH2), 2.38 (s, 3H, C4-CH3), 2.63 (t, 2H, l ’-CH2, J =  7.4 Hz), 6.19 (s, 1H,), 6.81 
(dd, 1H, C6-H, J =  2.3, 8.6 Hz), 6.91 (d, 1H, Cg-H, J =  2.3 Hz) and 7.48 (d, 1H, C5-H, J  
= 8.9 Hz); Found C, 76.60; H, 9.22; C22H32O3 requires C, 76.70; H, 9.36%.
8.5.24 3-Dodecyl-4-methylcouinarin-7-0-sulphaniate (80)
Compound 79 (100 mg; 0.29 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by preparative TLC (CHCl3/ethyl acetate, 6:1) and the 
white solid isolated was recrystallised from ethyl acetate/hexane to give 80 as white 
fine crystals (15 mg; 12%). R / 0.36 (CHCl3/ethyl acetate, 6:1); mp 157-159°C; MS 
(FAB+) m/z: 847.1 [15, (2M+H)+], 424.1 [100, (M+H)+], 245.1 [30, (M +H-HNS02)+]; 
MS (FAB') m/z: 422.1 [100, (M-H)'], 343.2 [55, (M-H2N S 0 2)']; Acc. MS (FAB+): 
424.1246, C22H34N0 5S requires 424.1241; ]H NMR (400 MHz; DMSO-d6) 5H: 0.88 (t, 
3H, CH3, J =  7.2 Hz), 1.24-1.48 (m, 20H, 10xCH2), 2.45 (s, 3H, C4-CH3), 2.61 (t, 2H, 
l ’-CH2, J =  7.4 Hz), 7.23 (d, 1H, Cg-H, J =  2.3 Hz), 7.27 (dd, 1H, C6-H, J=  2.3, 8.6 
Hz); 7.89 (d, 1H, C5-H, J=  8.9 Hz) and 8.21 (s, 2H, NH2).
8.5.25 Ethyl 2-acetylpentadecanoate (81)
Prepared by method 8.2.2, using K2C 0 3 (6.3 g; 46 mmol), water (60 ml), 1- 
bromotridecane (5.0 ml; 19 mmol), ethyl 3-oxobutanoate (2.42 ml; 18.9 mmol), 
CH2C12 (60 ml) and Bu4NC1 (11.0 g; 37.9 mmol). The crude oily residue was purified 
by distillation under reduced pressure to give 81 as a pale yellow oil (2.88 g; 49%). R /
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0.77 (CHC13); bp03 153-155°C; MS (FAB+) m/z: 313.3 [100, (M+H)+]; MS (FAB') m/z:
311.2 [100, (M-H)']; Acc. MS (FAB+): 313.2756, C 19H37O3 requires 313.2743; *H 
NMR (400 MHz; CDC13) 6H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 1.12-1.56 (m, 27H, 
CH2CH3 and 12xCH2), 2.22 (s, 3H, CH3CO), 3.53 (t, 1H, 2-H, J = 6.7 Hz) and 4.21 (q, 
2H, CH2CH3, <7=7.0 Hz).
8.5.26 7-Hydroxy-4-methyl-3-tridecyIcoumarin (82)
Prepared by method 8.2.4, using resorcinol (705 mg; 6.4 mmol), 81 (2.0 g; 6.4 mmol) 
and a mixture of CF3COOH (1.0 ml; 13 mmol) and conc. H2SO4 (0.7 ml; 13 mmol). 
The crude brown solid was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) and the pale yellow solid isolated was recrystallised from acetone/hexane 
to give 82 as white crystals (621 mg; 27%). R / 0.65 (CHC^/acetone, 3:1); mp 71- 
72°C; MS (FAB+) m/z: 359.4 [100, (M+H)+]; MS (FAB') m/z: 357.3 [100, (M-H)']; 
Acc. MS (FAB+): 359.2599, C23H35O3 requires 359.2586; 'H  NMR (400 MHz; CDC13) 
5H: 0.88 (t, 3H, CH3, J =  7.0 Hz), 1.26-1.84 (m, 22H, 11xCH2), 2.38 (s, 3H, C4-CH3), 
2.62 (t, 2H, r -C H 2, J=  7.4 Hz), 5.87 (s, 1H, OH), 6.81 (dd, 1H, C6-H, J=  2.3, 8.7 Hz),
6.86 (d, 1H, C8-H, J =  2.3 Hz) and 7.48 (d, 1H, C5-H, J  = 8.9 Hz); Found C, 77.20; H, 
10.00; C23H34O3 requires C, 77.05; H, 9.56%.
8.5.27 4-Methyl-3-tridecylcoumarin-7-0-suIphamate (83)
Compound 82 (400 mg; 1.12 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 83 as white fine crystals (35 mg; 7%). R / 0.67 (CHC^/ethyl acetate, 6:1); mp 
115-119°C; MS (FAB+) m/r  438.2 [100, (M+H)+[; MS (FAB ) m/r  436.2 [100, (M-H)' 
], 357.2 [30, (M-H2NSO2)']; Acc. MS (FAB+): 438.2291, C23H36NO5S requires 
438.2272; 'H N M R (400  MHz; DMSO-d6) 6H: 0.84 (t, 3H, CH3, J =  7.0 Hz), 1.23-1.44 
(m, 22H, 11xCH2), 2.42 (s, 3H, C4-CH3), 2.58 (t, 2H, l ’-CH2, J = 7 .8  Hz), 7.26 (d, 1H, 
C8-H, J =  2.3 Hz), 7.28 (m, 1H, C6-H), 7.88 (d, 1H, C5-1I, J =  8.6 Hz) and 8.21 (s, 2H,
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NH2); Found C, 63.60; H, 7.98; N, 3.17; C23H35NO5S requires C, 63.13; H, 8.06; N, 
3.20%.
8.5.28 Ethyl 2-acetyIhexadecanoate (84)
Prepared by method 8.2.2, using K2CO3 (5.6 g; 43 mmol), water (60 ml), 1- 
bromotetradecane (5.0 ml; 18 mmol), ethyl 3-oxobutanoate (2.3 ml; 18 mmol), CH2CI2 
(60 ml) and B U 4 N C I  (11.0 g; 36.1 mmol). The crude oily residue was purified by 
distillation under reduced pressure to give 84 as a pale yellow oil (2.32 g; 23?/o). Rf. 
0.65 (CHCI3); bpo,3 158-162°C. (425Lit. bp05 162 °C); MS (FAB4) m/r  327.2 [100, 
(M+H)4]; MS (FAB') m/r  325.2 [100, (M-H)']; Acc. MS (FAB4): 327.2900, C20H39O3 
requires 327.2899; 'H  NMR (400 MHz; CDCI3) SH: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 
1.20-1.81 (m, 29H, CH2CH3 and 13xCH2), 2.17 (s, 3H, CH3CO), 3.53 (t, 1H, 2-H, J  =
7.0 Hz) and 4 .19 (q, 2H, CHjCHj, J =  7.0 Hz).
8.5.29 7-Hydroxy-4-methyl-3-tetradecylcoumarin (85)
Prepared by method 8.2.4, using resorcinol (337 mg; 3.1 mmol), 84 (1.0 g; 3.1 mmol) 
and a mixture of CF3COOH (0.5 ml; 6.2 mmol) and conc. H2SO4 (0.4 ml; 6.2 mmol). 
The crude brown residue was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) to give 85 as pale yellow waxy solid (472 mg; 41%). R / 0.74 
(CHCl3/acetone, 3:1); mp 64-66°C; MS (FAB4) m/z: 373.1 [100, (M+H)4]; MS (FAB') 
m/r. 371.2 [100, (M-H)']; Acc. MS (FAB4): 373.2754, C24H3703 requires 373.2743; 'H 
NMR (400 MHz; CDCI3) 8H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 1.12-1.82 (m, 24H, 
12xCH2), 2.38 (s, 3H, C4-CH3), 2.62 (t, 2H, l ’-CH2, J  = 7.4 Hz), 6.21 (s, 1H, OH),
6.79 (dd, 1H, Qs-H, J  = 2.3, 8.6 Hz), 6.84 (d, 1H, Cg-H, J  = 2.3 Hz) and 8.59 (d, 1H, 
C5-H, J=  8.9 Hz); Found C, 77.11; H, 10.20; C24H36O3 requires C, 77.38; H, 9.74%.
8.5.30 4-Methyl 3-tetradecylcoumarin-7-0-sulphamate (86)
Compound 85 (300 mg; 0.81 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCb/ethyl acetate, 8:1 to
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2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 86 as white fine crystals (3 mg; 0.8 %). R / 0.62 (CHC^/ethyl acetate, 4:1); mp
119-121°C; MS (FAB+) m/z: 452.3 [100, (M+H)+], 373.3 [10, (M +H-HNS02)+]; MS 
(FAB’) m/z: 450.2 [100, (M-H)'], 371.3 [40, (M-H2N S 0 2)']; Acc. MS (FAB+): 
452.2455, C24H38N 0 5S requires 452.2471; 'H N M R  (400 MHz; DMSO-d6) 5H: 0.88 (t, 
3H, CH3, J =  7.0 Hz), 1.22-1.47 (m, 24H, 12xCH2), 2.41 (s, 3H, C4-CH3), 2.57 (t, 2H, 
l ’-CH2, y  = 7.8 Hz), 7.22 (d, 1H, Cg-H, J  -  2.3 Hz), 7.26 (dd, 1H, C6-H, J =  2.3, 8.6 
Hz), 7.79 (d, 1H, C5-H, J  = 8.9 Hz) and 8.20 (s, 2H, NH2); Found C, 63.74; H, 7.99; N, 
3.36 C24H37N 0 5S requires C, 63.83; H, 8.26; N, 3.10%.
8.5.31 Ethyl 2-acetylheptadecanoate (87)
Prepared by method 8.2.2, using K2C 0 3 (5.7 g; 41 mmol), water (60 ml), 1- 
bromopentadecane (5.0 ml; 17 mmol), ethyl 3-oxobutanoate (2.2 ml; 17 mmol), 
CH2C12 (60 ml) and Bu4NC1 (~10 g; 34 mmol). The crude oily residue was purified by 
distillation under reduced pressure to give 87 as pale yellow oil (1.78 g; 31%). R / 0.67 
(CHCI3); b p o .4  198-202°C; MS (FAB+) m/z: 341.2 [100, (M+H)+[; MS (FAB') m/z:
339.2 [100, (M-H)']; Acc. MS (FAB+): 341.3058, C21H40O3 requires 341.3056; ‘H 
NMR (400 MHz; CDCI3) 6H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 1.26-1.79 (m, 29H, 
CH2CH3 and 16xCH2), 2.22 (s, 3H, CH3CO), 3.53 (t, 2H, 3-H2, J =  6.7 Hz), 3.37 (t, 
1H, 2 -H ,/ =  7.0 Hz) and 4.18 (q, 2H, CH2CH3, J=  7.0 Hz).
8.5.32 7-Hydroxy-4-methyl-3-pentadecylcoumarin (88)
Prepared by method 8.2.4, using resorcinol (486 mg; 4.41 mmol), 87 (1.5g; 4.5 mmol) 
and a mixture o f CF3COOH (0.7 ml; 8.8 mmol) and conc. H2S 0 4 (0.5 ml; 8.8 mmol). 
The crude brown sticky solid was purified by flash chromatography (CHC^/acetone 
gradient, 8:1 to 4:1) and the off-white waxy solid isolated was recrystallised from 
acetone/hexane to give 88 as a white soft solid (123 mg; 0.07%). R / 0.86 
(CHCl3/acetone, 3:1); mp 59-61°C; MS (FAB+) m/z: 387.3 [100, (M+H)+]; MS (FAB') 
m/z: 385.3 [100, (M-H)']; Acc. MS (FAB+): 387.2892, C2SH3903 requires 387.2899; 'H
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NMR (400 MHz; CDC13) 5H: 0.88 (t, 3H, CH3, J  = 7.0 Hz), 1.11-1.80 (m, 26H, 
13xCH2), 2.38 (s, 3H, C4-CH3), 2.53 (t, 2H, l ’-CH2, J  = 6.6 Hz), 5.75 (s, 1H, OH),
6.79 (dd, 1H, C6-H, J  = 2.3, 8.6 Hz), 6.84 (d, 1H, Cg-H, J =  2.3 Hz) and 7.48 (d, 1H, 
C5-H, 7 = 8 .6  Hz).
8.5.33 4-Methyl-3-pentadecylcoumarin-7-0-sulphamate (89)
Compound 88 (90 mg; 0.23 mmol) was sulphamoylated by method A (8.2.5). The a 
crude white solid was purified by preparative TLC (CHCh/ethyl acetate gradient, 6:1) 
and the white solid isolated was recrstallised from ethyl acetate/hexane to give 89 as 
white fine solid (21 mg; 19%). R / 0.64 (CHC^/ethyl acetate, 4:1); mp 114-116°C; MS 
(FAB+) m/z: 466.3 [100, (M+H)+], 387.3 [10, (M +H-HNS02)+]; MS (FAB ) m/z: 464.2 
[100, (M-H)'], 385.3 [40, (M-H2N S 0 2)']; Acc. MS (FAB+): 466.2617, C25H4oN0 5S 
requires 466.2626; ]H NMR (400 MHz; DMSO-d6) 5H: 0.85 (t, 3H, CH3, J =  7.0 Hz), 
1.14-1.44 (m, 26H, 13xCH2), 2.43 (s, 3H, C4-CH3), 2.58 (t, 2H, l ’-CH2, J =  7.4 Hz),
7.25 (d, 1H, Cg-H, J =  2.3 Hz), 7.27 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 7.87 (d, 1H, C5-H, 
J =  8.6 Hz) and 8.16 (s, 2H, NH2); Found C, 64.00; H, 8.82; N, 3.26; C25H39N 0 5S 
requires C, 64.48; H, 8.44; N, 3.01%.
8.6 Other functionalities at the C-3 position of the coumarin ring
8.6.1 3-Chloro-7-hydroxy-4-methylcoumarin (90)
Prepared by method 8.2.4, using resorcinol (2.0 g; 18 mmol), ethyl 2-chloro-3- 
oxobutanoate (2.99 g; 18 mmol) and a mixture of CF3COOH (2.27 ml; 36.3 mmol) and 
conc. H2S04 (1.83 ml; 36.3 mmol). The crude brown solid was purified by flash 
chromatography (CHC^/acetone, 8:1 to 4:1 gradient) and the yellow solid isolated was 
recrystallised from acetone/hexane to give 90 as off-white crystals (692 mg; 18%). R / 
0.72 (CHCh/acetone, 3:1); mp 250-253°C (426Lit. mp 250°C); MS (FAB+) m/z: 211.1 
[100, (M(35Cl)+H)+[; MS (FAB") m/z: 209.1 [100, (M(35C1)-H)']; Acc. MS (FAB4) m/z: 
211.0178 C 10H835ClO3 requires 211.0162 and 213.0152 C IOHS37C103 requires
213.0132; ‘H NMR (400 MHz; DMSO-d6) SH: 2.09 (s, 3H, CH3), 6.76 (d, 1H, C8-H, J
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= 2.4 Hz), 6.86 (dd, 1H, C6-H, J =  2.4, 8.8 Hz), 7.69 (d, 1H, C5-H, J  = 8.8 Hz) and 
10.68 (s, 1H, OH); Found C, 57.30; H, 3.39; C 10H7ClO3 requires C, 57.03; H, 3.35%.
8.6.2 3-Chloro-4-methylcoumarin-7-0-sulphamate (91)
Compound 90 (400 mg; 1.9 mmol) was sulphamoylated by method A (8.2.5). The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 91 as white fine crystals (164 mg; 30%). R / 0.30 (CHCl3/ethyl acetate, 4:1); mp 
182-186°C; MS (FAB+) m/z: 290.0 [100, (M(37C1)+H)+]; MS (FAB-) m/z: 288.1 [100, 
(M(35C1)-H)-], 209.1 [50, (M-H2N S 0 2)']; Acc. MS (FAB+) m/z: 290.9860,
Ci0H937C1NO5S requires 290.9782 and 288.9814 Ci0H935C1NO5S requires 291.9813; 'H 
NMR (400 MHz; DMSO-d6) 5H: 2.59 (s, 3H, CH3), 7.35 (dd, 1H, C6-H, J =  2.1, 8.8 
Hz), 7.39 (d, 1H, C8-H, J  = 2.1 Hz), 7.98 (d, 1H, C5-H, J =  8.8 Hz) and 8.29 (s, 2H, 
NH2); Found C, 41.50; H, 2.62; N, 4.64; Ci0H8C1NO5S requires C, 41.46; H, 2.78; N, 
4.84%.
8.6.3 4-Methyl-3-phenyl-7-hydroxycoumarin (92)
Prepared by method 8.2.4, using resorcinol (2.13 g; 19.4 mmol), ethyl 3-oxo-2- 
phenylbutanoate (4.0 g; 19 mmol) and a mixture of CF3COOH (3.0 ml; 39 mmol) and 
conc. H2SO4 (2.0 ml; 39 mmol). The crude yellow solid was purified by 
recrystallisation from ethanol to give 92 as yellow needles (4.1 g; 83%). R / 0.59 
(CHCI3/acetone, 3:1); mp 226-228°C; (427Lit. mp 226-228°C); MS (FAB+) m/z: 505.1 
[10, (2M+H)4], 253.0 [100, (M+H)4]; MS (FAB') m/z: 503.1 [10, (2M-H)'], 251.1 [100, 
(M-H)']; Acc. MS (FAB4): 253.0798, C,6Hi20 3 requires 253.0786; 'H  NMR (400 
MHz; DMSO-d6) 5H: 2.21 (s, 3H, CH3), 6.75 (d, 1H, Cs-H, J  = 2.4 Hz), 6.84 (dd, 1H, 
C6-H, J =  2.4, 8.6 Hz), 7.27-7.47 (m, 5H, Ph-H), 7.66 (d, 1H, C5-H, J =  8.8 Hz) and 
10.67 (s, 1H, OH); Found C, 76.10; H, 4.84; C l6Hi20 3 requires C, 76.18; H, 4.79%.
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8.6.4 4-M ethyl-3-phenyIcoum arin-7-0-suIpham ate (93)
Compound 92 (400 mg; 1.6 mmol) was sulphamoylated by method 8.2.5 A. The crude 
white solid was purified by flash chromatography (CHCf/ethyl acetate, 8:1 to 2:1 
gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane to 
give 93 as white fine crystals (246 mg; 52%). R / 0.36 (CHC^/ethyl acetate, 4:1); mp 
184-187°C; MS (FAB+) m/z: 332.0 [100, (M+H)+], 253.0 [15, (M +H -HN S02)+]; MS 
(FAB') m/z: 330.1 [100, (M-H)'], 251.1 [60, (M-H2N S 0 2)']; Acc. MS (FAB+): 
332.0589, Ci6H,4N 0 5S requires 332.0593; 'H  NMR (400 MHz; DMSO-d6) 8H: 2.28 (s, 
3H, CH3), 7.31-7.38 (m, 2H, C6-H and C8-H), 7.40-7.49 (m, 5H, Ph-H), 7.95 (d, 1H, 
C5-H, J  = 8.8 Hz) and 8.27 (s, 2H, NH2); Found C, 58.00; H, 3.94; N, 4.21; 
C l6H ,3N 0 5S requires C, 58.00; H, 3.95; N, 4.23%.
8.6.5 3-Benzyl-4-methyl-7-hydroxycoumarin (94)
Prepared by method 8.2.4, using resorcinol (1.99 g; 18.2 mmol), ethyl 2-benzyl-3- 
oxobutanoate (4.0 g; 18 mmol) and a mixture of C F 3 C O O H  (2.8 ml; 36 mmol) and 
conc. H 2 S O 4  (1.8 ml; 36 mmol). The crude brown solid was purified by 
recrystallisation from ethanol to give 94 as white crystals (4.35 g; 90%). R / 0.79 
(CHCl3/acetone, 3:1); mp 230-232°C (428Lit. mp 226-227°C); MS (FAB4)  m/z: 532.9 
[10, (2M +H )4) ,  267.1 [100, (M +H)+]; MS (FA B) m/z: 265.1 [100, (M -H)']; Acc. MS 
(FAB4): 267.1026, C 17H 15O3 requires 267.1012; ‘H NMR (400 MHz; DM SO-d6) SH:
2.39 (s, 3H, CH3), 3.92 (s, 2H, CH2Ph), 6.71 (d, 1H, C8-H, J =  2.4 Hz), 6.80 (dd, 1H, 
C6-H, 2.4, 8.8 Hz), 7.15-7.28 (m, 5H, Ph-H), 7.64 (d, 1H, C 5-H, / =  8.8 Hz) and
10.48 (s, 1H, OH); Found C, 76.60; H, 5.34; C17H14O3 requires C, 76.68; H, 5.30%.
8 .6.6 3-BenzyI-4-m ethylcoum arin-7-0-sulpham ate (95)
Compound 94 (400 mg; 1.5 mmol) was sulphamoylated by method 8.2.5 A. The crude 
white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 2:1 
gradient) and the white solid isolated was recrystallised from THF/hexane to give 95 as 
white fine crystals (279 mg; 54%). R / 0.57 (CHC^/ethyl acetate, 4:1); mp 168-170°C; 
MS (FAB+) m/z: 346.1 [100, (M+H)+]; MS (FAB') m/z: 344.1 [100, (M-H)'], 265.1 [60,
245
(M-H2N S 0 2)']; A cc. MS (FA B+): 346.0755, Ci7Hi6N 0 5S requires 346.0749; !H NMR 
(400 MHz; DMSO-d6) 5 H: 2.39 (s, 3H, CH3), 3.99 (s, 2H, PhCH2), 7.17-7.31 (m, 6H, 
C6-H and Ph-H), 7.32 (d, 1H, C8-H, J  = 2.0 Hz), 7.92 (d, 1H, C5-H, J =  8.6 Hz) and
8.22 (s, 2H, NH2); Found C, 59.10; H, 4.39; N, 4.04; C 17H 15NO5S requires C, 59.12; H, 
4.38; N, 4.06%.
8.6.7 Ethyl 2-acetyl-4-phenylbutanoate (96)
Prepared by method 8.2.2, using K2C 0 3 (8.97 g; 64.85 mmol), water (50 ml), (2- 
bromoethyl)benzene (5.0 ml; 27 mmol), ethyl 3-oxobutanoate (3.44 ml; 27 mmol), 
CH2C12 (50 ml) and B U 4 N C I  (-10 g; 27 mmol). The crude oily residue was purified by 
flash chromatography (CHC13) to give 96 as a pale yellow oil (2.17 g; 34%). (429Lit. 
bp 1.4 167-168°C); R / 0.78 (CHC13); MS (FAB+) m/z: 235.0 [100, (M+H)+]; Acc. MS 
(FAB+): 235.1335, C 14H ,90 3 requires 235.1334; *H NMR (400 MHz; CDC13) SH: 1.25 
(t, 3H, CH2CH3, J =  6.7 Hz), 2.29 (s, 3H, CH3), 3.02 (q, 2H, CHsCHzPh, J =  7.1 Hz), 
3.71 (t, 1H, CH2, J =  7.3 Hz), 3.95 (t, 2H, CH2Ph, J =  7.1 Hz), 4.11 (q, 2H, CH2CH3, J  
= 7.1 Hz) and 7.16-7.34 (m, 5H, Ph-H).
8 .6.8 7-H ydroxy-4-m ethyl-3-(2-phenylethyl)coum arin (97)
Prepared by method 8.2.4, using resorcinol (705 mg; 6.4 mmol), 96 (1.5g; 6.4 mmol) 
and a mixture of CF3COOH (1 ml; 13 mmol) and conc. H2SC>4 (0.7 ml; 13 mmol). The 
crude brown solid was purified by flash chromatography (CHCl3/acetone gradient, 8:1 
to 4:1) and the white solid isolated was recrystallised from acetone/hexane to give 97 
as grey crystals (746 mg; 42%). R / 0.80 (CHCI3/acetone, 3:1); mp 175-178°C; MS 
(FAB+) m/z: 561.1 [10, (2M+H)+], 281.0 [100, (M+H)+]; MS (FAB') m/z: 279.1 [100, 
(M-H)']; Acc. MS (FAB+): 281.1182, C i8Hi70 3 requires 281.1178; ‘H NMR (400 
MHz; DMSO-ds) 8H: 2.16 (s, 3H, CH3), 2.73 (t, 2H, CHjCHjPh, J  = 5.5 Hz), 2.79 (t, 
2H, PhCH2> J  = 5.2 Hz), 6.69 (d, 1H, C8-H, J =  2.4 Hz), 6.78 (dd, 1H, C6-H, J =  2.4,
8.5 Hz), 7.16-7.29 (m, 5H, Ph-H), 7.56 (d, 1H, C5-H, J =  8.8 Hz) and 10.42 (s, 1H, 
OH); Found C, 77.35; H, 5.95; C ,8H |60 3requires C, 77.12; H, 5.75%.
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8.6.9 4-MethyI-3-(2-phenylethyl)coumarin-7-0-sulphamate (98)
Compound 97 (400 mg; 1.43 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 98 as white fine crystals (132 mg; 26%). R / 0.54 (CHCl3/ethyl acetate, 4:1); mp 
196-198°C; MS (FAB+) m/z: 360.0 [100, (M+H)+]; MS (FAB') m/z\ 358.0 [100, (M- 
H)'], 279.1 [40, (M-H2NSO2)']; Acc. MS (FAB+): 360.0917, C ,8H 18N 0 5S requires 
360.0906; ]H NMR (400 MHz; DMSO-d6) 5H: 2.21 (s, 3H, CH3), 2.76 (t, 2H, 
CH2CH2PI1, J =  7.3 Hz), 2.87 (t, 2H, PhCH2, J=  7.9 Hz), 7.17-7.27 (m, 7H, C6-H, C8- 
H and Ph-H), 7.83 (d, 1H, C5-H, J=  8.8 Hz) and 8.19 (s, 2H, NH2); Found C, 60.00; H, 
4.81; N, 3.89; C i8Hi7N 0 5S requires C, 60.16; H, 4.77; N, 3.90%.
8.6.10 Ethyl 2-acetyI-5-phenylpentanoate (99)
Prepared by method 8.2.2, using K2C 0 3 (16.7 g; 0.12 mol), water (60 ml), l-bromo-3- 
phenylpropane (10.0 ml; 50.2 mmol), ethyl 3-oxobutanoate (6.5 ml; 50.2 mmol), 
CH2C12 (60 ml) and Bu4NC1 (28 g; 0.1 mol). The crude oily residue was purified by 
flash chromatography (CHCl3/hexane, 10:1) to give 99 as a colourless oil (4.92 g; 
39%). R/. 0.61 (CHCl3/hexane, 10:1); MS (FAB+) m/z: 249.1 [100, (M+H)+]; MS 
(FAB') m/z: 247.1 [100, (M-H)']; Acc. MS (FAB+): 249.1491, C i5H2i0 3 requires 
249.1491; 'H  NMR (400 MHz; CDC13) 6H: 1.26 (t, 3H, CH2CH3, J =  7.0 Hz), 2.19 (s, 
3H, CH3), 1.85-2.61 (m, 6H, CH2), 2.64 (t, 1H, 2-H, J=  7.8 Hz), 4.21 (q, 2H, CH2CH3, 
J=  7.0 Hz) and 7.15-7.29 (m, 5H, Ph-H).
8.6.11 7-Hydroxy-4-methyl-3-[3-phenyIpropyl]coumarin (100)
Prepared by method 8.2.4, using resorcinol (443 mg; 4.03 mmol), 99 (1.0 g; 4.0 mmol) 
and a mixture o f CF3COOH (0.6 ml; 8.1 mmol) and conc. H2S 0 4 (0.4 ml; 8.1 mmol). 
The crude orange solid was purified by flash chromatography (CHCl3/acetone gradient, 
8:1 to 4:1) and the white solid isolated was recrystallised from THF/hexane to give 100 
as pale green crystals (275 mg; 22%). R / 0.76 (CHCl3/acetone, 3:1); mp 189-191°C; 
MS (FAB+) m/z\ 589.2 [10, (2M+H)+], 295.1 [100, (M+H)+]; MS (FAB') m/z: 293.1
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[100, (M-H)-]; Acc. MS (FAB+): 295.1675, C 19H I903  requires 295.1680; ‘H NMR (400 
MHz; DMSO-d6) 5H: 1.71 (quintet, 2H, CH2CH2CH2PI1, J =  7.8 Hz), 2.13 (s, 3H, CH3), 
2.54 (t, 2H, CH2CH2CH2Ph J=  7.8 Hz), 2.63 (t, 2H, CH2CH2CH2Ph, J  = 7.4 Hz), 6.82 
(d, 1H, C8-H, J =  2.4 Hz), 7.13-7.27 (m, 6H, C6-H and Ph-H), 7.42 (d, 1H, Cs-H, J  = 
8.8 Hz) and 10.25 (s, 1H, OH); Found C, 77.13; H, 6.28; Ci9H]803 requires C, 77.53; 
H, 6.16%.
8.6.12 4-M ethyl-3-[3-phenyIpropyl]coum arin-7-0-suIpham ate (101)
Compound 100 (230 mg; 0.78 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyI acetate gradient, 
8:1 to 2:1) and the white solid isolated was recrystallised from THF/hexane to give 101 
as white crystals (62 mg; 21%). R / 0.54 (CHCl3/ethyl acetate, 4:1); mp 154-156°C; 
MS (FAB+) m/z\ 374.0 [100, (M+H)+]; MS (FAB') m/z: 372.1 [100, (M-H)'], 293.1 [40, 
(M-H2N S 0 2)']; Acc. MS (FAB+): 374.1060, C 19H2oN05S requires 374.1062; JH NMR 
(400 MHz; DMSO-d6) 5H: 1.76 (pentet, 2H, CH2CH2CH2Ph, J  = 8.2 Hz), 2.49 (s, 3H, 
CH3), 2.62 (t, 2H, CH2CH2CH2Ph J  = 8.2 Hz), 2.67 (t, 2H, CH2CH2CH2Ph, J  = 7.4 
Hz), 7.15-7.39 (m, 7H, C8-H, C6-H and Ph-H), 7.87 (d, 1H, C5-H, J =  8.8 Hz) and 8.19 
(s, 2H, NH2); Found C, 61.30; H, 4.94; N, 3.49; C 19H 19NO5S requires C, 61.11; H, 
5.13; N, 3.75%.
8.6.13 Ethyl 2-(cyclohexylmethyI)-3-oxobutanoate (102)
Prepared by method 8.2.2, using K2C 0 3 (7.5 g; 54 mmol), water (50 ml), 
cyclohexylmethyl bromide (4.0 ml; 23 mmol), ethyl 3-oxobutanoate (2.9 ml; 23 
mmol), CH2C12 (50 ml) and BU4NCI (~10 g; 23 mol). The crude pale yellow oil was 
purified by flash chromatography (CHC13) to give 102 as a pale yellow oil (1.44 g; 
28%). (430Lit. bp19 166°C); R / 0.58 (CHC13); MS (FAB+) m/z: 227.3 [100, (M+H)+]; 
MS (FAB‘) m/z: 225.3 [100, (M-H)']; Acc. MS (FAB4): 227.1632, C ,3H230 3 requires 
227.1647; ‘H NMR (400 MHz; CDC13) 8H: 1.08-1.34 (m, 11H, cyclohexyl H), 1.27 (t,
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3H, CH2CH3, J =  7.0 Hz), 1.69 (t, 2H, CH2, J=  7.0 Hz), 2.22 (s, 3H, CH3), 3.53 (t, 1H, 
2-H, J = 7.4 Hz) and 4.21 (q, 2H, CH2CH3, J  = 7.0 Hz).
8.6.14 3-Cyclohexylmethyl-7-hydroxy-4-methylcoumarin (103)
Prepared by method 8.2.4, using resorcinol (487 mg; 4.42 mmol), 102 (1.0 g; 4.4 
mmol) and a mixture o f CF3COOH (0.7 ml; 8.8 mmol) and conc. H2SC>4 (0.5 ml; 8.8 
mmol). The crude orange solid was purified by flash chromatography (CHCl3/acetone, 
8:1 to 4:1 gradient) and the white solid isolated was recrystallised from THF/hexane to 
give 103 as fine white crystals (409 mg; 34%). R / 0.74 (CHCl3/acetone, 3:1); mp 193- 
196°C; MS (FAB+) m/z: 545.3 [15, (2M+H)+], 273.2 [100, (M+H)+]; MS (FAB') m/z:
271.2 [100, (M-H)']; Acc. MS (FAB+): 273.1491, C ,7H210 3 requires 273.1492; 'H 
NMR (400 MHz; DMSO-d6) 8H: 1.11-1.91 (m, 11H, cyclohexyl H), 2.35 (s, 3H, CH3), 
2.43 (d, 2H, CH2, J =  7.0 Hz), 6.68 (d, 1H, Cg-H, J =  2.3 Hz), 6.79 (dd, 1H, C6-H, J  = 
2.3, 8.6 Hz), 7.59 (d, 1H, C5-H, J=  8.6 Hz) and 10.21 (s, 1H, OH); Found C, 74.80; H, 
7.47; C ,7H20O3 requires C, 74.97; H, 7.40%.
8.6.15 3-Cyclohexylmethyl-4-methylcoumarin-7-0-sulphamate (104)
Compound 103 (300 mg; 1.10 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 104 as white crystals (46 mg; 12%). R / 0.55 (CHCl3/ethyl acetate, 4:1); mp 
170-171°C; MS (FAB+) m/z: 352.0 [100, (M+H)+[; MS (FAB') m/z: 350.0 [100, (M- 
H)'], 271.1 [45, (M-H2N S 0 2)']; A cc. MS (FAB+): 352.1214, Ci7H22N 0 5S requires 
352.1218; ‘H NMR (400 MHz; DMSO-d6) 8H: 1.22-1.31 (m, 11H, cyclohexyl H), 2.06 
(s, 3H, CH3), 2.58 (d, 2H, CH2, J=  7.0 Hz), 7.32-7.35 (m, 2H, Cr H and C6-H), 7.93 (d, 
1H, C5-H, J  = 8.6 Hz) and 8.39 (s, 2H, NH2); Found C, 58.30; H, 5.86; N, 3.79; 
Ci7H2|N 0 5S requires C, 58.10; H, 6.02; N, 3.99%.
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8.6.16 Ethyl 2-acetyl-4-cyclohexylbutanoate (105)
Prepared by method 8.2.2, using K2CO3 (8.68 g; 62.8 mmol), water (60 ml), 1-bromo- 
2-cyclohexylethane (5.0 ml; 26.2 mmol), ethyl 3-oxobutanoate (3.34 ml; 26.2 mmol), 
CH2CI2 (50 ml) and BU4NCI (7.3 g; 26 mmol). The crude orange oily residue was 
purified by flash chromatography (CHCI3) to give 105 as a pale yellow oil (850 mg; 
14%). (430Lit. bp l9 175°C); R / 0.72 (CHC13); MS (FAB+) m/r. 241.3 [100, (M+H)+]; 
MS (FAB') m/z: 239.3 [100, (M-H)']; Acc. MS (FAB+): 241.1804, C 14H25O3 requires 
241.1804; ‘H N M R  (400 MHz; CDC13) 5H: 1.19-1.66 (m, 13H, cyclohexyl H and CH2), 
1.27 (t, 3H, CH2CH3, J =  7.0 Hz), 1.80-1.87 (m, 2H, CH2), 2.22 (s, 3H, CH3), 3.35 (t, 
1H, 2-H, J  = 7.4 Hz) and 4.19 (q, 2H, CH2CH3, J=  7.0 Hz).
8.6.17 3-(2-Cyclohexylethyl)-4-methyl-7-hydroxycoumarin (106)
Prepared by method 8.2.4, using resorcinol (343 mg; 3.12 mmol), 105 (750 mg; 3.12 
mmol) and a mixture of CF3COOH (0.5 ml; 6.2 mmol) and conc. H2SO4 (0.4 ml; 6.2 
mmol). The crude orange solid was purified by flash chromatography (CHC^/acetone, 
8:1 to 4:1 gradient) and the white solid isolated was recrystallised from THF/hexane to 
give 106 as white crystals (352 mg; 39%). R / 0.79 (CHC^/acetone, 3:1); mp 148- 
151°C; MS (FAB+) m/z: 572.9 [10, (2M+H)+], 287.1 [100, (M+H)+]; MS (FAB-) m/z:
571.1 [10, (2M-H)'], 285.2 [100, (M-H)']; Acc. MS (FAB+): 287.1639, C 18H230 3 
requires 287.1647; ’H N M R  (400 MHz; DMSO-d6) 6H: 1.11-1.73 (m, 11H, cyclohexyl 
H), 2.34 (s, 3H, CH3), 2.51-2.53 (m, 4H, CH2CH2), 6.67 (d, 1H, C8-H, J  = 2.3 Hz), 
6.78 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 7.59 (d, 1H, C5-H, J =  8.9 Hz) and 10.38 (s, 1H, 
OH); Found C, 75.50; H, 7.67; C 18H220 3 requires C, 75.50; H, 7.74%.
8.6.18 3-(2-Cyclohexylethyl)-4-methyIcouinariii-7-0-sulphamate (107)
Compound 106 (250 mg; 0.87 mmol) was sulphamoylated by method 8.2.5 A. The 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane 
to give 107 as white fine crystals (155 mg; 49%). R / 0.47 (CHCl3/ethyl acetate, 4:1); 
mp 179-181°C; MS (FAB+) m/z: 366.0 [100, (M+H)+]; MS (FAB") m/z: 364.0 [100,
250
(M-H)'], 285.1 [40, (M-H2NSO2)-]; Acc. MS (FAB+): 366.1319, C I8H24N 0 5S requires 
366.1297; ‘H NMR (400 MHz; DMSO-d6) 8H: 1.19-1.78 (m, 11H, cyclohexyl H), 2.41 
(s, 3H, CH3), 2.49-2.59 (m, 4H, CH2CH2), 7.25-7.28 (m, 2H, Cg-H and C6-H), 7.87 (d, 
1H, C5-H, J =  8.6 Hz) and 8.20 (s, 2H, NH2); Found C, 59.10; H, 6.31; N, 3.62; 
C 18H23N 0 5S requires C, 59.16; H, 6.34; N, 3.83%.
8.7 Other substituted coumarins
8.7.1 Ethyl 2-nonyI-3-oxododecanoate (108)
Prepared by method 8.2.2, using K2CO3 (6.85 g; 49.5 mmol), water (60 ml), 16 (5.0 g; 
21 mmol), nonyl bromide (4.3 ml; 21 mmol), CH2C12 (60 ml) and Bu4NC1 (-6.0 g; 21 
mmol). The crude yellow oily residue was purified by flash chromatography (CHCI3) 
to give 108 as a pale yellow oil. (2.6 g; 34%). R / 0.89 (CHCI3); MS (FAB+) m/z: 369.4 
[100, (M+H)+]; MS (FAB') m/z: 367.4 [100, (M-H)']; Acc. MS (FAB+): 369.3370, 
C23H4503 requires 369.3369; 'H  NMR (400 MHz; CDC13) 6H: 0.88 (t, 6H, two terminal 
CH3) J =  7.4 Hz), 1.24-1.89 (m, 33H, CH2CH3 and 15xCH2), 2.73 (t, 2H, 4-CH2) J  =
7.4 Hz), 3.41 (t, 1H, 2-H, J=  7.4 Hz) and 4.18 (q, 2H, O ^CTH , J=  7.4 Hz).
8.7.2 3,4-Dinonyl-7-hydroxycoumarin (109)
Prepared by method 8.2.4, using resorcinol (597 mg; 5.4 mmol), 108 (4.0 g; 5.4 mmol) 
and a mixture of CF3COOH (0.8 ml; 11 mmol) and conc. H2S 0 4 (0.5 ml; 11 mmol). 
The crude brown residue was purified by flash chromatography (CHCf/acetone, 8:1 to 
4:1 gradient) to give 109 as a thick yellow syrup, which solidified on standing (874 
mg; 39%). This waxy solid could not be recrystallised. R / 0.90 (CHC^/acetone, 3:1); 
mp 49-51°C; MS (FAB+) m/z: 415.4 [100, (M+H)+]; MS (FAB') m/z: 413.3 [100, (M- 
H)3; Acc. MS (FAB+): 415.3206, C27H430 3 requires 415.3212; 'H  NMR (400 MHz; 
DMSO-d6) 8h: 0.85 (t, 6H, two terminal CH3, J  = 7A  Hz), 1.24-1.62 (m, 28H, 
14xCH2), 2.46 (t, 2H, C3-CH2, J =  7.4 Hz), 2.72-2.74 (m, 2H, C4-CH2), 6.67 (d, 1H, 
Cg-H, J =  2.3 Hz), 6.79 (dd, 1H, C6-H, J =  2.3, 8.6 Hz), 7.58 (d, 1H, C5-H, J =  8.9 Hz) 
and 10.41 (s, 1H, OH).
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8.7.3 3,4-DinonyIcoumarin-7-0-sulphamate (110)
Upon sulphamation (method A 8.2.5), compound 109 (300 mg; 0.72 mmol) gave a 
crude white solid, which was fractionated by flash chromatography (CHCl3/ethyl 
acetate, 8:1 to 2:1 gradient). The white solid isolated was recrystallised from 
THF/hexane to give 110 as white fine crystals (101 mg; 28%). R / 0.71 (CHCl3/ethyl 
acetate, 6:1); mp 86-87°C; MS (FAB+) m/z: 494.2 [100, (M+H)+]; MS (FAB') m/z:
492.2 [100, (M-H)'], 413.3 [15, (M-H2N S 0 2)']; Acc. MS (FAB+): 494.2652, 
Q 7H44NO 5S requires 494.2677; 'H NMR (400 MHz; DMSO-d6) 6H: 0.88 (t, 6H, two 
terminal CH3, J =  7.2 Hz), 1.22-1.58 (m, 28H, 14xCH2), 2.44-2.47 (m, 2H, C3-CH2), 
2.70-2.78 (m, 2H, C4-CH2), 6.61 (d, 1H, C8-H, J=  2.3 Hz), 6.78 (dd, 1H, C6-H, J=  2.3,
8.8 Hz), 7.57 (d, 1H, C5-H, J=  8.9 Hz) and 8.23 (s, 2H, NH2).
8.7.4 6-Ethyl-7-hydroxy-4-methyl-3-[3-phenylpropyl]coumarin (111)
Prepared by method 8.2.4, using 4-ethylresorcinol (556 mg; 4.03 mmol), 99 (1.0 g; 4.0 
mmol) and a mixture o f CF3COOH (0.6 ml; 8.1 mmol) and conc. H2S 0 4 (0.4 ml; 8.1 
mmol). The crude brown solid was purified by flash chromatography (CHCl3/acetone, 
8:1 to 4:1 gradient) and the pale yellow solid isolated was recrystallised from 
acetone/hexane to give 111 as white crystals (897 mg; 69%). R / 0.80 (CHCl3/acetone, 
3:1); mp 146-149°C; MS (FAB+) m/z: 323.3 [100, (M+H)+]; MS (FAB') m/z: 321.2 
[100, (M-H)']; Acc. MS (FAB+): 323.1644, C21H230 3 requires 323.1647; ]H NMR (400 
MHz; CDC13) 5h: 1.25 (t, 3H, CH2CH3, J=  7.4 Hz), 1.85 (quintet, 2H, CH2CH2CH2Ph 
J =  7.8 Hz), 2.31 (s, 3H, CH3), 2.66-2.74 (m, 6H, CH2CH3 and CH2CH2CH2Ph), 6.72 
(s, 1H, OH) and 7.06-7.32 (m, 7H, C8-H, Ph-H and C5-H); Found C, 77.90; H, 6.55; 
C2iH220 3 requires C, 78.23; H, 6 .88%.
8.7.5 6-Ethyl-4-methyl-3-[3-phenylpropyl]coumarin-7-0-sulphamate (112)
Upon sulphamoylation (Method 8.2.5 A), compound 111 (250 mg; 0.85 mmol) gave a 
crude white solid, which was fractionated by flash chromatography (CHCl3/ethyl 
acetate gradient, 8:1 to 2:1). The white solid that isolated was recrystallised from 
THF/hexane to give 112 as white fine crystals (184 mg; 54%). R / 0.54 (CHCl3/ethyl
252
acetate, 4:1); mp 199-201°C; MS (FAB4) m/z: 402.3 [100, (M+H)4], 295.1 [15, (M+H- 
H N S02)4]; MS (FAB ) m/z: 400.2 [100, (M-H)']; Acc. MS (FAB4): 402.1376, 
C21H24NO5S requires 402.1375; ‘H NMR (400 MHz; DMSO-d6) 6H: 1.17 (t, 3H, 
CH2CH3, J  = 7.4 Hz), 1.72 (quintet, 2H, CHjCHrCHjPh J  = 7.8 Hz), 2.36 (s, 3H, 
CH3), 2.56-2.69 (m, 6H, CH2CH3 and CH2CH2CH2PI1), 7.13-7.31 (m, 7H, Cs-H, Ph-H 
and C5-H) and 7.66 (s, 2H, NH2).
8.7.6 4,8-Dimethyl-7-hydroxy-3-[3-phenyIpropyl]coumarin (113)
Prepared by method 8.2.4, using 2-methylresorcinol (499 mg; 4.03 mmol), 99 (1 g; 4 
mmol) and a mixture o f CF3COOH (0.7 ml; 8.1 mmol) and conc. H2SO4 (0.5 ml; 8.1 
mmol). The crude brown solid was purified by flash chromatography (CHC^/acetone, 
8:1 to 4:1 gradient) and the pale yellow solid isolated was recrystallised from 
THF/hexane to give 113 as fine pale yellow crystals (1.03 g; 83%). R / 0.85 
(CHCl3/acetone, 4:1); mp 191-192°C; MS (FAB+) m/z: 617.3 [10, (2M+H)+], 309.3 
[100, (M+H)+]; MS (FAB’) m/z: 615.2 [10, (2M-H)'], 302.2 [100, (M-H)']; Acc. MS 
(FAB+): 309.1492, C20H21O3 requires 309.1491; 'H NMR (400 MHz; DMSO-d6) 5H:
1.74 (quintet, 2H, CH2CH2CH2Ph J  = 8.2 Hz), 2.15 (s, 3H, C4-CH3), 2.29 (s, 3H, C8- 
CH3), 2.58 (t, 2H, CH2CH2CH2Ph, J  = 7A  Hz), 2.65 (t, 2H, CH2Ph, J =  7.4 Hz), 6.84 
(d, 1H, C6-H, J=  8.6 Hz), 7.15-7.29 (m, 5H, Ph-H), 7.43 (d, 1H, C5-H, J=  8.6 Hz) and
10.28 (s, 1H, OH); Found C, 77.40; H, 6.62; C20H20O3 requires C, 77.90; H, 6.54%.
8.7.7 4,8-Dimethyl-3-[3-phenylpropyI]coumarin-7-<9-sulphamate (114)
Upon sulphamoylation (method 8.2.5 A), compound 113 (300 mg; 0.97 mmol) gave a 
crude white solid, which was fractionated by flash chromatography (CHC^/ethyl 
acetate, 8:1 to 2:1 gradient). The white solid isolated was recrystallised from 
THF/hexane to give 114 as white fine crystals (145 mg; 39%). R / 0.44 (CHC^/ethyl 
acetate, 4:1); mp 153-154°C; MS (FAB+) m/z: 388.0 [100, (M+H)+]; MS (FAB’) m/z:
386.0 [100, (M-H)’]; Acc. MS (FAB+): 388.1146, C20H22NO5S requires 388.1140; lH 
NMR (400 MHz; DMSO-d6) 6H: 1.75 (quintet, 2H, CH2CH2CH2Ph J  = 7.0 Hz), 2.32
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(s, 3H, C4-CH3), 2.37 (s, 3H, C8-CH3), 2.60-2.69 (m, 4H, C H 2 C H 2 C H 2 P I 1 ) ,  7.15-7.29 
(m, 5H, Ph-H), 7.31 (d, 1H, C6-H, J=  8.6 Hz), 7.71 (d, 1H, C5-H, J =  8.6 Hz) and 8.22 
(s, 2H, NH2); Found C, 61.50; H, 5.41; N, 3.58; C20H21NO5S requires C, 62.00; H, 
5.46; N, 3.62%.
8.7.9 7-Hydroxy-3-(4-methoxyphenyI)-4-methylcoumarin (115)
To a CH2CI2 (100 ml) solution o f 2,4-dihydroxyacetophenone (5.0 g; 33 mmol; 1 eq.), 
tetrabutylammonium hydrogensulphate (300 mg; 0.88 mmol; 0.03 eq.) and 20% aq. 
K2CO3 (100 ml) was added 4-methoxyphenylacetyl chloride (6.7 g; 36 mmol; 1.1 eq.) 
in CH2CI2 (30 ml) dropwise during 30 min and stirred for 4 hours at R.T. The organic 
layer was separated, washed with water (3x200 ml), dried and concentrated. The crude 
pale brown syrup was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
4:1 gradient) and the pale yellow solid isolated was recrystallised from THF/hexane to 
give 115 as white crystals (1.2 g; 13%). R / 0.68 (UV visible and fluorescent) (ethyl 
acetate/hexane, 1:1); mp 230-232°C (4!1Lit. mp 233-234°C); MS (FAB+) m/z: 283.2 
[100, (M+H)4]; MS (FAB') m/z: 281.2 [100, (M-H)']; Acc. MS (FAB+): 283.0898, 
C 17H 15O4 requires 283.0892; ‘H NMR (400 MHz; DMSO-d6) 5H: 2.60 (s, 3H, CH3), 
3.81 (s, 3H, OCH3), 6.63 (dd, 1H, C6-H, J=  2.3, 8.9 Hz), 6.71 (d, 1H, Cg-H, J =  2.3 
Hz), 6.90 (d, 2H, Ph-2,6-H2, J=  8.6 Hz), 7.29 (d, 2H, Ph-3,5-H2, J=  8.6 Hz), 7.72 (d, 
1H, Cs-H, J =  8.9 Hz) and 12.42 (s, 1H, OH); Found C, 71.98; H, 5.36; C]7H |404 
requires C, 72.33; H, 5.00%.
8.7.10 3-(4-Methoxyphenyl)-4-methyIcoumarin-7-6>-suIphamate (116)
Upon sulphamoylation by method 8.2.5 B, compound 115 (500 mg; 1.77 mmol) gave a 
crude white solid, which was fractionated by flash chromatography (CHC^/ethyl 
acetate 8:1 to 2:1 gradient,). The white solid isolated was recrystallised from ethyl 
acetate/hexane to give 116 as white fine leaves (331 mg; 52%). R / 0.86 (CHC^/ethyl 
acetate, 4:1); mp 129-132°C; MS (FAB4) m/z\ 362.1 [100, (M+H)4]; MS (FAB') m/r.
361.2 [100, (M-H)']; Acc. MS (FAB4): 362.0705, C l7H,6N 0 6S requires 362.0698; 'H 
NMR (400 MHz; DMSO-d6) SH: 2.77 (s, 3H, CH3), 3.75 (s, 3H, OCH3), 6.93 (d, 2H,
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Ph-2,6-H2, J=  8.6 Hz), 7.31 (d, 2H, Ph-3,5-H2, J=  8.6 Hz), 7.35 (dd, 1H, C6-H, J= 1.9,
8.9 Hz), 7.48 (d, 1H, Cg-H, J=  1.9 Hz), 8.21 (d, 1H, Cs-H, J =  8.9 Hz), 8.24 (s, 2H, 
NH2); Found C, 56.30; H, 4.21; N, 3.78; C 17H 15N 0 6S requires C, 56.50; H, 4.18; N, 
3.88%.
8.8 Tricyclic coum arin sulpham ates
8.8.1 Ethyl 2-oxocycIononanecarboxylate (117)
Prepared by method 8.2.3, by stirring a mixture of NaH (1.71 g, 42.8 mmol), diethyl 
carbonate (80 ml) and cyclononanone (3.0 g, 21 mmol). The crude yellow oily residue 
was purified by distillation under reduced pressure to give 117 as clear oil (4.15 g, 
91%). Rr : 0.72 (CHC13); b p o .3  146-150°C; (432Lit. bp2 108—110°C; MS (FAB+) m/z:
213.0 [100, (M+H)+]; Acc. MS (FAB+): 213.1499, Ci2H2,0 3 requires 213.1491; ‘H 
NMR (400 MHz; CDCI3) 8H: 1.23 (t, 1.8H, keto CH2CH3, J =  1 2  Hz), 1.30 (t, 1.2H, 
enol CH2CH3, J =  1 2  Hz), 1.37-2.66 (m, 14H), 3.62 (m, 0.6H, keto CH C=0), 4.14 (q, 
1.2H, keto CH2CH3, J =  7.2 Hz), 4.21 (q, 0.8H, enol CH2CH3, J=  1 2  Hz) and 12.76 (s, 
0.4H, enol OH exchanged with D20).
8.8.2 3-H ydroxy-6-oxo-8,9,10,ll512,13-hexahydro-7/f-cyclonona-[c][l]- 
benzopyran (118)
Prepared by method 8.2.4, using resorcinol (1.56 g; 14.1 mmol), 117 (3.0 g; 14 mmol) 
and a mixture o f CF3COOH (2.2 ml; 28 mmol) and conc. H2S04  (1.5 ml; 28 mmol). 
The crude orange solid was purified by flash chromatography (CHC^/acetone, 8:1 to 
4:1 gradient) and the white solid isolated was recrystallised from THF/hexane to give 
118 as white fine crystals (909 mg; 25%). R / : 0.82 (CHC^/acetone, 3:1); mp 197- 
200°C; MS (FAB+) m/r. 259.1 [100, (M+H)+]; MS (FAB') m/r. 257.1 [100, (M-H)']; 
Acc. MS (FAB+): 259.1323, Ci6Hi90 3 requires 259.1334; ‘H NMR (400 MHz; CDCI3) 
SH: 1.29-2.51 (m, 10H, 5xCH2), 2.66 (t, 2H, C8-CH2, J =  5.8 Hz), 2.93 (t, 2H, C ,4-CH2, 
J =  6.1 Hz), 6.69 (d, 1H, C4-H, .7= 2.4 Hz), 6.78 (dd, 1H, C2-H, J =  2.4, 8.8 Hz), 7.59 
(d, 1H, C r H, J  = 8.8 Hz) and 10.39 (s, 1H, OH); Found C, 74.10; H, 6.91; Ci6H ,80 3
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requires C, 74.40; H, 7.02%; HPLC: M e0H :H 20  (70:30); Flow rate = 2 ml/min, A,max =
323.2 nm; tR= 6.5 min.
8.8.3 6-O xo-8,9,lO ,ll,12,13-hexahydro-7//-cyclonona-[c][l]-benzopyran-3-0- 
sulpham ate (119)
Compound 118 (400 mg; 1.55 mmol) was sulphamoylated by method 8.2.5 A, and the 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient). The white solid isolated was recrystallised from THF/hexane to give 119 
as white fine crystals (201 mg; 38%). R /: 0.46 (CHC^/ethyl acetate, 4:1); mp 167- 
168°C; MS (FAB+) m/z: 338.0 [100, (M+H)+]; MS (FAB') m/z: 336.1 [100, (M-H)'],
257.1 [30, (M-H2N S 0 2)']; Acc. MS (FAB+): 338.1061, Ci6H2oN 05S requires 338.1062; 
'H  NMR (400 MHz; CDC13) 5H: 0.84-1.74 (m, 10H, 5xCH2), 1.52 (t, 2H, C8-CH2, J  =
5.8 Hz), 1.57 (t, 2H, C 14-CH2, J =  6.1 Hz), 7.26 (dd, 1H, C2-H, J =  2.4, 8.8 Hz), 7.31 
(d, 1H, C4-H, J =  2.1 Hz), 7.89 (d, 1H, C,-H, J =  8.8 Hz) and 8.20 (s, 2H, NH2); Found 
C, 56.85; H, 5.58; N, 4.00 C |6H,9N05S requires C, 56.96; H, 5.68; N, 4.15 %; HPLC: 
MeOH:H20  (70:30); Flow rate = 2 ml/min, ^ max = 284 and 312.5 nm; tR= 3.1 min.
8.8.4 Ethyl 2-oxocyclodecanecarboxylate (120)
Prepared by method 8.2.3, by stirring a mixture of NaH (1.3 g, 32 mmol), diethyl 
carbonate (60 ml) and cyclodecanone (2.5g, 16 mmol). The crude pale yellow oily 
residue was purified by distillation under reduced pressure to give 120 as a colourless 
oil (2.81 g, 76%). R /: 0.81 (CHCI3); bp023 84-87°C. (432Lit. bp, 118-120°C); MS 
(FAB+) m/z: 227.0 [100, (M+H)+]; Acc. MS (FAB4): 227.1644, C 13H23O3 requires 
227.1647; ‘H NMR (400 MHz; CDCI3) 8H: 1.24 (t, 1.2H, keto CH2CH3, J =  7.0 Hz),
1.31 (t, 1.8H, enol CH2CH3, J =  7.0 Hz), 1.34-2.76 (m, 16H), 3.82-3.85 (m, 0.7H, keto 
CH C=0), 4.13 (q, 0.5H, keto CH2CH3, 7 =  7.0 Hz), 4.22 (q, 1.5H, enol CH2CH3, /  = 




Prepared by method 8.2.4, using resorcinol (970 mg; 8.84 mmol), 120 (2.0 g; 8.8 
mmol) and a mixture of CF3COOH (1.5 ml; 18 mmol) and conc. H2SO4 (1.0 ml; 18 
mmol). The crude dark orange solid was purified by flash chromatography 
(CHCf/acetone, 8:1 to 4:1 gradient) and the white solid isolated was recrystallised 
from THF/hexane to give 121 as white crystals (789 mg; 33%). R / 0.72 
(CHCI3/acetone, 3:1); mp 240-241°C; MS (FAB+) m/r. 273.1 [100, (M+H)+[; MS 
(FA B ) m/r  271.1[100, (M -H)]; Acc. MS (FAB+): 273.1488, C ,7H2i03  requires
273.1491; 'H N M R  (400 MHz; DMSO-d6) SH: 0.88-2.18 (m, 12H, 6xCH2), 2.83 (t, 2H, 
C7-CH2, J =  6.7 Hz), 3.02 (t, 2H, CM-CH2, J =  6.7 Hz), 5.96 (s, 1H, OH), 6.78 (dd, 1H, 
C2-H, J =  2.7, 8.5 Hz), 6.83 (d, 1H, C4-H, J =  2.7 Hz) and 7.53 (d, 1H, C,-H, J =  8.5 
Hz); Found C, 74.30; H, 7.43; Ci7H20O3 requires C, 74.94; H, 7.40%; HPLC: 
MeOH:H20  (80:20); Flow rate = 2 ml/min, A,max = 322 nm; tR= 4.5 min.
8.8.6 6-Oxo-7,8,9,10,1142,13,14-octahydrocyclodeca-[c][l]-benzopyran-3-O- 
sulphamate (122)
Compound 121 (400 mg; 1.47 mmol) was sulphamoylated by method 8.2.5 A, and the 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient). The white solid isolated was recrystallised from THF/hexane to give 122 
as white fine crystals (235 mg; 46%). R / 0.71 (CHCL/ethyl acetate, 4:1); mp 183- 
185°C; MS (FAB+) m/z: 352.0 [100, (M+H)+]; MS (FAB") m/z: 350.1 [100, (M-H)"],
271.1 [100, (M-H2N S 0 2); Acc. MS (FAB+): 352.1223, C ,7H22N 0 5S requires 352.1219; 
*H NMR (400 MHz; DMSO-d6) 5H: 1.17-3.0 (m, 14H, 7xCH2), 3.09 (t, 2H, C ]4-CH2, J  
= 6.4 Hz), 7.26 (m, 1H, C2-CH), 7.46 (d, 1H, C4-H, J  = 1.2 Hz), 7.93 (d, 1H, C r H, J  =
8.8 Hz) and 8.21 (s, 2H, NH2); Found C, 58.40; H, 6.28; N, 2.63 C I7H2iN0 5S requires 
C, 58.10; H, 6.02; N, 3.99%; HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, ?imax = 
284 and 312.5 nm; tR= 6.3 min.
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8.8.7 Ethyl 2-oxocycloundecanecarboxylate (123)
Prepared by method 8.2.3, by stirring a mixture of NaH (1.19 g, 29.7 mmol), diethyl 
carbonate (70 ml) and cycloundecanone (2.5 g, 15 mmol). The crude yellow oily 
residue was purified by distillation under reduced pressure to give 123 as pale yellow 
oil (2.07g, 58%). R / 0.31 (CH2C12); bp0.15 103-108°C. (432Lit. bp5 140-143°C; MS 
(FAB4) m/z: 241.1 [100, (M+H)4]; MS (FAB') m/z: 239.0 [100, (M-H)']; Acc. MS 
(FAB4): 241.1806, C14H25O3 requires 241.1804; 'H  NMR (400 MHz; CDCI3) 8H: 2.20 




Prepared by method 8.2.4, using resorcinol (917 mg; 8.33 mmol), 123 (2.0 g; 8.3 
mmol) and a mixture o f CF3COOH (2.0 ml; 17 mmol) and conc. H2SO4 (1.6 ml; 17 
mmol). The crude yellow solid was purified by flash chromatography (CHCL/acetone, 
8:1 to 4:1 gradient) and the yellow solid isolated was recrystallised from THF/hexane 
to give 124 as pale yellow fine crystals (344 mg; 14%). R / 0.76 (CHCL/acetone, 3:1); 
mp 214-215°C; MS (FAB+) m/z\ 287.1 [100, (M+H)+]; MS (FAB’) m/z\ 285.1 [100, 
(M-H)’]; Acc. MS (FAB+): 287.1644, C 18H23O3 requires 287.1647; *H NMR (400 
MHz; DMSO-d6) 5H: 1.26-1.68 (m, 14H, 7xCH2), 2.56 (t, 2H, C8-CH2, J  = 7.0 Hz), 
2.84 (t, 2H, C ,6-CH2, J=  7.0 Hz), 6.67 (d, 1H, C4-H, J=  2.1 Hz), 6.78 (dd, 1H, C2-H, J  
= 2.1, 8.7 Hz), 7.63 (d, 1H, Ci-H, J=  8.8 Hz) and 10.42 (s, 1H, OH); Found C, 75.50; 
H, 7.75; Q 8H22O3 requires C, 75.50; H, 7.74%; HPLC: MeOH:H20  (80:20); Flow rate 
= 2 ml/min, ^ max = 323.2 nm; tR= 6.5 min.
8.8.9 6-Oxo-8,9,10,ll,12,13,14,15-octahydro-7/7-cycloundeca-[c][l]- 
benzopyran-3-O-sulphamate (125)
Compound 124 (300 mg; 1.05 mmol) was sulphamoylated by method 8.2.5 A, and the 
crude white solid was purified by flash chromatography (CHCfi/ethyl acetate, 8:1 to
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2:1 gradient). The white solid isolated was recrystallised from THF/hexane to give 125 
as white fine crystals (133 mg; 35%). R / 0.37 (CHCl3/ethyl acetate, 4:1); mp 145— 
148°C; MS (FAB+) m/z: 731.2 [10, (2M+H)4], 366.0 [100, (M+H)+[; MS (FAB') m/z:
364.1 [100, (M-H)"], 285.2 [40, (M-H2N S 0 2)']; Acc. MS (FAB4): 366.1368, 
C 18H24N 0 5S requires 366.1375; 'H  NMR (400 MHz; DMSO-d6) SH: 1.28-1.76 (m, 
14H, 7xCH2), 2.64 (t, 2H, C8-CH2, 7 =  7.0 Hz), 2.93 (t, 2H, C i5-CH2, 7  = 7.0 Hz), 7.26 
(dd, 1H, C2-H, 7 = 2 .1 , 8.8 Hz), 7.29 (d, 1H, C4-H, 7 = 2 .1  Hz), 7.93 (d, 1H, C !-H ,7  =
8.8 Hz) and 8.20 (s, 2H, NH2); Found C, 59.20; H, 6.57; Ci8H23N 0 5S requires C, 
59.16; H, 6.34%; HPLC: MeOH:H20  (80:20); Flow rate = 2 ml/min, 3.max = 285.2 and
312.5 nm; tR= 3.8 min.
8.8.10 Ethyl 2-oxocycIododecanecarboxylate (126)
Prepared by method 8.2.3, by stirring a mixture of NaH (2.19 g, 54.9 mmol), diethyl 
carbonate (100 ml) and cyclododecanone (5.0 g, 27 mmol). The crude dark yellow oily 
residue was purified by distillation under reduced pressure to give 126 as pale yellow 
oil (5.62 g, 81%). R / 0.72 (CH2C12); bp023 128-132°C; (432Lit. bp3 155-157°C; MS 
(FAB4) m/z: 255.1 [100, (M+H)4]; MS (FAB') m/z: 253.2 [100, (M-H)']; Acc. MS 
(FAB4): 255.1968, C |5H270 3 requires 255.1960; 'H NMR (400 MHz; CDC13) 5H: 1.25 




Prepared by method 8.2.4, using resorcinol (1.08 g; 9.8 mmol), 126 (2.5 g; 9.8 mmol) 
and a mixture of CF3COOH (1.5 ml; 20 mmol) and cone. H2SO4 (1.0 ml; 20 mmol). 
The crude pale yellow solid was purified by flash chromatography (CHCh/acetone, 8:1 
to 4:1 gradient) and the pale yellow solid isolated was recrystallised from THF/hexane 
to give 127 white crystals (972 mg; 33%). R / 0.76 (CHC^/acetone, 3:1); mp 249- 
251°C; MS (FAB+) m/z: 301.1 [100, (M+H)+]; MS (FAB') m/z: 299.1 [100, (M-H)'];
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Acc. MS (FAB+): 301.1806, C 19H25O3 requires 301.1804; 'H  NMR (400 MHz; DMSO- 
d6) 8h: 1.39-2.89 (m, 16H, 8xCH2), 2.93 (t, 2H, C7-CH2, J =  7.3 Hz), 3.22  (t, 2H, Ci6- 
CH2, J =  7.3 Hz), 6.66 (d, 1H, C4-H, J=  2.3 Hz), 6.78 (dd, 1H, C2-H, J =  2.3, 8.9 Hz), 
7.63 (d, 1H, C,-H, J  = 8.9 Hz) and 10.77 (s, 1H, OH); Found C, 75.90; H, 8.03; 
C |9H240 3 requires C, 75.97; H, 8.05%; HPLC: MeOH:H20  (90:10); Flow rate = 2 
ml/min, A,max = 324.4 nm; tR = 4.2 min.
8.8.12 6-O xo-7,8,9,10,ll?12,13,14,15,16-decahydrocycIododeca-[c][l]- 
benzopyran-3-O-sulphamate (128)
Compound 127 (400 mg; 1.33 mmol) was sulphamoylated by method A (8.2.5) and the 
crude white solid was purified by flash chromatography (CHC^/ethyl acetate, 8:1 to 
2:1 gradient). The white solid isolated was recrystallised from THF/hexane to give 128 
as white fine crystals (182 mg; 36%). R / 0.47 (CHC^/ethyl acetate, 4:1); mp 173- 
175°C; MS (FAB+) m/z\ 380.1 [100, (M+H)+], 301.1 [15, (M +H-HNS02)+]; MS (FAB’ 
) m/z\ 378.1 [100, (M-H)-], 299.1 [50, (M-H2N S 0 2)']; Acc. MS (FAB+): 380.1541, 
C 19H26N05S requires 380.1532; 'H NMR (400 MHz; DMSO-d6) 8H: 1.41-2.51 (m, 
16H, 8xCH2), 2.62 (t, 2H, C7-CH2, J=  7.3 Hz), 3.68 (t, 2H, C 16-CH2, J=  7.6 Hz), 7.26 
(dd, 1H, C2-H, J=  2.4, 8.5 Hz), 7.28 (d, 1H, C4-H, J =  2.4 Hz), 7.94 (d, 1H, C r H, J  =
8.5 Hz) and 8.20 (s, 2H, NH2); Found C, 60.30; H, 6.85; N, 3.62; C 19H25N 0 5S requires 
C, 60.14; H, 6.64; N, 3.69%; HPLC: MeOH:H20  (90:10); Flow rate = 2 ml/min, A,max =
285.2 and 312.5 nm; tR = 5.3 min.
8.8.13 Ethyl 2-oxocycIopentadecanecarboxylate (129)
Prepared by method 8.2.3, by stirring a mixture o f NaH (891 mg, 22.3 mmol), diethyl 
carbonate (70 ml) and cycloundecanone (2.5g, 11 mmol). The crude yellow syrup was 
purified by flash chromatography (CH2C12) to give 129 as pale yellow oil (1.62 g, 
49%). (432Lit. bp, 168-169°C); R / 0.70 (CH2C12); MS (FAB+) m/z: 297.2 [100, 
(M+H)+]; MS (FAB") m/z: 295.2 [100, (M-H)']; Acc. MS (FAB+): 297.2430, C,„H330 3 
requires 297.2429; 'H  NMR (400 MHz; CDC13) 8H: 1.64 (t, 3H, CH3CH2, . /=  6.7 Hz),
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Prepared by method 8.2.4, using resorcinol (558 mg; 5.06 mmol), 129 (1.5 g; 5.1 
mmol) and a mixture of CF3COOH (1.0 ml; 10 mmol) and conc. H2SC>4 (1.0 ml; 10 
mmol). The crude brown solid was purified by flash chromatography (CHCl3/acetone, 
8:1 to 4:1 gradient) and the yellow solid isolated was recrystallised from THF/hexane 
to give 130 as pale yellow crystals (432 g; 25%). R / 0.69 (CHCl3/acetone, 3:1); mp 
209-211°C; MS (FAB+) m /r  343.1 [100, (M+H)+]; MS (FAB') m /r  341.2 [100, (M-H)' 
]; Acc. MS (FAB+): 343.2269, C22H3I0 3 requires 343.2273; 'H  NMR (400 MHz; 
CDC13) Sh: 1.25-1.62 (m, 22H, 1 1xCH2), 2.57 (t, 2H, C7-CH2, J  = 7.8 Hz), 2.74 (t, 2H, 
C i9-CH2, 7 =  7.0 Hz), 6.04 (s, 1H, OH), 6.81 (dd, 1H, C2-H, J =  2.7, 8.9 Hz), 6.92 (d, 
1H, C4-H, y  = 2.7 Hz) and 7.45 (d, 1H, Cr H, J =  8.9 Hz); Found C, 77.12; H, 8.89; 
C22H30O3 requires C, 77.16; H, 8.83%; HPLC: MeOH:H20  (90:10); Flow rate = 2 
ml/min, A.max = 324.4 nm; tR= 8.5 min.
8.8.15 6-Oxo-8,9,10,ll,12,13,14,15,16,17,18,19-dodecahydrohydro-7/T- 
cyclopentadeca-[c] [l]-benzopyran-3-0-sulphamate (131)
Compound 130 (350 mg; 1.02 mmol) was sulphamoylated by method 8.2.5 A, and the 
crude white solid was purified by flash chromatography (CHCl3/ethyl acetate, 8:1 to 
2:1 gradient) to give a thick waxy solid, which was difficult to recrystallise. Further 
purification by preparative TLC (CHCl3/ethyl acetate, 4:1) gave a white solid (201 
mg), which was recrystallised from THF/hexane to give 131 as fine white film (185 
mg; 43%). R / 0.50 (CHCI3/ethylacetate, 4:1); mp 163-166°C; MS (FAB+) m/z\ 842.3 
[70, (2M+H)+], 422.1 [100, (M+H)+]; MS (FAB ) m/r  841.4 [80, (2M-H)'], 420.2 [100, 
(M-H)'], 341.2 [60, (M-H2N S 0 2)']; Acc. MS (FAB+): 422.1994, C22H32N0 5S requires 
422.1999; ‘H NMR (400 MHz; DMSO-d6) SH: 1.32-1.59 (m, 22H, 11 xCH2), 2.51 -2.81
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(m, 4H ,  C7-CH2 and C 1 9 - C H 2 ) ,  7.26-7.28 (m, 2H, C2-H and C4-H), 7.89 (d, 1H, C j - H ,  J  
= 7.8 Hz) and 8.19 (s, 2H, NH2); Found C, 62.80; H, 7.56; N, 3.00; C22H31NO5S 
requires C, 62.68; H, 7.41; N, 3.32%; H P L C :  MeOH:H20  (90:10); Flow rate = 2 
ml/min, X,max = 285.2 and 313.7 nm; tR= 4.2 min.
8.9 Indole Sulphamates
8.9.1 Indole-4-O-sulphamate (132)
Upon sulphamoylation by method 8.2.5 A, 4-hydroxyindole (200 mg; 1.5 mmol) gave 
a crude brown residue, which was fractionated by flash chromatography (ethyl 
acetate/hexane, 6:1 to 2:1 gradient) to give 132 as a brown syrup (125 mg; 39%). R / 
0.33 (ethyl acetate/hexane, 1:1); vmax (KBr) cm '1: 3402 (N-H), 3071 (NH2), 1396 
(S 0 2), 1100 (S 0 2); MS (FAB+) m/z: 425.1 [10, (2M+H)+], 213.1 [100, (M+H)+], 132.1 
[35, (M-H2N S 0 2)+]; MS (FAB') m/z\ 423.1 [10, (2M-H)'], 211.1 [100, (M-H)+]; Acc. 
MS (FAB+): 213.0321, C8H9N2 03S requires 213.0334; ]H NMR (400 MHz; DMSO-d6) 
5h : 6.48 (d, 1H, C3-H, J =  3.9 Hz), 6.89 (d, 1H, C5-H, J=  8.2 Hz), 7.07 (t, 1H, C6-H, J  
= 7.8 Hz), 7.28-7.32 (m, 2H, C2-H and C7-H), 7.84 (s, 2H, NH2) and 11.03 (s, 1H, 
NH).
8.9.2 Indole-5-O-suIphamate (133)
Upon sulphamoylation by method 8.2.5 A, 5-hydroxyindole (500 mg; 3.75 mmol) gave 
a crude brown solid, which was fractionated by flash chromatography (ethyl 
acetate/hexane gradient, 6:1 to 2 :1) and the brown solid isolated was recrystallised 
from ethyl acetate/hexane to give 133 as brown crystals (256 mg; 32%). R/: 0.48 (ethyl 
acetate/hexane, 1:1); mp 99-101°C; vmax (KBr) cm '1: 3389 (N-H), 3220 (NH2), 1390 
(S 0 2), 1091-1126 (S 0 2); MS (FAB+) m/z: 425.1 [30, (2M+H)+], 213.1 [100, (M+H)+],
132.1 [50, (M-H2N S 0 2)+]; MS (FAB') m/z: 423.1 [10, (2M-H)'], 211.1 [100, (M-H)']; 
Acc. MS (FAB+): 213.0339, C8H9N20 3S requires 213.0334; ]H NMR (400 MHz; 
DMSO-d6) 8h: 6.47 (m, 1H, C3-H), 7.01 (dd, 1H, C6-H, J=  2.3, 8.9 Hz), 7.40-7.45 (m, 
3H, C2-H, C4-H and C7-H), 7.76 (s, 2H, NH2) and 11.25 (s, 1H, NH).
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8.9.3 2-CarboxyindoIe-5-0-sulpham ate (134)
Upon sulphamoylation by method 8.2.5 A, 5-hydroxy-2-indolecarboxylic acid (900 
mg; 5.08 mmol) gave a crude white solid, which was purified by recrystallisation from 
ethyl acetate/hexane to give 134 as off-white crystals (642 mg; 49%). R/. 0.64 
(methanol); mp 203-205°C; vmax (KBr) cm '1; 3382 (N-H), 2362-3331 (NH2 and 
COOH), 1669 (C=0), 1393 (S 0 2), 1085-1130 (S 02); MS (FAB+) m/z: 513.1 [10, 
(2M+H)+], 257.0 [100, (M+H)+]; MS (FAB ) m/z: 511.1 [20, (2M-H)'], 255.1 [100, (M- 
H)']; Acc. MS (FAB+): 257.0224, C9H9N20 5S requires 257.0232; 'H  NMR (400 MHz; 
DMSO-d6) 8h : 7.09 (s, 1H, C3-H), 7.13 (dd, 1H, C6-H, 1.9, 8.9 Hz), 7.43 (d, 1H,
C7-H, J =  8.9 Hz), 7.52 (d, 1H, C4-H, / =  2.3 Hz), 7.79 (s, 2H, NH2), 7.84 (s, 1H, 
COOH) and 11.87 (s, 1H, NH); Found C, 42.40; H, 3.21; N, 10.80; C9H8N20 5S 
requires C, 42.19; H, 3.15; N, 10.93%.
8.9.4 3-M ethyl-l-pivaloyIindole (135)
To a suspension o f NaH (4.57 g; 114 mmol) in DMF (200 ml) was added 3- 
methylindole (10 g; 76 mmol) over 30 min at 0°C and stirred for 15 min. To this 
mixture was added pivaloyl chloride (12.2 ml; 99.1 mmol) dropwise at 4°C and stirred 
for further 15 min. This mixture was added to iceTUO (500 ml) and toluene (300 ml) 
and the organic layer was extracted. The combined extracts were washed with brine 
(3x200 ml), dried and evaporated to get a crude brown suspension, which was 
fractionated by flash chromatography (CHCl3/hexane, 8:4 to 2:1 gradient) to give 135 
as a pale yellow oil (12.7 g; 77%). R / 0.76 (CHCl3/hexane, 3:2); vmax (KBr) cm’1: 
1689 (C=0); MS (FAB+) m/z: 216.1 [100, (M+H)+]; MS (FAB') m/z: 214.1 [100, (M- 
H)‘]; Acc. MS (FAB+): 216.1713, C MH 18NO requires 216.1715; 'H  NMR (400 MHz; 
CDC13) 5h : 1.49 (s, 9H, (CH3)3), 2.29 (s, 3H, CH3), 7.22-7.36 (m, 4H, C4-H, C5-H, C6- 
H and C7-H) and 7.48 (s, 1H, C2-H); Found C, 78.04; H, 7.81; N, 6.43; C 14H 17NO 
requires C, 78.10; H, 7.96; N, 6.51%.
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8.9.5 6-Chloroacetyl-3-methyl-l-pivaloyIindole (136)
To a suspension of A I C I 3  (28 g; 209 mmol) in 1,2-dichloroethane (250 ml) was added 
chloroacetyl chloride (17.5 ml; 218 mmol) dropwise at 0°C and stirred for 20 min and 
then warmed to 20°C. To this solution was added 135 (10 g; 47 mmol) dropwise over 3 
h. The resulting mixture was stirred for an additional 15 min and then poured into ice- 
H2O (500 ml). The organic layer was extracted with 1,2-dichloroethane (3x200 ml). 
The combined extracts were washed with water (3x500 ml), 5% NaHC03  (3x300 ml), 
dried and evaporated to get a crude brown solid, which was purified by recrystallistion 
from hot ethyl acetate to give 136 as pale brown crystals (6.48 g; 48%). R / 0.74 (ethyl 
acetate/hexane, 1:1); mp 121-123°C; vmax (KBr) cm '1: 1690 (C=0); MS (FAB+) m/z:
292.2 [100, (M(35C1)+H)+]; MS (FAB') m/z: 290.1 [100, (M(35C1)-H)']; Acc. MS 
(FAB+) m/z: 292.1103, Ci6Hi935ClN0 2 requires 292.1104 and 294.1082,
Ci6H i937ClN0 2 requires 294.1035; ]H NMR (400 MHz; CDC13) 8H: 1.53 (s, 9H, 
(CH3)3), 2.33 (s, 3H, CH3), 4.85 (s, 2H, CH2C1), 7.58 (d, 1H, C4-H, J =  8.2 Hz), 7.68- 
7.69 (m, 1H), 7.95-7.97 (m, 1H) and 9.13 (s, 1H, C2-H).
8.9.6 6-Chloroacetoxy-3-methyl-l-pivaloylindole (137)
To a suspension o f anhydrous Na2H P04 (11.7 g; 82.5 mmol) and 136 (6.0 g; 21 mmol) 
in CH2C12 (50 ml) was added 80% w-CPBA (5.3 g; 31 mmol) at 20°C and stirred for 1 
h. The resulting mixture was poured into ice-H20  (200 ml) and the organic layer was 
extracted with CH2C12 (3x100 ml). The combined extracts were washed with water 
(3x300 ml), 5% NaHCC>3 (3x200 ml), dried and evaporated to get a crude pale yellow 
syrup, which was fractionated by flash chromatography (ethyl acetate/hexane, 1:1) to 
give 137 as a pale yellow syrup (4.82 g; 72%). R / 0.87 (ethyl acetate/hexane, 1:1); 
vmax (KBr) cm '1: 1695 (C=0); MS (FAB+) m/z: 308.2 [100, (M(35Cl)+H)+[; MS (FAB' 
) m/z: 306.2 [100, (M(35CI)-H)']; Acc. MS (FAB+) m/z: 308.0978, C 16H |935C 1N 0 3 
requires 307.0975 and 310.0983, Ci6H |937C1N03 requires 309.0946; ‘H NMR (400 
MHz; CDC13) 8h: 1.49 (s, 9H, (CH3)3), 2.28 (s, 3H, CH3), 4.31 (s, 2H, CH2C1), 7.05
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(dd, 1H, C5-H, J=  2.3, 8.6 Hz), 7.46 (d, 1H, C4-H, J =  8.6 Hz), 7.50 (d, 1H, C7-H, J  =
2.3 Hz) and 8.31 (s, 1H, C2-H).
8.9.7 6-H ydroxy-3-m ethyI-l-pivaIoylindole (138)
To a solution of 137 (3.5 g; 11 mmol) in methanol (100 ml) was added 15% sodium 
thiomethoxide (11 ml) at 20°C. After stirring for 2 h, the mixture was dissolved in 
ethyl acetate, neutralised with aq. 1M HC1 and the organic layer was extracted with 
ethyl acetate (3x100 ml). The combined extracts were washed with water (3x200 ml), 
brine (3x100 ml), dried and evaporated to give a crude pale yellow solid, which was 
fractionated by flash chromatography (ethyl acetate/hexane, 8:1 to 6:1 gradient). The 
crude pale yellow solid was recrystallised from THF/hexane to give 138 as pale yellow 
crystals (78 mg; 3%). R / 0.82 (ethyl acetate/hexane, 1:1); mp 119-120°C; vmax (KBr) 
cm '1: 3381 (O-H), 1653 (C=0); MS (FAB4) m/z: 232.2 [100, (M+H)4]; MS (FAB') 
m/z: 230.2 [100, (M-H)']; Acc. MS (FAB+): 232.1323, Ci4Hi8N 0 2 requires 232.1338; 
‘H NMR (400 MHz; CDCI3) 6H: 1.51 (s, 9H, (CH3)3), 2.25 (s, 3H, CH3), 6.05 (s, 1H, 
OH), 6.89 (dd, 1H, Cs-H, J =  2.3, 8.2 Hz), 7.32 (d, 1H, C4-H, J  = 8.2 Hz), 7.37 (d, 1H, 
C7-H, J  = 2.4 Hz) and 8.18 (s, 1H, C2-H); Found C, 72.61; H, 7.29; N, 5.88; 
C 14Hi7N 0 2 requires C, 72.70; H, 7.41; N, 6.06%.
8.9.8 3-M ethyl-l-pivaIoylindole-6-0-sulpham ate (139)
Upon sulphamoylation by method 8.2.5 A, compound 138 (50 mg; 0.22 mmol) gave a 
crude brown residue, which was purified by preparative TLC to give 139 as an off 
white syrup solidified on standing (16 mg; 24%). R / 0.51 (ethyl acetate/hexane, 1:1); 
mp 129-132°C; vmax (KBr) cm '1: 3387 (NH2), 1649 (0 = 0 ), 1399 (S 0 2), 1101-1129 
(S 0 2); MS (FAB+) m/z: 311.1 [100, (M+H)+J; MS (FAB') m/z: 309.0 [100, (M-H)']; 
Acc. MS (FAB4): 311.1087, Ci4H ,9N 20 4S requires 311.1066; 'H  NMR (400 MHz; 
CDC13) 8h : 1.41 (s, 9H, (CH3)3), 2.22 (s, 3H, CH3), 6.85 (dd, 1H, Cs-H, J =  2.4, 8.2 
Hz), 7.41 (d, 1H, C4-H, J =  8.2 Hz), 7.36 (d, 1H, C7-H, J =  2.4 Hz), 7.57 (s, 2H, NH2) 
and 8.06 (s, 1H, C2-H).
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8.9.9 5-Hydroxy-2-methylindoIe (140)
To a suspension o f aluminium chloride (2.48 g; 18.6 mmol) in dry toluene (80 ml), 5- 
methoxy-2-methylindole (1.0 g; 6.2 mmol) was added. The yellow mixture was boiled 
under reflux for 3 h under N2. Upon cooling o f the brown/green mixture to 0°C, water 
(50 ml) was added cautiously and the organic fraction was extracted into ethyl acetate 
(3x100 ml), washed with water (3x100 ml), dried, filtered and evaporated to give a 
crude brown residue, which was fractionated by flash chromatography (ethyl 
acetate/hexane, 6:1 to 1:1 gradient). The brown solid isolated was recrystallised from 
THF/hexane to give 140 as a pale brown crystals (321 mg; 35%). R / : 0.51 (ethyl 
acetate/hexane, 1:1); mp 128-129°C (433Lit. mp 132-134°C); vmax (KBr) cm '1: 3883 
(O-H), 3393 (N-H); MS (FAB+) m/z: 148.1 [100, (M+H)+]; MS (FAB’) m/z: 146.1 
[100, (M-H)’]; Acc. MS (FAB+): 148.0797, C9H 10NO requires 148.0762; *H NMR 
(400 MHz; acetone-d6) 8H: 2.36 (s, 3H, CH3), 5.97 (s, 1H, C3-H), 6.58 (dd, 1H, C6-H, J  
= 2.3, 8.6 Hz) 6.84 (broad s, 1H, C4-H), 7.08 (d, 1H, C7-H, J  = 8.2 Hz), 7.51 (s, 1H, 
OH) and 9.69 (s, 1H, NH); Found C, 73.45; H, 6.17; N, 9.50; C9H9NO requires C, 
73.45; H, 6.16; N, 9.52%.
8.9.10 3-Aminosulphonyl-5-sulphamoyloxy-2-methyIindole (141)
Upon sulphamoylation by method 8.2.5 A compound 140 (200 mg; 1.36 mmol) gave a 
crude white solid, which was fractionated by flash chromatography (CHCl3/methanol, 
6:1 to 1:1 gradient). The pale brown solid isolated was recrystallised from THF/hexane 
to give 141 as a pale brown crystals (72 mg; 17%). R / 0.70 (CHCI3/methanol, 3:2); mp 
230-233°C; vmax (KBr) cm’1: 3336 (N-H), 3214-3262 (NH2), 1379 (S 0 2), 1080 (S 0 2), 
MS (FAB+) m/z: 306.0 [100, (M+H)+], 226.1 [40, (M-H2N S 0 2)+]; MS (FAB’) m/z:
304.0 [100, (M-H)’]; Acc. MS (FAB+): 306.0209, C9H ]2N30 5S2 requires 306.0218; *H 
NMR (400 MHz; DMSO-d6) 6H: 2.48 (s, 3H, CH3), 7.04 (dd, 1H, C6-H, J =  2.3, 8.9 
Hz), 7.37 (d, 1H, C7-H, J=  8.6 Hz), 7.69 (d, 1H, C4-H, J =  2.3 Hz), 7.84 (s, 4H, NH2) 
and 11.86 (s, 1H, NH).
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8.9.11 l,2-Dimethyl-5-methoxyindole (142)
A solution o f 5-methoxy-2-methylindole (3.0 g; 19 mmol) in anhy. DMF (100 ml) was 
treated with NaH (1.11 g; 27.9 mmol) under N2 and stirred until all of the H2 evolution 
had ceased. Methyl iodide (1.75 ml; 27.9 mmol) was introduced and stirred for 3 h. 
The mixture was poured into brine (200 ml) and the organic layer was extracted with 
ethyl acetate (3x100 ml). The combined extracts were washed with water (3x200 ml), 
dried and evaporated to give a crude brown solid, which was fractionated by flash 
chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient). The brown solid isolated 
(1.63 g) was recrystallised from ethyl acetate/hexane to give 142 as a pale yellow 
needles (721 mg; 22%). R / 0.76 (ethyl acetate/hexane, 1:1); mp 74-76°C (434Lit. mp 
73-74°C); MS (FAB+) m/z: 176.2 [100, (M+H)+]; MS (FAB') m/z: 174.2 [100, (M-H)' 
]; Acc. MS (FAB+): 176.1003, C n H 13NO requires 176.0997; ]H NMR (400 MHz; 
CDCI3) 5H: 2.39 (s, 3H, CH3), 3.63 (s, 3H, NCH3), 3.84 (s, 3H, OCH3), 6.79 (dd, 1H, 
C6-H, J =  2.3, 8.9 Hz), 7.01 (d, 1H, C4-H, J =  2.3 Hz) and 7.13 (d, 1H, C7-H, J =  8.9 
Hz); Found C, 75.40; H, 7.54; N, 7.90; C n H 13NO requires C, 75.40; H, 7.48; N, 
7.99%.
8.9.12 l,2-Dimethyl-5-hydroxyindole (143)
Using the procedure described for the synthesis of compound 140, demethylation of 
compound 142 (1.0 g; 5.7 mmol) gave a crude brown solid, which was fractionated by 
flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient). The pale orange solid 
isolated was recrystallised from ethyl acetate/hexane to give 143 as a pale yellow 
crystals (514 mg; 56%). R / 0.72 (ethyl acetate/hexane, 1:1); mp 148-149°C (435Lit. mp 
143°C); MS (FAB+) m/z: 162.2 [100, (M+H)+]; MS (FAB') m/z: 160.2 [100, (M-H)'],
145.1 [60, (M-H-CH3)']; A cc. MS (FAB+): 162.0967, C ioH ,2NO  requires 162.0919; *H 
NMR (400 MHz; CDC13) 5H: 2.39 (s, 3H, CH3), 3.62 (s, 3H, NCH3), 4.79 (s, 1H, OH),
6.18 (s, 1H, C3-H), 6.71 (dd, 1H, C6-H, J=  2.7, 8.6 Hz), 6.93 (d, 1H, C4-H, J=  2.3 Hz) 
and 7.69 (d, 1H, C7-H, J  = 8.6 Hz); Found C, 74.60; H, 6.94; N, 8 .68 ; CioHnNO 
requires C, 74.51; H, 6 .88 ; N, 8.69%.
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8.9.13 l,2-DimethyIindole-5-0-sulphamate (144)
Upon sulphamoylation by method 8.2.5 A, compound 143 (400 mg; 2.48 mmol) gave a 
crude orange residue, which was fractionated by flash chromatography (ethyl 
acetate/hexane, 6:1 to 2:1 gradient). The yellow solid isolated was recrystallised from 
ethyl acetate/hexane to give 144 as fine grey crystals (81 mg; 14%). R / 0.47 (ethyl 
acetate/hexane, 1:1); mp 163-165°C; vmax (KBr) cm '1: 3283-3387 (NH2), 1356 (SO2), 
1100-1138 (S 0 2); MS (FAB+) m/z: 241.1 [100, (M+H)+], 160 (M-H2N S 0 2); MS (FAB' 
) m/z: 239.1 [100, (M-H)']; Acc. MS (FAB+): 241.0641, C 10H 13N2O3S requires 
241.0647; ’H NMR (400 MHz; DMSO-d6) 5H: 2.40 (s, 3H, CH3), 3.67 (s, 3H, NCH3),
6.25 (s, 1H, C3-H), 6.97 (dd, 1H, C6-H, J=  2.3, 8.6 Hz), 7.31 (d, 1H, C4-H ,J = 2 .3  Hz), 
7.39 (d, 1H, C7-H, J =  8.6 Hz) and 7.75 (s, 2H, NH2); Found C, 49.90; H, 5.09; N,
11.57; CioH12N20 3S requires C, 49.99; H, 5.03; N, 11.66%.
8.9.14 l-Ethyl-2-methyl-5-methoxyindole (145)
Following the method described for compound 142, a DMF (100 ml) solution o f 5- 
methoxy-2-methylindole (2.5 g; 16 mmol) was treated with NaH (931 mg; 23.3 mmol) 
and ethyl iodide (1.7 ml; 23 mmol). The crude brown syrup isolated was fractionated 
by flash chromatography (ethyl acetate/hexane, 6:1 to 1:1 gradient) to give 145 as a 
brown thick syrup (1.98 g; 68%). R / 0.77 (ethyl acetate/hexane, 1:1); 436Lit. mp 21°C; 
vmax (KBr) cm '1: 2934 (OCH3); MS (FAB+) m/z: 189.2 [100, (M+H)+]; MS (FAB') 
m/z\ 188.1 [100, (M-H)']; Acc. MS (FAB+): 189.1672, Ci2H i6NO requires 189.1699; 
*H NMR (400 MHz; CDC13) 8H: 1.27 (t, 3H, CH2CH3, J=  7.0 Hz), 2.36 (s, 3H, CH3), 
3.81 (s, 3H, OCH3), 4.02 (q, 2H, CH2CH3, J =  7.4 Hz), 6.13 (s, 1H, C3-H), 6.78 (dd, 
1H, C6-H, J =  2.3, 8.6 Hz), 6.99 (d, 1H, C4-H, J =  2.3 Hz) and 7.11 (d, 1H, C7-H, J  =




Following the procedure described for the preparation of compound 140, 
demethylation of compound 145 (1.5 g; 7.9 mmol) gave a crude brown solid, which 
was fractionated by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient). 
The yellow solid isolated was recrystallised from ethyl acetate/hexane to give 146 as 
pale yellow crystals (721 mg; 52%). R / 0.73 (ethyl acetate/hexane, 1:1); mp 109- 
111°C (436Lit. mp 114-115°C); vmax (KBr) c m 1: 3267 (O-H); MS (FAB+) mJr. 176.1 
[100, (M+H)+[; Acc. MS (FAB+): 176.1059, C u H |4NO requires 176.1075; ‘H NMR 
(400 MHz; CDC13) 8H: 1.31 (t, 3H, CH2CH3, J  = 1A  Hz), 2.39 (s, 3H, CH3), 4.07 (q, 
2H, CH2CH3, J =  7.4 Hz), 4.82 (s, 1H, OH), 6.12 (s, 1H, C3-H), 6.71 (dd, 1H, C6-H, J  
= 2.3, 8.6 Hz), 6.92 (d, 1H, C4-H, J  = 2.7 Hz) and 7.11 (d, 1H, C7-H, / =  8.6 Hz); 
Found C, 75.60; H, 7.44; N, 7.92; C i,H i3NO requires C, 75.40; H, 7.48; N, 7.99%.
8.9.16 l-Ethyl-2-methylindole-5-0-suIphamate (147)
Upon sulphamoylation by method 8.2.5 A, compound 146 (400 mg; 2.28 mmol) gave a
crude brown solid, which was fractionated by flash chromatography (ethyl
acetate/hexane, 6:1 to 2:1 gradient). The pale yellow solid isolated was recrystallised 
from ethyl acetate/hexane to give 147 as fine pale yellow crystals (56 mg; 10%). R / 
0.53 (ethyl acetate/hexane, 1:1); mp 116-117°C; vmax (KBr) cm '1: 3255-3327 (NH2), 
1351 (S 0 2), 1100-1143 (S 0 2); MS (FAB+) m/z: 254.1 [100, (M+H)+], 174.1 [55, 
(M +H-HNS02)+]; MS (FAB') m/z: 253.1 [100, (M-H)']; Acc. MS (FAB+): 254.0817, 
C nH i5N2 0 3S requires 254.0806; ]H NMR (400 MHz; DMSO-d6) 6H: 1.22 (t, 3H, 
CH2CH3, J  = 7.0 Hz), 2.41 (s, 3H, CH3), 4.16 (q, 2H, CH2CH3, J =  7.4 Hz), 6.24 (s, 
1H, C3-H), 6.97 (dd, 1H, C6-H, J  = 2.3, 8.6 Hz), 7.32 (d, 1H, C4-H, J =  2.3 Hz), 7.41 
(d, 1H, C7-H, J =  8.9 Hz) and 7.73 (s, 2H, NH2); Found C, 51.70; H, 5.43; N, 11.00; 
C h H 14N 20 3S requires C, 51.95; H, 5.55; N, 11.02%.
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8.9.17 l,2-DimethyI-3-benzoyl-5-methoxyindole (148)
To a solution of AICI3 (3.8 g; 28.5 mmol) in CH2CI2 (40 ml) at 25°C was added 
benzoyl chloride (5 ml; 42.8 mmol) and stirred for 15 min. When a clear mixture 
resulted, a solution of 142 (2.5 g; 14.27 mmol) in CH2CI2 (10 ml) was added dropwise 
and stirred for 3 h. The mixture was poured into crushed ice and the organic layer was 
extracted with CH2CI2 (3x100 ml). The combined extracts were washed with water 
(3x200 ml), brine (3x100 ml), aq. NaHC03 (2x50 ml), dried and evaporated to give a 
crude brown residue, which was fractionated by flash chromatography (ethyl 
acetate/hexane, 6:1 to 1:1 gradient). The pale brown solid isolated was recrystallised 
from THF/hexane to give 148 as pale brown crystals (532 mg; 13%). R / 0.59 (ethyl 
acetate/hexane, 1:1); mp 104-107°C; vmax (KBr) cm"1: 2936 (OCH3), 1624 (C=0); 
MS (FAB+) m/r. 559.2 [10, (2M+H)+], 280.2 [100, (M+H)+]; MS (FAB") m/z: 278.1 
[100, (M-H)"]; Acc. MS (FAB+): 280.1332, C i8H 18N 0 2 requires 280.1337; *H NMR 
(400 MHz; CDC13) 5H: 2.53 (s, 3H, CH3), 3.66 (s, 3H, NCH3), 3.71 (s, 3H, OCH3), 
6.83 (d, 1H, C4-H, J=  2.3 Hz), 7.20 (dd, 1H, C6-H, J=  2.3, 8.6 Hz), 7.46 (d, 2H, Ph-H, 
J=  7.4 Hz), 7.53 (d, 2H, Ph-H, J=  7.4 Hz) and 7.73 (d, 1H, C7-H, J =  8.9 Hz); Found 
C, 77.60; H, 6.09; N, 4.81; C 18Hi7N 0 2 requires C, 77.40; H, 6.13; N, 5.01%.
8.9.18 l,2-Dimethyl-3-benzoyI-5-hydroxyindoIe (149)
Using the procedure described for the preparation of compound 140, demethylation o f 
compound 148 (400 mg; 1.43 mmol) gave a crude brown solid, which was fractionated 
by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient). The brown solid 
isolated was recrystallised from THF/hexane to give 149 as fine brown crystals (167 
mg; 44%). R/. 0.41 (ethyl acetate/hexane, 1:1); mp 242-245°C (437Lit. mp 272-275°C); 
vmax (KBr) cm"1: 3156 (O-H), 1621 (C=0); MS (FAB+) m/z: 266.1 [100, (M+H)+]; 
MS (FAB") m/z: 264.1 [100, (M-H)"]; Acc. MS (FAB+): 266.1174, C ,7H 16N 0 2 requires 
266.1181; ’H NMR (400 MHz; CDC13) 5H: 2.51 (s, 3H, CH3), 3.49 (s, 1H, OH), 3.66 
(s, 3H, NCH3), 6.79 (dd, 1H, C6-H, J =  2.3, 8.9 Hz), 7.18 (d, 1H, C4-H, J  = 2.3 Hz),
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7.54 (d, 1H, C7-H, J=  8.8 Hz) and 7.71-7.75 (m, 5H, Ph-H); Found C, 76.92; H, 5.55; 
N, 4.98; C 17H I5N 0 2 requires C, 76.96; H, 5.70; N, 5.28%.
8.9.19 l,2-Dim ethyI-3-benzoyIindoIe-5-0-sulpham ate (150)
Upon sulphamoylation by method 8.2.5 A, compound 149 (100 mg; 0.38 mmol) gave a 
crude brown solid, which was purified by preparative TLC to give 150 as brown wax, 
which solidified on standing (42 mg; 32%). R / 0.44 (ethyl acetate/hexane, 1:1); mp 63- 
64°C; vmax (KBr) cm '1: 3306 (NH2), 1609 (C=0), 1379 (S 0 2), 1082-1122 (S 0 2); MS 
(FAB+) m/z: 345.1 [100, (M+H)+], 264.1 [15, (M-H2N S 0 2)']; MS (FAB ) m/z: 343.1 
[100, (M-H)']; Acc. MS (FAB"1}: 345.0908, C I7H I704N 2S requires 345.0909; 'H  NMR 
(400 MHz; CDCI3) 8H: 2.39 (s, 3H, CH3), 3.63 (s, 3H, NCH3), 6.78 (dd, 1H, C6-H, 7  =
2.1, 8.6 Hz), 7.22 (d, 1H, C4-H, 7 = 2 .1  Hz), 7.57 (d, 1H, C7-H, 7  = 8.9 Hz), 7.69-7.73 
(m, 5H, Ph-H) and 7.78 (s, 2H, NH2).
8.10 Derivatives of estrone-3-sulphonam ides and *S'-suIphamates
8.10.1 3-[(AyV-Dimethylthiocarbamoyl)oxy]estra-l,3,5(10)-trien-17-one (151)
NaH (60% dispersion in mineral oil; 888 mg; 22.2 mmol) was added to a solution of 
estrone (5.0 g; 18 mmol) in dry DMF (75 ml) under N2. After the evolution of H2 had 
ceased, the solution was cooled in an ice bath and 7V,T/-dimethylthiocarbamoyl chloride 
(3.43 g; 27.8 mmol) was added. The resulting solution was heated at 80°C for 1 h. 
Cooled to R.T and poured into cold water (100 ml). The crude pale brown precipitate 
was filtered, dried under vacuum and purified by flash chromatography (CH2C12). The 
white solid isolated was recrystallised from ethyl acetate to give 151 as fine white 
crystals (5.29 g; 80%). R / 0.52 (CH2C12); mp 211-213°C (184Lit. mp 210-212°C); MS 
(FAB+) m/z: 358.2 [100, (M+H)+]; Acc. MS (FAB+): 358.1767, C21H28N 0 2S requires 
358.1762; *H NMR (400 MHz; CDC13) 5H: 0.91 (s, 3H, CH3), 1.26-2.54 (m, 13H),
2.91-2.98 (m, 2H, CH2), 3.33 (s, 3H, NCH3), 3.46 (s, 3H, NCH3), 6.79 (d, 1H, C4-H, J  
= 2.3 Hz), 6.86 (dd, 1H, C2-H, J  = 2.7, 8.6 Hz) and 7.30 (d, 1H, C r H, J =  8.2 Hz);
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HPLC: M e0H :H 20 (70:30); Flow rate = 2 ml/min, A,max = 249.8 and 324.4 nm; tR =
10.7 min (c.f. for estrone = 4.4 min).
8.10.2 3-[(/V,7V-Dimethylcarbamoyl)thio]estra-l,3,5(10)-trien-17-one (152)
A suspension of 151 (4.0 g; 11 mmol) in white heavy mineral oil (70 ml) was heated 
under N 2 at 250°C for 6 h. The mixture was cooled to R.T. The precipitate formed was 
diluted with petroleum ether (40-60°C) (50 ml), filtered, washed thoroughly with 
petroleum ether and hexane and dried under vacuum. The crude pale brown solid was 
purified by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient) and the off 
white solid isolated was recrystallised from hot ethyl acetate to give 152 as off white 
needles (3.02 g, 76%). R / 0.56 (hexane/ethyl acetate, 1:1); mp 182-184°C (184Lit. mp 
173-175°C); MS (FAB+) m/z: 358.0 [100, (M+H)+]; Acc. MS (FAB+): 358.1771, 
C21H28NO2S requires 358.1763; ]H NMR (400 MHz; CDC13) 6H: 0.91 (s, 3H, CH3),
1.24-2.54 (m, 13H), 2.91-2.94 (m, 2H, CH2), 3.03 (s, 3H, NCH3), 3.89 (s, 3H, NCH3), 
7.21-7.23 (m, 1H, Ar-H), 7.24-7.26 (m, 1H, Ar-H) and 7.28-7.29 (m, 1H, Ar-H); 
HPLC: MeOH:H20 (70:30); Flow rate = 2 ml/min, A,max = 367 nm; tR= 14.1 min.
8.10.3 3-Mercaptoestra-l,3,5(10)-trien-17-one (153)
To a solution of 152 (2.5 g; 7.0 mmol.) in absolute ethanol (200 ml) was added NaOH 
(7.84 g; 196 mmol) dissolved in water (30 ml) and refluxed under boiling for 4 h under 
N2. The mixture was cooled to R.T and the excess NaOH was neutralised with 8% HC1 
(200 ml). This was then concentrated to remove ethanol and poured into water. The 
precipitate formed was filtered, washed with water and dried. The crude pale brown 
solid was purified by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient) 
and the off-white solid isolated was recrystallised from hot ethyl acetate to give 153 as 
off-white crystals (1.72 g; 86%). R / 0.91 (hexane/ethyl acetate, 1:1); mp 187-189°C 
( l84Lit. mp 195-197°C); MS (FAB+) m/z: 286.1 [100, (M+H)+[; MS (FAB') m/z: 285.1 
[100, (M-H)']; Acc. MS (FAB+): 286.1386, C |8H22OS requires 286.1391); 'H  NMR 
(400 MHz; CDCI3) 6H: 0.91 (s, 3H, CH3), 1.23-2.55 (m, 13H), 2.85-2.88 (m, 2H, CH2),
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3.36 (s, 1H, SH exchanged with D20 ), 7.05 (d, 1H, C4-H , J =  2.3 Hz), 7.07-7.11 (m, 
1H, C2-H) and 7.17 (d, 1H, C,-H, J=  8.6 Hz); HPLC: M e0H :H 20  (70:30); Flow rate = 
2 ml/min, A.max = 264.4 nm; tR= 16.1 min.
8.10.4 Estra-l,3,5(10)-trien-17-one-3-1S,-suIphamate (154)
Upon sulphamoylation by method 8.2.5 A, compound 153 (100 mg; 0.56 mmol) gave a 
crude pale yellow solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 8:1 to 2:1 gradient) and the yellow solid isolated (91 mg) was 
recrystallised from ethyl acetate/hexane to give a pale yellow crystals o f 154 (72 mg; 
56%). R / 0.74 (ethyl acetate/hexane, 4:1); mp 115-118°C ( 194Lit. mp 101-112°C); MS 
(e.s. in MeOH) m/z: 366.3 [60, (M+H)+], 287.4 [30, (M +H-HNS02)+], 97.2 [100, 
H2N S 0 2+H)+]; ’H N M R (400 MHz; CDC13) 5H: 0.90 (s, 3H, CH3), 1.13-2.54 (m, 13H), 
2.86-2.89 (m, 2H, CH2), 5.14 (s, 2H, NH2) and 7.24-7.28 (m, 3H, Ar-H); HPLC: 
MeOH:H20  (80:20); Flow rate = 2 ml/min, A,max = 256.9 and 271 nm; tR = 10.2 min.
8.10.5 3-(Benzylthio)estra-l,3,5(10)-trien-17-one (155)
To a solution o f 153 (1.5 g; 5.3 mmol) in dry DMF (70 ml) was added NaH (255 mg;
6.38 mmol) and stirred under N2. After all the H2 had evolved, benzyl bromide (0.8 ml;
6.38 mmol) was added and stirred for 4 h under N2. The mixture was poured into cold 
water and the resulting precipitate was filtered, washed with water and dried to obtain a 
pale yellow solid. An analytical sample was purified by flash chromatography (ethyl 
acetate/hexane, 8:1 to 2:1 gradient) and the yellow solid isolated was recrystallised 
from ethyl acetate to give 155 as off-white crystals (1.62 g, 82%). R / 0.77 
(hexane/ethyl acetate, 1:1); mp 122-125°C (184Lit. mp 127-129°C); MS (FAB+) m/z:
376.0 [100, (M+H)+], 91.1 [85, (PhCH2+H)+]; Acc. MS (FAB+): 376.1853, C25H28OS 
requires 376.1861; 'H  NMR (400 MHz; CDCI3) 5H: 0.91 (s, 3H, CH3), 1.24-2.54 (m, 
13H), 2.83-2.87 (m, 2H, CH2), 4.09 (s, 2H, SCH2), 7.05-7.07 (m, 1H, C4-H), 7.10 (dd, 
1H, C2-H, ,/ = 1.9, 8.2 Hz), 7.18 (d, 1H, C,-H, J =  8.2 Hz) and 7.29-7.31 (m, 5H, Ph- 
H); HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, ^ max = 257.4 nm; tR= 8.3 min.
273
8.10.6 Estra-l,3,5(10)-trien-17-one-3-sulphonylchIoride (156)
To a cool suspension of 155 (1.17 g; 3.05 mmol) in glacial acetic acid (50 ml) and 
water (2 ml), CI2 gas was bubbled for 15 min until completely reacted. Cold water (200 
ml) was added and the mixture was extracted with ethyl acetate (200 ml). The 
combined organic layers were then washed well with 5% NaHCOs, dried and 
evaporated to get a crude pale yellow solid, which was purified by flash 
chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient). The white solid isolated 
(987 mg) was recrystallised from ethyl acetate/hexane to give 156 as fine white crystals 
(832 mg, 78%). R / 0.62 (ethyl acetate/hexane, 1:1); mp 154-156°C ( I84Lit. mp 153- 
155°C); MS (FAB+) m/z: 353.0 [100, (M+H)+], 317.1 [60, (M-35C1)+]; MS (FAB') m/z:
351.1 [100, (M-H)']; Acc. MS m/z (FAB+): 352.0895, C18H2i35C103S requires 
352.0899 and 354.0964, Ci8H2i37C103S requires 354.0970; 'H  NMR (400 MHz; 
CDC13) SH: 0.93 (s, 3H, CH3), 1.46-2.57 (m, 13H), 3.01-3.04 (m, 2H, CH2), 7.53 (d, 
1H, Ci-H, J =  8.6 Hz), 7.76 (d, 1H, C4-H, J=  2.3 Hz) and 7.79 (dd, 1H, C2-H, J =  2.3,
8.6 Hz); HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, ^max = 229.8 and 271 nm; 
tR= 4.6 min.
8.10.7 Estra-l,3,5(10)-trien-17-one-3-sulphonyIfluoride (157)
To a solution of 156 (200 mg; 0.57 mmol) in 1,4-dioxane (4 ml) was added potassium 
fluoride (60 mg; 1.0 mmol) in water (1 ml) and heated at 50-55°C for 24 h. The solvent 
was evaporated to get a crude white solid, which was purified by flash chromatography 
(ethyl acetate/hexane, 8:1 to 2:1 gradient). The white solid isolated was recrystallised 
from THF/hexane to give 157 as white crystals (114 mg, 60%). R / 0.48 (ethyl 
acetate/hexane, 1:1); mp 163-165°C (184Lit. mp 160-162°C); MS (FAB+) m/z: 337.0 
[100, (M+H)+]; MS (FAB') m/z: 335.0 [100, (M-H)']; Acc. MS (FAB+): 337.1195 
C 18H22F 0 3S requires 337.1183; lU NMR (400 MHz; CDC13) 5H: 0.93 (s, 3H, CH3), 
1.46-2.57 (m, 13H), 2.99-3.07 (m, 2H, CH2), 7.53 (d, 1H, C,-H, J  = 8.2 Hz), 7.74 (d, 
1H, C4-H, J =  1.9 Hz) and 7.77 (dd, 1H, C2-H, J  = 1.9, 8.2 Hz); Found C, 64.28; H,
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6.23; C i8H2iF 0 3S requires C, 64.26; H, 6.29%; HPLC: M e0H :H 20  (70:30); Flow rate 
= 2 ml/min, Xmax = 233.3 and 272.2 nm; tR= 11.3 min.
8.10.8 Estra-l,3,5(10)-trien-17-one-3-sulphonamide (158)
Cold concentrated aqueous ammonium hydroxide (35% NH3 solution; 7 ml) was added 
to a solution o f 156 (200 mg; 0.57 mmol) in cold acetone (7 ml) and stirred at R.T. for 
15 min. The solution was extracted from CH2C12 (30 ml) and the combined extracts 
were then washed with water and brine, dried and evaporated to get a crude white 
solid, which was purified by flash chromatography (ethyl acetate/hexane, 8:1 to 1:1 
gradient). The white solid isolated was recrystallised from ethyl acetate/hexane to give 
158 as fine white crystals (155 mg; 82%). R / 0.36 (ethyl acetate/hexane, 1:1); mp 232- 
234°C ( 184Lit. mp 228-230°C); MS (FAB+) m/z: 334.0 [100, (M+H)+]; MS (FAB') m/z:
332.1 [100, (M-H)']; Acc. MS (FAB+): 334.1471, C I8H24N 0 3S requires 334.1477; ]H 
NMR (400 MHz; CDC13) 6H: 0.92 (s, 3H, CH3), 1.24-2.58 (m, 13H), 2.94-2.99 (m, 2H, 
CH2), 5.46 (s, 2H, NH2), 7.41 (d, 1H, C r H, J=  8.2 Hz), 7.66 (d, 1H, C4-U ,J  = 1.9 Hz) 
and 7.68 (dd, 1H, C2-H, J  = 1.9, 8.2 Hz); HPLC: MeOH:H20  (70:30); Flow rate = 2 
ml/min, A,max = 228.6 and 269.8 nm; tR= 2.3 min.
8.10.9 Estra-l,3,5(10)-trien-17-ol-3-sulphonamide (159)
To a solution of 158 (50 mg; 0.15 mmol) in isopropanol (3 ml) and THF (0.5 ml) was 
added NaBH4 (8.5 mg; 0.2 mmol) at 0°C. The mixture was stirred for 30 min at 0°C 
and quenched with aqueous NH4C1 (5 ml). H20  (30 ml) was added and the white 
precipitate formed was filtered out, washed with water, dried under vacuum and 
purified by preparative TLC to give 159 as white fine powder (13 mg; 26%). R / 0.38 
(ethyl acetate/hexane, 1:1); mp 191-193°C; MS (FAB*) m/z: 336.2 [30, (M+H)*], 97.1 
[100, (S 0 2NH2+H)*]; MS (FAB ) m/z: 334.3 [100, (M-H)']; Acc. MS (FAB+): 
336.1545, C |8H26N 0 3S requires 336.1555; 'H  NMR (400 MHz; DMSO-d6) 6H: 0.67 (s, 
3H, CH3), 1.21-2.51 (m, 13H), 2.77-2.86 (m, 2H, CH2), 3.53 (t, 1H, CH, J =  8.6 Hz),
4.54 (s, 1H, OH), 7.45 (s, 2H, NH2) and 7.47-7.56 (m, 3H, Ar-H); Found C, 64.30; H,
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7.41; N, 4.05; C 18H25N 0 3S requires C, 64.45; H, 7.51, N, 4.18%; HPLC: M e0H :H 20  
(80:20); Flow rate = 2 ml/min, ?tmax = 223.1 and 277.1 nm; tR= 1.8 min.
8.10.10 17,17-Ethylenedioxy-l,3,5[10]-estratriene-3-ol (160)
A suspension of estrone (25 g; 93 mmol), toluene (300 ml), ethylene glycol (26 ml; 462 
mmol) and p-toluenesulphonic acid monohydrate (300 mg) were boiled under reflux 
for 14 h under Dean-Stark conditions. The resultant pale pink solution was poured onto 
saturated aq. N aH C 03 (150 ml) and diluted with ethyl acetate (250 ml). The organic 
layers were extracted into ethyl acetate (100 ml), washed with water (3x350 ml) and 
brine (3x150 ml). The mixture was dried and evaporated to give a crude off-white 
crystalline solid (28.7 g, 96% crude). An analytical sample was purified by flash 
chromatography (ethyl acetate/hexane, 8:1 to 1:1 gradient) and the white solid isolated 
was recrystallised from ethyl acetate to give 160 as white fine crystals. R / 0.41 (ethyl 
acetate/hexane, 1:1); mp 173-175°C; (438Lit. mp 164-167°C); MS (FAB+) m/z: 315.1 
[100, (M+H)+]; MS (FAB') m/z: 313.2 [100, (M-H)']; Acc. MS (FAB+): 315.1964, 
C20H27O3 requires 315.1960; 'H  NMR (400 MHz; CDC13) 5H: 0.88 (s, 3H, CH3), 1.30-
2.18 (m, 11H), 2.21-2.30 (m, 1H, CH), 2.32-2.46 (m, 1H, CH), 2.77-2.87 (m, 2H, 
CH2), 3.89-3.99 (m, 4H, 0C H 2CH20), 4.71 (s, 1H, OH), 6.56 (d, 1H, C4-H, J  = 2.7 
Hz), 6.62 (dd, 1H, C2-H, J=  2.7, 8.6 Hz) and 7.15 (d, 1H, C,-H, J=  8.2 Hz); 13C NMR 
(100.5 MHz; CDC13) 6c : 14.2 (CH3), 22.4, 26.9, 32.1, 33.2 (all CH2), 37.7, 43.6, 49.2 
(all CH), 64.9, 65.1 (all CH2), 110.2, 112.3 (both CH), 116.1 (C), 127.1 (CH), 130.6,
138.1 (all C) and 154.6 (COH); Found C, 76.70; H, 8.15; C20H26O3 requires C, 76.40; 
H, 8.33%; HPLC: MeOH/H20  (70:30); Flow rate = 2 ml/min, A,max = 279.3 and 341.1 
nm; tR= 12.3 min.
8.10.11 Methyl chloromethyl ether (161)
A mixture of dimethoxymethane (300 ml, 3.94 mmol; 1 eq.), decanoyl chloride (818 
ml; 3.94 mmol; 1 eq.) and conc. H2S 0 4 (2.5 ml) was stirred at 50-55°C for 4 h. 
Na2C 0 3 (1 g) was added and 161 was collected by distillation under N 2 as a clear
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liquid (228 ml, 72 %). bp 56-59°C (439Lit. bp 57°C); 'H  NMR (400 MHz; CDCI3) 8H: 
3.52 (s, 3H, OCHj) and 5.47 (s, 2H, CH2CI).
8.10.12 17,17-Ethylenedioxy-l,3,5[10]-estratriene-3-methoxymethyl ether (162)
NaH (4.77 g, 119 mmol) was added in portions to a 0°C solution o f 160 (25 g, 80 
mmol) dissolved in dry DMF (400 ml). After H2 evolution had ceased 161 (1.82 ml; 
159 mmol) was added dropwise and the stirred solution was allowed to come to R.T. 
overnight. The solution was then poured onto aq. ammonia solution (100 ml, 2M) to 
destroy any remnant haloether contaminants. Ethyl acetate (500 ml) was added and the 
organic layer was then washed with water and brine (5x200 ml), dried and evaporated. 
The crude pale yellow syrup was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) to give 162 as a colourless oil, which solidified on 
standing to give a white crystalline solid (27.2 g, 95%). R / 0.74 (ethyl acetate/hexane, 
1:1); mp 63-65°C (388Lit. mp 62-63°C); MS (FAB+) m/z: 358.1 [100, (M+H)+]; Acc. 
MS (FAB+): 358.2158, C22H31O4 requires 358.2144; 'H  NMR (400 MHz; CDC13) 5H: 
0.88 (s, 3H, CH3), 1.25-2.05 (m, 11H), 2.21-2.29 (m, 1H, CH), 2.30-2.34 (m, 1H, CH), 
2.83-2.86 (m, 2H, CH2), 3.47 (s, 3H, OCH3), 3.88-3.98 (m, 4H, 0C H 2CH20 ), 5.14 (s, 
2H, OCH20), 6.77 (d, 1H, C4-H, J=  2.7 Hz), 6.82 (dd, 1H, C2-H, J =  2.7, 8.6 Hz) and
7.22 (d, 1H, Ci-H, J  = 8.6 Hz); 13C NMR (100.5 MHz; CDC13) 5c: 14.3 (CH3), 22.3,
26.1, 26.9, 29.7, 30.7, 34.2 (all CH2), 38.9, 43.7 (both CH), 46.1 (C), 49.3 (CH), 55.9 
(CH3), 64.5, 65.2, 94.5 (all CH2), 113.7, 116.2 (both CH), 119.4 (C), 126.3 (CH) and 
134.0, 138.1, 155.0 (all C); Found C, 72.90; H, 8.33; C22H30O4 requires C, 73.71; H, 




A solution o f 162 (10 g; 28 mmol) in freshly distilled THF (300 ml) was cooled to -  
78°C in a dry ice/acetone bath for 1 h and then treated with secbutyl lithium (7.0 ml; 84
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mmol.) dropwise over 4 h. After stirring for further 4 h, ethyl iodide (9.0 ml; 112 
mmol, freshly distilled from finely chopped sodium) was added and the mixture was 
allowed to warm to R.T. overnight. Saturated NH4CI solution (20 ml) was added 
followed by diethyl ether (400 ml). The mixture was washed with water (250 ml), brine 
(2x350 ml), dried and evaporated to give a white suspension, which was purified by 
flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give 163 as 
colourless syrup (9.82 g, 91 %). R / 0.84 (ethyl acetate/hexane, 1:1); MS (FAB+) m/z:
387.1 [100, (M+H)+]; Acc. MS (FAB+): 387.2509, C24H35O4 requires 387.2491; !H 
NMR (400 MHz; CDCI3); 5H: 0.88 (s, 3H, CH3), 1.19 (t, 3H, CH2CH3, J  = 7.8 Hz)
1.24-2.39 (m, 13H), 2.62 (q, 2H, CH2CH3, J  = 7.4 Hz), 2.81-2.86 (m, 2H, CH2), 3.48 
(s, 3H, OCH3), 3.85-3.98 (m, 4H, 0C H 2CH20), 5.17 (s, 1H, OCH20 ), 6.78 (s, 1H, Ar- 
H) and 7.09 (s, 1H, Ar-H).
8.10.14 2-Ethylestrone (164)
To cold anhy. methanol (50 ml) under N2, acetyl chloride (15.0 ml; 211 mmol) was 
syringed in drop-wise and when gas evolution ceased, 163 (9.5 g; 25 mmol) was added 
and cooled to 0°C. The mixture was sonicated for 15 min until the solution turned 
yellow. H20  (50 ml) was added and the pale yellow precipitate formed was filtered. 
Solid NaHC03 was added to the filtrate and the organic layer was extracted with ethyl 
acetate (2x200 ml), washed twice with H20  followed by brine dried and evaporated to 
give a pale yellow solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient). The white solid isolated was recrystallised from 
hot absolute ethanol to give 164 as white crystals (6.98 g, 95 %). R / 0.77 (ethyl 
acetate/hexane, 1:1); mp 182-183°C (268Lit mp 201-204°C); MS (FAB+) m/z\ 299.1 
[100, (M+H)+]; MS (FAB') m/z\ 297.1 [100, (M-H)']; Acc. MS (FAB+): 299.1994, 
C20H27O2 requires 299.2011; ]H NMR (400 MHz; CDC13) 5H: 0.91 (s, 3H, CH3), 1.22 
(t, 3H, CH2CH3, J  = 7.4 Hz) 1.25-2.54 (m, 13H), 2.59 (q, 2H, CH2CH3, J =  7.4 Hz), 
2.80-2.85 (m, 2H, CH2), 4.56 (s, 1H, OH), 6.52 (s, 1H, Ar-H) and 7.06 (s, 1H, Ar-H); 
13C NMR (100.5 MHz; CDC13) 5 c  14.2 (CH3), 22.3, 25.9, 26.6, 30.3, 30.5, 34.2 (all
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CH2), 38.7, 43.3 (both CH), 46.0 (C), 49.3 (CH), 56.4 (CH3), 64.6, 65.2, 94.5 (all 
CH2), 114.9, 119.2, 123.2 (all C), 125.2 (CH), 134.5, 146.3, 157.4 (all C) and 189.5




Using the procedure described for the preparation of compound 151, NaH (740 mg;
18.5 mmol) and TV^-dimethylthiocarbomyl chloride (2.86 g; 23.1 mmol) were added to 
a DMF (100 ml) solution of 164 (4.6 g; 15 mmol). The mixture was heated at 80°C for 
1 h, cooled to R.T and poured into cold water (200ml). The crude cream precipitate 
was filtered, dried under vacuum (6.66 g, 106% crude). An analytical sample was 
purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) and the 
white solid isolated was recrystallised from ethyl acetate to give 165 as white needles. 
R / 0.67 (ethyl acetate/hexane, 1:1); mp 235-237°C; MS (FAB+) m/z\ 386.0 [100, 
(M+H)+j; Acc. MS (FAB+): 386.2146, C23H32NO2S requires 386.2154; *H NMR (400 
MHz; CDCI3) 8h: 0.91 (s, 3H, CH3), 1.19 (t, 3H, CH2CH3, J =  7.8 Hz), 1.42-2.54 (m, 
15H), 2.89 (q, 2H, CH2CH3, J=  7.4 Hz), 3.34 (s, 3H, NCH3), 3.47 (s, 3H, NCH3), 6.73 
(s, 1H, Ar-H) and 7.18 (s, 1H, Ar-H); Found C, 71.70; H, 8.08; N, 3.54; C23H31NO2S 
requires C, 71.65; H, 8.10; N, 3.63%; HPLC: MeOH:H20  (70:30); Flow rate = 2 
ml/min, A,max = 249.8 nm; tR= 3.2 min.
8.10.16 2-Ethyl-3-[(A,7V-dimethyIcarbamoyl)thio]estra-l,3,5(10)-trien-17-one 
(166)
Using the procedure described for the preparation of 152, a suspension of 165 (5.0 g; 
13 mmol) in mineral oil (200 ml) was heated under N2 at 250-260°C overnight. The 
brown suspension formed was extracted with acetone (3x200 ml) and the crude brown 
solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient). 
The pale brown solid isolated was recrystallised from hot isopropyl alcohol to give 166
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as pale brown crystals (4.62 g; 92%). R / 0.56 (ethyl acetate/hexane, 1:1); mp 149- 
151°C; MS (FAB+) m/z: 386.0 [100, (M+H)+]; Acc. MS (FAB+): 386.2147, 
C23H32NO2S requires 386.2154; 'H  NMR (400 MHz; CDC13) 8H: 0.91 (s, 3H, CH3), 
1.18 (t, 3H, CH2CH3, J  = 7.8 Hz), 1.22-2.63 (m, 13H), 2.73 (q, 2H, CH2CH3, J =  7.4 
Hz), 2.86-2.89 (m, 2H, CH2), 3.01 (s, 3H ,N C H 3), 3.11 (s, 3H ,N C H 3), 6.79 (s, 1H, Ar- 
H) and 7.13 (s, 1H, Ar-H); Found C, 71.30; H, 8.05; N, 3.59; C23H31NO2S requires C, 
71.65; H, 8.10; N, 3.63%; HPLC: MeOH:H20  (80:20); Flow rate = 2 ml/min, >.max =
275.7 nm; tR= 8.4 min.
8.10.17 2-Ethyl-3-mercaptoestra-l,3,5(10)-trien-17-one (167)
Using the procedure described for the preparation o f 153, a solution o f 166 (4.5 g; 12 
mmol) in ethanol (300 ml) was hydrolysed with aqueous NaOH (13.1 g; 327 mmol). 
The precipitate formed was filtered, washed with water and dried to obtain a pale 
brown solid, which was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 
1:1 gradient). The pale brown solid isolated was recrystallised from isopropanol to give 
167 as off white crystals (3.26 mg; 89%). R / 0.78 (ethyl acetate/hexane, 1:1); mp 119- 
121°C; MS (FAB+) m/z: 314.0 [100, (M+H)+]; MS (FAB') m/z: 313.0 [100, (M-H)+]; 
Acc. MS (FAB+): 314.1711, C2oH26OS requires 314.1704; 'H  NMR (400 MHz; CDC13) 
6h: 0.91 (s, 3H, CH3), 1.23 (t, 3H, CH2CH3, J =  7.4 Hz), 1.36-2.54 (m, 13H), 2.65 (q, 
2H, CFhCTfs, J  = 7 A  Hz), 2.82-2.85 (m, 2H, CH2), 3.21 (s, 1H, SH), 7.04 (s, 1H, Ar- 
H) and 7.09 (s, 1H, Ar-H); Found C, 76.60; H, 8.22; C20H26OS requires C, 76.38; H, 
8.33%; HPLC: MeOH:H20  (85:15); Flow rate = 2 ml/min, ?Lmax = 213.4, 242.7, 285.2 
and 374.2 nm; tR = 17.3 min.
8.10.18 2-Ethylestra-l,3,5(10)-trien-17-one-3-<S,-sulphamate (168)
Upon sulphamoylation by method 8.2.5 A, a DMF solution of 167 (100 mg; 0.32 
mmol) gave a pale yellow solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) and the pale yellow solid isolated was recrystallised 
from ethyl acetate/hexane to get a pale yellow crystals of 168 (18 mg; 14%). R / 0.74
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(ethyl acetate/hexane, 1:1); mp 136-137°C; vmax (KBr) cm '1: 3400, 3300 (NH2), 1610 
(C=0), 1380 (S 0 2); MS (e.s. in MeOH) m/z: 394.4 [10, (M+H)+], 315.2 [100, (M+H- 
H N S02)+]; 'H  NMR (400 MHz; CDC13) 6H: 0.91 (s, 3H, CH3), 1.22 (t, 3H, CH2CH3, J  
= 7.4 Hz), 1.26-2.54 (m, 13H), 2.81 (q, 2H, CH2CH3, J =  7.4 Hz), 2.83-2.84 (m, 2H, 
CH2), 4.81 (s, 2H, NH2), 7.11 (s, 1H, Ar-H) and 7.29 (s, 1H, Ar-H); HPLC: 
Me0 H:H20  (90:10); Flow rate = 2 ml/min, ^max = 276.9, 322.0 and 368.2 nm; tR= 3.2 
min.
8.10.19 3-Benzylthio-2-ethylestra-l,3,5(10)-trien-17-one (169)
Using the procedure described for the preparation of 155, a DMF (50 ml) solution of 
167 (2.0 g; 6.4 mmol) was reacted with benzyl bromide (0.9 ml; 7.6 mmol) and the 
pale brown solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 
1:1 gradient). The white syrup obtained was further purified by preparative TLC to 
give 169 as white sticky foam (1.67 g, 65%). R / 0.77 (ethyl acetate/hexane, 1:1); mp 
32-33°C; MS (FAB+) m/z: 405.3 [100, (M+H)+], 312.2 [20, (C2oH25OS+H)+], 91.0 [90, 
(PhCH2)+]; Acc. MS (FAB+): 405.2236, C27H33OS requires 405.2252; ]H NMR (400 
MHz; CDC13) 8h: 0.91 (s, 3H, CH3), 1.17 (t, 3H, CH2CH3, J =  7.8 Hz), 1.21-2.54 (m, 
13H), 2.69 (q, 2H, CHzOTj, J=  7.8 Hz), 2.82-2.84 (m, 2H, CH2), 4.06 (s, 2H, CH2Ph),
7.04 (s, 1H, Ar-H), 7.11 (s, 1H, Ar-H) and 7.23-7.30 (m, 5H, Ph-H); HPLC: 
MeOH:H20  (70:30); Flow rate = 2 ml/min, Xmax = 233.1 and 377.9 nm; tR= 4.7 min.
8.10.20 2-Ethylestra-l,3,5(10)-trien-17-one-3-sulphonylchloride (170)
Using the procedure described for the preparation of 156, Cl2 gas was bubbled into a 
cool suspension of 169 (1.0 g; 2.5 mmol) in glacial acetic acid (30 ml) and water (1 
ml). The pale yellow syrup was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) to give 170 as a pale yellow sticky foam, which 
solidified on standing (517 mg, 55%). R / 0.71 (ethyl acetate/hexane, 1:1); mp 94- 
96°C; MS (FAB+) m/z: 381 [100, (M(35Cl)+H)+[; Acc. MS m/z (FAB+): 381.1298, 
C2oH2635C103S requires 381.1291 and 383.1253, C20H2637ClO3S requires 383.1283; 'H
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NMR (400 MHz; CDC13) 8H: 0.93 (s, 3H, CH3), 1.33 (t, 3H, CH2CH3, J =  7.4 Hz), 
1.37-2.83 (m, 13H), 2.92 (q, 2H, CH2CH3, J  = 7.8 Hz), 3.11-3.15 (m, 2H, CH2), 7.37 
(s, 1H, Ar-H) and 7.58 (s, 1H, Ar-H).
8.10.21 2-Ethylestra-l,3,5(10)-trien-17-one-3-sulphonamide (171)
Using the procedure described for the preparation of 158, cold aq. NH4OH (5 ml) was 
added to a solution of 170 (120 mg; 0.32 mmol) in cold acetone (5 ml). The crude off- 
white solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 
gradient). The white foam isolated was further purified by preparative TLC to give 171 
as fine white crystals (69 mg; 61%). R / 0.73 (ethyl acetate/hexane, 1:1); mp 132— 
133°C; MS (FAB+) m/z: 362.2 [100, (M+H)+]; MS (FAB') m/z: 360.1 [100, (M-H)']; 
Acc. MS (FAB+): 362.1799, C20H28NO3S requires 362.1789; ]H NMR (400 MHz; 
CDC13) 8h: 0.92 (s, 3H, CH3), 1.31 (t, 3H, CH2CH3, J =  7.8 Hz), 1.33-2.63 (m, 13H),
2.92-2.94 (m, 2H, CFhCH^, 2.99-3.01 (m, 2H, CH2), 4.71 (s, 2H, NH2), 7.30 (s, 1H, 
Ar-H) and 7.75 (s, 1H, Ar-H); Found C, 65.90; H, 7.33; N, 3.37; C20H27NO3S requires 
C, 66.45; H, 7.53; N, 3.87%;
8.10.22 2-Methoxy-l-[(Ar,A-dimethylthiocarbamoyI)oxy]benzene (172)
Using the procedure described for the preparation o f 151, NaH (1.93 g; 48.3 mmol) and 
dimethyl thiocarbomyl chloride (7.47 g; 60.4 mmol) was added to a DMF solution of 
2-methoxyphenol (5.0 g; 11 mmol). The crude brown suspension was purified by flash 
chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give 172 (7.33 mg; 86%) 
as a yellow syrup, which solidified on standing. R / 0.62 (ethyl acetate/hexane, 1:1); 
mp 62-63°C (396Lit. mp 61-62°C); MS (FAB+) m/z: 212.0 [100, (M+H)+], 180.0 [10, 
(M-OCH3)+]; A cc. MS (FAB3): 212.0744, C 10H 14NO2S requires 212.0745; 'H  NMR 
(400 MHz; CDCI3); SH : 3.35 (s, 3H, NCH3), 3.45 (s, 3H, NCH3), 3.82 (s, 3H, OCH3) 
and 6.95-7.26 (m, 4H, Ar-H); Found C, 56.70; H, 6.21; N, 6.59; CioH,3N 0 2S requires 
C, 56.85; H, 6.20; N, 6.63%; HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, =
249.8 nm; tR= 2.6 min.
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8.10.22 2-Methoxy-l-[(/V,/V-dimethylcarbamoyl)thio] benzene (173)
Using the procedure described for the preparation o f 152, a suspension o f 172 (6.0 g; 
28 mmol) in mineral oil (200 ml) was heated under N2 at 280°C overnight. The crude 
yellow solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 
gradient) and the pale yellow solid isolated was recrystallised from hot isopropyl 
alcohol to give 173 as off-white crystals (2.88 mg; 48%). R / 0.87 (ethyl 
acetate/hexane, 1:1); mp 92-93°C (440Lit. mp 89-91°C); MS (FAB+) m/z\ 212.0 [100, 
(M+H)+]; Acc. MS (FAB4): 212.0747, Ci0Hi4NO2S requires 212.0745; 'H  NMR (400 
MHz; CDCI3) 8h : 3.01 (s, 3H, NCH3), 3.14 (s, 3H, NCH3), 3.88 (s, 3H, OCH3), 6.95- 
6.99 (m, 2H, Ar-H), 7.38-7.42 (m, 1H, Ar-H) and 7.46 (dd, 1H, Ar-H, J =  1.6, 7.4 Hz); 
Found C, 56.90; H, 6.22; N, 6.58; CioH,3N 0 2S requires C, 56.85; H, 6.20; N, 6.63%; 
HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, A.max = 281.7 nm; tR= 2.7 min.
8.10.24 2-MethoxythiophenoI (174)
Using the procedure described for the preparation of 153, a solution o f 173 (2.7 g; 13 
mmol) in absolute ethanol (100 ml) was hydrolysed with NaOH (14.3 g; 358 mmol) in 
H2O (20 ml). The crude brown syrup was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) to give 174 as pale brown oil (1.32 g; 74%). R / 
0.75 (hexane/ethyl acetate, 1:1); (441Lit. bp20 115-116°C); MS (FAB+) m/z\ 279.0 [100, 
(2M+H)+], 141.2 [60, (M+H)+]; MS (FAB') m/z: 277.0 [100, (2M-H)'], 139.1 [75, (M- 
H)']; Acc. MS (FAB+): 141.1216, C7H8OS requires 141.1292; ]H NMR (400 MHz; 
CDCI3) 8h: 3.81 (s, 3H, SH exchanged with D20), 3.89 (s, 3H, OCH3), 6.83-6.89 (m, 
2H, Ar-H), 7.09-7.18 (m, 1H, Ar-H) and 7.24 (dd, 1H, Ar-H, J=  1.9 Hz and 7.8 Hz).
8.10.25 l-Benzylthio-2-methoxybenzene (175)
Using the procedure described for the preparation o f 155, to a DMF solution of 274 
(1.5 g; 11 mmol), NaH (513 mg; 12.8 mmol) followed by benzyl bromide (1.53 ml;
12.8 mmol) was added. The white precipitate formed was filtered, washed with water, 
dried and purified by recrystallisation from ethyl acetate/hexane to give 175 as white
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needles (2.16 g, 88%). R / 0.60 (ethyl acetate/hexane, 1:1); mp 69-70°C; MS (FAB+) 
m/z: 230.0 [100, (M+H)+], 91.1 [60, (PhCH2)+]; Acc. MS (FAB+): 230.0770, Ci4H ]4OS 
requires 230.0765; *H NMR (400 MHz; CDCI3) 6H: 3.89 (s, 3H, OCH3), 4.09 (s, 2H, 
CH2Ph), 6.84-6.88 (m, 2H, Ar-H) and 7.17-7.31 (m, 2H, Ar-H). Found C, 72.90; H, 
6.05; Ci4Hi4OS requires C, 73.01; H, 6.13%; HPLC: MeOH:H20  (70:30); Flow rate = 
2 ml/min, ^ max = 285.2 nm; tR= 9.9 min.
8.10.26 2-M ethoxybenzenesulphonyl chloride (176)
Using the procedure described for the preparation o f 156, Cl2 gas was bubbled in to a 
cool suspension of 175 (500 mg; 2.17 mmol) in acetic acid (50 ml) and water (8 ml). 
The crude pale yellow solid was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) and the pale yellow solid isolated was recrystallised 
from isopropyl alcohol to give 176 as fine white crystals (420 mg, 94%). R / 0.64 (ethyl 
acetate/hexane, 1:1); mp 58-59°C (442Lit. mp 56°C); MS (FAB+) m/z: 206.2 [100, 
(M(37CI)+H)4]; MS (FAB') m/z: 204.2 [100, (M-H)']; Acc. MS m/z (FAB+): 204.2194, 
C7H735C103S requires 204.2201 and 206.2186, C7H737C I03S requires 206.2191; 'H 
NMR (400 MHz; DMSO-d6) 8H: 3.75 (s, 3H, OCH3), 6.84-6.88 (m, 1H, Ar-H), 6.96- 
7.29 (m, 1H, Ar-H), 7.32-7.35 (m, 1H, Ar-H) and 7.67 (dd, 1H, Ar-H, J=  1.9, 7.8 Hz).
8.10.27 2-M ethoxybenzenesulphonam ide (177)
Using the procedure described for the preparation of 158, cold aq. NH4OH (5 ml) was 
added to a solution of 176 (200 mg; 0.98 mmol) in cold acetone (5 ml). The crude 
yellow solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 
gradient) and the white solid isolated was recrystallised from ethyl acetate/hexane to 
give 177 as fine white crystals (144 mg; 80%). R / 0.26 (ethyl acetate/hexane, 1:1); mp 
137-138°C (443Lit. mp 171°C); MS (FAB4) m/z: 188.1 [100, (M+H)4]; MS (FAB') m/z:
186.1 [100, (M-H)']; Acc. MS (FAB4): 188.0379, C7H ,0NO3S requires 188.0381; ‘H 
NMR (400 MHz; CDC13) 8H: 4.03 (s, 3H, OCH3), 5.03 (s, 2H, NH2), 6.99 (d, 1H, Ar- 
H, J =  7.0 Hz), 7.05-7.10 (m, 1H, Ar-H), 7.49-7.58 (m, 1H, Ar-H) and 7.92 (dd, 1H,
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Ar-H, J  = 1.6, 7.8 Hz); Found C, 44.30; H, 4.31; N, 6.90; C7H9NO3S requires C, 44.91; 
H, 4.85; N, 7.48%; HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, ?,max = 222.7 
and 280.5 nm; tR= 1.7 min.
8.10.28 17,17-EthyIenedioxy-2-formyl-3-(methoxymethoxy)-l,3,5[10]- 
estratriene (178)
A solution of 162 (17 g, 48 mmol) in freshly distilled THF (300 ml) was cooled to -  
78°C in a dry ice/acetone bath for 1 h and then treated with secbutyl lithium (12.0 ml, 
142 mmol) dropwise over 4 h. After a further 4 h at this temperature DMF, freshly 
distilled from CaH2 (15.0 ml, 190 mmol) was added and the mixture was allowed to 
come to R.T. overnight. Saturated aq. NH4C1 solution (200 ml) was added followed by 
diethyl ether (400 ml). The extracts were washed with water (250 ml), brine (2x350 
ml), dried and evaporated to give a white suspension. This was purified by flash 
chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give an off-white solid, 
which was recrystallised with ethanol to give 178 as white needles (17.89 g, 98 %). R / 
0.73 (ethyl acetate/hexane, 1:1, a fluorescent spot); \n p  104-105°C; MS (FAB+) m/z\
387.1 [100, (M+H)+]; Acc. MS (FAB+): 387.2161, C23H31O5 requires 387.2171; 'H 
NMR (400 MHz; CDCI3) 5H: 0.88 (s, 3H, CH3), 1.30-2.12 (m, 11H), 2.16-2.30 (m, 1H, 
CH), 2.35-2.46 (m, 1H, CH), 2.87-2.91 (m, 2H, CH2), 3.51 (s, 3H, OCH3), 3.87-3.98 
(m, 4H, OCH2CH2O), 5.26 (s, 2H, OCH20 ), 6.91 (s, 1H, Ar-H), 7.77 (s, 1H, Ar-H) and 
10.42 (s, 1H, CHO); l3C NMR (100.5 MHz; CDC13) 8c :  14.2 (CH3), 22.3, 25.9, 26.6, 
30.3, 30.5, 34.2 (all CH2 ), 38.7, 43.3 (both CH), 46.0 (C), 49.3 (CH), 56.4 (CH3),
64.6, 65.2, 94.5 (all CH2), 114.9, 119.2, 123.2 (all C), 125.2 (CH), 134.5, 146.3, 157.4 
(all C) and 189.5 (CHO), Found C, 70.80; H, 7.76; C23H30O5 requires C, 71.48; H, 
7.82%; HPLC: MeOH:H20  (70:30); Flow rate = 2 ml/min, Xmax = 223.9, 268.7, 325.6 
and 391 nm; tR= 8.2 min.





The impurities present in wCPBA used in this reaction were removed by extraction 
with CH2CI2 and brine. The purified wCPBA was dried at <50°C to remove water. A 
solution of mCPBA (14.7 g, 5.45 mmol, purified ca 95 % purity) in anhy. CH2CI2 (300 
ml) was added dropwise to a solution of 178 (16.5 g, 42.7 mmol) in CH2CI2 (150 ml) 
containing Na2HP0 4 (24.2 g, 171 mmol). The mixture was stirred for 3 h before 
pouring onto ice-water (300 ml), the organic layer was separated and the aqueous layer 
was extracted with CH2CI2 (3x75 ml). The combined extracts were washed with 
saturated NaHC03 solution (100 ml), brine (2x100 ml) and evaporated. The resultant 
foam was taken up in degassed methanol (100 ml), and treated with NaOH (18 ml of 
1M aq. solution). After 2 h o f stirring, the mixture was neutralised by addition of aq. 
HC1 (1M), methanol was removed by evaporation, ethyl acetate and water were added, 
the combined extracts were dried and evaporated to give a yellow syrup. This was 
purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give 179 
as a clear syrup, which solidified on standing (12.8 g, 80 %). R / 0.53 (ethyl 
acetate/hexane, 1:1); mp 84-86°C (388Lit. mp 88°C); MS (FAB+) m/z\ 375.3 [100, 
(M+H)+]; MS (FAB') m/z\ 373.3 [100, (M-H)']; Acc. MS (FAB+): 375.2096, C22H31O5 
requires 375.2093; ]H NMR (400 MHz; CDCI3) 5H: 0.87 (s, 3H, CH3), 1.24-2.18 (m, 
11H), 2.21-2.29 (m, 2H), 2.75-2.80 (m, 2H, CH2), 3.51 (s, 3H, OCH3), 3.87-3.99 (m, 
4H, 0C H 2CH20 ), 5.16 (s, 2H, OCH20), 5.74 (s, 1H, OH), 6.79 (s, 1H, Ar-H) and 6.90 
(s, 1H, Ar-H); 13C NMR (100.5 MHz; CDC13) 5c: 14.3 (CH3), 22.3, 26.1, 27.1, 29.0,
30.7, 34.2 (all CH2), 38.8, 43.8 (both CH), 46.1 (C), 49.3 (CH), 56.3 (CH3), 64.6, 65.2, 
96.0 (all CH2), 112.3, 115.8 (both CH2), 119.4, 128.4, 135.2, 142.3, 144.1 (all C) and
145.1 (CHO); Found C, 69.90; H, 8.07; C22H30O5 requires C, 70.56; H, 8.07%; HPLC: 




mCPBA (970 mg, 5.62 mmol, purified ca 95 % purity) was added to a solution o f 178 
(1.0 g, 2.6 mmol) in a 1:3 mixture o f CHCI3: CH2CI2 (27 ml) and the mixture was 
stirred at R.T. for 24 h. The resulting milky white mixture was worked up by 
consecutive extractions with CH2CI2 (3x75 ml) and the combined organics were 
washed with saturated aq. Na2S03 (100 ml) and aq. NaHC03 solutions (100 ml), brine 
(2 x 100 ml) and evaporated to give a yellow syrup, which was purified by flash 
chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give 180 as an off-white 
syrup (520 mg, 61 %). R / 0.68 (ethyl acetate/hexane, 1:1); MS (FAB+) m/z: 331.1 
[100, (M+H)+]; MS (FAB') m/z: 329.1 [100, (M-H)']; Acc. MS (FAB+): 331.1842, 
C20H27O4 requires 331.1856; *H NMR (400 MHz; CDC13) 5H: 0.87 (s, 3H, CH3), 1.22-
2.10 (m, 11H), 2.18-2.32 (m, 2H), 2.76-2.89 (m, 2H, CH2), 3.51 (s, 3H, OCH3), 5.14 
(s, 2H, OCH20 ), 4.79 (s, 1H, OH), 6.93 (s, 1H, Ar-H) and 7.01 (s, 1H, Ar-H).
8.10.31 17,17-Ethylenedioxy-2-methoxy-3-(methoxymethyloxy)-l,3,5[10]- 
estratriene (181)
A stirred solution o f 179 (12 .0g, 32.1 mmol) in anhy. DMF (200 ml) was treated with 
anhy. K2CO3 (44.34 g, 320.1 mmol) and, after a further 10 min, methyl iodide (22 ml, 
153 mmol) followed by Bu4NI (300 mg). After 20 h the mixture was poured onto brine 
(200 ml) and extracted with ethyl acetate (3x200 ml), washed with brine (5x100 ml), 
dried and evaporated to give a yellow oil, which was purified by flash chromatography 
(ethyl acetate/hexane, 5:1 to 1:1 gradient). The white solid isolated was recrystallised 
with ethyl acetate/hexane to give 181 as a white solid (11.3 g, 90 %). R / 0.70 (ethyl 
acetate/hexane, 1:1); mp 87-89°C; MS (FAB+) m/z: 388.3 [100, (M+H)+]; Acc. MS 
(FAB+): 388.2241, C23H33O5 requires 388.2249; 'H  NMR (400 MHz; CDC13) 5H: 0.89 
(s, 3H, CH3), 1.26-2.32 (m, 13H), 2.77-2.81 (m, 2H, CH2), 3.52 (s, 3H, OCH3), 3.86 (s, 
3H, CH3OAr), 3.88-3.99 (m, 4H, 0C H 2CH20), 5.20 (s, 2H, OCH20 ), 6.85 (s, 1H, Ar- 
H) and 6.87 (s, 1H, Ar-H).
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8.10.32 2-Methoxy-l,3,5[10]-estratriene-3-ol (182)
Using the procedure described for the preparation of 164, a methanolic solution o f 181 
(11.0 g; 28.3 mmol) was deprotected by acetyl chloride (16.0 ml; 227 mmol). The 
crude pale yellow solid was recrystallised from ethanol to give 182 as white crystals 
(5.97 g, 70 %). R / 0.61 (ethyl acetate/hexane, 1:1); mp 184-186°C (445Lit. mp 188- 
191°C); MS (FAB+) m/z\ 301.1 [100, (M+H)+]; MS (FAB') m/z: 299.1 [100, (M-H)']; 
Acc. MS (FAB+): 301.1725, C 19H25O3 requires 301.1721; 'H N M R  (400 MHz; CDC13) 
8h : 0.92 (s, 3H, C I 8 - C H 3 ) ,  1.35-2.55 (m, 13H), 2.80-2.84 (m, 2H, CH2), 3.86 (s, 3H, 
OCH3), 5.45 (s, 1H, OH), 6.66 (s, 1H, Ar-H) and 6.79 (s, 1H, Ar-H); 13C NMR (100.5 
MHz; CDCI3) 5C: 14.3 (CH3), 22.0, 26.7, 27.0, 29.3, 32.0, 36.3 (all CH2), 38.7 (CH),
44.6 (CH), 48.4 (C), 50.8 (CH), 56.3 (CH3), 108.3, 114.9 (both CH), 129.5, 131.3, 
143.8, 144.8 (all C) and 221.0 (CO); Found C, 75.60; H, 8.01; C 19H2403 requires C, 




Using the procedure described for the preparation o f 151, NaH (479 mg; 11.9 mmol) 
and A,N-dimethylthiocarbamyl chloride (1.85 g; 15.0 mmol) were added to a DMF 
solution o f 182 (3.0 g; 10 mmol). The crude pale yellow precipitate was filtered and 
dried to get a pale yellow solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 6:1 to 1:1 gradient). The white solid isolated was recrystallised from 
isopropyl alcohol to give 183 as white needles (2.85 g, 74%). R / 0.39 (ethyl 
acetate/hexane, 1:2); mp 217-219°C; MS (FAB"1)  m/z: 388.1 [100, (M+H)+], 87.9 [50, 
((CH3)2NC=S+H)+]; A cc. MS (FAB+): 388.1938, C22H30NO3S requires 388.1946; 'H  
NMR (400 MHz; CDCI3) 8H: 0.92 (s, 3H, CH3), 1.26-2.55 (m, 13H), 2.84-2.86 (m, 2H, 
CH2), 3.34 (s, 3H, NCH3), 3.46 (s, 3H, NCH3), 3.80 (s, 3H, OCH3), 6.76 (s, 1H, Ar-H) 
and 6.89 (s, 1H, Ar-H); HPLC: MeOH:H20  (80:20); Flow rate = 2 ml/min, Xmax =




Using the procedure described for the preparation of 152, a suspension of 183 (2.7 g;
7.0 mmol) in mineral oil (200 ml) was heated under N2 at 270°C overnight. The crude 
brown solid was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 
gradient) and the pale brown solid isolated was recrystallised from ethyl acetate to give 
184 as off-white crystals (1.21 g; 45%). R / 0.24 (ethyl acetate/hexane, 3:4); mp 209- 
211°C; MS (FAB*) m/z\ 388.1 [100, (M+H)*]; Acc. MS (FAB*): 388.1946, 
C22H30NO3S requires 388.1946; ]H NMR (400 MHz; CDCI3) 8H: 0.92 (s, 3H, CH3), 
1.16-2.55 (m, 13H), 2.84-2.86 (m, 2H, CH2), 3.01 (s, 3H, NCH3), 3.13 (s, 3H, NCH3),
3.85 (s, 3H, OCH3), 6.89 (s, 1H, Ar-H) and 7.19 (s, 1H, Ar-H); HPLC: MeOH:H20  
(80:20); Flow rate = 2 ml/min, A,max = 291.1 nm; tR = 4.5 min.
8.10.35 3-Mercapto-2-methoxyestra-l,3,5(10)-trien-17-one (185)
Using the procedure described for the preparation of 153, a solution o f 184 (1.0 g; 2.6 
mmol) in ethanol (300 ml) was hydrolysed by aqueous NaOH (2.9 g; 72 mmol) in H2O 
(30 ml). The precipitate was filtered, washed with water and dried to get a brown solid, 
which was purified by flash chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient). 
The pale brown solid isolated was recrystallised from hot ethyl acetate to give 185 as 
off-white crystals (201 mg; 25%). R / 0.77 (ethyl acetate/hexane, 1:1); mp 157-159°C; 
MS (FAB+) m/z: 316.1 [100, (M)+]; MS (FAB") m/z: 315.1 [100, (M-H)"]; Acc. MS 
(FAB+): 316.1495, C 19H25O2S requires 316.1497; ]H NMR (400 MHz; CDC13) 5H: 
0.92 (s, 3H, CH3), 1.21-2.55 (m, 13H), 2.70-2.82 (m, 2H, CH2), 3.72 (s, 1H, SH), 3.86 
(s, 3H, OCH3), 6.78 (m, 1H, Ar-H) and 6.99 (s, 1H, Ar-H); Found C, 71.50; H, 7.61; 
Q 9H24O2S requires C, 72.11; H, 7.64%; HPLC: MeOH:H20  (80:20); Flow rate = 2 
ml/min, A.max = 213.4, 243.9 and 361.8 nm; tR = 7.9 min.
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8.10.36 2-Methoxyestra-l,3,5(10)-trien-17-one-3-5'-suIphamate (186)
Upon sulphamoylation by method 8.2.5 A, a DMF solution o f 185 (50 mg; 0.16 mmol) 
gave a pale brown solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient). The pale yellow solid isolated was recrystallised 
from ethyl acetate/hexane to get a pale yellow crystals o f 186 (9 mg; 14%). R / 0.69 
(ethyl acetate/hexane, 1:1); mp 118-119°C; MS (e.s. in MeOH) m/z: 396.4 [20, 
(M+H)+], 317.1 [45, (M +H-HNS02)+]; NMR (400 MHz; CDC13) 6H: 0.91 (s, 3H, CH3), 
1.20-2.54 (m, 13H), 2.72-2.85 (m, 2H, CH2), 3.89 (s, 3H, OCH3), 5.22 (s, 2H, NH2), 
6.95 (s, 1H, Ar-H) and 6.99 (s, 1H, Ar-H); HPLC: MeOH:H20  (70:30); Flow rate = 2 
ml/min, ^ max = 209.8 nm; tR= 2.4 min.
8.10.37 3-Benzylthio-2-methoxyestra-l,3,5(10)-trien-17-one (187)
Using the procedure described for the preparation of 155, a DMF (10 ml) solution of 
185 (100 mg; 0.38 mmol) was stirred with benzyl bromide (0.5 ml; 0.38 mmol) at R.T. 
for 3 h under N2. The crude brown syrup was purified by flash chromatography (ethyl 
acetate/hexane, 5:1 to 1:1 gradient) and the pale brown sticky foam isolated was further 
purified by preparative TLC to get 187 as a pale yellow solid (27 mg, 21%). R / 0.59 
(ethyl acetate/hexane, 1:1); mp 69-71°C; MS (FAB+) m/z: 406.3 [50, (M+H)+], 91.1 
[100, (PhCH2)+]; Acc. MS (FAB+): 406.1951, C26H30O2S requires 460.1966; *H NMR 
(400 MHz; CDC13) 5H: 0.92 (s, 3H, CH3), 1.24-2.59 (m, 13H), 2.76-2.84 (m, 2H, CH2), 
3.86 (s, 3H, OCH3), 4.07 (s, 2H, SCH2), 6.78 (s, 1H, Ar-H), 6.97 (s, 1H, Ar-H) and
7.26-7.38 (m, 5H, Ph-H); HPLC: MeOH:H20  (85:15); Flow rate = 2 ml/min, A™ax =
294.7 nm; tR= 17.1 min.
8.10.38 2-Ethenyl-17,17-ethylenedioxy-3-0-methoxymethylene-l,3,5[lO]- 
estratriene (188)
To a solution o f methyltriphenylphosphonium iodide (3.92 g, 9.71 mmol) in freshly 
distilled THF (40 ml), potassium tertbutoxide in THF (1.21 ml, 9.71 mmol) was added 
and stirred at R.T. for 1 h. To the mixture, 178 (1.5 g, 3.9 mmol) dissolved in THF (10
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ml) was added and left to stir for 2 h. The milky white mixture was quenched with H2O 
and extracted with ethyl acetate. The combined organics were washed with water, dried 
and evaporated to give a yellow suspension, which was purified by flash 
chromatography (ethyl acetate/hexane, 5:1 to 1:1 gradient) to give 188 as colourless 
syrup (1.22 g; 82 %). R / 0.77 (ethyl acetate/hexane, 1:2); MS (FAB+) m/z\ 384.2 [100, 
(M+H)+]; MS (FAB') m/z: 383.2 [100, (M-H)']; Acc. MS (FAB+): 384.3367, C24H33O4 
requires 384.3391; 'H  NMR (400 MHz; CDC13) 5H: 0.88 (s, 3H, CH3), 1.24-2.11 (m, 
11H), 2.15-2.35 (m, 1H, CH), 2.36-2.45 (m, 1H, CH), 2.83-2.87 (m, 2H, CH2), 3.48 (s, 
3H, OCH3), 3.88-3.99 (m, 4H, 0C H 2CH20), 5.17 (s, 2H, OCH20), 5.22 (d, 1H, 
CH2=CH, J=  11 Hz), 5.71 (d, 1H, CH2=CH, J=  9.0 Hz), 6.81 (s, 1H, Ar-H), 7.01 (dd, 
1H, CH2=CH, J =  9.0, 11 Hz) and 7.41 (s, 1H, Ar-H); HPLC: MeOH:H20  (90:10); 
Flow rate - 2 ml/min, ^ max = 215.7, 254.5 and 304.2 nm; tR= 9.0 min.
8.11 Derivatives of estrone-3-sulphamide
8.11.1 3-(2,-Phenyl-4’-quinazolinyloxy)estra-l,3,5(10)-trien-17-one (189)
A solution o f estrone (3.0 g; 11 mmol) in dry diglyme (100 ml) was treated with NaH 
(60% dispersion in mineral oil, 591 mg; 14.8 mmol). The mixture was stirred under N2 
until the evolution o f H2 ceased. To this suspension was added 4-chloro-2- 
phenylquinazoline (3.2 g; 13.3 mmol) and stirred and boiled under reflux for 3 h. The 
cooled pale yellow mixture was poured into cold water (500 ml). The precipitate 
formed was then filtered, washed with water and dried. The crude yellow solid was 
purified by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient) and the 
pale yellow solid isolated was recrystallised from isopropanol to give 189 as pale 
yellow fine crystals (4.21 g; 80%). R / 0.52 (ethyl acetate/hexane, 1:1); mp 189-191°C 
( 194Lit. mp 193-195°C); MS (FAB+) m/z: 475.1 [100, (M+H)*]; Acc. MS (FAB+): 
475.2386, C32H31N2O2 requires 475.2385; 'H  NMR (400 MHz; CDC13) 5H: 0.98 (s, 3H, 
CH3), 1.25-2.58 (m, 13H), 2.98-3.06 (m, 2H, CH2), 7.13 (d, 1H, C4-H, J  = 1.9 Hz), 
7.20 (dd, 1H, C2-H, J =  2.3, 8.6 Hz), 7.40-7.44 (m, 4H, C,-H, meta and para H o f 2 ’- 
phenyl ring), 7.60 (t, 1H, C6 ’-H, J=  8.2 Hz), 7.89 (t, 1H, C7’-H, J =  8.2 Hz), 8.35 (d,
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1H, C8 ’-H, J  = 8.2 Hz) and 8.37-8.39 (m, 3H, C5’-H, and ortho H of 2 ’-phenyl ring); 
HPLC: Me0 H:H20  (70:30); Flow rate = 2 ml/min, A.max = 238 and 286.4 nm; tR= 3.2 
min.
8.11.2 3-[4’-Oxo-2’-phenyl-3’(4 /0 -qu inazoIinyI]estra-l,3,5(10)-trien-17-one
(190)
A suspension of 189 (4.0 g; 8.4 mmol) in heavy mineral oil (100 ml) was stirred and 
heated at 300 -310°C for 7 h under N2. The mixture was cooled to R.T, diluted with 
petroleum ether (40-60°C) and the precipitate formed was filtered and dried under 
vacuum. The crude yellow solid was purified by flash chromatography (ethyl 
acetate/hexane, 6:1 to 2:1 gradient) and the pale yellow solid isolated was recrystallised 
from isopropyl alcohol to give 190 as fine pale yellow crystals (3.18 g; 79% ).194 R /
0.61 (ethyl acetate/hexane, 3:4); mp 251-253°C; MS (FAB+) m/z\ 475.2 [100, (M+H)+]; 
Acc. MS (FAB+): 475.2389, C32H31N2O2 requires 475.2385; ’H NMR (400 MHz; 
CDCI3) 6h: 0.89 (s, 3H, CH3), 1.24-2.54 (m, 13IT), 2.74-2.87 (m, 2H, CH2), 6.84-6.87 
(m, 2H), 7.19-7.27 (m, 2H), 7.35-7.37 (m, 2H), 7.51-7.55 (m, 1H), 7.79-7.82 (m, 2H) 
and 8.35 (d, 1H, J=  7.8 Hz); HPLC: MeOH:H20  (80:20); Flow rate = 2 ml/min, Xmax =
226.3 and 276.9 nm; tR= 4.8 min.
8.11.3 3-Aminoestra-l,3,5(10)-trien-17-one (191)
A solution o f 190 (3.0 g; 6.3 mmol) dissolved in ethanol (150 ml) was treated with 
40% aq. NaOH solution (25.0 ml; 177 mmol) and boiled under reflux for 7 h under N 2. 
This solution was cooled in ice, treated with 12M aq. HC1 (50 ml) and allowed to stand 
overnight at R.T. The mixture was stirred and boiled under reflux for 1.5 h, cooled and 
the NaCl precipitate was filtered out, washed thoroughly and discarded. The filtrate 
and washings were concentrated under reduced pressure, poured into water and 
filtered. The filtrate was made alkaline with NaOH solution, saturated with K 2 C O 3  and 
the precipitate formed was filtered out washed well with water and dried under 
vacuum. The crude pale brown solid was purified by flash chromatography (ethyl 
acetate/hexane, 6:1 to 2:1 gradient) and the pale yellow solid isolated was recrystallised
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from isopropanol to give 191 as brown flaky crystals (274 mg, 16%). R / 0.44 (ethyl 
acetate/hexane, 1:1); mp 193-195°C ( ,94Lit. mp 183-190°C1); MS (FAB+) m/z: 270.1 
[100, (M+H)+]; MS (FAB') m/z: 268.1 [100, (M-H)']; Acc. MS (FAB+): 270.1834, 
C 18H24NO requires 270.1858; 'H N M R  (400 MHz; CDC13) 8H: 0.90 (s, 3H, CH3), 1.20- 
2.55 (m, 13H), 2.81-2.95 (m, 2H, CH2), 3.54 (s, 2H, NH2), 6.45 (d, 1H, C4-H, J =  2.3 
Hz), 6.52 (dd, 1H, C2-H, J =  2.3, 8.2 Hz) and 7.08 (d, 1H, C r H, J  = 8.2 Hz); HPLC: 
MeOH:H20  (70:30); Flow rate = 2 ml/min, Xmax = 236.8 and 290 nm; tR= 3.9 min.
8.11.4 Estra-l,3,5(10)-trien-17-one-3-sulphamide (192)
Upon sulphamoylation using method 8.2.5 A, compound 191 (100 mg; 0.37 mmol) 
gave a crude brown solid, which was purified by preparative TLC (ethyl 
acetate/hexane, 1:1) and the pale yellow solid isolated was recrystallised from ethyl 
acetate/hexane to give 192 as cream crystals (22 mg; 17%). R / 0.26 (ethyl 
acetate/hexane, 1:1); mp 214-216°C (194Lit. mp 215-220°C-dec.); MS (FAB+) m/z:
349.0 [100, (M+H)+]; MS (FAB') m/z: 347.0 [100, (M-H)']; Acc. MS (FAB+): 
349.1560, C 18H25N20 3S requires 349.1586; 'H  NMR (400 MHz; CDC13) 8H: 0.91 (s, 
3H, CH3), 1.21-2.55 (m, 13H), 2.89-2.93 (m, 2H, CH2), 4.67 (s, 2H, NH2), 6.99 (s, 1H, 
NH), 7.26-7.28 (m, 2H, Ar-H) and 7.30-7.31 (m, 1H, Ar-H); Found HPLC: 
MeOH/H20  (70:30); Flow rate = 2 ml/min, A,max = 232.1 and 278.1 nm; tR= 2.5 min.
8.11.5 2-Ethyl-3-(2’-phenyl-4’-quinazolinyloxy)estra-l,3,5(10)-trien-17-one 
(193)
As previously described for the preparation of compound 189, a solution o f 164 (2.1 g;
7.0 mmol) in dry diglyme (80 ml) was treated with NaH (375 mg; 9.37 mmol) and 4- 
chloro-2-phenylquinazoline (2.0 g; 8.5 mmol). The precipitate formed was filtered, 
washed with water and dried under vacuum. The crude white solid was purified by 
recrystallisation from isopropyl alcohol to give 193 as white fine crystals (2.49 g; 
70%). R/. 0.78 (ethyl acetate/hexane, 1:1); mp 147-149°C; MS (FAB+) m/z: 503.0 [100, 
(M+H)+]; MS (FAB') m/z: 501.0 [100, (M-H)']; Acc. MS (FAB+): 503.2712,
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C34H35N2O2 requires 503.2708; 'H  NMR (400 MHz; CDC13) 5H: 0.98 (s, 3H, CH3), 
1.78 (t, 3H, CH2CH3, J =  7.4 Hz), 1.22-2.53 (m, 13H), 2.59 (q, 2H, CH2CH3, J =  7.4 
Hz), 2.93-2.96 (m, 2H, CH2), 7.07 (s, 1H, Ar-H), 7.29 (s, 1H, Ar-H), 7.32-7.43 (m, 3H, 
meta and para H of 2 ’-phenyl ring), 7.61 (t, 1H, C6 ’-H, J =  8.2 Hz), 7.89 (t, 1H, C7’-H, 
J=  8.2 Hz), 8.05 (d, 1H, C8 ’-H, 7 =  8.6 Hz) and 8.34-8.38 (m, 3H, C5’-H, and ortho H 
of 2 ’-phenyl ring); Found C, 80.50; H, 6.67; N, 5.55; C34H34N 2O2 requires C, 81.24; H, 
6.82, N, 5.57; HPLC: M e0H /H 20  (90:10); Flow rate = 2 ml/min, Xmax = 209.8 nm; tR =
18.5 min.
8.11.6 2-Ethyl-3-[4’-oxo-2’-phenyl-3’(4//)-quinazolinyl]estra-l,3 ,5(10)-trien- 
17-one (194)
As previously described for the preparation o f compound 190, a suspension o f 193 (2.0 
g; 4.0 mmol) in heavy mineral oil (80 ml) was heated at 320-330°C overnight under 
N 2. The pale brown precipitate formed was filtered out, washed with petroleum ether 
(40-60°C), dried and purified by flash chromatography (ethyl acetate/hexane, 6:1 to 
2:1 gradient). The white solid isolated was recrystallised from isopropyl alcohol to give 
194 as white crystals (1.13 g, 57%). R / 0.56 (ethyl acetate/hexane, 1:1); mp 151- 
152°C; MS (FAB+) m/z: 503.1 [100, (M+H)+]; MS (FAB') m/z: 501.1 [100, (M-H)']; 
Acc. MS (FAB+): 503.2617, C34H35N2O2 requires 503.2698; ‘H NMR (400 MHz; 
CDCI3) 8h: 0.90 (s, 3H, CH3), 1.07 (t, 3H, CH2CH3, J=  7.4 Hz), 1.23-2.54 (m, 14H), 
2.76 (q, 2H, CH2CH3, J=  7.4 Hz), 2.82-2.90 (m, 2H, CH2), 6.84 (s, 1H, Ar-H), 7.12 (s, 
1H, Ar-H), 7.20-7.28 (m, 2H), 7.31-7.37 (m, 2H), 7.50-7.57 (m, 1H), 7.79-7.84 (m, 
2H) and 8.36 (d, 1H, J =  8.2 Hz); HPLC: MeOH/H20  (90:10); Flow rate = 2 ml/min, 
A.max = 276.9 nm; tR = 3.6 min.
8.11.7 3-Am ino-2-ethyIestra-l,3,5(10)-trien-17-one (195)
A solution of 194 (1.0 g; 2.0 mmol) in absolute ethanol (50 ml) was hydrolysed with 
40% aq. NaOH solution (14 ml) as previously described for the preparation of 
compound 191. The precipitate formed was filtered out washed with water and dried
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under vacuum. The crude pale brown solid was purified by flash chromatography 
(ethyl acetate/hexane, 6:1 to 2:1 gradient) and the beige solid isolated was 
recrystallised from ethyl acetate/hexane to give 195 as pale brown fine crystals (212 
mg, 36%). R / 0.74 (ethyl acetate/hexane, 1:1); mp 149-150°C; MS (FAB+) m/z: 298.1 
[100, (M+H)+]; MS (FAB') m/z: 296.1 [100, (M-H)']; Acc. MS (FAB+): 298.2097, 
C2oH28NO requires 298.2093; ’H NMR (400 MHz; CDC13) 6H: 0.91 (s, 3H, CH3), 1.24 
(t, 3H, CH2CH3, J  -  7 A  Hz), 1.25-2.43 (m, 15H reduced to 13H with D20 ), 2.51 (q, 
2H, CH2CH3, J=  7.8 Hz), 2.81-2.82 (m, 2H, CH2), 6.46 (s, 1H, Ar-H) and 7.00 (s, 1H, 
Ar-H); HPLC: MeOH/H20  (70:30); Flow rate = 2 ml/min, A,max = 291.1 nm; tR = 7.6 
min.
8.11.8 2-Ethylestra-l,3,5(10)-trien-17-one-3-sulphamide (196)
Upon sulphamoylation using method 8.2.5 A, compound 195 (200 mg; 0.67 mmol) 
gave a crude pale yellow solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 6:1 to 2:1 gradient). The off-white solid isolated was recrystallised 
from THF/hexane to give 196 as off-white crystals (73 mg, 29%). R / 0.38 (ethyl 
acetate/hexane, 1:1); mp 153-154°C; vmax (KBr) cm '1: 3392 (NH2), 3243 (N-H), 1725 
(C=0), 1252 (S 0 2); MS (FAB+) m/z: 376.2 [100, (M+H)+]; 296.3 [35,
(C2oH27N O +H )+]; MS (FAB') m/z: 375.2 [100, (M-H)']; Acc. MS (FAB+): 376.1807, 
C20H28N2O3S requires 376.1821; ]H NMR (400 MHz; CDC13) 5H: 0.91 (s, 3H, CH3), 
1.22 (t, 3H, CH2CH3, J=  7.8 Hz), 1.25-2.55 (m, 13H), 2.63 (q, 2H, CH2CH3, J =  7.4 
Hz), 2.83-2.91 (m, 2H, CH2), 4.71 (s, 2H, NH2), 6.19 (s, 1H, NH), 7.16 (s, 1H, Ar-H) 
and 7.23 (s, 1H, Ar-H); Found C, 63.10; H, 7.46; N, 7.17; C20H28N2O3S requires C, 
63.80; H, 7.50, N, 7.44%; HPLC: MeOH/H20  (70:30); Flow rate = 2 ml/min, Xmax =
280.5 nm; tR= 3.5 min.
8.11.9 2-Ethylestra-l,3,5(10)-trien-17-oI-3-suIphamide (197)
To a solution of 196 (25.0 mg; 0.07 mmol) in isopropanol (1.5 ml) and THF (0.5 ml) 
was added NaBH4 (3.8 mg; 0.1 mmol) at 0°C. The mixture was stirred for 30 min at
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0°C, quenched with aq. NH4CI (5 ml). H2O (30 ml) was added and the precipitate 
formed was filtered out, washed with water and dried under vacuum. The crude white 
solid was purified by preparative TLC to give 197 as a white fine powder (9 mg; 36%). 
R / 0.40 (ethyl acetate/hexane, 1:1); mp 138-140°C; vmax (KBr) cm '1: 3446 (OH), 
3370 (NH2), 3261 (N-H), 1260 (S 0 2); MS (FAB+) m/z\ 379.3 [100, (M+H)+]; MS 
(FAB') m/z: 377.3 [100, (M-H)']; Acc. MS (FAB+): 379.2015, C20H3iN2O3S requires 
379.2055; *H NMR (400 MHz; CDC13) 8H: 0.91 (s, 3H, C18-CH3), 1.22 (t, 3H, 
CH2CH3, J=  7.8 Hz), 1.25-2.55 (m, 13H), 2.63 (q, 2H, CH2CH3, J=  7.4 Hz), 2.83-2.91 
(m, 2H, CH2), 3.73 (t, 1H, C17-H, J  = 8.6 Hz), 4.63 (s, 2H, NH2), 6.12 (s, 1H, NH), 
7.16 (s, 1H, Ar-H) and 7.21 (s, 1H, Ar-H).
8.11.10 2-Methoxy-3-(2’-phenyI-4’-quinazolinyIoxy)estra-l,3,5(10)-trien-17-one 
(198)
As previously described for the preparation o f compound 189, a solution o f 182 (2.5 g;
8.3 mmol) in dried diglyme (70 ml) was treated with NaH (443 mg; 11.1 mmol) and 4- 
chloro-2-phenylquinazoline (2.41 g; 9.99 mmol). The precipitate formed was filtered, 
washed with water and dried under vacuum. The crude pale yellow solid was purified 
by flash chromatography (ethyl acetate/hexane, 6:1 to 2:1 gradient) and the white solid 
isolated was recrystallised from isopropyl alcohol to give 198 as white crystals (3.49 g, 
83%). R / 0.62 (ethyl acetate/hexane, 1:1); mp 191-192°C; MS (FAB+) m/z: 505.1 
[100, (M+H)+j; Acc. MS (FAB+): 505.2494, C33H33N20 3 requires 505.2491; 'H  NMR 
(400 MHz; CDC13) 8H: 0.99 (s, 3H, CH3), 1.22-2.58 (m, 13H), 2.98-3.02 (m, 2H, CH2), 
3.71 (s, 3H, OCH3), 7.01 (s, 1H, Ar-H), 7.03 (s, 1H, Ar-H), 7.39-7.41 (m, 3H, meta and 
para H o f 2 ’-phenyl ring), 7.59 (t, 1H, C6 ’-H, J=  7.0 Hz), 7.88 (t, 1H, C7’-H, J =  7.0 
Hz), 8.04 (d, 1H, C8 ’-H, J =  8.6 Hz), 8.31-8.33 (m, 2H, ortho H of 2 ’-phenyl ring) and 
8.39 (d, 1H, C5’-H, J  = 8.2 Hz); HPLC: MeOH/H20  (90:10); Flow rate = 2 ml/min, 




As previously described for the preparation of compound 190, a suspension o f 198 (3.2 
g; 6.4 mmol) in heavy mineral oil (100 ml) was heated at 310-320°C overnight under 
N2. The precipitate formed was filtered, washed with petroleum ether (40-60°C) and 
dried under vacuum. The crude pale brown solid was purified by flash chromatography 
(ethyl acetate/hexane, 6:1 to 2:1 gradient) and the yellow solid isolated was 
recrystallised from isopropyl alcohol to give 199 as pale yellow crystals (1.91 g, 60%). 
R / 0.43 (ethyl acetate/hexane, 1:1); mp 144-145°C; MS (FAB+) m/z: 505.3 [100, 
(M+H)+]; MS (FAB') m/z: 503.2 [100, (M-H)']; Acc. MS (FAB+): 505.2472, 
C33H33N2O3 requires 505.2491; ]H NMR (400 MHz; CDCI3) 5H: 0.93 (s, 3H, CH3),
1.26-2.59 (m, 14H), 2.81-2.87 (m, 2H, CH2), 3.63 (s, 3H, OCH3), 6.71 (s, 1H, Ar-H),
6.85 (s, 1H, Ar-H), 7.19-7.28 (m, 2H), 7.37-7.39 (m, 2H), 7.49-7.59 (m, 1H), 7.79-7.83 
(m, 2H) and 8.35 (d, 1H, J  = 7.4 Hz); HPLC: MeOH/H20  (70:30); Flow rate = 2 
ml/min, A,max = 238 and 287.6 nm; tR= 3.3 min.
8.11.12 3-Amino-2-methoxyestra-l,3,5(10)-trien-17-one (200)
A solution of 199 (1.5 g; 3.0 mmol) in ethanol (90 ml) was hydrolysed with 40% aq. 
NaOH solution (21 ml) as previously described for the preparation o f compound 191. 
The precipitate formed was filtered, washed with water and dried under vacuum. The 
crude brown solid was purified by flash chromatography (ethyl acetate/hexane, 6:1 to 
2:1 gradient) and the brown solid isolated was recrystallised from isopropyl alcohol to 
give 200 as pale brown crystals (589 mg, 66%). R / 0.62 (ethyl acetate/hexane, 1:1); 
mp 129-130°C; MS (FAB+) m/r. 299.2 [100, (M+H)+J; Acc. MS (FAB+): 299.1986, 
C i9H26N 0 2 requires 299.1966; 'H  NMR (400 MHz; DMSO-d6) 8H: 0.81 (s, 3H, CH3),
1.24-2.48 (m, 13H), 2.58-2.69 (m, 2H, CH2), 3.32 (s, 3H, OCH3), 4.42 (s, 2H, NH2),
6.30 (s, 1H, Ar-H) and 6.64 (s, 1H, Ar-H); HPLC: MeOH/H20  (70:30); Flow rate = 2 
ml/min, ^ max = 292.3 and 348.2 nm; tR= 4.9 min.
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8.11.13 2-Methoxyestra-l,3,5(10)-trien-17-one-3-sulphamide (201)
Upon sulphamoylation using method 8.2.5 A, compound 200 (400 mg; 1.34 mmol) 
gave a crude brown solid, which was purified by flash chromatography (ethyl 
acetate/hexane, 6:1 to 1:1 gradient). The white solid isolated was recrystallised from 
ethyl acetate/hexane to give 201 as white crystals (72 mg; 14%). R / 0.28 (ethyl 
acetate/hexane, 1:1); mp 98-99°C; vmax (KBr) cm '1: 3370 (NH2), 3261 (N-H), 3940 
(OCH3), 1650 (C=0), 1252 (S 0 2); MS (FAB+) m/z: 379.2 [100, (M+H)+]; MS (FAB') 
m/z: 377.2 [100, (M-H)']; Acc. MS (FAB+): 379.1668, Ci9H27N20 4S requires 
379.1679; ‘H N M R  (400 MHz; CDC13) 8H: 0.92 (s, 3H, CH3), 1.36-2.55 (m, 13H), 3.85 
(s, 3H, OCH3), 2.89-2.94 (m, 2H, CH2), 4.61 (s, 2H, NH2), 6.81 (s, 1H, NH), 6.83 (m, 
1H, Ar-H) and 7.26 (s, 1H, Ar-H); HPLC: Mobile phase, MeOH/H20  (70:30); Flow 
rate = 2 ml/min, A,max = 287.6 nm; tR= 2.8 min.
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Summary
A steroid sulphatase inhibitor can be used as a new form of treatment for hormone 
dependent breast cancer (HDBC) by virtue of its ability to inhibit estrone sulphatase 
(El-STS), which catalyses the hydrolysis o f estrone sulphate to estrone, and 
dehydroepiandrostenedione sulphatase (DHA-STS), which has an important role in 
regulating the production of the estrogenic steroid androstenediol. The first potent 
steroid sulphatase inhibitor, estrone 3-O-sulphamate, (EMATE) is orally active and an 
irreversible active site-directed inhibitor with in vivo antitumour properties. However, 
EMATE proved to be highly estrogenic. Therefore, a number of strategies have been 
adopted to design and synthesise potent non-steroidal, non-estrogenic inhibitors and to 
explore further structure-activity relationship for sulphamate based steroid sulphatase 
inhibitors.
4-Methylcoumarin-7-(9-sulphamate (COUMATE) is an orally active, non-steroidal, 
non-estrogenic and an active site-directed inhibitor, showing inhibitory activity against 
both El-STS and DHA-STS in MCF-7 cells and placental microsomes. This led to the 
design o f series o f COUMATE analogues. A structure-activity study was carried out by 
synthesising coumarin analogues with longer alkyl chains and other functionalities at 
the C-4 and/or C-3 position o f the coumarin ring. Another series o f tricyclic coumarin 
sulphamates, which structurally mimic the ABCD rings o f the steroid were also, 
synthesised as potentially more effective inhibitors than EMATE and COUMATE. 
Although much success and progress have been with coumarin sulphamates, other 
heterocyclic ring containing sulphamates are also o f considerable interest as potential 
STS inhibitors. The indole ring system is useful to explore, since incorporation o f an 
indole moiety in compounds intended for endocrine therapy has not been reported so 
far. Therefore several novel, 1/2 or 3-substituted indole sulphamates were syntheisesd.
The best analogues in the C-3 and C-4 alkyl series were found to be compounds with 
7-9 and 6-9 carbon containing alkyl chains, respectively inhibiting the El-STS activity 
in MCF-7 cells at 0.01 juM by 85-91% and >90%. (c.f. 35% for COUMATE). The 3- 
benzyI-4-methylcoumarin-7-0-sulphamate (95) was found to be a potent inhibitor with
299
an IC50 o f 8 nM in vivo. Other compounds such as 4-methyl-3-phenethylcoumarin-7-0- 
sulphamate (18) 4-isopropylcoumarin-7-0-sulphamate (32) were also identified to be 
potent in this series with 91% and 86% inhibition respectively in placental microsomes 
at 0.1 //M concentration. In the tricyclic coumarin-based analogues the compounds 
synthesised possess a third ring that contain between 5 and 15 carbons (665-6615 
COUMATES). These compounds were found to be more powerful non-steroidal, non- 
estrogenic and active site-directed inhibitors than EMATE, COUMATE and its 
analogues. The most potent compound in this series, 6610 COUMATE (122) has an 
IC50 o f 1 nM in vitro followed by 669 COUMATE (119) with an IC50 o f 2.4 nM. 
Interestingly, 6615 COUMATE (131) the least active compound with an IC50 o f 370 
nM in vitro proved to be the most active congener in vivo. This could be due to the 
difference in in vitro and in vivo biological testing. In an animal model the entry o f this 
compound into tissues being facilitated by its higher lipophilicity and taken into cells 
more effectively. Therefore, its greater activity might be attributed to a combination of 
factors in vivo.
The higher potencies observed for the alkyl series o f compounds can be attributed to 
their bicyclic system mimicking the A/B rings o f steroid and that the 3- or 4- alkyl 
substituents interacting with the amino acid residues at the active site, which normally 
recognise the C/D rings o f steroid. The greater inhibition observed for the tricyclic 
COUMATEs could be due to the fact that their third cycloalkenone ring folds in such a 
way that they mimic the C/D ring conformation o f the steroid and hence have a better 
recognition for binding at the enzyme active site. It is promising that at least one of 
these tricyclic coumarin sulphamates seems likely to be useful whereby the efficacy o f 
treating hormone dependent breast cancer with a steroid sulphatase inhibitor can be 
fully evaluated. Additionally, sulphatase inhibition may have potential therapeutic 
benefit in the immune system and for neuro-degenerative diseases, such as 
Alzheimer’s.
In addition, The X-ray crystal structures o f compounds 119 and 122 were determined 
to explore the conformation o f their respective third rings at least in the crystalline
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state. The lipophilicity of the tricyclic compounds was also studied by calculating the 
log P values by an HPLC technique. As expected, this study revealed that the 
lipophilicity of the tricyclic compounds increased steadily with the increase in the 
number o f carbon atom in the third ring and sulphamoylation reduced the log P o f the 
corresponding hydroxycoumarin. Interestingly, the log P value obtained for the most 
potent compound in this series in vitro, 122 was found to be 3.92, which turned out to 
be the same as that o f EMATE (3.92).
In addition to inhibiting the sulphatase enzyme as a treatment for hormone dependent 
breast tumours, inhibiting the microtubules, which are involved in diverse cellular 
processes such as cell division, locomotion and intracellular transport is currently 
gaining attention as a potential target for hormone dependent and independent cancers 
in general. As a consequence any selective agent that can cause inhibition o f tubulin 
polymerisation, angiogenesis and induction of apoptosis is a popular choice for new 
chemotherapeutics. 2-Methoxyestradiol (2-MeOE2), a natural estradiol metabolite, is 
non-estrogenic, known to induce G2/M phase cell cycle arrest and bcl-2 
phosphorylation, two key markers o f apoptosis. It is known that the synthetic 
sulphamate derivatives of this molecule 2-MeOEMATE, 2-MeOE2EMATE, 2- 
EtEMATE and 2-EtE2EMATE are highly potent, non-estrogenic steroid sulphatase 
inhibitors and as expected are shown to trigger apoptosis and inhibit the tubulin 
polymeraisation and angiogenesis. It has been recognised that the potent activities 
observed for these synthetic sulphamates compared to those o f 2-MeOE2 are due to the 
presence o f the sulphamoyloxy group, which is indispensable for potent irreversible 
inhibition o f STS enzyme. Although the role o f sulphamoyloxy group in these 
compounds remain unclear. The potency might have possibly arisen as a result from 
their absorption by the red blood cells, which protect these drugs from inactivation 
during passage through the liver and hence slowly released to cause the desired effect 
at the target site. It is possible that these sulphamates are acting as prodrugs of their 
respective parent compounds, which are relatively easily metabolised during their 
passage through the liver.
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It is therefore interesting to establish some degree of structure-activity relationship for 
the 2-MeOEMATE class of compounds by synthesising structurally similar 
derivatives, such as 2 -substituted estrone 3-sulphamide, 3-sulphonamide and 3-S- 
sulphamates, with nitrogen or sulphur bridging heteroatoms at the C-3 position instead 
o f the O-atom in sulphamoyl group. These compounds with non- hydrolysable moieties 
at the C-3 position would provide an indication about the importance o f the 
sulphamoyloxy group for the potent activity observed in the sulphamates. The 
sulphonamides are known to bind to carbonic anhydrase enzyme in the blood therefore 
might well show similar inhibitory activities to that of the sulphamates by being taken 
up into the blood cells. Most importantly, these compounds would offer useful 
information about the nature of the site where sulphamoyl group binds in tubulin. It 
will also reveal how the sulphamoyloxy group binds to tubulin to produce the 
irreversible inhibition as observed with EMATE and 2-MeOEMATE. Their increased 
binding affinity to the colchicine receptor might be the driving force behind the 
increase in potency observed or the binding pattern might be similar to that of 
sulphamoylation of sulphatase enzyme. Therefore, several novel sulphamate surrogates 
such as 2-methoxy and 2-ethylestrone-3-sulphamide, 3-sulphonamide and 3-S- 
sulphamate analogues were synthesised in this project and their synthetic procedures 
are reported here. The nature o f inhibition o f these compounds can only be validated 
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All the compounds submitted were tested for their biological activity at the Department 
o f Endocrinology and Metabolic Medicine, St. Mary’s Hospital Medical School, 
Imperial College, London, by Dr. A. Purohit and Ms. B. Malini.
Cell culture
MCF-7 breast cancer cells were maintained in minimal essential medium containing 20 
mM A^-hydroxyethylpiperazine-A^-ethanesulphonic acid, 5% fetal bovine serum, 2 
mM glutamine, nonessential amino acids and 0.075% sodium bicarbonate. For 
experiments, up to 30 replicate 25 cm2 tissue culture flasks were seeded with about 
1x10s cells/flasks using the medium described above. For testing the effect o f inhibitor 
in vitro El-STS activity, the cells were allowed to grow to 80% confluency and the 
medium was changed on every third day.
(A) In vitro estrone sulphatase (El-STS) assay
(i) On cell monolayers188,224
Intact monolayers o f MCF-7 cells in triplicate 25 cm2 tissue culture flasks were washed 
with Earle’s balanced salt solution and incubated for 20 h at 37 °C with [3H]E1S (5 
pmol, 7 x l0 5dpm) in serum-free minimal essential medium (2.5 ml) with or without the 
synthetic analogues (0.25 - 25 nmol). Substrate and inhibitor were added to medium in 
ethanol, with the final concentration being <1%. After incubating, each flask was 
cooled and the medium (1 ml) was pipetted into separate tubes containing [14C]E1 
(7 x l0 3 dpm). The mixture was shaken vigorously for 30 s with toluene (5 ml). 
Preliminary experiments showed that >90% [14C]E1 and <0.1% [3H]E1S was removed 
from the aqueous phase by this treatment. A portion (2 ml) o f the organic phase was 
removed and evaporated and the 3H and 14C content o f the residue was determined by
I
scintillation spectrometry. The mass of E1S hydrolysed was calculated from the 3H 
counts obtained (corrected for the volumes o f the medium and organic phase used and 
for recovery o f [14C]E1 added) and the specific activity o f the substrate. Each batch of 
experiments included incubation o f microsomes prepared from a sulphatase positive 
human placenta (positive control) and the flasks without cells (to assess apparent non- 
enzymic hydrolysis o f the substrate). The number o f cell nuclei per flask was 
determined using a Coulter Counter after treating the cell monolayers with zaponin. 
Unless otherwise stated, the results are expressed as the means ± SD o f the total 
product (estrone + estradiol) formed during the incubation period (3 - 4 h) and 
calculated for 106 cells.
(ii) On placental microsomes188
The ability o f the compounds synthesised to inhibit steroid sulphatase activity was 
tested using a placental microsomal preparation from a sulphatase-positive human 
placenta from a normal term pregnancy. El-STS activity was measured in the absence 
and presence of inhibitors using [6,7-3H ]ElS (4x l05 dpm, NEN-Du Pont, Boston, 
MA) adjusted to a final concentration o f 20 fiM with unlabelled substrate. After 
incubation o f the substrate inhibitor with placental microsomes (100 protein) at 37 
°C for 30 min, the product formed was isolated from the mixture by extraction with 
toluene (4 ml). [4-14C]El (7x l03 dpm) was used to monitor procedural losses.
The ability o f the tricyclic COUMATEs to inhibit STS activity was examined using
placental microsomes. Supernatants prepared from homogenised rat liver tissues were
• 188 used to test the potency o f selected inhibitors in vitro following the same procedure.
Statistics
Unpaired Student’s t test was used to test the statistical significance o f our findings. 
One flask in each batch was used to assess cell membrane status and viability using the 
trypan blue exclusion method.
II
(B) In vivo studies220
Selected drugs were tested in vivo for their ability to inhibit STS activity. Female 
Wistar rats (200 - 250 g) were obtained from Harlan Olac (Bicester, Oxon, U.K). 
Groups o f rats, with three rats in each group for each experiment, were tested p.o. with 
vehicle (propylene glycol) or drug (0.1 mg/Kg and 1.0 mg/Kg) with animals receiving 
a single dose. Animals were killed, using an approved procedure, 24 h after drug 
administration to assess the extent o f STS inhibition. For this, samples o f liver tissue 
were removed and immediately frozen on solid carbon dioxide and stored at -2 0  °C 
until assayed. For some animals samples o f brain tissue were also collected to assess 
the extent o f inhibition o f STS in this tissue. Tissues were homogenised and after 
centrifugation to remove cell debris, aliquots of the supernatant were used for the STS 
assay.224 For some animals, blood was also collected by cardiac puncture under 
anesthesia. White blood cells (WBCs) were obtained by centrifugation with Histopaque 
1077 (Sigma, Poole, Dorset, U.K.) and used to assay STS activity.266
in
Appendix B
N u m b e r i n g  a n d  n o m e n c l a t u r e  o f  c o m p o u n d s
(1) Ethyl 3-oxoalkanoates
o o
6 4 3 T  1 ° CH2CH3
(2) Ethyl 2-acetylalkanoates
o o
1 ' o c h 2c h 3
3^





(4) Tricyclic Coumarin Nucleus
3-Alkyl-4-methylcoumarin Nucleus
(CH2)n
e .g .: 6-Oxo-
8,9,10,11,12,13,14,15,16,1 
7,18,19-dodecahydro- 7H- 















L o g  P  C a l c u l a t i o n s
(A) 90: 10 M ethanol: Water




l°g K S.D av log kw
Diethylstilbestrol 1.765 1.764 1.766 1.765 0.215 0.13870 5.07 4.16 -0.857893 0.001 4.3525
Nifedipine 1.819 1.817 1.82 1.81866 0.26866 0.17333 3.17 2.46 -0.761117 0.00152 2.3602
Testosterone 2.265 2.267 2.268 2.26666 0.71666 0.46236 3.29 2.74 -0.335014 0.00152 2.8089
Quinoline 1.93 1.926 1.924 1.92666 0.37666 0.24301 2.03 1.56 -0.614374 0.00305 1.3329
3-Br-quinoline 2.359 2.353 2.348 2.35333 0.80333 0.51827 3.03 2.54 -0.285435 0.00550 2.2028
3,5 -Dichlorophenol 2.132 2.123 2.135 2.13 0.58 0.37419 3.68 3.4 -0.426903 0.00624 3.0781
Bifonazole 2.719 2.713 2.71 2.714 1.164 0.75096 4.77 4.37 -0.124378 0.00458 4.635
Clotrimazole 2.829 2.813 2.99 2.87733 1.32733 0.85634 5.2 4.13 -0.067351 0.09789 4.3719
Tolnaftate 2.848 2.865 2.843 2.852 1.302 0.84 5.4 4.55 -0.075720 0.01153 4.7549
Estradiol 1.905 1.905 1.906 1.90533 0.35533 0.22924 4.01 3.34 -0.639695 5.77350 3.0412
Diazepam 2.036 2.038 2.035 2.03633 0.48633 0.31376 2.79 2.63 -0.503397 0.00152 1.9688
3-Chlorophenol 1.791 1.793 1.792 1.792 0.242 0.15612 2.5 2.49 -0.806516 0.001 2.0917
665 Coumarin 1.831 1.832 1.838 1.83366 0.28366 0.18301 1.88 -0.737523 0.00378
666 Coumarin 1.977 1.974 1.973 1.97466 0.42466 0.27397 2.3 -0.562283 0.00208
667 Coumarin 2.018 2.018 2.019 2.01833 0.46833 0.30215 2.71 -0.519776 5.77350
668 Coumarin 2.155 2.153 2.152 2.15333 0.60333 0.38924 3.13 -0.409774 0.00152
669 Coumarin 2.405 2.408 2.408 2.407 0.857 0.55290 3.55 -0.257350 0.00173
6610 Coumarin 2.768 2.754 2.772 2.76466 1.21466 0.78365 3.97 -0.105874 0.00945
6611 Coumarin 3.365 3.362 3.362 3.363 1.813 1.16967 4.38 0.068066 0.00173
V
6612 Coumarin 4.235 4.243 4.258 4.24533 2.69533 1.73892 4.8 0.240280 0.01167
6613 Coumarin 5.367 5.29 5.248 5.30166 3.75166 2.42043 5.22 0.383892 0.06035
6615 Coumarin 8.515 8.646 8.687 8.616 7.066 4.55870 6.05 0.658841 0.08983
Coumarin 1.753 1.758 1.763 1.758 0.208 0.13419 -0.872268 0.005
EMATE 1.733 1.739 1.739 1.737 0.187 0.12064 3.73 -0.918490 0.00346
Estrone 1.946 1.995 2.007 1.98266 0.43266 0.27913 4.4 -0.554178 0.03231
665 Coumate 1.61 1.613 1.611 1.61133 0.06133 0.03956 1.21 -1.402635 0.00152
666 Coumate 1.669 1.668 1.667 1.668 0.118 0.07612 1.63 -1.118449 0.001
667 Coumate 1.7 1.7 1.71 1.70333 0.15333 0.09892 2.04 -1.004695 0.00577
668 Coumate 1.752 1.75 1.765 1.75566 0.20566 0.13268 2.46 -0.877167 0.00814
669 Coumate 1.842 1.841 1.84 1.841 0.291 0.18774 2.88 -0.726438 0.001
6610 Coumate 1.987 1.992 1.989 1.98933 0.43933 0.28344 3.29 -0.547537 0.00251
6611 Coumate 2.23 2.28 2.21 2.24 0.69 0.44516 3.71 -0.351482 0.03605
6612 Coumate 2.57 2.62 2.51 2.56666 1.01666 0.65591 4.13 -0.183153 0.05507
6613 Coumate 3.066 3.069 3.054 3.063 1.513 0.97612 4.55 -0.010492 0.00793
6615 Coumate 4.208 4.211 4.205 4.208 2.658 1.71483 5.38 0.234223 0.003
Coumate 1.559 1.558 1.557 1.558 0.008 0.00516 -2.287241 0.001
(B) 80 : 20 M ethanol: Water
Diethylstilbestrol 2.326 2.329 2.327 2.32733 0.77733 0.50150 -0.299724 0.00152
Nifedipine 2.163 2.151 2.155 2.15633 0.60633 0.39118 -0.407620 0.00611
Testosterone 3.071 3.062 3.07 3.06766 1.51766 0.97913 -0.009155 0.00493
Quinoline 2.158 2.166 2.159 2.161 0.611 0.39419 -0.404290 0.00435
3-Br-quinoline 3.124 3.114 3.116 3.118 1.568 1.01161 0.005014 0.00529
3,5-Dichlorophenol 3.005 2.981 3.015 3.00033 1.45033 0.93569 -0.028863 0.01747
Bifonazole 5.437 5.464 5.442 5.44766 3.89766 2.51462 0.400472 0.01436
Clotrimazole 5.591 5.544 5.541 5.55866 4.00866 2.58623 0.412668 0.02804
VI
Tolnaftate 6.193 6.159 6.17 6.174 4.624 2.98322 0.474686 0.01734
Estradiol 2.581 2.567 2.566 2.57133 1.02133 0.65892 -0.181164 0.00838
Diazepam 2.773 2.77 2.771 2.77133 1.22133 0.78795 -0.103497 0.00152
3-Chlorophenol 2.142 2.125 2.133 2.13333 0.58333 0.37634 _0.424414 0.00850
665 Coumarin 2.047 2.05 2.048 2.04833 0.49833 0.32150 -0.492811 0.00152
666 Coumarin 2.354 2.355 2.355 2.35466 0.80466 0.51913 -0.284715 5.77350
667 Coumarin 2.514 2.53 2.521 2.52166 0.97166 0.62688 -0.202814 0.00802
668 Coumarin 2.892 2.88 2.89 2.88733 1.33733 0.86279 -0.064092 0.00642
669 Coumarin 3.513 3.512 3.511 3.512 1.962 1.26580 0.102367 10.0000
6610 Coumarin 4.532 4.53 4.531 4.531 2.981 1.92322 0.284030 0.001
6611 Coumarin 6.458 6.457 6.45 6.455 4.905 3.16451 0.500307 0.00435
6612 Coumarin 9.916 9.911 9.914 9.91366 8.36366 5.39591 0.732065 0.00251
6613 Coumarin 15.207 15.2 15.211 15.206 13.656 8.81032 0.944991 0.00556
6615 Coumarin 30.213 30.214 30.209 30.212 28.662 18.4916 1.266974 0.00264
Coumarin 1.865 1.862 1.863 1.86333 0.31333 0.20215 -0.694325 0.00152
EMATE 2.051 2.057 2.056 2.05466 0.50466 0.32559 -0.487327 0.00321
Estrone 2.697 2.681 2.666 2.68133 1.13133 0.72989 -0.136741 0.01550
665 Coumate 1.752 1.744 1.747 1.74766 0.19766 0.12752 -0.894398 0.00404
666 Coumate 1.893 1.894 1.895 1.894 0.344 0.22193 -0.653773 10.0000
667 Coumate 1.995 1.992 1.993 1.99333 0.44333 0.28602 -0.543601 0.00152
668 Coumate 2.162 2.144 2.158 2.15466 0.60466 0.39010 -0.408815 0.00945
669 Coumate 2.46 2.44 2.465 2.455 0.905 0.58387 -0.233683 0.01322
6610 Coumate 2.936 2.941 2.929 2.93533 1.38533 0.89376 -0.048777 0.00602
6611 Coumate 3.79 3.82 3.75 3.78666 2.23666 1.44301 0.159269 0.03511
6612 Coumate 5.309 5.299 5.311 5.30633 3.75633 2.42344 0.384432 0.00642
6613 Coumate 6.523 6.519 6.526 6.52266 4.97266 3.20817 0.506257 0.00351
6615 Coumate 10.83 10.799 10.845 10.8246 9.27466 5.98365 0.776966 0.02345
Coumate 1.636 1.63 1.638 1.63466 0.08466 0.05462 -1.262619 0.00416
VII
(C) 70 : 30 M ethanol: Water
Diethylstilbestrol 4.653 4.652 4.655 4.65333 3.10333 2.00215 0.301496 0.00152
Nifedipine 2.875 2.871 2.88 2.87533 1.32533 0.85505 -0.068006 0.00450
Testosterone 5.16 5.161 5.116 5.14566 3.59566 2.31978 0.365447 0.02569
Quinoline 2.568 2.568 2.578 2.57133 1.02133 0.65892 -0.181164 0.00577
3-Br-quinoline 4.411 4.415 4.412 4.41266 2.86266 1.84688 0.266439 0.00208
3,5 -Dichlorophenol 5.088 4.986 5.01 5.028 3.478 2.24387 0.350997 0.05332
Bifonazole 14.853 14.85 14.852 14.8516 13.3016 8.58172 0.933574 0.00152
Clotrimazole 14.447 14.448 14.446 14.447 12.897 8.32064 0.920157 10.0000
Tolnaftate 16.934 16.932 16.933 16.933 15.383 9.92451 0.996709 0.001
Estradiol 3.867 3.865 3.867 3.86633 2.31633 1.49440 0.174469 0.00115
Diazepam 3.221 3.237 3.248 3.23533 1.68533 1.08731 0.036354 0.01357
3-Chlorophenol 2.606 2.61 2.599 2.605 1.055 0.68064 -0.167079 0.00556
665 Coumarin 2.519 2.521 2.518 2.51933 0.96933 0.62537 -0.203858 0.00152
666 Coumarin 3.202 3.2 3.199 3.20033 1.65033 1.06473 0.027239 0.00152
667 Coumarin 3.788 3.782 3.779 3.783 2.233 1.44064 0.158557 0.00458
668 Coumarin 4.759 4.748 4.761 4.756 3.206 2.06838 0.315631 0.007
669 Coumarin 6.505 6.499 6.509 6.50433 4.95433 3.19634 0.504653 0.00503
6610 Coumarin 9.772 9.769 9.771 9.77066 8.22066 5.30365 0.724575 0.00152
6611 Coumarin 16.861 16.854 16.869 16.8613 15.3113 9.87827 0.994681 0.00750
6612 Coumarin 33.954 33.955 33.951 33.9533 32.4033 20.9053 1.320257 0.00208
6613 Coumarin 59.109 59.047 59.07 59.0753 57.5253 37.1131 1.569527 0.03134
6615 Coumarin 77.85 78.217 76.98 77.6823 76.1323 49.1176 1.691237 0.63531
Coumarin 2.098 2.099 2.1 2.099 0.549 0.35419 -0.450759 10.0000
EMATE 3.182 3.174 3.125 3.16033 1.61033 1.03892 0.016584 0.03085
Estrone 4.162 4.161 4.159 4.16066 2.61066 1.68430 0.226419 0.00152
665 Coumate 2.018 2.022 2.02 2.02 0.47 0.30322 -0.518233 0.002
VIII
666 Coumate 2.379 2.373 2.375 2.37566 0.82566 0.53268 -0.273526 0.00305
667 Coumate 2.762 2.809 2.791 2.78733 1.23733 0.79827 -0.097844 0.02371
668 Coumate 3.256 3.263 3.259 3.25933 1.70933 1.10279 0.042495 0.00351
669 Coumate 4.258 4.252 4.256 4.25533 2.70533 1.74537 0.241889 0.00305
6610 Coumate 6.145 6.144 6.146 6.145 4.595 2.96451 0.471953 0.001
6611 Coumate 9.654 9.649 9.662 9.655 8.105 5.22903 0.718421 0.00655
6612 Coumate 16.313 16.315 16.309 16.3123 14.7623 9.52408 0.978823 0.00305
6613 Coumate 27.836 27.828 27.841 27.835 26.285 16.9580 1.229376 0.00655
6615 Coumate 60.274 60.252 60.248 60.258 58.708 37.8761 1.578365 0.014
Coumate 1.744 1.747 1.745 1.74533 0.19533 0.12602 -0.899555 0.00152
IX
( D )  D e t e r m i n e d  l o g  P  v a l u e s
Compounds Mobile
Phase
k log k log kw logP
Diethylstilbestrol 70% 2.0024 0.301550 4.16 5.07
80% 0.50151 -0.299720
90% 0.1387 -0.857923
Nifedipine 70% 0.85505 -0.068008 2.46 3.17
80% 0.39118 -0.407623
90% 0.17333 -0.761126
Testosterone 70% 2.31978 0.365446 2.74 3.29
80% 0.97914 -0.009155
90% 0.46237 -0.335010
Quinoline 70% 0.65892 -0.181167 1.56 2.03
80% 0.39419 -0.404294
90% 0.24301 -0.614375
3-Br-quinoline 70% 1.84688 0.266438 2.54 3.03
80% 1.01161 0.005013
90% 0.51828 -0.285435
3,5 -Dichlorophenol 70% 2.2439 0.351003 3.4 3.68
80% 0.94495 -0.024591
90% 0.3742 -0.426896
Bifonazole 70% 8.5817 0.933573 4.37 4.77
80% 2.51462 0.400472
90% 0.75097 -0.124377
Clotrimazole 70% 8.32065 0.920157 4.13 5.20
80% 2.58624 0.412668
90% 0.85634 -0.067353
Tolnaftate 70% 9.9245 0.996708 4.55 5.40
80% 2.98323 0.474686
90% 0.84 -0.075720
Estradiol 70% 1.49441 0.174469 3.34 4.01
80% 0.65892 -0.181167
90% 0.22925 -0.639690
Diazepam 70% 1.0873 0.036349 2.63 2.79
80% 0.788 -0.103473
90% 0.31376 -0.503402
3-Chlorophenol 70% 0.68065 -0.167076 2.49 2.50
80% 0.37634 -0.424419
90% 0.15613 -0.806513
665 Coumarin 70% 0.6254 -0.203842 1.66 2.39
80% 0.32151 -0.492805
90% 0.18301 -0.737525




667 Coumarin 70% 1.4406 0.158543 2.52 3.22
80% 0.62688 -0.202815
90% 0.30215 -0.519777
668 Coumarin 70% 2.0684 0.315634 2.84 3.52
80% 0.8628 -0.064089
90% 0.38925 -0.409771
669 Coumarin 70% 3.1963 0.504647 3.16 3.82
80% 1.26581 0.102368
90% 0.5529 -0.257353
6610 Coumarin 70% 2.9645 0.471951 3.62 4.26
80% 1.92323 0.284031
90% 0.78366 -0.105872
6611 Coumarin 70% 9.8783 0.994682 4.23 4.83
80% 3.16452 0.500307
90% 1.16968 0.068067
6612 Coumarin 70% 20.905 1.320250 5.08 5.64
80% 5.39591 0.732064
90% 1.73892 0.240279
6613 Coumarin 70% 37.113 1.569526 5.21 5.76
80% 8.81032 0.944991
90% 2.42043 0.383892
6615 Coumarin 70% 49.1176 1.691237 5.71 6.24
80% 18.4916 1.266974
90% 4.55871 0.658841
Coumarin 70% 0.35419 -0.450763 1.01 1.82
80% 0.20215 -0.694326
90% 0.13419 -0.872279
EMATE 70% 1.0389 0.016573 3.28 3.92
80% 0.32559 -0.487328
90% 0.12065 -0.918472
Estrone 70% 1.6843 0.226419 2.97 3.64
80% 0.72989 -0.136742
90% 0.27914 -0.554177
665 COUMATE 70% 0.3032 -0.518270 1.61 2.34
80% 0.1275 -0.894489
90% 0.0396 -1.402304
666 COUMATE 70% 0.5327 -0.273517 1.99 2.71
80% 0.2219 -0.653842
90% 0.0761 -1.118615
667 COUM ATE 70% 0.7983 -0.097833 2.46 3.15
80% 0.286 -0.543633
90% 0.0989 -1.004803




669 COUMATE 70% 1.7454 0.241894 3.09 3.75
80% 0.5839 -0.233661
90% 0.1877 -0.726535
6610 COUMATE 70% 2.9847 0.474900 3.26 3.92
80% 0.8938 -0.048759
90% 0.2834 -0.547600
6611 COUMATE 70% 5.229 0.718418 4.19 4.80
80% 1.443 0.159266
90% 0.4452 -0.351444
6612 COUM ATE 70% 9.5241 0.978823 5.02 5.58
80% 2.4234 0.384425
90% 0.6559 -0.183162
6613 COUM ATE 70% 16.958 1.229374 5.18 5.74
80% 3.2082 0.506261
90% 0.9761 -0.010505
6615 COUMATE 70% 37.876 1.578364 5.66 6.22
80% 5.9837 0.776969
90% 1.7148 0.234213
COUMATE 70% 0.126 -0.899629 1.01 1.77
80% 0.546 -0.262807
90% 0.0052 -2.283996
Key : —  Known log P values from the literature
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Appendix D
Table 1. Crystal data and structure refinement for 669 COUMATE (119)
Identification c o d e k00bvlp2
Empirical formula C 1 7 .5 0  H 22 .50  N 0 5  S
Formula w eight 3 5 8 .9 2
Tem perature 170(2) K
W avelength 0 .7 1 0 7 0  A
Crystal s y s te m Monoclinic
S p a c e  group P 2i/n
Unit cell d im en sion s a = 9 .9 9 6 0 (2 )A  a  = 90°
b = 1 8 .5330 (4 )A  (3 = 9 8 .4 9 7 0 (1 3 )°
c =  1 8 .9 8 9 0 (4 )A y  = 90°
V olum e 3 4 7 9 .2 1 (1 3 )  A"
Z 8
D ensity  (calculated) 1 .370  Mg/m"
Absorption coefficient 0 .2 1 4  m m '1
F(000) 1524
Crystal s iz e 0 .2 5  x 0 .2 5  x 0 .1 0  mm
T heta  range for data collection 3 .5 3  to 2 7 .8 9  °.
Index ran ges 0<=h<=13; -24<=k<=24; -24< = l< = 24
R eflections co llected 3 4 9 2 8
Independent reflections 8111 [R(int) = 0 .0517 ]
R eflections o b served  (>2cr) 6 9 5 6
R efin em ent m ethod Full-matrix lea s t -sq u a res  on F2
Data /  restraints / param eters 8111 / 0 / 4 5 9
G oodness-o f-f it  on F2 0 .9 1 3
Final R indices [l>2a(l)] Ri = 0 .0 7 5 7  w R 2 = 0 .2 1 9 5
R ind ices  (all data) R 1 = 0 .0 9 4 7  w R 2 = 0 .2 3 3 0
Largest diff. peak  and hole 0 .3 3 0  and -0 .3 6 4  e.A'"
Notes:
Asymmetric unit = 2 molecules of compound plus Vz molecule of 
hexane. Latter straddles space group inversion centre. 
Intra/intermolecular hydrogen bonding contacts involving NH2 
hydrogens. Distances/angles summarised below.
Hydrogen bonds with H..A < r(A) + 2.000 Angstroms and <DHA >110
deg.
D-H d(D-H) d(H..A) <DHA d(D..A) A
N1-H1A 0.814 2.244 160.43 3.023 O10
N1-H1A 0.814 2.629 144.54 3.325 0 9
N1-H1B 0.888 1.969 165.15 2.836 0 5  [ x+1/2, -y+1/2, z+1/2 ]
N2-H2A 0.784 2.412 175.29 3.194 0 4
N2-H2B 0.824 2.065 166.06 2.871 01 [x-1/2 ,-y+1/2 , z-1/2 ]
XIII
Table 2 : Atom ic coord inates  ( x 104) and equivalent isotropic d isp lacem en t  
param eters  (A2 x 1 0 3) for 1 .U(eq) is defined a s  o n e  third of the trace o f  the  
orthogonalized Uij tensor.
Atom X y z U(eq)
S (1) 8 3 05 (1 ) 2 9 18 (1 ) 4 4 0 7 (1 ) 27(1 )
S(2) 7 4 8 2 (1 ) 2 6 4 9 (1 ) 1281(1) 27(1 )
0 ( 1 ) 9 6 0 3 (2 ) 2 7 8 6 (2 ) 4 8 0 8 (1 ) 37(1)
0 ( 2 ) 8 180 (3 ) 3 0 80 (2 ) 3 667 (1 ) 35(1)
0 ( 3 ) 7 5 6 1 (2 ) 2 1 5 6 (1 ) 4 4 8 7 (1 ) 29(1 )
0 ( 4 ) 4 6 2 7 (2 ) 1785(1) 2 3 1 9 (1 ) 22(1 )
0 ( 5 ) 3 405 (2 ) 1606(1) 1282(1) 31(1)
0 ( 6 ) 83 33 (3 ) 2 7 1 9 (2 ) 750 (2 ) 4 2 (1 )
0(7) 8 0 35 (2 ) 2 5 8 8 (2 ) 2 0 1 1 (1 ) 34(1)
0 ( 8 ) 6 6 0 2 (2 ) 3381 (1 ) 1178(1) 31(1)
0 ( 9 ) 5129 (2 ) 3748 (1 ) 3412 (1 ) 25 (1 )
0 ( 1 0 ) 4 6 0 0 (3 ) 3 9 34 (2 ) 4 4 7 6 (1 ) 36(1)
N(1) 7 5 5 0 (3 ) 3514 (2 ) 4 7 9 5 (2 ) 33(1)
N(2) 6 4 6 4 (3 ) 1991(2) 1093(2) 32(1)
C(1) 6 2 4 5 (3 ) 20 7 2 (2 ) 4 1 1 3 (2 ) 25(1 )
C(2) 6 0 7 3 (3 ) 1958(2) 33 87 (2 ) 22(1 )
C(3) 4 7 5 6 (3 ) 1880(2) 3047 (2 ) 20(1 )
C(4) 3 379 (3 ) 1699(2) 1916(2) 22 (1 )
C(5) 2 1 7 0 (3 ) 1743(2) 2 2 5 9 (2 ) 23(1)
C(6) 867 (3 ) 1657(2) 1749(2 ) 28 (1 )
C(7) 501 (4 ) 865 (2 ) 1547(2) 37(1)
C(8) -791(4 ) 592(2 ) 1815(2) 39(1)
C(9) -909(4 ) 741 (2 ) 2 5 8 9 (2 ) 39(1)
C(10) 338(4 ) 567 (2 ) 31 40 (2 ) 38(1)
C(11) 7 05 (4 ) 1173(2) 36 86 (2 ) 33(1)
C(12) 1066(3) 1896(2) 33 60 (2 ) 26(1 )
C (1 3) 2 2 7 9 (3 ) 1841(2) 2 9 7 5 (2 ) 22(1 )
C(14) 36 22 (3 ) 1899(2) 3 3 9 4 (2 ) 21(1 )
C(15) 3869 (3 ) 20 0 2 (2 ) 4 1 3 7 (2 ) 26(1 )
C (16) 5 165 (3 ) 20 9 0 (2 ) 4 4 9 7 (2 ) 28(1 )
C(17) 55 55 (3 ) 3456 (2 ) 1596(2 ) 26(1 )
C(18) 5861 (3 ) 3579 (2 ) 2 3 1 8 (2 ) 24(1 )
C (19) 4 7 8 2 (3 ) 3 6 48 (2 ) 2 6 9 5 (2 ) 22 (1 )
C (20) 4 1 6 3 (3 ) 3 8 34 (2 ) 38 5 6 (2 )  _ 27(1 )
C(21) 2 7 3 6 (3 ) 3778 (2 ) 35 44 (2 ) 25(1 )
C (22) 1791(4) 3 8 70 (2 ) 4 0 9 0 (2 ) 29 (1 )
C(23) 1564(4) 4 6 7 5 (2 ) 4 2 6 7 (2 ) 37(1)
C(24) 131(4) 4 9 5 7 (2 ) 4 0 4 0 (2 ) 42(1 )
C(25) -505(4 ) 4 7 9 0 (2 ) 3 277 (2 ) 38(1)
C(26) 365(4 ) 4 9 4 4 (2 ) 2 6 8 7 (2 ) 36(1)
0 ( 2 7 ) 366(4 ) 4 3 2 4 (2 ) 2 1 5 4 (2 ) 32(1)
XIV
C (28) 920(3 ) 3 6 12 (2 ) 2 4 8 7 (2 ) 26(1 )
C(29) 2 3 7 8 (3 ) 3671 (2 ) 2 8 37 (2 ) 24(1 )
C(30) 3 4 32 (3 ) 3610 (2 ) 23 8 3 (2 ) 22(1)
C(31) 31 86 (3 ) 3 501 (2 ) 1644(2) 27(1 )
C(32) 4 2 3 1 (4 ) 3423 (2 ) 1247(2) 28(1 )
C (101) 55 47 (4 ) -24(2) 4 7 6 4 (2 ) 46 (1 )
C (102) 6 8 9 8 (5 ) 284 (3 ) 50 99 (3 ) 50(1)
C (103) 7 9 9 9 (6 ) 200 (3 ) 4 6 3 3 (3 ) 68(2 )
XV
Table 3 : Bond lengths [A] and a n g le s  [°] for 1.
S ( 1 ) - 0 ( 1 ) 1 .424(3)
S ( 1 ) - 0 ( 2 ) 1 .424(2)
S(1)-N (1) 1 .581(4)
S ( 1 ) - 0 ( 3 ) 1 .614(3)
S ( 2 ) - 0 ( 6 ) 1 .418(3)
S ( 2 ) - 0 ( 7 ) 1 .420(2)
S(2)-N (2) 1.595(3)
S (2 ) - 0 ( 8 ) 1 .613(3)
0 (3 )-C (1 ) 1 .407(4)
0 (4 ) -C (4 ) 1 .373(4)
0 (4 )-C (3 ) 1 .379(4)
0 (5 )-C (4 ) 1 .219(4)
0 (8 ) -C (1 7 ) 1 .409(4)
0 (9 ) -C (1 9 ) 1 .367(4)
O (9)-C (20) 1 .382(4)
O (10)-C (20) 1 .207(4)
C(1)-C(2) 1 .382(4)
C(1)-C (16) 1 .390(5)
C(2)-C(3) 1 .386(4)
C(3)-C (14) 1 .394(4)
C(4)-C(5) 1 .457(4)





C (9)-C (10) 1 .538(5)
C (10)-C (11) 1 .536(6)
C (11)-C (12) 1 .541(5)
C (12)-C (13) 1 .509(4)
C (13)-C (14) 1 .459(4)
C (14)-C (15) 1 .409(4)
C (15)-C (16) 1 .382(5)
C (17)-C (18) 1 .380(5)
C (17)-C (32) 1 .390(5)
C (18)-C (19) 1 .386(4)
C (19)-C (30) 1 .394(4)
C (20)-C (21) 1 .466(5)
C (21)-C (29) 1 .353(5)
C (21)-C (22) 1.512(4)
C (22)-C (23) 1.552(5)
C (23)-C (24) 1.526(6)
C (24)-C (25) 1 .524(6)
C (25)-C (26) 1 .544(5)
C (26)-C (27) 1 .532(5)
C (27)-C (28) 1 .531(5)
XVI
C (28)-C (29) 1 .514(4)
C (29)-C (30) 1 .461(4)
C (30)-C (31) 1 .403(5)
C (31)-C (32) 1 .383(5)
C (101)-C (101)#1 1.515(9)
C (101 )-C (102 ) 1 .516(6)
C (102 )-C (103 ) 1 .519(7)
0 ( 1  )-S(1 ) -0 (2 ) 1 20 .25 (16 )
0 (1 )-S (1 )-N (1 ) 1 09 .28 (17 )
0 (2 )-S (1 )-N (1 ) 1 09 .49 (18 )
0 ( 1 ) - S ( 1 ) - 0 ( 3 ) 101 .3 2 (1 5 )
0 ( 2 ) - S ( 1 ) - 0 ( 3 ) 107 .67 (14 )
N (1 ) -S (1 ) -0 (3 ) 108 .00 (16 )
0 ( 6 ) - S ( 2 ) - 0 ( 7 ) 120 .8 7 (1 7 )
0 (6 )-S (2 )-N (2 ) 109 .96 (19 )
0 (7 )-S (2 )-N (2 ) 1 07 .50 (18 )
0 ( 6 ) - S ( 2 ) - 0 ( 8 ) 1 02 .23 (15 )
0 ( 7 ) - S ( 2 ) - 0 ( 8 ) 108 .1 7 (1 4 )
N (2 ) -S (2 ) -0 (8 ) 107 .33 (15 )
C (1 ) -0 (3 )-S (1 ) 117 .3(2)
C (4 )-0 (4 )-C (3 ) 121 .1(2)
C (1 7 ) -0 (8 ) -S (2 ) 116 .9(2)
C (19)-O (9)-C (20) 121 .7(3)
C (2)-C (1)-C (16) 122 .4(3)
C (2 )-C (1 )-0 (3 ) 119 .3(3)
C (1 6 ) -C (1 ) -0 (3 ) 118 .3(3)
C(1)-C (2)-C (3) 116 .8(3)
0 (4 )-C (3 )-C (2 ) 115 .0(3)
0 (4 )-C (3 )-C (1 4 ) 121 .0(3)
C (2)-C (3)-C (14) 124 .1(3)
0 ( 5 ) - C ( 4 ) - 0 ( 4 ) 114 .6(3)
0 (5 )-C (4 )-C (5 ) 126 .1(3)
0 (4 )-C (4 )-C (5 ) 119 .2(3)
C (13)-C (5)-C (4) 120 .4(3)
C (13)-C (5)-C (6) 126 .1(3)
C (4)-C (5)-C (6) 113 .6(3)
C (5)-C (6)-C (7) 114 .0(3)
C(8)-C (7)-C (6) 114 .1(3)
C(9)-C (8)-C (7) 116 .6(3)
C (8)-C (9)-C (10) 116 .7(3)
C ( 1 1 )-C (10)-C (9) 113 .3(3)
C (10)-C (11)-C (12) 114 .3(3)
C (1 3 )-C (1 2 )-C (1 1) 112 .9(3)
C (5)-C (13)-C (14) 119 .1(3)
C (5)-C (13)-C (12) 122 .8(3)
C (14)-C (13)-C (12) 118 .1(3)
C (3)-C (14)-C (15) 116 .2(3)
XVII
C (3)-C (14)-C (13) 119 .2(3)
C (15)-C (14)-C (13) 124 .5(3)
C (16)-C (15)-C (14) 121 .7(3)
C(15)-C (16)-C (1) 118 .8(3)
C (18)-C (17)-C (32) 122 .4(3)
C (1 8 ) -C (1 7 ) -0 (8 ) 120 .1(3)
C (3 2 ) -C (1 7 ) -0 (8 ) 117 .5(3)
C (17)-C (18)-C (19) 117 .0(3)
0 (9 )-C (1 9 )-C (1 8 ) 115 .2(3)
O (9)-C (19)-C (30) 121 .2(3)
C (18)-C (19)-C (30) 123 .6(3)
0 (1 0 ) - C ( 2 0 ) - 0 ( 9 ) 115 .3(3)
0 (1 0 )-C (2 0 )-C (2 1 ) 126 .5(3)
O (9)-C (20)-C (21) 118 .1(3)
C (29)-C (21)-C (20) 120 .7(3)
C (29)-C (21)-C (22) 126 .7(3)
C (20)-C (21)-C (22) 112 .6(3)
C (21)-C (22)-C (23) 112 .5(3)
C (24)-C (23)-C (22) 115 .4(3)
C (25)-C (24)-C (23) 116 .1(3)
C (24)-C (25)-C (26) 116 .8(3)
C (27)-C (26)-C (25) 113 .4(3)
C (28)-C (27)-C (26) 114 .1(3)
C (29)-C (28)-C (27) 112 .7(3)
C (21)-C (29)-C (30) 119 .3(3)
C (21)-C (29)-C (28) 122 .9(3)
C (30)-C (29)-C (28) 117 .8(3)
C (19)-C (30)-C (31) 116 .7(3)
C (19)-C (30)-C (29) 118 .8(3)
C (31)-C (30)-C (29) 124 .5(3)
C (32)-C (31)-C (30) 121 .7(3)
C (31)-C (32)-C (17) 118 .6(3)
C (10 1 )# 1 -C (1 0 1 )-C (1 0 2 ) 114 .0(4)
C (101 )-C (102 )-C (103 ) 113 .2(4)
Sym m etry  transformations u se d  to ge n e r a te  equivalent atom s:  
#1 -x+1,-y,-z+1
XVIII
T a b le  4  : Anisotropic d isp lacem en t param eters  (A2 x 1 0 3J for 1. T h e
anisotropic d isp lacem en t factor ex p o n en t  ta k es  the form: -2 gpi [ h2 a*2 U 1 1 
+ ... + 2 h k a* b* U
A to m U11 U 22 U 33 U 23 U 13 U 12
S (1 ) 21(1 ) 42(1 ) 18(1) 4 (1) -1(1) -6(1)
S (2 ) 19(1) 4 1 (1 ) 21(1) 2(1) 6(1) 5(1)
0 ( 1 ) 2 1(1 ) 61(2 ) 28(1) 3(1) -2(1) -5(1)
0 ( 2 ) 31 (1 ) 53(2) 2 1(1 ) 7(1) 1(1) -13 (1 )
0 ( 3 ) 24(1 ) 37(1) 24(1 ) 5(1) -5(1) -1(1)
0 ( 4 ) 19(1) 29(1 ) 17(1) -2(1) 4(1) -1(1)
0 ( 5 ) 28(1 ) 4 5 (2 ) 20(1) -4(1) 2(1) -1(1)
0 ( 6 ) 33(1) 62(2 ) 36(2) 4 (1) 21(1 ) 5(1)
0 ( 7 ) 25(1 ) 52(2) 24(1) -3(1) 0(1) 10(1)
0 ( 8 ) 31(1) 37(1) 27(1) 9(1) 12(1) 7(1)
0 ( 9 ) 2 2(1 ) 32(1 ) 21(1) -2(1) 2(1) 3(1)
0 ( 1 0 ) 32(1) 50(2) 26(1) -6(1) 3(1) 4(1)
N(1) 31(2) 4 2 (2 ) 25(2 ) 1(1) -5(1) -1(1)
N(2) 2 8(2 ) 41 (2 ) 26(2 ) -2(1) 2(1) 5(1)
C(1) 2 2(2 ) 26 (2 ) 26(2 ) 4(1) 1(1) -1(1)
C(2) 20(1) 25(2) 22(2) 2(1) 4(1) 0(1)
C(3) 2 2(1 ) 22(1) 17(1) 0(1) 3(1) 0(1)
C(4) 23(2 ) 24 (2 ) 20(1) 1(1) 1(1) 0(1)
C(5) 19(1) 21 (1 ) 28(2) 2(1) 4 (1 ) 0(1)
C(6) 20(2 ) 32(2) 30(2) 2(1) -1(1) 2(1)
C(7) 26(2 ) 42 (2 ) 4 1(2 ) -14(2) -4(2) 1(2)
C(8) 27(2 ) 30(2) 58(3) -8(2) -1(2) -2(1)
C(9) 30(2) 31(2) 55(2) 2(2) 5(2) -7(2)
C (10) 36(2 ) 30(2) 47(2 ) 5(2) 6(2) -4(2)
C (11) 28(2 ) 37(2) 38(2) 6(2) 13(2) -5(1)
C (12) 22(2 ) 26 (2 ) 33(2) -2(1) 8(1) -1(1)
C (13) 21(1 ) 20(1) 2 4(2 ) 1(1) 6(1) -2(1)
C (14) 22 (1 ) 22(1 ) 20(1 ) 0(1) 5(1) 0(1)
C (15) 25(2 ) 31(2) 22(2 ) -1(1) 8(1) -3(1)
C (16) 29(2 ) 35(2) 19(1) 2(1) 5(1) -3(1)
C (17) 25(2) 28(2) 26(2) 3(1) 8(1) 4(1)
C (18) 19(1) 24(2 ) 28(2) 2(1) 2(1) 2(1)
C (19) 24(2 ) 21(1) 22(2 ) 0(1) 3(1) 2(1)
C (20) 28(2 ) 28(2) 25(2 ) 1(1) 8(1) 1(1)
C (21) 25(2 ) 20(1 ) 30(2) 3(1) 6(1) 2(1)
C (22) 29(2 ) 33(2) 28(2) 5(1) 12(1) 1(1)
C (23) 35(2) 41(2 ) 38(2) -9(2) 14(2) 1(2)
C (24) 38(2) 4 2 (2 ) 51(2) -3(2) 22(2 ) 7(2)
C (25) 29(2 ) 36(2) 51(2) -4(2) 13(2) 10(2)
C (26) 40(2 ) 26(2 ) 43 (2 ) 3(2) 9(2) 6(2)
C (27) 24(2 ) 34(2) 38(2) 3(2) 1(1) 5(1)
C (28) 18(1) 29(2 ) 31(2) -2(1) 2(1) 0(1)
XIX
C (29) 19(1) 20(1) 33(2) 2(1) 5(1) 3(1)
C(30) 22(1) 21(1) 24(2) 1(1) 2(1) 3(1)
C (31) 24(2) 25(2) 30(2) 0(1) -2(1) 4(1)
C (32) 32(2) 30(2) 22(2) 0(1) 1(1) 7(1)
C (101) 52(3) 48(2) 36(2) -5(2) 5(2) -7(2)
C (102) 52(3) 47(2) 52(3) 0(2) 6(2) -1(2)
C (103) 58(3) 65(3) 87(4) -8(3) 27(3) -9(3)
XX
Table 5 : Hydrogen coord inates  ( x 104) and isotropic d isp lacem en t
param eters  (A2 x 103) for 1.
Atom X y z U(eq)
H(1A) 6 8 1 0 (5 0 ) 3 6 5 0 (3 0 ) 4 6 1 0 (3 0 ) 50 (14 )
H(1B) 7 6 8 0 (5 0 ) 3 4 3 0 (2 0 ) 5 2 6 0 (3 0 ) 4 5 (1 3 )
H(2A) 6 0 5 0 (5 0 ) 1920(30) 1400 (30 ) 4 1 (1 3 )
H(2B) 6 0 4 0 (6 0 ) 2 0 3 0 (3 0 ) 6 9 0 (3 0 ) 5 8 (16 )
H(2) 6 8 2 2 1933 3 1 3 2 2 7
H(6A) 9 4 4 1930 1308 34
H(6B) 120 1873 1966 34
H(7A) 3 8 2 8 1 8 1022 4 5
H(7B) 1266 551 1746 4 5
H(8A) -1 5 8 0 8 1 3 1 516 4 7
H(8B) -852 6 4 1737 4 7
H(9A) -1 6 8 3 4 6 0 2 7 1 3 4 6
H(9B) -1 1 2 8 1258 2 6 3 5 4 6
H(10A) 162 119 3 3 9 5 4 5
H(10B) 1 120 4 7 6 2 8 8 7 4 5
H(11A) 1 483 1014 4 0 3 5 4 0
H(11B) -69 1252 3 9 4 8 4 0
H(12A) 2 8 0 2 0 6 5 3 0 2 2 32
H(12B) 1252 2 2 5 9 3 7 4 4 32
H(15) 3 1 2 7 2 0 1 0 4 3 9 7 31
H(16) 5 3 1 4 2 1 6 2 4 9 9 8 33
H(18) 6771 36 1 5 2 5 4 7 2 9
H(22A) 2 1 7 0 3 6 1 4 4 5 3 2 35
H(22B) 90 8 3 6 4 6 3 9 0 7 35
H(23A) 1802 4 7 4 2 4 7 8 7 4 5
H(23B) 2 1 9 4 4 9 7 3 4 0 3 3 4 5
H(24A) -4 5 8 4 7 5 3 4 3 6 6 51
H(24B) 141 5 4 8 7 4 1 0 4 51
H(25A) -1 3 5 2 5 0 7 2 3171 4 6
H(25B) -757 4 2 7 3 3 2 5 2 4 6
H(26A) 22 5 3 8 6 2 4 2 7 4 3
H(26B) 1308 5 0 3 9 2911 4 3
H(27A) -572 4 2 4 5 1915 39
H(27B) 9 1 5 4 4 6 9 1 784 39
H(28A) 3 5 7 3 4 5 8 2 8 4 7 31
H(28B) 851 3 2 3 7 2 1 1 2 31
H(31) 2 2 7 9 3 4 8 0 1410 32
H(32) 4 0 4 9 3 3 4 9 7 4 7 34
H(10C) 5 2 4 0 2 3 7 4 3 1 5 55
H(10D) 5 6 7 5 -537 4 6 4 4 55
H(10E) 7 1 8 8 39 5 5 6 0 6 0
H(10F) 6 7 8 3 8 0 3 5 1 9 8 6 0
H(10G) 8 8 4 6 4 0 5 4 8 7 8 102
XXI
H(1 OH) 7 7 3 2 4 5 4 4181 102
H(1 Ol) 8 1 3 0 -313 4 5 3 9 102
XXII
Table 1. Crystal data and structure refinement for 6610 COUMATE 
(122)
Identification c o d e k00bvlp3
Empirical formula C 1 8 .5 0  H 24 .50  N 0 5  S
Formula weight 3 7 2 .9 5
T em perature 170(2)  K
W avelength 0 .7 1 0 7 0  A
Crystal s y s te m Monoclinic
S p a c e  group P 2i/n
Unit cell d im en sion s a = 9 .9 0 3 0 (2 )A  a  = 90°
b = 19 .3 4 5 0 (3 )A  3 = 9 7 .6 7 9 0 (1 0 )°
c =  1 9 .3 0 2 0 (3 )A y  = 90°
V olum e 3 6 6 4 .5 9 (1 1 )  A"
Z 8
D ensity  (calculated) 1 .352  Mg/m3
Absorption coefficient 0 .2 0 6  m m '1
F(000) 1588
Crystal s iz e 0 . 3 0 x 0 . 2 0 x 0 . 2 0  mm
T heta  range for data collection 3 .5 7  to 2 7 .5 0  °.
Index ran ges 0<=h<=12; -25<=k<=25; - 
2 5< = l< = 24
R eflections collected 4 8 8 9 6
Independent reflections 8 3 8 9  [R(int) = 0 .0563 ]
R eflections o b served  (>2a) 6 2 9 2
R efin em ent m ethod Full-matrix lea s t -sq u a re s  on F2
Data / restraints /  param eters 8 3 8 9 / 0 / 4 7 7
G oodness-o f-f it  on F2 1 .433
Final R indices [l>2a(l)] R 1 = 0 .0 6 0 7  w R 2 = 0 .1 8 9 8
R ind ices  (all data) R 1 = 0 .0 8 4 2  w R 2 = 0 .2 0 4 9
Largest diff. peak  and hole 1 .023  and -0 .6 0 5  e .A '3
Notes:
Asymmetric unit = 2 molecules of compound plus Vz molecule of 
hexane. Latter straddles space group inversion centre. 
Intra/intermolecular hydrogen bonding contacts involving NH2 
hydrogens. Distances/angles summarised below.




N1-H1A 0.711 2.154 165.73 2.849 0 5  [x -1 /2 ,-y + 1 /2 ,  z-1/2 ]
N1-H1B 0.836 2.211 152.95 2.980 O10
N1-H1B 0.836 2.588 153.38 3.356 0 9
N2-H2A 0.744 2.551 169.19 3.284 0 4
N2-H2A 0.744 2 .587 130.47 3.122 0 5
N2-H2B 1.018 1.919 158.21 2.889 0 2  [ x+1/2, -y+1/2, z+1/2  ]
XXIII
Table 2 : Atom ic coord inates  ( x 104) and equivalent isotropic d isp lacem en t  
param eters  (A2 x 103) for 1 .U(eq) is defined a s  o n e  third of the  trace o f  the  
orthogonalized  Uij tensor.
Atom X y z U(eq)
S (1 ) 1653(1) 2 2 6 4 (1 ) 693 (1 ) 29(1 )
S (2) 2 4 7 0 (1 ) 2 2 9 5 (1 ) 3 8 28 (1 ) 32(1)
0 ( 1 ) 1743(2) 2 0 8 1 (1 ) 1409(1) 37(1)
0 ( 2 ) 367(2 ) 2 4 1 6 (1 ) 2 99 (1 ) 38(1)
0 ( 3 ) 2 4 3 3 (2 ) 2 9 9 1 (1 ) 642 (1 ) 31(1)
0 ( 4 ) 5 3 00 (2 ) 3 258 (1 ) 2 7 9 7 (1 ) 27(1 )
0 ( 5 ) 6 4 7 6 (2 ) 3268 (1 ) 3834 (1 ) 33(1)
0 ( 6 ) 1927(2) 2 4 0 7 (1 ) 3 1 19 (1 ) 4 3(1 )
0 ( 7 ) 1606(2 ) 2 1 88 (1 ) 4 3 4 5 (1 ) 4 9 (1 )
0 ( 8 ) 3 3 52 (2 ) 1594(1) 3 8 72 (1 ) 37(1)
0 ( 9 ) 4 8 2 1 (2 ) 1367(1) 1647(1 ) 32(1)
0 ( 1 0 ) 5 341 (2 ) 1312(1) 584(1 ) 43 (1 )
N(1) 2 4 0 9 (3 ) 1703(1) 296 (1 ) 37(1)
N(2) 3 495 (2 ) 2 9 08 (1 ) 4 0 6 2 (2 ) 37(1)
C(1) 3 749 (2 ) 3 0 56 (1 ) 1023(1) 28(1 )
C(2) 3 8 8 7 (2 ) 3142 (1 ) 1731(1 ) 2 7(1 )
C(3) 5 204 (2 ) 3200 (1 ) 2 0 8 3 (1 ) 24(1 )
C(4) 6 5 3 7 (2 ) 3262 (1 ) 3 2 10 (1 ) 26(1 )
C(5) 7 7 8 2 (2 ) 3 2 50 (1 ) 2 8 8 2 (1 ) 26(1 )
C(6) 9 0 66 (2 ) 3204 (1 ) 3 401 (1 ) 32(1)
C(7) 9 4 70 (3 ) 3835 (1 ) 3 8 65 (1 ) 36(1)
C(8) 9 7 2 3 (3 ) 4 5 1 9 (2 ) 3 5 23 (2 ) 51(1)
C(9) 10970 (3 ) 4 6 1 0 (2 ) 3 180 (2 ) 66(1 )
C (10) 10945 (3 ) 4 2 9 5 (2 ) 2 4 8 7 (2 ) 81(1 )
C(11) 9 6 6 5 (3 ) 4 4 2 9 (1 ) 1907(2 ) 50(1)
C(12) 9 3 30 (3 ) 3 816 (1 ) 1421(1) 36(1)
C (1 3) 8 9 4 1 (2 ) 3150 (1 ) 1787(1 ) 29(1 )
C(14) 7 7 0 9 (2 ) 3 211 (1 ) 2 1 7 0 (1 ) 25(1)
C( 15) 6 3 6 8 (2 ) 3 187(1 ) 1750(1) 24(1 )
C(16) 6 1 5 0 (2 ) 3 109 (1 ) 1017(1 ) 28(1 )
C(17) 4 8 6 1 (2 ) 3 042 (1 ) 656 (1 ) 30(1)
C(18) 4 4 0 6 (2 ) 1546(1) 3 449 (1 ) 30(1)
C (19) 4 0 9 6 (2 ) 1478(1) 2 7 4 0 (1 ) 29 (1 )
C (20) 51 8 1 (2 ) 1420(1) 2 3 5 7 (1 ) 26(1 )
C(21) 57 95 (3 ) 1337(1) 1203(1) 31(1)
C (22) 7 2 3 1 (2 ) 1355(1) 1488(1) 29(1 )
C(23) 81 81 (3 ) 1389(1) 938(1 ) 37(1)
C (24) 8 2 6 5 (3 ) 753 (1 ) 4 6 4 (1 ) 40(1 )
C(25) 86 48 (3 ) 66(1) 808(2 ) 45 (1 )
C(26) 10097 (4 ) -54(2) 1149(2 ) 69(1)
C (27) 10520 (3 ) 261(2 ) 1824(2 ) 65(1 )
C(28) 9 621 (3 ) 155(1) 24 2 0 (2 ) 4 4 (1 )
XXIV
C(29) 9 6 33 (3 ) 775(1 ) 2 8 9 6 (1 ) 36(1)
C(30) 9067 (2 ) 1444(1) 2 5 33 (1 ) 34(1)
C(31) 7 6 0 7 (2 ) 1396(1) 21 9 1 (1 ) 28(1 )
C(32) 6 5 4 0 (2 ) 1427(1) 2 6 5 4 (1 ) 26(1 )
C(33) 6 7 8 8 (3 ) 1489(1) 3 3 82 (1 ) 31(1)
C(34) 5 7 35 (3 ) 1548(1) 3 7 82 (1 ) 33(1)
C (101) 1982(5) 4 8 2 3 (2 ) 391(3 ) 104(2)
C (102) 3 073 (5 ) 4 7 4 4 (2 ) -85(2) 84(1)
C (103) 4 4 3 0 (4 ) 5028 (2 ) 222 (2 ) 71(1)
XXV
Table 3 : Bond lengths [A] and a n g le s  [°] for 1.
S ( 1 ) - 0 ( 1 ) 1 .4180 (18 )
S ( 1 ) - 0 ( 2 ) 1 .42 3 7 (1 7 )
S(1)-N (1) 1 .576(2)
S ( 1 ) - 0 ( 3 ) 1 .6141 (17 )
S ( 2 ) - 0 ( 7 ) 1 .4146 (19 )
S ( 2 ) - 0 ( 6 ) 1 .4187 (19 )
S(2)-N (2) 1 .587(2)
S ( 2 ) - 0 ( 8 ) 1 .60 8 6 (1 7 )
0 (3 )-C (1 ) 1 .413(3)
0 (4 ) -C (4 ) 1 .369(3)
0 (4 )-C (3 ) 1 .373(3)
0 (5 ) -C (4 ) 1.215(3)
0 (8 ) -C (1 8 ) 1 .412(3)
O (9)-C (20) 1.373(3)
0 (9 ) -C (2 1 ) 1 .374(3)
O (10)-C (21) 1 .220(3)
C(1)-C(2) 1 .366(3)
C (1)-C (17) 1 .388(3)
C(2)-C(3) 1 .392(3)
C (3)-C (15) 1 .394(3)
C(4)-C(5) 1 .459(3)






C (10)-C (11) 1.597(5)
C (11)-C (12) 1 .520(4)
C (12)-C (13) 1 .543(3)
C (13)-C (14) 1 .514(3)
C (14)-C (15) 1 .461(3)
C (15)-C (16) 1 .410(3)
C (16)-C (17) 1 .377(3)
C (18)-C (19) 1 .367(3)
C (18)-C (34) 1 .386(3)
C (19)-C (20) 1 .389(3)
C (20)-C (32) 1 .391(3)
C (21)-C (22) 1.454(4)
C (22)-C (31) 1.361(3)
C (22)-C (23) 1.510(3)
C (23)-C (24) 1 .543(3)
C (24)-C (25) 1 .511(4)
C (25)-C (26) 1 .514(5)
C (26)-C (27) 1 .447(5)
C (27)-C (28) 1 .560(4)
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C (28)-C (29) 1 .510(4)
C (29)-C (30) 1 .542(3)
C (30)-C (31) 1 .510(3)
C (31)-C (32) 1 .474(3)
C (32)-C (33) 1 .398(3)
C (33)-C (34) 1 .383(4)
C (101 )-C (102 ) 1 .518(6)
C (102 )-C (103 ) 1 .498(6)
C (103)-C (103)#1 1.510(8)
0 ( 1 ) - S ( 1 ) - 0 ( 2 ) 120 .52 (11 )
0 (1 )-S (1 )-N (1 ) 109 .25 (13 )
0 (2 )-S (1 )-N (1 ) 109 .3 3 (1 3 )
0 ( 1  )-S(1 ) -0 (3 ) 108 .02 (10 )
0 ( 2 ) - S ( 1 ) - 0 ( 3 ) 100 .92 (10 )
N (1 ) -S (1 ) -0 (3 ) 107 .94 (11 )
0 ( 7 ) - S ( 2 ) - 0 ( 6 ) 121 .09 (13 )
0 (7 )-S (2 )-N (2 ) 109 .40 (14 )
0 (6 )-S (2 )-N (2 ) 1 07 .83 (14 )
0 ( 7 ) - S ( 2 ) - 0 ( 8 ) 1 02 .43 (11 )
0 ( 6 ) - S ( 2 ) - 0 ( 8 ) 1 08 .22 (10 )
N (2 ) -S (2 ) -0 (8 ) 1 07 .02 (11 )
C (1 ) -0 (3 )-S (1 ) 1 17 .43 (14 )
C (4 )-0 (4 )-C (3 ) 121 .40 (18 )
C (1 8 ) -0 (8 ) -S (2 ) 117 .61 (14 )
C(20)-O (9)-C (21) 120 .97 (19 )
C (2)-C (1)-C (17) 122.2(2)
C (2 )-C (1 )-0 (3 ) 119 .6(2)
C (1 7 )-C (1 )-0 (3 ) 118 .2(2)
C (1)-C (2)-C (3) 117 .4(2)
0 (4 )-C (3 )-C (2 ) 115 .5(2)
0 (4 )-C (3 )-C (1 5 ) 120 .9(2)
C (2)-C (3)-C (15) 123 .5(2)
0 (5 ) - C ( 4 ) - 0 ( 4 ) 114 .7(2)
0 (5 )-C (4 )-C (5 ) 125 .9(2)
0 (4 )-C (4 )-C (5 ) 119 .4(2)
C (14)-C (5)-C (4) 120 .1(2)
C (14)-C (5)-C (6) 126 .1(2)
C(4)-C (5)-C (6) 113 .5(2)
C(5)-C (6)-C (7) 118 .1(2)
C(8)-C(7)-C(6) 119 .1(2)
C (9)-C (8)-C (7) 119 .5(3)
C (10)-C (9)-C (8) 116 .3(3)
C (9 )-C (10 )-C (11) 119 .1(3)
C (12)-C (11)-C (10) 113 .2(2)
C (1 1 )-C (12)-C (13) 114 .6(2)
C (14)-C (13)-C (12) 1 15 .17 (19 )
C(5)-C (14)-C (15) 118 .8(2)
XXVII
C (5)-C (14)-C (13) 123 .9(2)
C (15)-C (14)-C (13) 117 .3(2)
C (3)-C (15)-C (16) 116 .1(2)
C (3)-C (15)-C (14) 119 .3(2)
C (16)-C (15)-C (14) 124.5(2)
C (17)-C (16)-C (15) 121 .7(2)
C (16)-C (17)-C (1) 119 .0(2)
C (19)-C (18)-C (34) 122 .5(2)
C (1 9 ) -C (1 8 )-0 (8 ) 120.1(2)
C (3 4 )-C (1 8 ) -0 (8 ) 117 .4(2)
C (18)-C (19)-C (20) 117 .1(2)
O (9)-C (20)-C (19) 115 .0(2)
O (9)-C (20)-C (32) 121.4(2)
C (19)-C (20)-C (32) 123 .6(2)
O (10)-C (21)-O (9) 114 .4(2)
O (10)-C (21)-C (22) 125 .8(2)
0 (9 )-C (2 1 )-C (2 2 ) 119.8(2)
C (31)-C (22)-C (21) 120 .1(2)
C (31)-C (22)-C (23) 125 .8(2)
C (21)-C (22)-C (23) 113 .9(2)
C (22)-C (23)-C (24) 118 .0(2)
C (25)-C (24)-C (23) 118 .1(2)
C (24)-C (25)-C (26) 119 .5(3)
C (27)-C (26)-C (25) 118 .1(3)
C (26)-C (27)-C (28) 118.9(3)
C (29)-C (28)-C (27) 112 .7(3)
C (28)-C (29)-C (30) 114 .7(2)
C (31)-C (30)-C (29) 114 .5(2)
C (22)-C (31)-C (32) 119.0(2)
C (22)-C (31)-C (30) 123 .9(2)
C (32)-C (31)-C (30) 117 .0(2)
C (20)-C (32)-C (33) 116.5(2)
C (20)-C (32)-C (31) 118 .8(2)
C (33)-C (32)-C (31) 124 .7(2)
C (34)-C (33)-C (32) 121.6(2)
C (33)-C (34)-C (18) 118 .7(2)
C (103 )-C (102 )-C (101 ) 113.4(4)
C (102 )-C (103)-C (103)#1 116.6(4)
Sym m etry  transformations u se d  to ge n e r a te  equivalent atom s:  
#1 -x+1 ,-y+1 ,-z
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T a b le  4  : Anisotropic d isp lacem en t param eters (A2 x 103) for 1. T he  
anisotropic d isp lacem en t factor ex p o n en t  ta k es  the  form: -2 gpi2 [ h2 a*2 U 1 1 
+ ... + 2 h k a* b* U
Atom U11 U22 U33 U23 U13 U12
S (1) 22(1 ) 43 (1 ) 23(1) 1(1) 1(1) -4(1)
S (2) 21(1) 4 5 (1 ) 30(1) -1(1) 7(1) 3(1)
0 ( 1 ) 33(1) 54(1) 24(1 ) 5(1) 2(1) -11(1)
0 ( 2 ) 2 1(1 ) 60(1) 30(1) -1 (1) . -2(1) -2 (1)
0 ( 3 ) 24(1) 39(1) 28(1 ) 4(1) -3(1) -2(1)
0 ( 4 ) 21(1) 37(1) 23(1 ) -3(1) 4(1) -2 (1 )  .
0 ( 5 ) 31(1) 4 4(1 ) 24(1 ) -2(1) 3(1) -4(1)
0 ( 6 ) 28(1 ) 67(1 ) 31(1) -9(1) -5(1) 13(1)
0 ( 7 ) 38(1) 66(1) 4 9 (1 ) 2(1) 25 (1 ) 2(1)
0 ( 8 ) 36(1) 4 2(1 ) 36(1) 7(1) 18(1) 7(1)
0 ( 9 ) 28(1 ) 39(1) 28(1) -2(1) 4(1) 5(1)
0 ( 1 0 ) 4 6 (1 ) 54(1) 28(1) -1(1) 4 (1 ) 12(1)
N(1) 36(1) 4 8(1 ) 26(1) -4(1) -3(1) 3(1)
N(2) 29(1 ) 44(1 ) 38(1) -2(1) 5(1) 3(1)
C(1) 23(1) 30(1) 28(1 ) 1(1) 1(1) -2(1)
C(2) 2 2(1 ) 32(1) 28(1) -1(1) 6(1) 1(1)
C(3) 22(1) 27(1 ) 23(1) 0(1) 4(1) 1(1)
C(4) 24(1 ) 25(1) 28(1 ) -1(1) 0(1) -2(1)  _
C(5) 21(1 ) 24(1 ) 32(1) -1(1) . ] 4 (1) -2(1)
C(6) 23(1 ) 37(1) 35(1) -2(1) 0(1) 3(1)
C(7) 28(1 ) 44(1 ) 34(2) -4(1) -1(1) -5(1)
C(8) 33(2) 58(2) 60(2) 8(1) 4(1) -7(1)
C(9) 41 (2 ) 79(2 ) 80(3) 10(2) 13(2) -6(2)
C (10) 21(2 ) 84(3) 140(4) -57(2) 2 0(2 ) -18(2)
C (11) 46 (2 ) 37(2) 73(2) -2(1) 2 7(2 ) -8(1)
C (12) 30(1) 4 2 (1 ) 39(2) 6(1) 13(1) -3(1)
C (1 3) 21(1) 31(1) 35(1) -4(1) _ 8(1) -1(1)
C (14) 22(1) 23(1 ) 30(1) 1(1) 7(1) -2(1)
C (15) 24(1) 22(1 ) 26(1) 1(1) 6(1) -1(1)
C (16) 25 (1 ) 32(1) 30(1) -2(1) 9(1) -3(1)
C (17) 32(1) 37(1) 22(1) 1(1) 6(1) -2(1)  _
C( 18) 28 (1 ) 29(1 ) 34(1) 4(1) 11(1) 5(1)
0 ( 1 9 ) 22 (1 ) 31(1) 34(1) 2(1) 4(1) 3(1)
0 ( 2 0 ) 29(1) 25(1 ) 25 (1 ) 0(1) 3(1) 4 (1 )
0 ( 2 1 ) 37(1) 30(1) 29 (1 ) 0(1) 8(1) 8(1) .
C (22) 31(1) 23(1 ) 35(1) -1(1) 11(1) 3(1)
C(23) 41(2 ) 34(1) 40(2 ) 0(1) 19(1) 2(1)
0 ( 2 4 ) 46(2 ) 4 2 (1 ) 36(2) -4(1) 16(1) 6(1)
0 ( 2 5 ) 49(2 ) 4 4 (2 ) 45(2 ) -3(1) 19(1) 4(1)
0 ( 2 6 ) 52(2) 9 2(3 ) 67(2 )  ... 16(2) 2 6 (2 ) 13(2)
0 ( 2 7 ) 36(2) 85(2) 77(3) -22(2) 18(2) 11(2)
0 ( 2 8 ) 40(2 ) 39(1) 52(2) 2(1) 4(1) 15(1)
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C (29) 30(1) 36(1) 40 (2 ) 3(1) 0(1) 8(1)
C (30) 25(1 ) 30(1) 48 (2 ) 0(1) 8(1) 3(1)
C (31) 26(1 ) 19(1) 38(1) 1(1) 8(1) 4(1)
C (32) 28(1 ) 21(1) 31(1) 0(1) 7(1) 5(1)
C (33) 28(1 ) 32(1) 31(1) -1(1) 0(1) 4(1)
C (34) 37(1) 34(1) 27(1) 1(1) 5(1) 6(1)
C (101) 87(3) 76(3 ) 160(5) -16(3) 59(3) -3(2)
C (102) 86(3) 70(2) 93(3) -2(2) -1(2) -4(2)
C (103) 82(3) 61(2) 69(3) -3(2) 3(2) -8(2)
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Table 5 : Hydrogen coord inates  ( x 104) and isotropic d isp lacem en t  
param eters  (A2 x 1 0 3) for 1.
Atom X y z U(eq)
H(1A) 2 3 0 0 (3 0 ) 1737 (1 6 ) -75(18) 4 1 (1 0 )
H(1B) 3 1 6 0 (4 0 ) 1585 (1 9 ) 515 (19 ) 6 9 (11 )
H(2A) 3 8 9 0 (3 0 ) 3 0 4 1 (1 7 ) 3 7 9 0 (1 8 ) 4 7 (1 0 )
H(2B) 4 0 1 0 (3 0 ) 2 8 8 2 (1 5 ) 4 5 5 4 (1 8 ) 49 (8 )
H(2) 3 1 1 5 3 1 6 3 1974 33
H(6A) 9 8 3 2 3 0 9 9 3 1 3 7 38
H(6B) 8 9 6 8 2 8 0 5 3711 38
H(7A) 8 7 4 4 3 9 0 9 4 1 6 3 4 3
H(7B) 10 3 0 9 3 7 1 3 4 1 8 0 4 3
H(8A) 8 9 2 8 4 6 1 3 3 1 6 7 61
H(8B) 9 7 3 3 4 8 8 3 3 8 8 5 61
H(9A) 11 1 3 8 5111 3 1 3 7 80
H(9B) 11751 4 4 1 5 3 4 9 2 80
H(10A) 1 1 0 3 5 3 7 8 9 2 5 5 5 97
H(10B) 1 1 7 6 8 4 4 5 3 2 2 9 4 97
H(11A) 8861 4 5 3 7 2 1 4 2 60
H(11B) 9 8 5 3 4 8 3 7 1626 6 0
H(12A) 1 0 1 2 9 3 7 1 8 1179 4 3
H(12B) 8 5 6 5 3 9 4 6 1061 4 3
H(13A) 8 7 6 6 2 7 8 0 1431 35
H(13B) 9 7 3 0 3 0 0 4 2 1 2 5 35
H(16) 6 9 1 3 3 1 0 4 7 6 6 34
H(17) 4 7 3 5 2 9 8 7 162 37
H(19) 3 1 7 9 1470 2 5 2 0 35
H(23A) 9 1 0 9 1484 1178 4 4
H(23B) 7 9 0 8 1790 6 3 3 4 4
H(24A) 7 3 6 7 6 9 7 175 4 8
H(24B) 8 9 3 5 8 5 6 141 4 8
H(25A) 8431 -2 9 8 4 5 0 54
H(25B) 8 0 4 2 -10 1170 54
H(26A) 1 0 2 3 6 -5 5 9 1201 82
H(26B) 1 0 7 1 7 113 8 2 3 82
H(27A) 1 0 6 0 2 7 6 5 1749 78
H(27B) 1 1 4 4 5 87 1995 7 8
H(28A) 8671 60 2 2 0 9 53
H(28B) 9 9 5 5 -2 5 4 2 7 0 0 53
H(29A) 1 0582 8 6 0 3 1 1 2 4 3
H(29B) 9 0 9 0 6 6 4 3 2 7 6 4 3
H(30A) 9 1 3 7 1821 2 8 8 3 41
H(30B) 9 6 4 6 1572 2 1 7 3 41
H(33) 7 7 0 2 1 490 3 6 0 6 37
H(34) 5 9 1 9 1 590 4 2 7 6 39
H(10C) 1124 4 6 2 6 163 156
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H(10D) 1851 5 3 1 5 4 8 5 156
H(10E) 2 2 6 5 4581 8 3 2 156
H(10F) 3 1 7 9 4 2 4 7 -189 101
H(10G) 2771 4 9 8 3 -532 101
H(10H) 4 7 1 8 4 7 8 8 6 7 0 86
H(10l) 4 3 0 8 5 5 2 3 3 3 0 86
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